{"PMC7235440": [["BackgroundThe Herpesviridae family comprises over 100 viruses that can infect a wide variety of species of at least two animal phyla, the Chordata (mammals, birds, fishes, reptiles, and amphibians) and the Mollusca (oysters), with each member consisting of an enveloped icosahedral capsid containing a proteinaceous tegument and a dsDNA genome [1].", [["tegument", "ANATOMY", 316, 324], ["Herpesviridae family", "PROTEIN", 14, 34], ["enveloped icosahedral capsid", "PROTEIN", 260, 288], ["proteinaceous tegument", "PROTEIN", 302, 324], ["dsDNA genome", "DNA", 331, 343], ["an enveloped icosahedral capsid", "TREATMENT", 257, 288], ["a proteinaceous tegument and a dsDNA genome", "TREATMENT", 300, 343], ["Herpesviridae", "OBSERVATION", 14, 27]]], ["The Herpesviridae family is divided into three subfamilies (Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae) based on their biological properties and genome sequences [2].", [["Herpesviridae", "GENE_OR_GENE_PRODUCT", 4, 17], ["Betaherpesvirinae", "GENE_OR_GENE_PRODUCT", 80, 97], ["Herpesviridae family", "PROTEIN", 4, 24], ["genome sequences", "DNA", 164, 180], ["Betaherpesvirinae", "TREATMENT", 80, 97], ["Gammaherpesvirinae", "TREATMENT", 103, 121], ["Herpesviridae", "OBSERVATION", 4, 17]]], ["The Alphaherpesvirinae subfamily contains HSV-1/2; the Betaherpesvirinae subfamily contains human cytomegalovirus (HCMV) and human herpesvirus-6A and 6B (HHV-6A and -6B) [3]; and the Gammaherpesvirinae subfamily contains Kaposi\u2019s sarcoma-associated herpesvirus (KSHV), Epstein-Barr virus (EBV) and murine gammaherpesvirus 68 (MHV68) [4].", [["Kaposi\u2019s sarcoma-associated herpesvirus", "DISEASE", 221, 260], ["Alphaherpesvirinae", "GENE_OR_GENE_PRODUCT", 4, 22], ["HSV-1/2", "ORGANISM", 42, 49], ["Betaherpesvirinae", "GENE_OR_GENE_PRODUCT", 55, 72], ["human cytomegalovirus", "ORGANISM", 92, 113], ["HCMV", "ORGANISM", 115, 119], ["human herpesvirus-6A", "ORGANISM", 125, 145], ["6B (HHV-6A", "ORGANISM", 150, 160], ["-6B", "GENE_OR_GENE_PRODUCT", 165, 168], ["Gammaherpesvirinae", "GENE_OR_GENE_PRODUCT", 183, 201], ["Kaposi\u2019s sarcoma-associated herpesvirus", "ORGANISM", 221, 260], ["KSHV", "ORGANISM", 262, 266], ["Epstein-Barr virus", "ORGANISM", 269, 287], ["EBV", "ORGANISM", 289, 292], ["murine gammaherpesvirus 68", "ORGANISM", 298, 324], ["Alphaherpesvirinae subfamily", "PROTEIN", 4, 32], ["Betaherpesvirinae subfamily", "PROTEIN", 55, 82], ["Gammaherpesvirinae subfamily", "PROTEIN", 183, 211], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 125, 130], ["herpesvirus", "SPECIES", 131, 142], ["Kaposi\u2019s sarcoma-associated herpesvirus", "SPECIES", 221, 260], ["Barr virus", "SPECIES", 277, 287], ["murine", "SPECIES", 298, 304], ["HSV-1/2", "SPECIES", 42, 49], ["human cytomegalovirus", "SPECIES", 92, 113], ["HCMV", "SPECIES", 115, 119], ["human herpesvirus-6A", "SPECIES", 125, 145], ["Kaposi\u2019s sarcoma-associated herpesvirus", "SPECIES", 221, 260], ["KSHV", "SPECIES", 262, 266], ["Epstein-Barr virus", "SPECIES", 269, 287], ["EBV", "SPECIES", 289, 292], ["murine gammaherpesvirus 68", "SPECIES", 298, 324], ["HSV", "TEST", 42, 45], ["human cytomegalovirus", "PROBLEM", 92, 113], ["HCMV", "TEST", 115, 119], ["human herpesvirus", "TEST", 125, 142], ["6B", "TEST", 150, 152], ["HHV", "TEST", 154, 157], ["the Gammaherpesvirinae subfamily", "TEST", 179, 211], ["Kaposi\u2019s sarcoma", "PROBLEM", 221, 237], ["associated herpesvirus (KSHV", "PROBLEM", 238, 266], ["Epstein", "TEST", 269, 276], ["Barr virus", "PROBLEM", 277, 287], ["murine gammaherpesvirus", "TEST", 298, 321], ["human cytomegalovirus", "OBSERVATION", 92, 113], ["Kaposi\u2019s sarcoma", "OBSERVATION", 221, 237]]], ["A characteristic feature that is common to all herpesvirus infections is the establishment of latent infections, a state from which the virus can be reactivated and result in recurring disease [2].BackgroundHost shutoff, on the one hand, means directly reducing the levels of cellular mRNAs or preventing their association with ribosomes and translation initiation factors that can facilitate the translation of viral mRNAs [5].", [["cellular", "ANATOMY", 276, 284], ["ribosomes", "ANATOMY", 328, 337], ["herpesvirus infections", "DISEASE", 47, 69], ["infections", "DISEASE", 101, 111], ["herpesvirus", "ORGANISM", 47, 58], ["cellular", "CELL", 276, 284], ["ribosomes", "CELLULAR_COMPONENT", 328, 337], ["cellular mRNAs", "RNA", 276, 290], ["translation initiation factors", "PROTEIN", 342, 372], ["viral mRNAs", "RNA", 412, 423], ["all herpesvirus infections", "PROBLEM", 43, 69], ["latent infections", "PROBLEM", 94, 111], ["the virus", "PROBLEM", 132, 141], ["recurring disease", "PROBLEM", 175, 192], ["cellular mRNAs", "TREATMENT", 276, 290], ["ribosomes", "TREATMENT", 328, 337], ["translation initiation factors", "TREATMENT", 342, 372], ["viral mRNAs", "PROBLEM", 412, 423], ["herpesvirus", "OBSERVATION_MODIFIER", 47, 58], ["infections", "OBSERVATION", 59, 69], ["latent", "OBSERVATION_MODIFIER", 94, 100], ["infections", "OBSERVATION", 101, 111], ["Host shutoff", "OBSERVATION", 207, 219], ["cellular mRNAs", "OBSERVATION", 276, 290]]], ["A common theme is that different viruses encode a few proteins that block host gene expression by promoting global mRNA degradation, such as the virion host shutoff (VHS) protein of HSV-1/2 [6], SOX and its homologs in gammaherpesviruses [7, 8], Nsp1 of SARS-coronaviruses [9] and PA-X from influenza A virus [10].", [["influenza A", "DISEASE", 291, 302], ["VHS", "GENE_OR_GENE_PRODUCT", 166, 169], ["HSV-1/2 [6", "GENE_OR_GENE_PRODUCT", 182, 192], ["SOX", "GENE_OR_GENE_PRODUCT", 195, 198], ["gammaherpesviruses", "GENE_OR_GENE_PRODUCT", 219, 237], ["Nsp1", "GENE_OR_GENE_PRODUCT", 246, 250], ["SARS-coronaviruses", "ORGANISM", 254, 272], ["PA-X", "GENE_OR_GENE_PRODUCT", 281, 285], ["influenza A virus", "ORGANISM", 291, 308], ["virion host shutoff (VHS) protein", "PROTEIN", 145, 178], ["HSV-1/2 [6]", "PROTEIN", 182, 193], ["SOX", "PROTEIN", 195, 198], ["gammaherpesviruses", "PROTEIN", 219, 237], ["Nsp1", "PROTEIN", 246, 250], ["influenza A virus", "SPECIES", 291, 308], ["SARS-coronaviruses", "SPECIES", 254, 272], ["influenza A virus", "SPECIES", 291, 308], ["different viruses", "PROBLEM", 23, 40], ["global mRNA degradation", "PROBLEM", 108, 131], ["the virion host shutoff", "TREATMENT", 141, 164], ["HSV", "TEST", 182, 185], ["SARS", "PROBLEM", 254, 258], ["coronaviruses", "TEST", 259, 272], ["PA", "TEST", 281, 283], ["influenza A virus", "PROBLEM", 291, 308], ["viruses", "OBSERVATION", 33, 40], ["global mRNA", "OBSERVATION", 108, 119]]], ["In cells, each protein targets host RNA polymerase II (Pol II) transcripts for cleavage and requires host Xrn1 to complete RNA degradation, although the mechanism of targeting and the position of the primary cleavage differs [11, 12].", [["cells", "ANATOMY", 3, 8], ["cells", "CELL", 3, 8], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 36, 53], ["Pol II", "GENE_OR_GENE_PRODUCT", 55, 61], ["Xrn1", "GENE_OR_GENE_PRODUCT", 106, 110], ["RNA polymerase II", "PROTEIN", 36, 53], ["Pol II) transcripts", "PROTEIN", 55, 74], ["Xrn1", "PROTEIN", 106, 110], ["each protein targets host RNA polymerase II (Pol II) transcripts", "TREATMENT", 10, 74], ["cleavage", "PROBLEM", 79, 87], ["host Xrn1", "TREATMENT", 101, 110], ["complete RNA degradation", "PROBLEM", 114, 138]]], ["On the other hand, HSV-1 ICP27 interacts with splicing proteins and inhibits cellular pre-mRNA splicing early after infection, resulting in a decrease in the splicing of products into cellular translation machinery; therefore, HSV-1 ICP27 also contributes to the shutoff of host protein synthesis [13, 14].", [["cellular", "ANATOMY", 77, 85], ["cellular", "ANATOMY", 184, 192], ["infection", "DISEASE", 116, 125], ["HSV-1", "ORGANISM", 19, 24], ["ICP27", "GENE_OR_GENE_PRODUCT", 25, 30], ["cellular", "CELL", 77, 85], ["cellular", "CELL", 184, 192], ["HSV-1", "ORGANISM", 227, 232], ["ICP27", "GENE_OR_GENE_PRODUCT", 233, 238], ["HSV-1 ICP27", "PROTEIN", 19, 30], ["splicing proteins", "PROTEIN", 46, 63], ["HSV-1 ICP27", "PROTEIN", 227, 238], ["HSV-1", "SPECIES", 19, 24], ["HSV-1", "SPECIES", 227, 232], ["HSV", "TEST", 19, 22], ["splicing proteins", "PROBLEM", 46, 63], ["cellular pre-mRNA splicing", "PROBLEM", 77, 103], ["infection", "PROBLEM", 116, 125], ["HSV", "TEST", 227, 230], ["pre-mRNA splicing", "OBSERVATION", 86, 103], ["decrease", "OBSERVATION_MODIFIER", 142, 150]]], ["However, betaherpesviruses, such as HCMV, do not shut off host macromolecular synthesis [15].", [["betaherpesviruses", "GENE_OR_GENE_PRODUCT", 9, 26], ["HCMV", "ORGANISM", 36, 40], ["HCMV", "SPECIES", 36, 40], ["betaherpesviruses", "PROBLEM", 9, 26], ["HCMV", "PROBLEM", 36, 40]]], ["In this review, we will discuss host shutoff mechanisms of HSV-1 and members of the Gammaherpesvirinae subfamilies and their roles in immune evasion.mRNA processing ::: Main textHSV infection leads to suppression of cellular protein synthesis through at least two distinct inhibitory pathways.", [["cellular", "ANATOMY", 216, 224], ["infection", "DISEASE", 182, 191], ["HSV-1", "ORGANISM", 59, 64], ["Gammaherpesvirinae", "GENE_OR_GENE_PRODUCT", 84, 102], ["textHSV", "GENE_OR_GENE_PRODUCT", 174, 181], ["cellular", "CELL", 216, 224], ["Gammaherpesvirinae subfamilies", "PROTEIN", 84, 114], ["HSV-1", "SPECIES", 59, 64], ["Main textHSV infection", "PROBLEM", 169, 191], ["cellular protein synthesis", "PROBLEM", 216, 242], ["textHSV", "OBSERVATION_MODIFIER", 174, 181], ["infection", "OBSERVATION", 182, 191], ["cellular protein synthesis", "OBSERVATION", 216, 242], ["distinct", "OBSERVATION_MODIFIER", 264, 272], ["inhibitory pathways", "OBSERVATION", 273, 292]]], ["In the first pathway, delivery of the VHS protein, encoded by the HSV UL41 gene, into the cytoplasm after fusion of the viral envelope with the host cell membrane.", [["cytoplasm", "ANATOMY", 90, 99], ["cell membrane", "ANATOMY", 149, 162], ["VHS", "GENE_OR_GENE_PRODUCT", 38, 41], ["HSV", "ORGANISM", 66, 69], ["UL41", "GENE_OR_GENE_PRODUCT", 70, 74], ["cytoplasm", "ORGANISM_SUBSTANCE", 90, 99], ["cell membrane", "CELLULAR_COMPONENT", 149, 162], ["VHS protein", "PROTEIN", 38, 49], ["HSV UL41 gene", "DNA", 66, 79], ["HSV", "SPECIES", 66, 69], ["the VHS protein", "TEST", 34, 49], ["fusion", "TREATMENT", 106, 112], ["the viral envelope", "PROBLEM", 116, 134], ["viral envelope", "OBSERVATION", 120, 134], ["host cell membrane", "OBSERVATION", 144, 162]]], ["This event leads to an increase in the global mRNA degradation rate in the cytoplasm, and the precipitous decrease in the levels of most host mRNAs curtails the synthesis of the corresponding proteins [16].", [["cytoplasm", "ANATOMY", 75, 84], ["cytoplasm", "ORGANISM_SUBSTANCE", 75, 84], ["host mRNAs", "RNA", 137, 147], ["an increase", "PROBLEM", 20, 31], ["the global mRNA degradation rate in the cytoplasm", "PROBLEM", 35, 84], ["the precipitous decrease", "PROBLEM", 90, 114], ["the corresponding proteins", "TEST", 174, 200], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["global", "OBSERVATION_MODIFIER", 39, 45], ["mRNA degradation", "OBSERVATION", 46, 62], ["cytoplasm", "OBSERVATION_MODIFIER", 75, 84], ["precipitous", "OBSERVATION_MODIFIER", 94, 105], ["decrease", "OBSERVATION_MODIFIER", 106, 114]]], ["VHS and its homologs are only present in the genomes of Alphaherpesvirinae subfamily members, and as an endoribonuclease with similar substrate specificity to RNase A, VHS triggers the rapid shutoff of host cell protein synthesis and disrupts preexisting polyribosomes [17].", [["cell", "ANATOMY", 207, 211], ["polyribosomes", "ANATOMY", 255, 268], ["VHS", "GENE_OR_GENE_PRODUCT", 0, 3], ["Alphaherpesvirinae", "GENE_OR_GENE_PRODUCT", 56, 74], ["RNase A", "GENE_OR_GENE_PRODUCT", 159, 166], ["VHS", "GENE_OR_GENE_PRODUCT", 168, 171], ["host cell", "CELL", 202, 211], ["VHS", "PROTEIN", 0, 3], ["Alphaherpesvirinae subfamily members", "PROTEIN", 56, 92], ["endoribonuclease", "PROTEIN", 104, 120], ["RNase A", "PROTEIN", 159, 166], ["VHS", "PROTEIN", 168, 171], ["VHS", "TEST", 0, 3], ["host cell protein synthesis", "TREATMENT", 202, 229], ["host cell protein synthesis", "OBSERVATION", 202, 229]]], ["The pseudorabies virus (PRV) UL41 gene-encoding protein is the homologue of the HSV UL41 protein and has a similar shutoff function [18].", [["pseudorabies virus", "ORGANISM", 4, 22], ["PRV", "ORGANISM", 24, 27], ["UL41", "GENE_OR_GENE_PRODUCT", 29, 33], ["HSV", "ORGANISM", 80, 83], ["UL41", "GENE_OR_GENE_PRODUCT", 84, 88], ["pseudorabies virus (PRV) UL41 gene", "DNA", 4, 38], ["HSV UL41 protein", "PROTEIN", 80, 96], ["pseudorabies virus", "SPECIES", 4, 22], ["pseudorabies virus", "SPECIES", 4, 22], ["PRV", "SPECIES", 24, 27], ["HSV", "SPECIES", 80, 83], ["The pseudorabies virus", "PROBLEM", 0, 22], ["pseudorabies virus", "OBSERVATION", 4, 22]]], ["In contrast, the varicella-zoster virus (VZV) open reading frame 17 (ORF17) protein, a homolog of HSV UL41 protein, can also induce RNA cleavage, but to a substantially lesser extent than HSV-1 VHS and has no major function in the VZV-mediated delayed host shutoff [19].", [["varicella-zoster", "DISEASE", 17, 33], ["varicella-zoster virus", "ORGANISM", 17, 39], ["VZV", "ORGANISM", 41, 44], ["open reading frame 17", "GENE_OR_GENE_PRODUCT", 46, 67], ["ORF17", "GENE_OR_GENE_PRODUCT", 69, 74], ["HSV", "ORGANISM", 98, 101], ["UL41", "GENE_OR_GENE_PRODUCT", 102, 106], ["HSV-1 VHS", "ORGANISM", 188, 197], ["VZV", "ORGANISM", 231, 234], ["varicella-zoster virus (VZV) open reading frame 17 (ORF17) protein", "PROTEIN", 17, 83], ["HSV UL41 protein", "PROTEIN", 98, 114], ["VHS", "PROTEIN", 194, 197], ["varicella-zoster virus", "SPECIES", 17, 39], ["varicella-zoster virus", "SPECIES", 17, 39], ["VZV", "SPECIES", 41, 44], ["HSV", "SPECIES", 98, 101], ["HSV-1", "SPECIES", 188, 193], ["VZV", "SPECIES", 231, 234], ["the varicella-zoster virus", "PROBLEM", 13, 39], ["protein", "TEST", 76, 83], ["HSV UL41 protein", "TEST", 98, 114], ["RNA cleavage", "PROBLEM", 132, 144], ["HSV", "TEST", 188, 191], ["the VZV", "PROBLEM", 227, 234], ["varicella", "ANATOMY", 17, 26], ["zoster virus", "OBSERVATION", 27, 39], ["RNA cleavage", "OBSERVATION", 132, 144], ["lesser extent", "OBSERVATION_MODIFIER", 169, 182], ["no major", "UNCERTAINTY", 206, 214], ["host shutoff", "OBSERVATION", 252, 264]]], ["Interestingly, ORF17 protein is crucial for VZV replication at 37 \u00b0C [20].", [["ORF17", "GENE_OR_GENE_PRODUCT", 15, 20], ["VZV", "ORGANISM", 44, 47], ["ORF17 protein", "PROTEIN", 15, 28], ["VZV", "SPECIES", 44, 47], ["VZV replication", "TREATMENT", 44, 59]]], ["Thus, VHS likely plays a fundamental and conserved role in the biology of infections caused by alphaherpesviruses, but its effect in different viral infections is distinct.", [["infections", "DISEASE", 74, 84], ["viral infections", "DISEASE", 143, 159], ["VHS", "GENE_OR_GENE_PRODUCT", 6, 9], ["VHS", "PROTEIN", 6, 9], ["VHS", "PROBLEM", 6, 9], ["infections", "PROBLEM", 74, 84], ["alphaherpesviruses", "PROBLEM", 95, 113], ["different viral infections", "PROBLEM", 133, 159], ["infections", "OBSERVATION", 74, 84], ["alphaherpesviruses", "OBSERVATION", 95, 113], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["infections", "OBSERVATION", 149, 159]]], ["In addition, VHS reduces dsRNA levels by reducing the potential for generating dsRNA and directly removing dsRNA after its formation [21].", [["VHS", "GENE_OR_GENE_PRODUCT", 13, 16], ["VHS", "PROTEIN", 13, 16], ["VHS reduces dsRNA levels", "PROBLEM", 13, 37], ["generating dsRNA", "PROBLEM", 68, 84], ["dsRNA", "TREATMENT", 107, 112], ["dsRNA", "OBSERVATION", 79, 84]]], ["This novel function would be important in immune evasion and may exist in other alphaherpesviruses.mRNA processing ::: Main textSecond, HSV-1 ICP27 has role in pre-mRNA polyadenylation and splicing that inhibits host mRNA maturation [22].", [["HSV-1", "ORGANISM", 136, 141], ["ICP27", "GENE_OR_GENE_PRODUCT", 142, 147], ["ICP27", "PROTEIN", 142, 147], ["HSV-1", "SPECIES", 136, 141], ["immune evasion", "TREATMENT", 42, 56], ["HSV", "TEST", 136, 139], ["pre-mRNA polyadenylation", "TREATMENT", 160, 184], ["pre-mRNA polyadenylation", "OBSERVATION", 160, 184]]], ["Eukaryotic pre-mRNAs are processed after synthesis in the nucleus and then translated in the cytoplasm, although an unusual feature of HSV-1 transcripts is that the majority are intronless (except ICP22, ICP0, ICP47, UL15, LAT and gC) and thus do not interact with the splicing machinery [23].", [["nucleus", "ANATOMY", 58, 65], ["cytoplasm", "ANATOMY", 93, 102], ["nucleus", "CELLULAR_COMPONENT", 58, 65], ["cytoplasm", "ORGANISM_SUBSTANCE", 93, 102], ["HSV-1", "GENE_OR_GENE_PRODUCT", 135, 140], ["ICP22", "GENE_OR_GENE_PRODUCT", 197, 202], ["ICP0", "GENE_OR_GENE_PRODUCT", 204, 208], ["ICP47", "GENE_OR_GENE_PRODUCT", 210, 215], ["UL15", "GENE_OR_GENE_PRODUCT", 217, 221], ["LAT", "GENE_OR_GENE_PRODUCT", 223, 226], ["gC", "GENE_OR_GENE_PRODUCT", 231, 233], ["Eukaryotic pre-mRNAs", "RNA", 0, 20], ["HSV-1 transcripts", "RNA", 135, 152], ["ICP22", "DNA", 197, 202], ["ICP0", "PROTEIN", 204, 208], ["ICP47", "PROTEIN", 210, 215], ["UL15", "DNA", 217, 221], ["LAT", "PROTEIN", 223, 226], ["gC", "PROTEIN", 231, 233], ["HSV-1", "SPECIES", 135, 140], ["Eukaryotic pre-mRNAs", "PROBLEM", 0, 20], ["synthesis in the nucleus", "PROBLEM", 41, 65], ["HSV", "PROBLEM", 135, 138], ["ICP22", "TEST", 197, 202], ["ICP0", "TEST", 204, 208], ["ICP47", "TEST", 210, 215], ["UL15", "TEST", 217, 221], ["nucleus", "ANATOMY", 58, 65]]], ["ICP27 interacts with and recruits cytoplasmic kinase SR protein kinase 1 (SRPK1) to the nucleus to inhibit host cell splicing, after which the unspliced host mRNAs in the nucleus cannot be exported to the cytoplasm for translation, leading to host protein synthesis shutoff [24].", [["cytoplasmic", "ANATOMY", 34, 45], ["nucleus", "ANATOMY", 88, 95], ["cell", "ANATOMY", 112, 116], ["nucleus", "ANATOMY", 171, 178], ["cytoplasm", "ANATOMY", 205, 214], ["ICP27", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasmic", "ORGANISM_SUBSTANCE", 34, 45], ["kinase SR protein kinase 1", "GENE_OR_GENE_PRODUCT", 46, 72], ["SRPK1", "GENE_OR_GENE_PRODUCT", 74, 79], ["nucleus", "CELLULAR_COMPONENT", 88, 95], ["host cell", "CELL", 107, 116], ["nucleus", "CELLULAR_COMPONENT", 171, 178], ["cytoplasm", "ORGANISM_SUBSTANCE", 205, 214], ["ICP27", "PROTEIN", 0, 5], ["cytoplasmic kinase SR protein kinase 1", "PROTEIN", 34, 72], ["SRPK1", "PROTEIN", 74, 79], ["unspliced host mRNAs", "RNA", 143, 163], ["cytoplasmic kinase SR protein kinase", "TEST", 34, 70], ["SRPK1", "TEST", 74, 79], ["host cell splicing", "TREATMENT", 107, 125], ["host protein synthesis shutoff", "TREATMENT", 243, 273], ["nucleus", "ANATOMY", 88, 95], ["host cell splicing", "OBSERVATION", 107, 125], ["host mRNAs", "OBSERVATION", 153, 163], ["nucleus", "ANATOMY", 171, 178]]], ["Recently, ICP27 has been shown to inhibit the splicing of specific introns and promote the use of alternative 5\u2032 splice sites (ss).", [["ICP27", "GENE_OR_GENE_PRODUCT", 10, 15], ["ICP27", "PROTEIN", 10, 15], ["introns", "DNA", 67, 74], ["5\u2032 splice sites", "DNA", 110, 125], ["ICP27", "TREATMENT", 10, 15], ["specific introns", "TREATMENT", 58, 74], ["alternative 5\u2032 splice sites", "TREATMENT", 98, 125]]], ["Furthermore, ICP27 targets high GC content and cytosine-rich sequences that are similar to those of HSV genes spared by the VHS, possibly promoting virus-induced host shutoff [25].", [["cytosine", "CHEMICAL", 47, 55], ["cytosine", "CHEMICAL", 47, 55], ["ICP27", "GENE_OR_GENE_PRODUCT", 13, 18], ["cytosine", "SIMPLE_CHEMICAL", 47, 55], ["HSV", "ORGANISM", 100, 103], ["VHS", "GENE_OR_GENE_PRODUCT", 124, 127], ["ICP27", "PROTEIN", 13, 18], ["cytosine-rich sequences", "DNA", 47, 70], ["HSV genes", "DNA", 100, 109], ["VHS", "DNA", 124, 127], ["HSV", "SPECIES", 100, 103], ["ICP27", "TEST", 13, 18], ["cytosine-rich sequences", "TEST", 47, 70], ["HSV genes", "PROBLEM", 100, 109], ["the VHS", "PROBLEM", 120, 127], ["promoting virus", "PROBLEM", 138, 153], ["host shutoff", "OBSERVATION", 162, 174]]], ["In addition, transcription termination affects mRNA production and translation, and HSV-1 induces the disruption of transcription termination of host genes [26].", [["HSV-1", "ORGANISM", 84, 89], ["host genes", "DNA", 145, 155], ["HSV-1", "SPECIES", 84, 89], ["mRNA production", "PROBLEM", 47, 62], ["translation", "TEST", 67, 78], ["HSV", "TEST", 84, 87]]], ["HSV-1 ICP27 was recently shown to block the transcription termination of host genes by inhibiting mRNA 3\u2032 processing.", [["HSV-1", "ORGANISM", 0, 5], ["ICP27", "GENE_OR_GENE_PRODUCT", 6, 11], ["HSV-1 ICP27", "PROTEIN", 0, 11], ["host genes", "DNA", 73, 83], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["host genes", "OBSERVATION", 73, 83]]], ["Furthermore, ICP27 can act as a sequence-dependent activator of mRNA 3\u2032 processing to promote efficient transcription termination of viral transcripts, indicating that HSV-1 ICP27 plays an important role in host shutoff [27].mRNA processing ::: Main textSimilar to alphaherpesviruses, gammaherpesviruses promote host shutoff by inducing widespread cellular mRNA degradation during the early lytic phase of viral infection [7, 8, 28].", [["cellular", "ANATOMY", 348, 356], ["viral infection", "DISEASE", 406, 421], ["ICP27", "GENE_OR_GENE_PRODUCT", 13, 18], ["3", "GENE_OR_GENE_PRODUCT", 69, 70], ["HSV-1", "ORGANISM", 168, 173], ["ICP27", "GENE_OR_GENE_PRODUCT", 174, 179], ["cellular", "CELL", 348, 356], ["ICP27", "PROTEIN", 13, 18], ["mRNA 3", "RNA", 64, 70], ["viral transcripts", "RNA", 133, 150], ["ICP27", "PROTEIN", 174, 179], ["mRNA", "RNA", 225, 229], ["cellular mRNA", "RNA", 348, 361], ["HSV-1", "SPECIES", 168, 173], ["viral transcripts", "PROBLEM", 133, 150], ["HSV", "PROBLEM", 168, 171], ["widespread cellular mRNA degradation", "PROBLEM", 337, 373], ["viral infection", "PROBLEM", 406, 421], ["viral transcripts", "OBSERVATION", 133, 150], ["alphaherpesviruses", "OBSERVATION", 265, 283], ["host shutoff", "OBSERVATION", 312, 324], ["widespread", "OBSERVATION_MODIFIER", 337, 347], ["cellular mRNA degradation", "OBSERVATION", 348, 373], ["lytic", "OBSERVATION_MODIFIER", 391, 396], ["viral", "OBSERVATION_MODIFIER", 406, 411], ["infection", "OBSERVATION", 412, 421]]], ["The KSHV host shutoff RNase is not homologous to VHS, but is the alkaline exonuclease ORF37 protein, also known as SOX, a member of the PD(D/E) XK restriction endonuclease superfamily.", [["KSHV", "ORGANISM", 4, 8], ["RNase", "GENE_OR_GENE_PRODUCT", 22, 27], ["VHS", "GENE_OR_GENE_PRODUCT", 49, 52], ["ORF37", "GENE_OR_GENE_PRODUCT", 86, 91], ["SOX", "GENE_OR_GENE_PRODUCT", 115, 118], ["KSHV host shutoff RNase", "PROTEIN", 4, 27], ["VHS", "PROTEIN", 49, 52], ["alkaline exonuclease ORF37 protein", "PROTEIN", 65, 99], ["SOX", "PROTEIN", 115, 118], ["PD(D/E) XK restriction endonuclease superfamily", "PROTEIN", 136, 183], ["KSHV", "SPECIES", 4, 8], ["The KSHV host shutoff RNase", "TREATMENT", 0, 27], ["the alkaline exonuclease", "TEST", 61, 85], ["the PD(D/E) XK restriction endonuclease superfamily", "TREATMENT", 132, 183], ["host shutoff", "OBSERVATION", 9, 21]]], ["While its homologs in other gammaherpesviruses are also host shutoff factors, SOX homologs are also present in other herpesviruses, including those such as HCMV that fail to inhibit host gene expression [11].", [["gammaherpesviruses", "GENE_OR_GENE_PRODUCT", 28, 46], ["SOX", "GENE_OR_GENE_PRODUCT", 78, 81], ["herpesviruses", "ORGANISM", 117, 130], ["HCMV", "ORGANISM", 156, 160], ["shutoff factors", "PROTEIN", 61, 76], ["SOX homologs", "PROTEIN", 78, 90], ["HCMV", "SPECIES", 156, 160], ["gammaherpesviruses", "OBSERVATION", 28, 46]]], ["However, the SOX protein and its homologs (muSOX and BGLF5) in gammaherpesviruses possess both exonucleolytic DNase and RNase activities.", [["SOX", "GENE_OR_GENE_PRODUCT", 13, 16], ["muSOX", "GENE_OR_GENE_PRODUCT", 43, 48], ["BGLF5", "GENE_OR_GENE_PRODUCT", 53, 58], ["gammaherpesviruses", "GENE_OR_GENE_PRODUCT", 63, 81], ["DNase", "GENE_OR_GENE_PRODUCT", 110, 115], ["RNase", "GENE_OR_GENE_PRODUCT", 120, 125], ["SOX protein", "PROTEIN", 13, 24], ["muSOX", "PROTEIN", 43, 48], ["BGLF5", "PROTEIN", 53, 58], ["gammaherpesviruses", "PROTEIN", 63, 81], ["exonucleolytic DNase", "PROTEIN", 95, 115], ["RNase", "PROTEIN", 120, 125], ["the SOX protein", "TEST", 9, 24], ["its homologs (muSOX and BGLF5) in gammaherpesviruses", "PROBLEM", 29, 81], ["exonucleolytic DNase", "TREATMENT", 95, 115], ["exonucleolytic DNase", "OBSERVATION", 95, 115]]], ["These activities are genetically separable, and the shutoff activity does not require DNase activity, although the processing of DNA and RNA substrates requires the same catalytic center [29].mRNA processing ::: Main textIn contrast to VHS, SOX is not packaged in virion particles and is expressed with early kinetics [8].", [["DNase", "GENE_OR_GENE_PRODUCT", 86, 91], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["VHS", "GENE_OR_GENE_PRODUCT", 236, 239], ["SOX", "GENE_OR_GENE_PRODUCT", 241, 244], ["DNase", "PROTEIN", 86, 91], ["VHS", "PROTEIN", 236, 239], ["SOX", "PROTEIN", 241, 244], ["DNase activity", "TREATMENT", 86, 100], ["DNA and RNA substrates", "PROBLEM", 129, 151], ["virion particles", "OBSERVATION", 264, 280]]], ["SOX targets a degenerate motif to degrade many mRNAs in the cytoplasm [29, 30].", [["cytoplasm", "ANATOMY", 60, 69], ["SOX", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytoplasm", "ORGANISM_SUBSTANCE", 60, 69], ["SOX", "PROTEIN", 0, 3], ["mRNAs", "RNA", 47, 52], ["a degenerate motif", "PROBLEM", 12, 30]]], ["In addition, it induces nascent cellular mRNAs to undergo poly(A) tail extension (hyperadenylation), which prevents the export of nascent nuclear messages [31, 32]. muSOX continues to accumulate during the late stages of the viral replicative cycle and broadly targets viral mRNAs from all three kinetic classes, which generally results in a decrease in relevant viral protein levels at each class [33].", [["cellular", "ANATOMY", 32, 40], ["nuclear", "ANATOMY", 138, 145], ["muSOX", "CHEMICAL", 165, 170], ["cellular", "CELL", 32, 40], ["poly(A) tail", "GENE_OR_GENE_PRODUCT", 58, 70], ["nuclear", "CELLULAR_COMPONENT", 138, 145], ["muSOX", "GENE_OR_GENE_PRODUCT", 165, 170], ["nascent cellular mRNAs", "RNA", 24, 46], ["poly(A) tail", "PROTEIN", 58, 70], ["muSOX", "PROTEIN", 165, 170], ["viral mRNAs", "RNA", 269, 280], ["viral protein", "PROTEIN", 363, 376], ["poly(A) tail extension (hyperadenylation)", "TREATMENT", 58, 99], ["muSOX", "PROBLEM", 165, 170], ["the viral replicative cycle", "TREATMENT", 221, 248], ["viral mRNAs", "TEST", 269, 280], ["a decrease in relevant viral protein levels", "PROBLEM", 340, 383], ["nascent cellular mRNAs", "OBSERVATION", 24, 46], ["viral replicative cycle", "OBSERVATION", 225, 248], ["decrease", "OBSERVATION_MODIFIER", 342, 350]]], ["Selective inactivation of the mRNA degradation activity of muSOX results in altered protein composition of progeny virions, which ultimately impacts subsequent rounds of infection by favoring lytic cycle entry over latency [33, 34].", [["virions", "ANATOMY", 115, 122], ["infection", "DISEASE", 170, 179], ["muSOX", "GENE_OR_GENE_PRODUCT", 59, 64], ["muSOX", "PROTEIN", 59, 64], ["Selective inactivation", "TREATMENT", 0, 22], ["the mRNA degradation", "TEST", 26, 46], ["altered protein composition of progeny virions", "PROBLEM", 76, 122], ["infection", "PROBLEM", 170, 179], ["progeny virions", "OBSERVATION", 107, 122], ["infection", "OBSERVATION", 170, 179]]], ["The deletion of BGLF5 results in the accumulation of several viral proteins during EBV infection and causes nuclear egress defects [35].", [["nuclear", "ANATOMY", 108, 115], ["EBV infection", "DISEASE", 83, 96], ["BGLF5", "GENE_OR_GENE_PRODUCT", 16, 21], ["EBV", "ORGANISM", 83, 86], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["BGLF5", "PROTEIN", 16, 21], ["viral proteins", "PROTEIN", 61, 75], ["EBV", "SPECIES", 83, 86], ["The deletion of BGLF5", "PROBLEM", 0, 21], ["several viral proteins", "PROBLEM", 53, 75], ["EBV infection", "PROBLEM", 83, 96], ["nuclear egress defects", "PROBLEM", 108, 130], ["several", "OBSERVATION_MODIFIER", 53, 60], ["viral proteins", "OBSERVATION", 61, 75], ["EBV infection", "OBSERVATION", 83, 96], ["egress defects", "OBSERVATION", 116, 130]]], ["In addition, SOX and its homologs possess intrinsic RNase activity, but they cannot solely account for host shutoff in vitro [36].mRNA processing ::: Main textAlthough a wide variety of mRNAs are degraded by viral endonucleases, some mRNAs contain a SOX resistance element (SRE) in their 3\u2032 untranslated region (UTR) that prevents their degradation by multiple viral endonucleases, such as C19ORF66, IL-6 and DNA damage-inducible gene 45 (GADD45\u03b2) [37\u201339].", [["SOX", "GENE_OR_GENE_PRODUCT", 13, 16], ["RNase", "GENE_OR_GENE_PRODUCT", 52, 57], ["SOX", "GENE_OR_GENE_PRODUCT", 250, 253], ["C19ORF66", "GENE_OR_GENE_PRODUCT", 390, 398], ["IL-6", "GENE_OR_GENE_PRODUCT", 400, 404], ["DNA damage-inducible gene 45", "GENE_OR_GENE_PRODUCT", 409, 437], ["GADD45\u03b2", "GENE_OR_GENE_PRODUCT", 439, 446], ["SOX", "PROTEIN", 13, 16], ["RNase", "PROTEIN", 52, 57], ["mRNAs", "RNA", 186, 191], ["viral endonucleases", "PROTEIN", 208, 227], ["mRNAs", "RNA", 234, 239], ["SOX resistance element", "DNA", 250, 272], ["SRE", "DNA", 274, 277], ["3\u2032 untranslated region", "DNA", 288, 310], ["UTR", "DNA", 312, 315], ["viral endonucleases", "PROTEIN", 361, 380], ["C19ORF66", "PROTEIN", 390, 398], ["IL-6", "PROTEIN", 400, 404], ["DNA damage-inducible gene 45", "DNA", 409, 437], ["GADD45\u03b2", "DNA", 439, 446], ["SOX", "TREATMENT", 13, 16], ["viral endonucleases", "PROBLEM", 208, 227], ["a SOX resistance element", "PROBLEM", 248, 272], ["their degradation", "PROBLEM", 331, 348], ["multiple viral endonucleases", "PROBLEM", 352, 380], ["IL", "TEST", 400, 402], ["DNA damage", "PROBLEM", 409, 419], ["RNase activity", "OBSERVATION", 52, 66], ["wide", "OBSERVATION_MODIFIER", 170, 174], ["variety", "OBSERVATION_MODIFIER", 175, 182], ["viral endonucleases", "OBSERVATION", 208, 227], ["SOX resistance element", "OBSERVATION", 250, 272], ["multiple", "OBSERVATION_MODIFIER", 352, 360], ["viral endonucleases", "OBSERVATION", 361, 380]]], ["A number of ribonucleoprotein complex proteins are involved in this process, for example, nucleolin (NCL) binds the IL-6 mRNA 3\u2019UTR and eIF4H to protect IL-6 mRNA from degradation [37], although a detailed mechanism how SREs promote the escape of mRNAs from viral endonucleases mediated decay remains unknown.", [["nucleolin", "GENE_OR_GENE_PRODUCT", 90, 99], ["NCL", "GENE_OR_GENE_PRODUCT", 101, 104], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["eIF4H", "GENE_OR_GENE_PRODUCT", 136, 141], ["IL-6", "GENE_OR_GENE_PRODUCT", 153, 157], ["ribonucleoprotein complex proteins", "PROTEIN", 12, 46], ["nucleolin", "PROTEIN", 90, 99], ["NCL", "PROTEIN", 101, 104], ["IL-6 mRNA 3\u2019UTR", "DNA", 116, 131], ["eIF4H", "DNA", 136, 141], ["IL-6 mRNA", "RNA", 153, 162], ["mRNAs", "RNA", 247, 252], ["viral endonucleases", "PROTEIN", 258, 277], ["ribonucleoprotein complex proteins", "PROBLEM", 12, 46], ["the IL", "TEST", 112, 118], ["UTR", "TEST", 128, 131], ["eIF4H", "TEST", 136, 141], ["IL", "TEST", 153, 155], ["viral endonucleases mediated decay", "PROBLEM", 258, 292], ["ribonucleoprotein complex", "OBSERVATION_MODIFIER", 12, 37], ["viral endonucleases", "OBSERVATION", 258, 277]]], ["Apoptosis enhancing nuclease (AEN) mRNA is also spared from SOX-mediated decay without a clear protective element in its sequence [40], and VHS cannot degrade tristetraprolin (TTP) [41].", [["tristetraprolin", "CHEMICAL", 159, 174], ["tristetraprolin", "CHEMICAL", 159, 174], ["TTP", "CHEMICAL", 176, 179], ["Apoptosis enhancing nuclease", "GENE_OR_GENE_PRODUCT", 0, 28], ["AEN", "GENE_OR_GENE_PRODUCT", 30, 33], ["SOX", "GENE_OR_GENE_PRODUCT", 60, 63], ["VHS", "GENE_OR_GENE_PRODUCT", 140, 143], ["tristetraprolin", "SIMPLE_CHEMICAL", 159, 174], ["TTP", "SIMPLE_CHEMICAL", 176, 179], ["Apoptosis enhancing nuclease (AEN) mRNA", "RNA", 0, 39], ["SOX", "PROTEIN", 60, 63], ["Apoptosis enhancing nuclease (AEN) mRNA", "PROBLEM", 0, 39], ["VHS", "PROBLEM", 140, 143]]], ["These results suggest that multiple mechanisms can apparently promote mRNA escape.", [["mRNA escape", "OBSERVATION", 70, 81]]], ["However, with the exception of the SREs, whether some mRNAs involved in the viral or cellular life cycle are spared viral endonuclease-mediated decay remains unknown, and these spared mRNAs may be needed for viral gene expression or to activate the immune response to inhibit viral replication.Downregulation of host mRNA translation ::: Main textIn eukaryotes, a key factor in translation control is eukaryotic translation initiation factor 2 (eIF2).", [["cellular", "ANATOMY", 85, 93], ["cellular", "CELL", 85, 93], ["eukaryotic translation initiation factor 2", "GENE_OR_GENE_PRODUCT", 401, 443], ["eIF2", "GENE_OR_GENE_PRODUCT", 445, 449], ["SREs", "DNA", 35, 39], ["mRNAs", "RNA", 54, 59], ["viral endonuclease", "PROTEIN", 116, 134], ["spared mRNAs", "RNA", 177, 189], ["host mRNA", "RNA", 312, 321], ["eukaryotic translation initiation factor 2", "PROTEIN", 401, 443], ["eIF2", "PROTEIN", 445, 449], ["the SREs", "PROBLEM", 31, 39], ["some mRNAs", "PROBLEM", 49, 59], ["the viral or cellular life cycle", "PROBLEM", 72, 104], ["viral endonuclease", "PROBLEM", 116, 134], ["viral gene expression", "PROBLEM", 208, 229], ["viral replication", "TREATMENT", 276, 293], ["translation control", "TREATMENT", 378, 397], ["SREs", "OBSERVATION", 35, 39], ["viral", "OBSERVATION", 76, 81], ["host mRNA", "OBSERVATION", 312, 321]]], ["The \u03b1 subunit of eIF2 is phosphorylated by a number of kinases, including protein kinase (PKR), PKR-like endoplasmic reticulum kinase (PERK), general control nonderepressible-2 kinase (GCN2), and heme-regulated eIF2a kinase (HRI), resulting in translation arrest and, ultimately, a general translational shutoff [42].", [["\u03b1 subunit", "GENE_OR_GENE_PRODUCT", 4, 13], ["eIF2", "GENE_OR_GENE_PRODUCT", 17, 21], ["protein kinase", "GENE_OR_GENE_PRODUCT", 74, 88], ["PKR", "GENE_OR_GENE_PRODUCT", 90, 93], ["PKR-like endoplasmic reticulum kinase", "GENE_OR_GENE_PRODUCT", 96, 133], ["PERK", "GENE_OR_GENE_PRODUCT", 135, 139], ["general control nonderepressible-2 kinase", "GENE_OR_GENE_PRODUCT", 142, 183], ["GCN2", "GENE_OR_GENE_PRODUCT", 185, 189], ["heme-regulated eIF2a kinase", "GENE_OR_GENE_PRODUCT", 196, 223], ["HRI", "GENE_OR_GENE_PRODUCT", 225, 228], ["\u03b1 subunit", "PROTEIN", 4, 13], ["eIF2", "PROTEIN", 17, 21], ["kinases", "PROTEIN", 55, 62], ["protein kinase", "PROTEIN", 74, 88], ["PKR", "PROTEIN", 90, 93], ["PKR-like endoplasmic reticulum kinase", "PROTEIN", 96, 133], ["PERK", "PROTEIN", 135, 139], ["general control nonderepressible-2 kinase", "PROTEIN", 142, 183], ["GCN2", "PROTEIN", 185, 189], ["heme", "PROTEIN", 196, 200], ["eIF2a kinase", "PROTEIN", 211, 223], ["HRI", "PROTEIN", 225, 228], ["protein kinase", "TEST", 74, 88], ["PKR", "TEST", 90, 93], ["PKR", "TEST", 96, 99], ["endoplasmic reticulum kinase", "TEST", 105, 133], ["PERK", "TEST", 135, 139], ["general control nonderepressible", "TEST", 142, 174], ["GCN2", "TEST", 185, 189], ["heme", "TEST", 196, 200], ["translation arrest", "PROBLEM", 244, 262], ["reticulum kinase", "OBSERVATION", 117, 133], ["translation arrest", "OBSERVATION", 244, 262]]], ["This effect is harmful to viruses that need the host translation machinery to synthesize viral proteins.", [["viral proteins", "PROTEIN", 89, 103], ["harmful to viruses", "PROBLEM", 15, 33], ["the host translation machinery", "TREATMENT", 44, 74], ["viral proteins", "PROBLEM", 89, 103]]], ["However, VHS blocks PKR activation via its endoribonuclease activity during the immediate onset of viral infection to counteract the activation of eIF2 by kinases, and VHS-defective viruses induce the phosphorylation of eIF2\u03b1 [43, 44].", [["viral infection", "DISEASE", 99, 114], ["VHS", "GENE_OR_GENE_PRODUCT", 9, 12], ["PKR", "GENE_OR_GENE_PRODUCT", 20, 23], ["eIF2", "GENE_OR_GENE_PRODUCT", 147, 151], ["VHS", "GENE_OR_GENE_PRODUCT", 168, 171], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 220, 225], ["VHS", "PROTEIN", 9, 12], ["PKR", "PROTEIN", 20, 23], ["endoribonuclease", "PROTEIN", 43, 59], ["eIF2", "PROTEIN", 147, 151], ["kinases", "PROTEIN", 155, 162], ["VHS", "PROTEIN", 168, 171], ["eIF2\u03b1", "PROTEIN", 220, 225], ["VHS blocks PKR activation", "PROBLEM", 9, 34], ["its endoribonuclease activity", "PROBLEM", 39, 68], ["viral infection", "PROBLEM", 99, 114], ["kinases", "TEST", 155, 162], ["VHS", "TEST", 168, 171], ["defective viruses", "PROBLEM", 172, 189], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["infection", "OBSERVATION", 105, 114], ["defective viruses", "OBSERVATION", 172, 189]]], ["In addition, HSV-1 ICP27 inhibits PKR binding to dsRNA and its autophosphorylation but has no direct effect on eIF2\u03b1 phosphorylation, potentially by only causing conformational changes in PKR [45].Downregulation of host mRNA translation ::: Main textIn vitro-translated VHS exhibits endonuclease activity with no selectivity.", [["HSV-1", "ORGANISM", 13, 18], ["ICP27", "GENE_OR_GENE_PRODUCT", 19, 24], ["PKR", "GENE_OR_GENE_PRODUCT", 34, 37], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 111, 116], ["PKR", "GENE_OR_GENE_PRODUCT", 188, 191], ["VHS", "GENE_OR_GENE_PRODUCT", 270, 273], ["HSV-1 ICP27", "PROTEIN", 13, 24], ["PKR", "PROTEIN", 34, 37], ["eIF2\u03b1", "PROTEIN", 111, 116], ["PKR", "PROTEIN", 188, 191], ["host mRNA", "RNA", 215, 224], ["textIn vitro-translated VHS", "PROTEIN", 246, 273], ["endonuclease", "PROTEIN", 283, 295], ["HSV-1", "SPECIES", 13, 18], ["HSV", "TEST", 13, 16], ["PKR binding", "PROBLEM", 34, 45], ["dsRNA", "PROBLEM", 49, 54], ["its autophosphorylation", "PROBLEM", 59, 82], ["eIF2\u03b1 phosphorylation", "TREATMENT", 111, 132], ["conformational changes in PKR", "PROBLEM", 162, 191], ["Main textIn vitro", "TREATMENT", 241, 258], ["no", "UNCERTAINTY", 91, 93], ["host mRNA", "OBSERVATION", 215, 224], ["endonuclease activity", "OBSERVATION", 283, 304]]], ["Nevertheless, VHS shows a strong preference for mRNAs in vivo [46], degrading the 5\u2032 end of mRNAs prior to the 3\u2032 end, and is targeted to regions of translation initiation through its interaction with eIF4H [47].", [["VHS", "GENE_OR_GENE_PRODUCT", 14, 17], ["VHS", "PROTEIN", 14, 17], ["mRNAs", "RNA", 48, 53], ["5\u2032 end", "RNA", 82, 88], ["mRNAs", "RNA", 92, 97], ["3\u2032 end", "DNA", 111, 117], ["eIF4H", "PROTEIN", 201, 206], ["VHS", "TEST", 14, 17]]], ["Interestingly, several VHS mutations that abrogate its ability to bind eIF4H also abolish its mRNA-degrading activity, even though the mutant proteins retain endonuclease activity.", [["VHS", "GENE_OR_GENE_PRODUCT", 23, 26], ["eIF4H", "GENE_OR_GENE_PRODUCT", 71, 76], ["VHS", "PROTEIN", 23, 26], ["eIF4H", "PROTEIN", 71, 76], ["mutant proteins", "PROTEIN", 135, 150], ["endonuclease", "PROTEIN", 158, 170], ["several VHS mutations", "PROBLEM", 15, 36]]], ["Interestingly, several point mutations that abolish its mRNA-degrading activity also abrogate its ability to bind eIF4H, the depletion of which impedes VHS-mediated degradation [48].", [["eIF4H", "GENE_OR_GENE_PRODUCT", 114, 119], ["VHS", "GENE_OR_GENE_PRODUCT", 152, 155], ["eIF4H", "PROTEIN", 114, 119], ["VHS", "PROTEIN", 152, 155], ["several point mutations", "PROBLEM", 15, 38], ["its mRNA", "PROBLEM", 52, 60]]], ["Furthermore, eIF4H switches from cytoplasmic to nuclear localization during the initial shutdown of translation after viral infection [49].", [["cytoplasmic", "ANATOMY", 33, 44], ["nuclear", "ANATOMY", 48, 55], ["viral infection", "DISEASE", 118, 133], ["eIF4H", "GENE_OR_GENE_PRODUCT", 13, 18], ["cytoplasmic", "ORGANISM_SUBSTANCE", 33, 44], ["nuclear", "CELLULAR_COMPONENT", 48, 55], ["eIF4H", "PROTEIN", 13, 18], ["viral infection", "PROBLEM", 118, 133], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["infection", "OBSERVATION", 124, 133]]], ["However, the interaction between VHS and eIF4B or eIF4F is not sufficient to induce mRNA decay [50].", [["VHS", "GENE_OR_GENE_PRODUCT", 33, 36], ["eIF4B", "GENE_OR_GENE_PRODUCT", 41, 46], ["eIF4F", "GENE_OR_GENE_PRODUCT", 50, 55], ["VHS", "PROTEIN", 33, 36], ["eIF4B", "PROTEIN", 41, 46], ["eIF4F", "PROTEIN", 50, 55], ["VHS", "TEST", 33, 36]]], ["Alternatively, the targeting of VHS may depend upon its ability to interact with translation factors, whether the preferred cleavage sites are in regions of translation initiation or not [51].", [["VHS", "GENE_OR_GENE_PRODUCT", 32, 35], ["VHS", "PROTEIN", 32, 35], ["translation factors", "PROTEIN", 81, 100], ["VHS", "PROBLEM", 32, 35], ["translation factors", "TREATMENT", 81, 100], ["the preferred cleavage sites", "PROBLEM", 110, 138]]], ["However, VHS cleaves mRNAs close to AU-rich elements (AREs) in their 3\u2032 UTRs by interacting with tristetraprolin (TTP) [52].", [["tristetraprolin", "CHEMICAL", 97, 112], ["tristetraprolin", "CHEMICAL", 97, 112], ["TTP", "CHEMICAL", 114, 117], ["VHS", "GENE_OR_GENE_PRODUCT", 9, 12], ["tristetraprolin", "SIMPLE_CHEMICAL", 97, 112], ["TTP", "SIMPLE_CHEMICAL", 114, 117], ["VHS", "PROTEIN", 9, 12], ["mRNAs", "RNA", 21, 26], ["AU-rich elements", "DNA", 36, 52], ["AREs", "DNA", 54, 58], ["UTRs", "DNA", 72, 76], ["TTP", "PROTEIN", 114, 117]]], ["The internal ribosome entry site (IRES) derived from encephalomyocarditis virus (EMCV) or poliovirus acts to strongly target VHS-dependent RNA cleavage events to a narrow zone located immediately 3\u2032 to the IRES [53].", [["ribosome", "ANATOMY", 13, 21], ["encephalomyocarditis virus", "ORGANISM", 53, 79], ["EMCV", "ORGANISM", 81, 85], ["poliovirus", "ORGANISM", 90, 100], ["VHS", "GENE_OR_GENE_PRODUCT", 125, 128], ["internal ribosome entry site", "DNA", 4, 32], ["IRES", "DNA", 34, 38], ["VHS", "PROTEIN", 125, 128], ["IRES", "DNA", 206, 210], ["encephalomyocarditis virus", "SPECIES", 53, 79], ["encephalomyocarditis virus", "SPECIES", 53, 79], ["EMCV", "SPECIES", 81, 85], ["poliovirus", "SPECIES", 90, 100], ["The internal ribosome entry site", "PROBLEM", 0, 32], ["encephalomyocarditis virus", "PROBLEM", 53, 79], ["EMCV", "PROBLEM", 81, 85], ["poliovirus acts", "PROBLEM", 90, 105], ["dependent RNA cleavage events", "PROBLEM", 129, 158], ["internal", "OBSERVATION_MODIFIER", 4, 12], ["ribosome", "OBSERVATION", 13, 21], ["entry site", "OBSERVATION", 22, 32], ["encephalomyocarditis virus", "OBSERVATION", 53, 79], ["RNA cleavage", "OBSERVATION", 139, 151]]], ["These two degradation models require neither ribosome scanning nor interaction with translation initiation factors to select the cleavage sites.", [["translation initiation factors", "PROTEIN", 84, 114], ["cleavage sites", "PROTEIN", 129, 143], ["ribosome scanning", "TEST", 45, 62], ["translation initiation factors", "TREATMENT", 84, 114], ["the cleavage sites", "PROBLEM", 125, 143]]], ["Unlike VHS, SOX has no interaction with eIF4H and cosediments with 40S ribosomal subunits, depletes polysomes, and specifically recognizes mRNAs at an early stage of translation, although the factor(s) involved SOX recruitment to its mRNA targets remain unknown [32].", [["polysomes", "ANATOMY", 100, 109], ["VHS", "GENE_OR_GENE_PRODUCT", 7, 10], ["SOX", "GENE_OR_GENE_PRODUCT", 12, 15], ["eIF4H", "GENE_OR_GENE_PRODUCT", 40, 45], ["40S ribosomal subunits", "GENE_OR_GENE_PRODUCT", 67, 89], ["polysomes", "CELLULAR_COMPONENT", 100, 109], ["SOX", "GENE_OR_GENE_PRODUCT", 211, 214], ["VHS", "PROTEIN", 7, 10], ["SOX", "PROTEIN", 12, 15], ["eIF4H", "PROTEIN", 40, 45], ["40S ribosomal subunits", "PROTEIN", 67, 89], ["mRNAs", "RNA", 139, 144], ["SOX", "PROTEIN", 211, 214], ["cosediments", "TREATMENT", 50, 61], ["40S ribosomal subunits", "TREATMENT", 67, 89], ["depletes polysomes", "PROBLEM", 91, 109], ["SOX recruitment", "TREATMENT", 211, 226], ["depletes polysomes", "OBSERVATION", 91, 109]]], ["During MHV68 infection, because the translation factors are unlimited, the targeting of viral mRNAs during gammaherpesvirus infection is not a mechanism to redirect the translation machinery towards host genes [34].Downregulation of host mRNA translation ::: Main textCytoplasmic poly (A)-binding protein (PABPC) is a predominantly cytoplasmic protein that is required for efficient translation initiation and binds to mRNA poly(A) tails to enhance mRNA stability, translation efficiency, and quality control in the cytoplasm, in part through its interactions with the eIF4G translation initiation factor [54].", [["cytoplasmic", "ANATOMY", 332, 343], ["cytoplasm", "ANATOMY", 516, 525], ["infection", "DISEASE", 13, 22], ["gammaherpesvirus infection", "DISEASE", 107, 133], ["MHV68", "GENE_OR_GENE_PRODUCT", 7, 12], ["gammaherpesvirus", "ORGANISM", 107, 123], ["textCytoplasmic poly (A)-binding protein", "GENE_OR_GENE_PRODUCT", 264, 304], ["PABPC", "GENE_OR_GENE_PRODUCT", 306, 311], ["cytoplasmic", "ORGANISM_SUBSTANCE", 332, 343], ["poly(A) tails", "GENE_OR_GENE_PRODUCT", 424, 437], ["cytoplasm", "ORGANISM_SUBSTANCE", 516, 525], ["eIF4G", "GENE_OR_GENE_PRODUCT", 569, 574], ["translation factors", "PROTEIN", 36, 55], ["viral mRNAs", "RNA", 88, 99], ["host genes", "DNA", 199, 209], ["host mRNA", "RNA", 233, 242], ["textCytoplasmic poly (A)-binding protein", "PROTEIN", 264, 304], ["PABPC", "PROTEIN", 306, 311], ["cytoplasmic protein", "PROTEIN", 332, 351], ["mRNA poly(A) tails", "PROTEIN", 419, 437], ["eIF4G translation initiation factor", "PROTEIN", 569, 604], ["MHV68 infection", "PROBLEM", 7, 22], ["the translation factors", "PROBLEM", 32, 55], ["viral mRNAs during gammaherpesvirus infection", "PROBLEM", 88, 133], ["Main textCytoplasmic poly", "TEST", 259, 284], ["a predominantly cytoplasmic protein", "PROBLEM", 316, 351], ["mRNA poly(A) tails", "TREATMENT", 419, 437], ["mRNA stability", "TEST", 449, 463], ["translation efficiency", "PROBLEM", 465, 487], ["infection", "OBSERVATION", 13, 22], ["viral mRNAs", "OBSERVATION", 88, 99], ["gammaherpesvirus infection", "OBSERVATION", 107, 133], ["host mRNA", "OBSERVATION", 233, 242], ["predominantly", "OBSERVATION_MODIFIER", 318, 331], ["cytoplasmic protein", "OBSERVATION", 332, 351]]], ["During lytic HSV-1 infection, VHS, ICP27 and other viral proteins induce the translocation of PABPC from the cytoplasm to the nucleus [55\u201357].", [["cytoplasm", "ANATOMY", 109, 118], ["nucleus", "ANATOMY", 126, 133], ["infection", "DISEASE", 19, 28], ["HSV-1", "ORGANISM", 13, 18], ["VHS", "GENE_OR_GENE_PRODUCT", 30, 33], ["ICP27", "GENE_OR_GENE_PRODUCT", 35, 40], ["PABPC", "GENE_OR_GENE_PRODUCT", 94, 99], ["cytoplasm", "ORGANISM_SUBSTANCE", 109, 118], ["nucleus", "CELLULAR_COMPONENT", 126, 133], ["VHS", "PROTEIN", 30, 33], ["ICP27", "PROTEIN", 35, 40], ["viral proteins", "PROTEIN", 51, 65], ["PABPC", "PROTEIN", 94, 99], ["HSV-1", "SPECIES", 13, 18], ["HSV-1", "SPECIES", 13, 18], ["lytic HSV", "PROBLEM", 7, 16], ["1 infection", "PROBLEM", 17, 28], ["VHS", "PROBLEM", 30, 33], ["ICP27", "TEST", 35, 40], ["other viral proteins", "PROBLEM", 45, 65], ["the translocation of PABPC", "PROBLEM", 73, 99], ["lytic", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 19, 28], ["nucleus", "ANATOMY", 126, 133]]], ["In addition, ICP27 associates with PABP and eIF4G to promote translation initiation [58].", [["ICP27", "GENE_OR_GENE_PRODUCT", 13, 18], ["PABP", "GENE_OR_GENE_PRODUCT", 35, 39], ["eIF4G", "GENE_OR_GENE_PRODUCT", 44, 49], ["ICP27", "PROTEIN", 13, 18], ["PABP", "PROTEIN", 35, 39], ["eIF4G", "PROTEIN", 44, 49], ["PABP", "TREATMENT", 35, 39], ["eIF4G", "TREATMENT", 44, 49]]], ["SOX and its homologs also relocalize PABPC into the nucleus [30, 57, 59, 60], where intranuclear PABPC accumulation leads to excessive nuclear mRNAs and a block in the nuclear export of mRNAs, resulting in restricted protein expression [57].Boosting the expression of viral proteins ::: Main textVHS directly or indirectly enhances the translation of viral mRNAs.", [["nucleus", "ANATOMY", 52, 59], ["intranuclear", "ANATOMY", 84, 96], ["nuclear", "ANATOMY", 135, 142], ["nuclear", "ANATOMY", 168, 175], ["SOX", "GENE_OR_GENE_PRODUCT", 0, 3], ["PABPC", "GENE_OR_GENE_PRODUCT", 37, 42], ["nucleus", "CELLULAR_COMPONENT", 52, 59], ["PABPC", "GENE_OR_GENE_PRODUCT", 97, 102], ["nuclear", "CELLULAR_COMPONENT", 135, 142], ["nuclear", "CELLULAR_COMPONENT", 168, 175], ["textVHS", "GENE_OR_GENE_PRODUCT", 292, 299], ["SOX", "PROTEIN", 0, 3], ["PABPC", "PROTEIN", 37, 42], ["PABPC", "PROTEIN", 97, 102], ["nuclear mRNAs", "RNA", 135, 148], ["mRNAs", "RNA", 186, 191], ["viral proteins", "PROTEIN", 268, 282], ["textVHS", "PROTEIN", 292, 299], ["viral mRNAs", "RNA", 351, 362], ["intranuclear PABPC accumulation", "PROBLEM", 84, 115], ["excessive nuclear mRNAs", "PROBLEM", 125, 148], ["a block", "PROBLEM", 153, 160], ["restricted protein expression", "PROBLEM", 206, 235], ["viral mRNAs", "PROBLEM", 351, 362], ["nucleus", "ANATOMY", 52, 59], ["excessive", "OBSERVATION_MODIFIER", 125, 134], ["nuclear mRNAs", "OBSERVATION", 135, 148], ["protein expression", "OBSERVATION", 217, 235], ["viral proteins", "OBSERVATION", 268, 282], ["viral mRNAs", "OBSERVATION", 351, 362]]], ["VHS boosts the translation of viral true late mRNAs in a cell type-dependent manner and then determines the viral growth phenotype in the respective cell type, such as Hela cells [61, 62].", [["cell", "ANATOMY", 57, 61], ["cell type", "ANATOMY", 149, 158], ["Hela cells", "ANATOMY", 168, 178], ["VHS", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 57, 61], ["cell type", "CELL", 149, 158], ["Hela cells", "CELL", 168, 178], ["VHS", "PROTEIN", 0, 3], ["viral true late mRNAs", "RNA", 30, 51], ["Hela cells", "CELL_LINE", 168, 178], ["VHS", "PROBLEM", 0, 3], ["viral true late mRNAs", "PROBLEM", 30, 51], ["the viral growth phenotype", "PROBLEM", 104, 130], ["viral true", "OBSERVATION", 30, 40], ["late mRNAs", "OBSERVATION", 41, 51], ["viral growth phenotype", "OBSERVATION", 108, 130], ["respective cell type", "OBSERVATION", 138, 158]]], ["First, VHS refines the transition between the successive expression of viral IE, E, and late (L) genes to facilitate the turnover of all kinetic classes of viral mRNAs [63], preventing \u201cmRNA overload\u201d during the late stages of infection by eliminating host mRNAs and promoting the decay of viral IE and E transcripts [64].", [["infection", "DISEASE", 227, 236], ["VHS", "GENE_OR_GENE_PRODUCT", 7, 10], ["E", "GENE_OR_GENE_PRODUCT", 81, 82], ["late (L)", "GENE_OR_GENE_PRODUCT", 88, 96], ["VHS", "PROTEIN", 7, 10], ["viral IE, E, and late (L) genes", "DNA", 71, 102], ["viral mRNAs", "RNA", 156, 167], ["host mRNAs", "RNA", 252, 262], ["viral IE and E transcripts", "RNA", 290, 316], ["late (L) genes", "TREATMENT", 88, 102], ["viral mRNAs", "PROBLEM", 156, 167], ["mRNA overload", "PROBLEM", 186, 199], ["infection", "PROBLEM", 227, 236], ["viral IE", "TREATMENT", 290, 298], ["viral", "OBSERVATION", 71, 76], ["overload", "OBSERVATION", 191, 199], ["late stages", "OBSERVATION_MODIFIER", 212, 223], ["infection", "OBSERVATION", 227, 236]]], ["In the absence of VHS, the half-lives of all classes of viral transcripts are dramatically increased, and the resulting accumulation of viral mRNAs overwhelms the capacity of the host translational machinery, leading to functional deficiency of the L mRNAs that are made during infection.", [["infection", "DISEASE", 278, 287], ["VHS", "GENE_OR_GENE_PRODUCT", 18, 21], ["VHS", "PROTEIN", 18, 21], ["viral transcripts", "RNA", 56, 73], ["viral mRNAs", "RNA", 136, 147], ["L mRNAs", "RNA", 249, 256], ["VHS", "PROBLEM", 18, 21], ["viral transcripts", "TREATMENT", 56, 73], ["viral mRNAs", "PROBLEM", 136, 147], ["functional deficiency of the L mRNAs", "PROBLEM", 220, 256], ["infection", "PROBLEM", 278, 287], ["viral transcripts", "OBSERVATION", 56, 73], ["dramatically", "OBSERVATION_MODIFIER", 78, 90], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["accumulation", "OBSERVATION_MODIFIER", 120, 132], ["viral mRNAs", "OBSERVATION", 136, 147], ["functional deficiency", "OBSERVATION", 220, 241], ["infection", "OBSERVATION", 278, 287]]], ["Second, recent reports have shown that the translational defect observed for L mRNAs in the absence of VHS does not stem from one or more structural features of the affected mRNAs, since these transcripts accumulate late during infection [64].", [["infection", "DISEASE", 228, 237], ["VHS", "GENE_OR_GENE_PRODUCT", 103, 106], ["L mRNAs", "RNA", 77, 84], ["VHS", "PROTEIN", 103, 106], ["affected mRNAs", "RNA", 165, 179], ["the translational defect", "PROBLEM", 39, 63], ["L mRNAs", "PROBLEM", 77, 84], ["VHS", "PROBLEM", 103, 106], ["the affected mRNAs", "PROBLEM", 161, 179], ["infection", "PROBLEM", 228, 237], ["defect", "OBSERVATION", 57, 63]]], ["Third, VHS is more sensitive to unspliced mRNAs than spliced mRNAs, and exon junction complexes (EJCs) may transiently protect spliced mRNAs from VHS degradation, causing a modest stimulation in translation and accumulation of spliced mRNA [65].", [["VHS", "GENE_OR_GENE_PRODUCT", 7, 10], ["exon junction complexes", "GENE_OR_GENE_PRODUCT", 72, 95], ["VHS", "GENE_OR_GENE_PRODUCT", 146, 149], ["VHS", "PROTEIN", 7, 10], ["unspliced mRNAs", "RNA", 32, 47], ["spliced mRNAs", "RNA", 53, 66], ["exon junction complexes", "PROTEIN", 72, 95], ["EJCs", "PROTEIN", 97, 101], ["spliced mRNAs", "RNA", 127, 140], ["VHS", "PROTEIN", 146, 149], ["spliced mRNA", "RNA", 227, 239], ["unspliced mRNAs than spliced mRNAs", "PROBLEM", 32, 66], ["exon junction complexes", "PROBLEM", 72, 95], ["VHS degradation", "PROBLEM", 146, 161], ["a modest stimulation in translation", "PROBLEM", 171, 206], ["spliced mRNA", "PROBLEM", 227, 239], ["spliced mRNAs", "OBSERVATION", 127, 140]]], ["Thus, VHS may also enhance the expression of these viral genes depending on other functions.Boosting the expression of viral proteins ::: Main textTo avoid multiple viral mRNAs being degraded by VHS at later times of infection in an unrestrained fashion, the viral proteins ICP27, VP13/14, VP16 or VP22 interact with and attenuate VHS RNase activity [66, 67].", [["infection", "DISEASE", 217, 226], ["VHS", "GENE_OR_GENE_PRODUCT", 6, 9], ["VHS", "GENE_OR_GENE_PRODUCT", 195, 198], ["ICP27", "GENE_OR_GENE_PRODUCT", 274, 279], ["VP13/14", "GENE_OR_GENE_PRODUCT", 281, 288], ["VP16", "GENE_OR_GENE_PRODUCT", 290, 294], ["VP22", "GENE_OR_GENE_PRODUCT", 298, 302], ["VHS RNase", "GENE_OR_GENE_PRODUCT", 331, 340], ["VHS", "PROTEIN", 6, 9], ["viral genes", "DNA", 51, 62], ["viral proteins", "PROTEIN", 119, 133], ["viral mRNAs", "RNA", 165, 176], ["VHS", "PROTEIN", 195, 198], ["viral proteins", "PROTEIN", 259, 273], ["ICP27", "PROTEIN", 274, 279], ["VP13", "PROTEIN", 281, 285], ["/14", "PROTEIN", 285, 288], ["VP16", "PROTEIN", 290, 294], ["VP22", "PROTEIN", 298, 302], ["VHS", "PROTEIN", 331, 334], ["RNase", "PROTEIN", 335, 340], ["VHS", "PROBLEM", 6, 9], ["these viral genes", "PROBLEM", 45, 62], ["multiple viral mRNAs", "PROBLEM", 156, 176], ["VHS", "PROBLEM", 195, 198], ["infection", "PROBLEM", 217, 226], ["the viral proteins ICP27", "TEST", 255, 279], ["VP13", "TEST", 281, 285], ["VP16", "TEST", 290, 294], ["viral genes", "OBSERVATION", 51, 62], ["viral proteins", "OBSERVATION", 119, 133], ["multiple", "OBSERVATION_MODIFIER", 156, 164], ["viral mRNAs", "OBSERVATION", 165, 176], ["infection", "OBSERVATION", 217, 226]]], ["Furthermore, the VP16-VP22 complex rescues the nuclear retention of VHS mRNA and the VHS-induced nuclear retention of late transcripts during HSV-1 infection, allowing for their efficient translation [67, 68].", [["nuclear", "ANATOMY", 47, 54], ["nuclear", "ANATOMY", 97, 104], ["infection", "DISEASE", 148, 157], ["VP16", "GENE_OR_GENE_PRODUCT", 17, 21], ["VP22", "GENE_OR_GENE_PRODUCT", 22, 26], ["nuclear", "CELLULAR_COMPONENT", 47, 54], ["VHS", "GENE_OR_GENE_PRODUCT", 68, 71], ["VHS", "GENE_OR_GENE_PRODUCT", 85, 88], ["nuclear", "CELLULAR_COMPONENT", 97, 104], ["HSV-1", "ORGANISM", 142, 147], ["VP16", "PROTEIN", 17, 21], ["VP22 complex", "PROTEIN", 22, 34], ["VHS mRNA", "RNA", 68, 76], ["VHS", "PROTEIN", 85, 88], ["HSV-1", "SPECIES", 142, 147], ["HSV-1", "SPECIES", 142, 147], ["the VP16", "TEST", 13, 21], ["VHS mRNA", "PROBLEM", 68, 76], ["the VHS", "PROBLEM", 81, 88], ["late transcripts", "PROBLEM", 118, 134], ["HSV", "PROBLEM", 142, 145], ["1 infection", "PROBLEM", 146, 157], ["nuclear retention", "OBSERVATION", 47, 64], ["nuclear retention", "OBSERVATION", 97, 114], ["infection", "OBSERVATION", 148, 157]]], ["VP13/14 stabilizes host and viral IE mRNAs and effectively blocks the degradation of E and L mRNAs, but it has no effect on the processing of AU-rich mRNAs [66, 69].", [["VP13", "GENE_OR_GENE_PRODUCT", 0, 4], ["E", "GENE_OR_GENE_PRODUCT", 85, 86], ["VP13/14", "PROTEIN", 0, 7], ["host and viral IE mRNAs", "RNA", 19, 42], ["E and L mRNAs", "RNA", 85, 98], ["AU-rich mRNAs", "RNA", 142, 155], ["VP13", "TEST", 0, 4], ["viral IE mRNAs", "PROBLEM", 28, 42], ["E and L mRNAs", "TREATMENT", 85, 98]]], ["ICP27 also interacts with VHS, which may impact the stability of ARE-containing mRNAs, although this function remains controversial [70].", [["ICP27", "GENE_OR_GENE_PRODUCT", 0, 5], ["VHS", "GENE_OR_GENE_PRODUCT", 26, 29], ["ARE", "GENE_OR_GENE_PRODUCT", 65, 68], ["ICP27", "PROTEIN", 0, 5], ["VHS", "PROTEIN", 26, 29], ["ARE-containing mRNAs", "RNA", 65, 85], ["VHS", "TREATMENT", 26, 29], ["this function", "TEST", 96, 109], ["with VHS", "OBSERVATION_MODIFIER", 21, 29]]], ["ICP27 and VP13/14 as nucleocytoplasmic shuttling proteins that can bind and transport RNA [71, 72], we speculate there are unknown associations between VHS, mRNA, VP13/14 and ICP27.", [["ICP27", "GENE_OR_GENE_PRODUCT", 0, 5], ["VP13/14", "GENE_OR_GENE_PRODUCT", 10, 17], ["VHS", "GENE_OR_GENE_PRODUCT", 152, 155], ["VP13/14", "GENE_OR_GENE_PRODUCT", 163, 170], ["ICP27", "GENE_OR_GENE_PRODUCT", 175, 180], ["ICP27", "PROTEIN", 0, 5], ["VP13", "PROTEIN", 10, 14], ["/14", "PROTEIN", 14, 17], ["nucleocytoplasmic shuttling proteins", "PROTEIN", 21, 57], ["VHS", "PROTEIN", 152, 155], ["mRNA", "RNA", 157, 161], ["VP13", "PROTEIN", 163, 167], ["/14", "PROTEIN", 167, 170], ["ICP27", "PROTEIN", 175, 180], ["ICP27", "TEST", 0, 5], ["VP13", "TEST", 10, 14], ["nucleocytoplasmic shuttling proteins", "PROBLEM", 21, 57], ["transport RNA", "TEST", 76, 89], ["mRNA", "TEST", 157, 161], ["VP13", "TEST", 163, 167], ["ICP27", "TREATMENT", 175, 180], ["shuttling proteins", "OBSERVATION", 39, 57]]], ["And these interactions may also facilitate incorporation of VHS into the tegument of progeny virions.", [["tegument", "ANATOMY", 73, 81], ["virions", "ANATOMY", 93, 100], ["VHS", "GENE_OR_GENE_PRODUCT", 60, 63], ["tegument", "CELLULAR_COMPONENT", 73, 81], ["VHS", "PROTEIN", 60, 63], ["VHS", "TREATMENT", 60, 63], ["progeny virions", "OBSERVATION", 85, 100]]], ["Unlike alphaherpesviruses, there are few reports regarding other viral proteins that regulate host shutoff-associated activity in gammaherpesviruses, with the exception of the EBV protein kinase BGLF4 that antagonizes BGLF5-mediated viral gene shutoff [73].", [["gammaherpesviruses", "CANCER", 130, 148], ["EBV", "ORGANISM", 176, 179], ["BGLF4", "GENE_OR_GENE_PRODUCT", 195, 200], ["BGLF5", "GENE_OR_GENE_PRODUCT", 218, 223], ["viral proteins", "PROTEIN", 65, 79], ["EBV protein kinase", "PROTEIN", 176, 194], ["BGLF4", "PROTEIN", 195, 200], ["BGLF5", "PROTEIN", 218, 223], ["viral gene", "DNA", 233, 243], ["Unlike alphaherpesviruses", "PROBLEM", 0, 25], ["other viral proteins", "PROBLEM", 59, 79], ["host shutoff", "PROBLEM", 94, 106], ["associated activity in gammaherpesviruses", "PROBLEM", 107, 148], ["the EBV protein kinase", "TEST", 172, 194], ["BGLF5", "TEST", 218, 223], ["alphaherpesviruses", "OBSERVATION", 7, 25], ["host shutoff", "OBSERVATION", 94, 106]]], ["Thus, it is necessary to continue exploring the viral proteins regulate SOX or muSOX activity after gammaherpesvirus infection.Boosting the expression of viral proteins ::: Main textIn addition, ICP27 facilitates viral RNA export by recruiting mRNA export adaptors to viral replication sites and binding intronless viral mRNAs through its RGG domain [22, 74\u201378].", [["gammaherpesvirus infection", "DISEASE", 100, 126], ["SOX", "GENE_OR_GENE_PRODUCT", 72, 75], ["muSOX", "GENE_OR_GENE_PRODUCT", 79, 84], ["gammaherpesvirus", "ORGANISM", 100, 116], ["ICP27", "GENE_OR_GENE_PRODUCT", 195, 200], ["viral proteins", "PROTEIN", 48, 62], ["SOX", "PROTEIN", 72, 75], ["muSOX", "PROTEIN", 79, 84], ["viral proteins", "PROTEIN", 154, 168], ["ICP27", "PROTEIN", 195, 200], ["mRNA", "RNA", 244, 248], ["viral replication sites", "DNA", 268, 291], ["binding intronless viral mRNAs", "RNA", 296, 326], ["RGG domain", "PROTEIN", 339, 349], ["the viral proteins", "TREATMENT", 44, 62], ["muSOX activity", "PROBLEM", 79, 93], ["gammaherpesvirus infection", "PROBLEM", 100, 126], ["viral RNA export", "TREATMENT", 213, 229], ["mRNA export adaptors", "TREATMENT", 244, 264], ["viral replication sites", "TREATMENT", 268, 291], ["binding intronless viral mRNAs", "PROBLEM", 296, 326], ["gammaherpesvirus infection", "OBSERVATION", 100, 126], ["viral proteins", "OBSERVATION", 154, 168], ["viral RNA", "OBSERVATION", 213, 222], ["viral replication", "OBSERVATION", 268, 285]]], ["ICP27 promotes expression of the full-length gC protein and tightly regulates the expression of HSV-2 monocistronic ICP34.5 mRNA by inhibiting splicing and activating a cryptic polyadenylation signal (PAS) in new introns [23].", [["ICP27", "GENE_OR_GENE_PRODUCT", 0, 5], ["gC", "GENE_OR_GENE_PRODUCT", 45, 47], ["HSV-2", "GENE_OR_GENE_PRODUCT", 96, 101], ["ICP34.5", "GENE_OR_GENE_PRODUCT", 116, 123], ["ICP27", "PROTEIN", 0, 5], ["gC protein", "PROTEIN", 45, 55], ["HSV-2 monocistronic ICP34.5 mRNA", "RNA", 96, 128], ["introns", "DNA", 213, 220], ["HSV", "PROBLEM", 96, 99], ["a cryptic polyadenylation signal", "PROBLEM", 167, 199]]], ["The PRV UL54 protein is a homolog of HSV-1 ICP27 and has a drastic impact of the genome-wide expression of PRV genes, especially on the transcription of the true late genes [79].", [["PRV", "ORGANISM", 4, 7], ["UL54", "GENE_OR_GENE_PRODUCT", 8, 12], ["HSV-1", "ORGANISM", 37, 42], ["ICP27", "GENE_OR_GENE_PRODUCT", 43, 48], ["PRV", "ORGANISM", 107, 110], ["PRV UL54 protein", "PROTEIN", 4, 20], ["HSV-1 ICP27", "PROTEIN", 37, 48], ["PRV genes", "DNA", 107, 116], ["PRV", "SPECIES", 4, 7], ["HSV-1", "SPECIES", 37, 42], ["PRV", "SPECIES", 107, 110], ["HSV", "TEST", 37, 40], ["drastic", "OBSERVATION_MODIFIER", 59, 66], ["PRV genes", "OBSERVATION", 107, 116]]], ["These studies have provided insights into the crucial role of ICP27 and its homologs in selectively regulating viral mRNA nuclear export to favor viral RNA transcription and protein translation.Immune evasion ::: Main textThe detection of microbial pathogens is an essential first step in mounting an innate immune response to infection.", [["nuclear", "ANATOMY", 122, 129], ["infection", "DISEASE", 327, 336], ["ICP27", "GENE_OR_GENE_PRODUCT", 62, 67], ["nuclear", "CELLULAR_COMPONENT", 122, 129], ["ICP27", "PROTEIN", 62, 67], ["viral mRNA", "RNA", 111, 121], ["These studies", "TEST", 0, 13], ["ICP27", "TREATMENT", 62, 67], ["viral RNA transcription", "TREATMENT", 146, 169], ["microbial pathogens", "PROBLEM", 239, 258], ["infection", "PROBLEM", 327, 336], ["viral mRNA", "OBSERVATION", 111, 121], ["microbial pathogens", "OBSERVATION", 239, 258], ["infection", "OBSERVATION", 327, 336]]], ["Pattern recognition receptors (PRRs) recognize pathogen-associated molecular patterns (PAMPs) and trigger the production of numerous host defense molecules, including interferons (IFNs), proinflammatory cytokines and chemokines [80].", [["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 0, 29], ["PRRs", "GENE_OR_GENE_PRODUCT", 31, 35], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 47, 85], ["interferons", "GENE_OR_GENE_PRODUCT", 167, 178], ["IFNs", "GENE_OR_GENE_PRODUCT", 180, 184], ["Pattern recognition receptors", "PROTEIN", 0, 29], ["PRRs", "PROTEIN", 31, 35], ["pathogen-associated molecular patterns", "PROTEIN", 47, 85], ["PAMPs", "PROTEIN", 87, 92], ["host defense molecules", "PROTEIN", 133, 155], ["interferons", "PROTEIN", 167, 178], ["IFNs", "PROTEIN", 180, 184], ["proinflammatory cytokines", "PROTEIN", 187, 212], ["chemokines", "PROTEIN", 217, 227], ["pathogen", "PROBLEM", 47, 55], ["numerous host defense molecules", "PROBLEM", 124, 155], ["interferons (IFNs)", "TREATMENT", 167, 185], ["proinflammatory cytokines", "TREATMENT", 187, 212], ["host defense", "OBSERVATION_MODIFIER", 133, 145]]], ["In addition, IFNs can be classified into three groups (types I, II and III), where IFN-I (IFN-\u03b1/\u03b2) and III are crucial antiviral factors that stimulate the synthesis of a variety of antiviral effector molecules [81].", [["IFNs", "GENE_OR_GENE_PRODUCT", 13, 17], ["IFN-I", "GENE_OR_GENE_PRODUCT", 83, 88], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 90, 95], ["\u03b2", "GENE_OR_GENE_PRODUCT", 96, 97], ["III", "GENE_OR_GENE_PRODUCT", 103, 106], ["IFNs", "PROTEIN", 13, 17], ["IFN", "PROTEIN", 83, 86], ["IFN", "PROTEIN", 90, 93], ["\u03b1", "PROTEIN", 94, 95], ["\u03b2", "PROTEIN", 96, 97], ["III", "PROTEIN", 103, 106], ["antiviral factors", "PROTEIN", 119, 136], ["antiviral effector molecules", "PROTEIN", 182, 210], ["IFN", "TEST", 83, 86], ["IFN", "TEST", 90, 93], ["crucial antiviral factors", "PROBLEM", 111, 136], ["antiviral effector molecules", "TREATMENT", 182, 210], ["antiviral factors", "OBSERVATION", 119, 136]]], ["A number of innate immune mechanisms are invoked following infection, and herpesviruses in turn takes different measures to neutralize these host responses, with host shutoff proteins playing crucial roles in escaping innate immune.VHS as an IFN-\u03b1/\u03b2 resistance factor ::: Main textVHS has been identified as an IFN-\u03b1/\u03b2 resistance factor that is essential for viral survival.", [["infection", "DISEASE", 59, 68], ["VHS", "GENE_OR_GENE_PRODUCT", 232, 235], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 242, 247], ["\u03b2", "GENE_OR_GENE_PRODUCT", 248, 249], ["textVHS", "GENE_OR_GENE_PRODUCT", 277, 284], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 311, 316], ["\u03b2", "GENE_OR_GENE_PRODUCT", 317, 318], ["shutoff proteins", "PROTEIN", 167, 183], ["VHS", "PROTEIN", 232, 235], ["IFN", "PROTEIN", 242, 245], ["\u03b1", "PROTEIN", 246, 247], ["\u03b2 resistance factor", "PROTEIN", 248, 267], ["textVHS", "PROTEIN", 277, 284], ["IFN", "PROTEIN", 311, 314], ["\u03b1", "PROTEIN", 315, 316], ["\u03b2 resistance factor", "PROTEIN", 317, 336], ["infection", "PROBLEM", 59, 68], ["herpesviruses", "PROBLEM", 74, 87], ["different measures", "TREATMENT", 102, 120], ["host shutoff proteins", "TREATMENT", 162, 183], ["VHS", "TEST", 232, 235], ["an IFN", "TEST", 239, 245], ["an IFN", "TEST", 308, 314], ["\u03b2 resistance factor", "PROBLEM", 317, 336], ["viral survival", "PROBLEM", 359, 373], ["innate immune", "OBSERVATION_MODIFIER", 12, 25], ["infection", "OBSERVATION", 59, 68], ["escaping innate immune", "OBSERVATION", 209, 231]]], ["Primary murine embryonic fibroblasts (MEFs) infected with HSV-2 \u0394VHS mutants were observed to produce > 50-fold more IFN-a/\u03b2 than cells infected with wild-type and VHS-rescued viruses.", [["embryonic fibroblasts", "ANATOMY", 15, 36], ["MEFs", "ANATOMY", 38, 42], ["cells", "ANATOMY", 130, 135], ["murine", "ORGANISM", 8, 14], ["embryonic fibroblasts", "CELL", 15, 36], ["MEFs", "CELL", 38, 42], ["HSV-2 \u0394VHS", "ORGANISM", 58, 68], ["IFN-a", "GENE_OR_GENE_PRODUCT", 117, 122], ["\u03b2", "GENE_OR_GENE_PRODUCT", 123, 124], ["cells", "CELL", 130, 135], ["VHS", "GENE_OR_GENE_PRODUCT", 164, 167], ["Primary murine embryonic fibroblasts", "CELL_TYPE", 0, 36], ["MEFs", "CELL_TYPE", 38, 42], ["IFN", "PROTEIN", 117, 120], ["\u03b2", "PROTEIN", 123, 124], ["VHS", "PROTEIN", 164, 167], ["murine", "SPECIES", 8, 14], ["HSV-2", "SPECIES", 58, 63], ["Primary murine embryonic fibroblasts (MEFs)", "PROBLEM", 0, 43], ["HSV", "TEST", 58, 61], ["\u0394VHS mutants", "PROBLEM", 64, 76], ["IFN", "TEST", 117, 120], ["cells infected", "PROBLEM", 130, 144], ["VHS", "PROBLEM", 164, 167], ["rescued viruses", "PROBLEM", 168, 183], ["embryonic fibroblasts", "OBSERVATION", 15, 36], ["viruses", "OBSERVATION", 176, 183]]], ["In addition, pretreatment of MEFs with IFN-I inhibited the replication of HSV-2 \u0394VHS more than that of wild-type and VHS-rescued viruses, indicating that VHS interferes with activation of the IFN-a/\u03b2-induced antiviral response.", [["MEFs", "ANATOMY", 29, 33], ["IFN-I", "CHEMICAL", 39, 44], ["MEFs", "CELL", 29, 33], ["IFN-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["HSV-2 \u0394VHS", "ORGANISM", 74, 84], ["VHS", "GENE_OR_GENE_PRODUCT", 117, 120], ["VHS", "GENE_OR_GENE_PRODUCT", 154, 157], ["IFN-a", "GENE_OR_GENE_PRODUCT", 192, 197], ["\u03b2", "GENE_OR_GENE_PRODUCT", 198, 199], ["IFN-I", "PROTEIN", 39, 44], ["VHS", "PROTEIN", 117, 120], ["VHS", "PROTEIN", 154, 157], ["IFN", "PROTEIN", 192, 195], ["\u03b2", "PROTEIN", 198, 199], ["HSV-2 \u0394VHS", "SPECIES", 74, 84], ["MEFs", "PROBLEM", 29, 33], ["IFN", "TREATMENT", 39, 42], ["HSV", "PROBLEM", 74, 77], ["2 \u0394VHS", "PROBLEM", 78, 84], ["VHS", "PROBLEM", 117, 120], ["rescued viruses", "PROBLEM", 121, 136], ["VHS", "PROBLEM", 154, 157], ["the IFN", "PROBLEM", 188, 195], ["a/\u03b2", "PROBLEM", 196, 199], ["induced antiviral response", "PROBLEM", 200, 226], ["antiviral response", "OBSERVATION", 208, 226]]], ["The authors further examined whether VHS interferes with key mediators of the IFN-a/\u03b2 response, PKR and RNase L [82].", [["VHS", "GENE_OR_GENE_PRODUCT", 37, 40], ["IFN-a", "GENE_OR_GENE_PRODUCT", 78, 83], ["\u03b2", "GENE_OR_GENE_PRODUCT", 84, 85], ["PKR", "GENE_OR_GENE_PRODUCT", 96, 99], ["RNase L [82]", "GENE_OR_GENE_PRODUCT", 104, 116], ["VHS", "PROTEIN", 37, 40], ["IFN", "PROTEIN", 78, 81], ["\u03b2", "PROTEIN", 84, 85], ["PKR", "PROTEIN", 96, 99], ["RNase L", "PROTEIN", 104, 111], ["the IFN", "TEST", 74, 81], ["PKR", "TEST", 96, 99]]], ["Furthermore, HSV-1 VHS-defective viruses have been shown to induce increased, physiologically active levels of IFN and increased amounts of ISGs.", [["HSV-1", "ORGANISM", 13, 18], ["VHS", "ORGANISM", 19, 22], ["IFN", "GENE_OR_GENE_PRODUCT", 111, 114], ["VHS", "PROTEIN", 19, 22], ["IFN", "PROTEIN", 111, 114], ["ISGs", "PROTEIN", 140, 144], ["HSV-1", "SPECIES", 13, 18], ["HSV-1", "SPECIES", 13, 18], ["HSV", "TEST", 13, 16], ["VHS", "TEST", 19, 22], ["defective viruses", "PROBLEM", 23, 40], ["IFN", "PROBLEM", 111, 114], ["increased amounts of ISGs", "PROBLEM", 119, 144], ["defective viruses", "OBSERVATION", 23, 40], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["active", "OBSERVATION_MODIFIER", 94, 100], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["amounts", "OBSERVATION_MODIFIER", 129, 136]]], ["VHS-defective HSV-1 viruses have increased susceptibility to IFN in cells [44], but not in culture, and the virulence of these viruses is not restored in IFN-a/\u03b2/\u03b3 R\u2212/\u2212 mice [83].", [["cells", "ANATOMY", 68, 73], ["IFN", "CHEMICAL", 61, 64], ["VHS", "GENE_OR_GENE_PRODUCT", 0, 3], ["HSV-1 viruses", "ORGANISM", 14, 27], ["IFN", "GENE_OR_GENE_PRODUCT", 61, 64], ["cells [44]", "CELL", 68, 78], ["IFN", "GENE_OR_GENE_PRODUCT", 154, 157], ["\u03b2", "GENE_OR_GENE_PRODUCT", 160, 161], ["\u03b3", "GENE_OR_GENE_PRODUCT", 162, 163], ["VHS", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 154, 157], ["\u03b2", "PROTEIN", 160, 161], ["HSV-1", "SPECIES", 14, 19], ["mice", "SPECIES", 169, 173], ["HSV-1 viruses", "SPECIES", 14, 27], ["VHS", "TEST", 0, 3], ["defective HSV", "PROBLEM", 4, 17], ["1 viruses", "PROBLEM", 18, 27], ["increased susceptibility to IFN in cells", "PROBLEM", 33, 73], ["culture", "TEST", 91, 98], ["these viruses", "PROBLEM", 121, 134], ["defective", "OBSERVATION_MODIFIER", 4, 13], ["HSV", "OBSERVATION", 14, 17], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["viruses", "OBSERVATION", 127, 134]]], ["The HSV-2 VHS protein is ~ 40-fold more active than that of HSV-1 and has a more crucial role in HSV-2 than its HSV-1 counterpart in promoting resistance to the IFN response and plays an important role in damaging the host defense mechanism.", [["HSV-2", "ORGANISM", 4, 9], ["VHS", "GENE_OR_GENE_PRODUCT", 10, 13], ["HSV-1", "ORGANISM", 60, 65], ["HSV-2", "ORGANISM", 97, 102], ["HSV-1", "ORGANISM", 112, 117], ["HSV-2 VHS protein", "PROTEIN", 4, 21], ["IFN", "PROTEIN", 161, 164], ["HSV-2", "SPECIES", 4, 9], ["HSV-1", "SPECIES", 60, 65], ["HSV", "SPECIES", 97, 100], ["HSV-1", "SPECIES", 112, 117], ["The HSV", "TEST", 0, 7], ["VHS protein", "TEST", 10, 21], ["HSV", "TEST", 60, 63], ["HSV", "TEST", 97, 100], ["its HSV", "TEST", 108, 115]]], ["In addition, Bovine herpesvirus 1 (BHV-1) ICP27, as a potent IFN-\u03b2 antagonist, interferes with the promoter activity of IFN-\u03b21 and IFN-\u03b23 [84].Inhibition of cellular PRR-mediated antiviral responses ::: Main textCyclic-GMP-AMP (cGAMP) synthase (cGAS), the most recently identified cytosolic DNA sensor, plays an important role in IFN-I responses against DNA viruses, including HSV-1 and KSHV.", [["cellular", "ANATOMY", 157, 165], ["cytosolic", "ANATOMY", 281, 290], ["AMP", "CHEMICAL", 223, 226], ["cGAMP", "CHEMICAL", 228, 233], ["textCyclic-GMP-AMP", "CHEMICAL", 208, 226], ["cGAMP", "CHEMICAL", 228, 233], ["Bovine herpesvirus 1", "ORGANISM", 13, 33], ["BHV-1", "ORGANISM", 35, 40], ["ICP27", "GENE_OR_GENE_PRODUCT", 42, 47], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 61, 66], ["IFN-\u03b21", "GENE_OR_GENE_PRODUCT", 120, 126], ["IFN-\u03b23", "GENE_OR_GENE_PRODUCT", 131, 137], ["cellular", "CELL", 157, 165], ["textCyclic-GMP-AMP (cGAMP) synthase", "GENE_OR_GENE_PRODUCT", 208, 243], ["cGAS", "GENE_OR_GENE_PRODUCT", 245, 249], ["cytosolic", "CELLULAR_COMPONENT", 281, 290], ["DNA", "CELLULAR_COMPONENT", 291, 294], ["IFN-I", "GENE_OR_GENE_PRODUCT", 330, 335], ["DNA", "CELLULAR_COMPONENT", 354, 357], ["HSV-1", "ORGANISM", 377, 382], ["KSHV", "ORGANISM", 387, 391], ["Bovine herpesvirus 1 (BHV-1) ICP27", "PROTEIN", 13, 47], ["IFN", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 120, 123], ["\u03b21", "PROTEIN", 124, 126], ["IFN", "PROTEIN", 131, 134], ["PRR", "PROTEIN", 166, 169], ["Main textCyclic-GMP-AMP (cGAMP) synthase", "PROTEIN", 203, 243], ["cGAS", "PROTEIN", 245, 249], ["IFN", "PROTEIN", 330, 333], ["Bovine herpesvirus 1", "SPECIES", 13, 33], ["HSV-1", "SPECIES", 377, 382], ["Bovine herpesvirus 1 (BHV-1", "SPECIES", 13, 40], ["HSV-1", "SPECIES", 377, 382], ["KSHV", "SPECIES", 387, 391], ["Bovine herpesvirus", "TEST", 13, 31], ["BHV", "TEST", 35, 38], ["ICP27", "TEST", 42, 47], ["a potent IFN-\u03b2 antagonist", "TREATMENT", 52, 77], ["IFN", "TEST", 120, 123], ["IFN", "TEST", 131, 134], ["Main textCyclic-GMP", "TEST", 203, 222], ["AMP (cGAMP) synthase (cGAS", "TEST", 223, 249], ["cytosolic DNA sensor", "PROBLEM", 281, 301], ["DNA viruses", "PROBLEM", 354, 365], ["HSV", "TEST", 377, 380], ["KSHV", "PROBLEM", 387, 391], ["cellular PRR", "OBSERVATION", 157, 169]]], ["Interestingly, HSV-1 UL41 degrades cGAS mRNAs via its RNase activity to evade the cGAS/STING-mediated DNA-sensing pathway [85].", [["HSV-1", "ORGANISM", 15, 20], ["UL41", "GENE_OR_GENE_PRODUCT", 21, 25], ["cGAS", "GENE_OR_GENE_PRODUCT", 35, 39], ["RNase", "GENE_OR_GENE_PRODUCT", 54, 59], ["cGAS", "GENE_OR_GENE_PRODUCT", 82, 86], ["STING", "GENE_OR_GENE_PRODUCT", 87, 92], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["HSV-1 UL41", "PROTEIN", 15, 25], ["cGAS mRNAs", "RNA", 35, 45], ["RNase", "PROTEIN", 54, 59], ["cGAS", "PROTEIN", 82, 86], ["STING", "PROTEIN", 87, 92], ["HSV-1", "SPECIES", 15, 20], ["HSV", "TEST", 15, 18], ["the cGAS", "TEST", 78, 86], ["STING", "PROBLEM", 87, 92]]], ["Furthermore, ICP27 interacts with the TBK1-STING signalosome in the cytoplasm through its RGG motif to inhibit interferon regulatory factors 3 (IRF3) activation and IFN production through the cGAS-STING pathway in macrophages [86].", [["cytoplasm", "ANATOMY", 68, 77], ["macrophages", "ANATOMY", 214, 225], ["ICP27", "GENE_OR_GENE_PRODUCT", 13, 18], ["TBK1", "GENE_OR_GENE_PRODUCT", 38, 42], ["STING", "GENE_OR_GENE_PRODUCT", 43, 48], ["cytoplasm", "ORGANISM_SUBSTANCE", 68, 77], ["interferon regulatory factors 3", "GENE_OR_GENE_PRODUCT", 111, 142], ["IRF3", "GENE_OR_GENE_PRODUCT", 144, 148], ["IFN", "GENE_OR_GENE_PRODUCT", 165, 168], ["cGAS", "GENE_OR_GENE_PRODUCT", 192, 196], ["STING", "GENE_OR_GENE_PRODUCT", 197, 202], ["macrophages", "CELL", 214, 225], ["ICP27", "PROTEIN", 13, 18], ["TBK1", "PROTEIN", 38, 42], ["STING signalosome", "PROTEIN", 43, 60], ["RGG motif", "PROTEIN", 90, 99], ["interferon regulatory factors 3", "PROTEIN", 111, 142], ["IRF3", "PROTEIN", 144, 148], ["IFN", "PROTEIN", 165, 168], ["cGAS", "PROTEIN", 192, 196], ["STING", "PROTEIN", 197, 202], ["macrophages", "CELL_TYPE", 214, 225], ["its RGG motif", "TREATMENT", 86, 99], ["interferon regulatory factors", "TREATMENT", 111, 140], ["IRF3) activation", "TREATMENT", 144, 160], ["IFN production", "TEST", 165, 179], ["the cGAS", "TEST", 188, 196]]], ["In addition, HSV-2 ICP27 also directly associates with IRF3 and inhibits its phosphorylation and nuclear translocation, resulting in the inhibition of IFN-\u03b2 production [87].Inhibition of cellular PRR-mediated antiviral responses ::: Main textIFI16 was identified as a DNA sensor that also signals through STING-TBK1 to detect viral DNA in both the cytoplasm and nucleus [88].", [["nuclear", "ANATOMY", 97, 104], ["cellular", "ANATOMY", 187, 195], ["cytoplasm", "ANATOMY", 348, 357], ["nucleus", "ANATOMY", 362, 369], ["HSV-2", "ORGANISM", 13, 18], ["ICP27", "GENE_OR_GENE_PRODUCT", 19, 24], ["IRF3", "GENE_OR_GENE_PRODUCT", 55, 59], ["nuclear", "CELLULAR_COMPONENT", 97, 104], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 151, 156], ["cellular", "CELL", 187, 195], ["textIFI16", "GENE_OR_GENE_PRODUCT", 238, 247], ["DNA", "CELLULAR_COMPONENT", 268, 271], ["STING", "GENE_OR_GENE_PRODUCT", 305, 310], ["TBK1", "GENE_OR_GENE_PRODUCT", 311, 315], ["DNA", "CELLULAR_COMPONENT", 332, 335], ["cytoplasm", "ORGANISM_SUBSTANCE", 348, 357], ["nucleus", "CELLULAR_COMPONENT", 362, 369], ["ICP27", "PROTEIN", 19, 24], ["IRF3", "PROTEIN", 55, 59], ["IFN", "PROTEIN", 151, 154], ["\u03b2", "PROTEIN", 155, 156], ["PRR", "PROTEIN", 196, 199], ["textIFI16", "PROTEIN", 238, 247], ["STING", "PROTEIN", 305, 310], ["TBK1", "PROTEIN", 311, 315], ["viral DNA", "DNA", 326, 335], ["HSV-2", "SPECIES", 13, 18], ["HSV", "TEST", 13, 16], ["IRF3", "PROBLEM", 55, 59], ["nuclear translocation", "PROBLEM", 97, 118], ["IFN", "PROBLEM", 151, 154], ["a DNA sensor", "TEST", 266, 278], ["STING-TBK1", "TEST", 305, 315], ["viral DNA", "PROBLEM", 326, 335], ["IRF3", "OBSERVATION", 55, 59], ["cellular PRR", "OBSERVATION", 187, 199], ["viral DNA", "OBSERVATION", 326, 335], ["cytoplasm", "OBSERVATION_MODIFIER", 348, 357], ["nucleus", "ANATOMY", 362, 369]]], ["Interestingly, nuclear IFI16 can assemble inflammasomes during infection by KSHV and HSV-1, leading to the secretion of proinflammatory interleukins [89, 90].", [["nuclear", "ANATOMY", 15, 22], ["infection", "DISEASE", 63, 72], ["nuclear", "CELLULAR_COMPONENT", 15, 22], ["IFI16", "GENE_OR_GENE_PRODUCT", 23, 28], ["KSHV", "ORGANISM", 76, 80], ["HSV-1", "ORGANISM", 85, 90], ["interleukins", "GENE_OR_GENE_PRODUCT", 136, 148], ["IFI16", "PROTEIN", 23, 28], ["proinflammatory interleukins", "PROTEIN", 120, 148], ["KSHV", "SPECIES", 76, 80], ["HSV-1", "SPECIES", 85, 90], ["infection", "PROBLEM", 63, 72], ["KSHV", "PROBLEM", 76, 80], ["HSV", "TEST", 85, 88], ["proinflammatory interleukins", "TEST", 120, 148]]], ["HSV-1 rapidly blocks IFI16-mediated immune responses during infection by catalyzing its degradation, in part via the contribution of ICP0 [90].", [["infection", "DISEASE", 60, 69], ["HSV-1", "ORGANISM", 0, 5], ["IFI16", "GENE_OR_GENE_PRODUCT", 21, 26], ["ICP0", "GENE_OR_GENE_PRODUCT", 133, 137], ["IFI16", "PROTEIN", 21, 26], ["ICP0", "PROTEIN", 133, 137], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["IFI16", "TEST", 21, 26], ["infection", "PROBLEM", 60, 69], ["ICP0", "TEST", 133, 137]]], ["However, ICP0 is not necessary or sufficient for the loss of IFI16 in a tumor-derived cell line, and the ICP0-independent loss of IFI16 in HeLa cells is dependent in part on VHS RNase activity [91].Inhibition of cellular PRR-mediated antiviral responses ::: Main textTLRs and RLRs are also fundamental sensor molecules of the host innate immune system that detect conserved molecular signatures of a wide range of microbial pathogens and initiate innate immune responses via distinct signaling pathways [92].", [["tumor-derived cell line", "ANATOMY", 72, 95], ["HeLa cells", "ANATOMY", 139, 149], ["cellular", "ANATOMY", 212, 220], ["tumor", "DISEASE", 72, 77], ["ICP0", "GENE_OR_GENE_PRODUCT", 9, 13], ["IFI16", "GENE_OR_GENE_PRODUCT", 61, 66], ["tumor-derived cell line", "CELL", 72, 95], ["ICP0", "GENE_OR_GENE_PRODUCT", 105, 109], ["IFI16", "GENE_OR_GENE_PRODUCT", 130, 135], ["HeLa cells", "CELL", 139, 149], ["VHS", "GENE_OR_GENE_PRODUCT", 174, 177], ["RNase", "GENE_OR_GENE_PRODUCT", 178, 183], ["cellular", "CELL", 212, 220], ["textTLRs", "GENE_OR_GENE_PRODUCT", 263, 271], ["RLRs", "GENE_OR_GENE_PRODUCT", 276, 280], ["ICP0", "PROTEIN", 9, 13], ["IFI16", "PROTEIN", 61, 66], ["tumor-derived cell line", "CELL_LINE", 72, 95], ["ICP0", "PROTEIN", 105, 109], ["IFI16", "PROTEIN", 130, 135], ["HeLa cells", "CELL_LINE", 139, 149], ["VHS", "PROTEIN", 174, 177], ["RNase", "PROTEIN", 178, 183], ["PRR", "PROTEIN", 221, 224], ["textTLRs", "PROTEIN", 263, 271], ["RLRs", "PROTEIN", 276, 280], ["ICP0", "PROBLEM", 9, 13], ["the loss of IFI16", "PROBLEM", 49, 66], ["a tumor-derived cell line", "TREATMENT", 70, 95], ["the ICP0", "PROBLEM", 101, 109], ["IFI16 in HeLa cells", "TREATMENT", 130, 149], ["microbial pathogens", "PROBLEM", 414, 433], ["cell line", "OBSERVATION", 86, 95], ["HeLa cells", "OBSERVATION_MODIFIER", 139, 149], ["cellular PRR", "OBSERVATION", 212, 224]]], ["The HSV-2 VHS protein inhibits TLR3 and RIG-I/Mda-5 as well as TLR2-mediated antiviral pathways for sensing dsRNA and effectively suppresses IFN-\u03b2 antiviral responses in human vaginal epithelial cells (ECs) [93].", [["vaginal epithelial cells", "ANATOMY", 176, 200], ["ECs", "ANATOMY", 202, 205], ["HSV-2", "ORGANISM", 4, 9], ["VHS", "GENE_OR_GENE_PRODUCT", 10, 13], ["TLR3", "GENE_OR_GENE_PRODUCT", 31, 35], ["RIG-I", "GENE_OR_GENE_PRODUCT", 40, 45], ["Mda-5", "GENE_OR_GENE_PRODUCT", 46, 51], ["TLR2", "GENE_OR_GENE_PRODUCT", 63, 67], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 141, 146], ["human", "ORGANISM", 170, 175], ["vaginal epithelial cells", "CELL", 176, 200], ["ECs", "CELL", 202, 205], ["HSV-2 VHS protein", "PROTEIN", 4, 21], ["TLR3", "PROTEIN", 31, 35], ["RIG", "PROTEIN", 40, 43], ["Mda", "PROTEIN", 46, 49], ["TLR2", "PROTEIN", 63, 67], ["IFN", "PROTEIN", 141, 144], ["human vaginal epithelial cells", "CELL_TYPE", 170, 200], ["ECs", "CELL_TYPE", 202, 205], ["human", "SPECIES", 170, 175], ["HSV-2", "SPECIES", 4, 9], ["human", "SPECIES", 170, 175], ["The HSV", "TEST", 0, 7], ["VHS protein", "TEST", 10, 21], ["TLR3", "TEST", 31, 35], ["RIG", "TEST", 40, 43], ["Mda", "TEST", 46, 49], ["TLR2-mediated antiviral pathways", "TREATMENT", 63, 95], ["sensing dsRNA", "TREATMENT", 100, 113], ["IFN", "TEST", 141, 144], ["antiviral responses", "TEST", 147, 166], ["vaginal epithelial", "ANATOMY", 176, 194]]], ["ICP27 also inhibits signaling downstream of the RIG-I adaptor protein MAVS and the TLR adaptor protein TRIF, while the KSHV ORF57 protein inhibits TLR3 phosphorylation [45, 94].", [["ICP27", "GENE_OR_GENE_PRODUCT", 0, 5], ["RIG-I", "GENE_OR_GENE_PRODUCT", 48, 53], ["MAVS", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLR", "GENE_OR_GENE_PRODUCT", 83, 86], ["TRIF", "GENE_OR_GENE_PRODUCT", 103, 107], ["KSHV", "ORGANISM", 119, 123], ["ORF57", "GENE_OR_GENE_PRODUCT", 124, 129], ["TLR3", "GENE_OR_GENE_PRODUCT", 147, 151], ["ICP27", "PROTEIN", 0, 5], ["RIG-I adaptor protein", "PROTEIN", 48, 69], ["MAVS", "PROTEIN", 70, 74], ["TLR adaptor protein", "PROTEIN", 83, 102], ["TRIF", "PROTEIN", 103, 107], ["KSHV ORF57 protein", "PROTEIN", 119, 137], ["TLR3", "PROTEIN", 147, 151], ["KSHV", "SPECIES", 119, 123], ["ICP27", "PROBLEM", 0, 5], ["adaptor protein MAVS", "TREATMENT", 54, 74], ["the TLR adaptor protein TRIF", "TREATMENT", 79, 107], ["the KSHV ORF57 protein", "TEST", 115, 137], ["TLR3 phosphorylation", "TEST", 147, 167], ["downstream", "OBSERVATION_MODIFIER", 30, 40]]], ["In addition, the EBV lytic-phase protein BGLF5 contributes to downregulation of TLR9 levels through RNA degradation [95] (Fig. 1).", [["EBV", "ORGANISM", 17, 20], ["BGLF5", "GENE_OR_GENE_PRODUCT", 41, 46], ["TLR9", "GENE_OR_GENE_PRODUCT", 80, 84], ["EBV lytic-phase protein", "PROTEIN", 17, 40], ["BGLF5", "PROTEIN", 41, 46], ["TLR9", "PROTEIN", 80, 84], ["the EBV lytic-phase protein BGLF5", "TEST", 13, 46], ["downregulation of TLR9 levels", "PROBLEM", 62, 91], ["RNA degradation", "TEST", 100, 115], ["lytic", "OBSERVATION_MODIFIER", 21, 26]]]], "16eb1eabf8de9345fb630b6f90b2c6f0dbbe5c04": [["IntroductionPower grid is a typical cyber-physical system [1] , which means that at any time, there is not only the energy flow travelling from one location to another in the network, but also information flow moving across the power grid and control centers.", [["flow", "OBSERVATION", 123, 127]]], ["Secure and reliable grid operation requires controlling the energy flow in a manner that supply and demand can be well balanced in real time by employing the information flow.", [["reliable grid operation", "TREATMENT", 11, 34], ["the energy flow", "TREATMENT", 56, 71], ["grid operation", "OBSERVATION", 20, 34]]], ["Ensuring the information moves as expected is thus a prerequisite for the sustained operation of power systems under normal conditions.", [["the sustained operation of power systems", "TREATMENT", 70, 110], ["normal conditions", "OBSERVATION", 117, 134]]], ["Alternatively speaking, any interruption of information flow would disturb the right behavior of energy flow, and further undermine the system's secure and reliable operation.IntroductionTo enable real-time monitoring and data acquisition that is essential for the system operation and control, the modern power grid primarily relies on the Supervisory Control and Data Acquisition (SCADA) system, which is tightly coupled with the Energy Management System (EMS) to guarantee the critical information is transferred reliably.", [["reliable operation", "TREATMENT", 156, 174], ["data acquisition", "TEST", 222, 238], ["the system operation", "TREATMENT", 261, 281], ["right", "ANATOMY_MODIFIER", 79, 84]]], ["After decades of development, the SCADA/EMS has been designed to be fault-tolerant and highly available.", [["SCADA", "CHEMICAL", 34, 39]]], ["The system is usually built with physical redundancy by means of dual servers and software redundancy through in-memory data replication mechanism [2] ; however, loss of SCADA/ EMS system, either partially or entirely, could still happen from time to time.", [["SCADA", "GENE_OR_GENE_PRODUCT", 170, 175], ["SCADA", "PROTEIN", 170, 175]]], ["In this report, communication interruption was found to be the major factor leading to these system failures [3] .", [["communication interruption", "TREATMENT", 16, 42], ["these system failures", "PROBLEM", 87, 108], ["failures", "OBSERVATION", 100, 108]]], ["According to a guideline developed by NERC, loss of SCADA or EMS is categorized as an \"Emergency\", and each Transmission Operator and Balancing Authority (BA) must have operating procedures and plans to mitigate its effects on the grid operation [4] .IntroductionTo balance the power supply and demand for a specific control area in real time, grid operators run a Security Constrained Economic Dispatch (SCED) program at the control center and issue dispatch orders to all dispatchable generators.", [["loss of SCADA", "PROBLEM", 44, 57], ["operating procedures", "TREATMENT", 169, 189], ["the grid operation", "TREATMENT", 227, 245], ["the power supply", "TREATMENT", 274, 290], ["demand", "TREATMENT", 295, 301], ["a specific control area", "TREATMENT", 306, 329], ["Economic Dispatch (SCED) program", "TREATMENT", 386, 418]]], ["BAs also rely on Automatic Generation Control (AGC), a critical application in EMS, to send control orders at every four seconds to AGC-participating generators.", [["BAs", "CHEMICAL", 0, 3], ["BAs", "SIMPLE_CHEMICAL", 0, 3], ["Automatic Generation Control (AGC)", "TREATMENT", 17, 51], ["AGC", "TEST", 132, 135]]], ["The inputs to AGC, which come from SCADA system, include measurements of the power flow on the tie-lines that connect two neighboring control areas and frequencies on key buses in the control area.", [["AGC", "DNA", 14, 17], ["AGC", "TEST", 14, 17], ["the tie-lines", "TREATMENT", 91, 104]]], ["Obviously, loss of SCADA or EMS will paralyze SCED and AGC, further threatening the power balance and frequency regulation.", [["EMS", "CHEMICAL", 28, 31], ["SCADA", "GENE_OR_GENE_PRODUCT", 19, 24], ["SCADA", "PROTEIN", 19, 24], ["loss of SCADA", "PROBLEM", 11, 24], ["AGC", "TEST", 55, 58]]], ["On the other hand, the generator dispatch instructions and AGC control set points are sent through a dedicated communication system that connects the BA and generators, for example, PJMnet at PJM [5] , Automated Dispatch System at California ISO [6] , and Electronic Dispatch system at ISO New England [7] .", [["the generator dispatch", "TREATMENT", 19, 41], ["AGC control", "TREATMENT", 59, 70]]], ["The general data flow of the dispatch instructions from the system operator to the responsible participant for generator control is illustrated in Fig. 1 .IntroductionAs it can be seen from Fig. 1 , a typical dispatch communication system consists of three main parts, the Remote Telemetry Unit (RTU) at each participating unit, a private redundant communication network established by the BA, and the Communication Front End (CFE) Servers at the grid control center.", [["generator control", "TREATMENT", 111, 128], ["IntroductionAs", "TREATMENT", 155, 169]]], ["Communication between each RTU and the CFE uses a proprietary protocol over TCP/IP to provide the ability to collect data and distribute supervisory control commands to and from generators in real time.", [["a proprietary protocol", "TREATMENT", 48, 70], ["TCP/IP", "TREATMENT", 76, 82]]], ["Under normal condition, the generator Desired Dispatch Points (DDPs) are calculated by SCED and AGC at the BA side, passed to the CFE servers and then transmitted to the generator's RTU via the private communication route.IntroductionThough the functionality of the automatic generator dispatch could be interrupted, maintaining the real-time supply-demand balance cannot be paused because it is the foundation for the stable operation of entire power systems.", [["AGC", "TEST", 96, 99], ["the automatic generator dispatch", "TREATMENT", 262, 294], ["the stable operation of entire power systems", "TREATMENT", 415, 459], ["normal condition", "OBSERVATION", 6, 22], ["stable", "OBSERVATION_MODIFIER", 419, 425], ["operation", "OBSERVATION", 426, 435]]], ["Current operating procedures require operators continuing performing \"Emergency\" dispatch, in the event of loss of SCADA or EMS, by manually sending estimated DDPs to generators via the dispatch communication system [8] .", [["loss of SCADA", "PROBLEM", 107, 120]]], ["Unfortunately, a manual dispatch could lead to inaccuracies and errors.", [["a manual dispatch", "TREATMENT", 15, 32], ["inaccuracies and errors", "PROBLEM", 47, 70]]], ["Specifically, when the system has large uncertainty and variability with high penetration of renewable energy, manual dispatch using the data from the outdated system snapshot and lagged forecast will become increasingly inaccurate.", [["large uncertainty", "PROBLEM", 34, 51], ["the data", "TEST", 133, 141], ["large", "OBSERVATION_MODIFIER", 34, 39], ["uncertainty", "OBSERVATION", 40, 51]]], ["Such a procedure has significant manual efforts involved, making the system operation performance vulnerable to human errors.", [["human", "ORGANISM", 112, 117], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["a procedure", "TREATMENT", 5, 16]]], ["Besides, it is also progressively difficult to dispatch multiple generators verbally in a short interval to balance the system.IntroductionIn addition to critical infrastructure failures, operators may also have to deal with unusual times when the facilities are inaccessible, like COVID-19.", [["critical infrastructure failures", "PROBLEM", 154, 186], ["infrastructure failures", "OBSERVATION", 163, 186]]], ["The virus outbreak greatly increases the probability of operation disruption because operators may lack timely support from IT and operation engineers, who are required to work from home amid the pandemic.", [["The virus outbreak", "PROBLEM", 0, 18], ["operation disruption", "PROBLEM", 56, 76], ["virus", "OBSERVATION", 4, 9], ["operation", "OBSERVATION", 56, 65]]], ["An even worse circumstance is operators are infected and home quarantined.", [["infected", "OBSERVATION", 44, 52]]], ["Since not all essential applications for generation dispatch allow remote access, how to continue operating the grid during such situations becomes of particular interest to grid operators.IntroductionIn our previous work [10] , a synchrophasor infrastructure based control framework was first proposed to use Phasor Measurement Unit (PMU) data as a backup of SCADA data, in case the latter is unavailable, to calculate Area Control Error (ACE) and corresponding generation dispatch amount.", [["a synchrophasor infrastructure", "TREATMENT", 229, 259], ["Error (ACE)", "TREATMENT", 433, 444]]], ["Then in the subsequent work [11] , an on-premises PMU-based generation control scheme was developed to perform AGClike dispatch to minimize ACE and economic dispatch to follow the projected load change.", [["ACE", "TREATMENT", 140, 143], ["the projected load change", "TREATMENT", 176, 201]]], ["The control scheme can maintain system balance in a way that the NERC's balancing control performance requirements can be met even during the \"Emergency\" period.", [["the NERC's", "TREATMENT", 61, 71]]], ["Although these works have put forward an effective method of grid monitoring and control in the event of SCADA or EMS failure, their realizations still have high dependence on the BA's infrastructure for computing and communication.", [["SCADA", "DISEASE", 105, 110], ["BA", "CHEMICAL", 180, 182], ["grid monitoring", "TEST", 61, 76], ["control", "TREATMENT", 81, 88], ["SCADA", "PROBLEM", 105, 110], ["EMS failure", "PROBLEM", 114, 125], ["high dependence", "PROBLEM", 157, 172]]], ["Just a few months later, FERC issued a Notice of Inquiry (NOI) to seek additional comments and suggestions regarding the potential benefits and risks associated with the use of virtualization and cloud computing technologies [13] .IntroductionGive the background, we present a serverless solution for the realization of the entire emergency generation dispatch based on public cloud services.", [["virtualization", "TREATMENT", 177, 191], ["a serverless solution", "TREATMENT", 275, 296]]], ["In this work, we continue to use the PMU data that is independent of SCADA.", [["SCADA", "PROTEIN", 69, 74], ["the PMU data", "TEST", 33, 45]]], ["Different from [11] , which developed a PMUbased generation dispatch scheme running in control center to counteract the impact of SCADA/EMS failures, this work presents a brandnew architecture with cloud-hosted data ingestion, processing, storage, visualization and sharing to ensure the operation continuity in case of unavailability and inaccessibility of control center facilities.", [["EMS failures", "PROBLEM", 136, 148], ["the operation continuity", "TREATMENT", 284, 308], ["EMS failures", "OBSERVATION", 136, 148]]], ["This cloudcentric architecture has two major advantages over the traditional solution architecture that heavily relies on on-premises infrastructure.", [["the traditional solution architecture", "TREATMENT", 61, 98], ["two", "OBSERVATION_MODIFIER", 35, 38], ["major", "OBSERVATION_MODIFIER", 39, 44], ["advantages", "OBSERVATION_MODIFIER", 45, 55]]], ["Firstly, the cloud infrastructure is independent and fault-tolerant, providing backup grid monitoring and control capability even when EMS loses its corresponding functionality or when operators need to work remotely away from the control center.", [["EMS", "CHEMICAL", 135, 138], ["backup grid monitoring", "TEST", 79, 101], ["cloud infrastructure", "OBSERVATION", 13, 33]]], ["This serverless architecture relieves customers from the burden of server management and eliminates the cost of server provisioning.", [["server management", "TREATMENT", 67, 84]]], ["Section 3 first describes the current operation practice when there is a loss of SCADA or EMS, followed by the revisiting of the PMU based generation dispatch algorithm that is proposed in our prior work to counteract the impact of SCADA/EMS failures, then it points out the challenges to this on-premises control scheme in case of control center infrastructure unavailability or inaccessibility.", [["SCADA", "CHEMICAL", 232, 237], ["a loss of SCADA", "PROBLEM", 71, 86], ["EMS failures", "PROBLEM", 238, 250]]], ["Section 4 presents a cloud-hosted framework for emergency generation dispatch.", [["emergency generation dispatch", "TREATMENT", 48, 77]]], ["Next, Section 5 presents a serverless solution that fits into this cloud framework to securely address the need of data processing, storage, visualization and sharing for emergency dispatch, with a highlight on how to meet the cyber security requirements.", [["a serverless solution", "TREATMENT", 25, 46]]], ["It is emerging as a new and compelling paradigm for the deployment of cloud applications, mostly due to the recent shift of enterprise application architectures to containers and microservices [17] .Understanding serverless computingThe conceptual hierarchy of the serverless architecture is shown in Fig. 2 with a comparison to the traditional Infrastructure-as-a-Service (IaaS) model [18] .Understanding serverless computingIn this figure, the business features, which are represented by block Bk (k = 1~4), are built on a group of functions.", [["cloud applications", "TREATMENT", 70, 88], ["enterprise application architectures", "TREATMENT", 124, 160], ["k", "TEST", 500, 501], ["conceptual", "OBSERVATION_MODIFIER", 237, 247], ["hierarchy", "OBSERVATION_MODIFIER", 248, 257], ["Fig", "OBSERVATION_MODIFIER", 301, 304]]], ["It is comprised of a module from the data layer, which is illustrated by block Dk (k = 1~4), to ingest data, and a corresponding module from the application layer, indicated by block Ak (k = 1~4), to carry out necessary calculation as \"function\".", [["block Dk (k", "TEST", 73, 84], ["k", "TEST", 187, 188], ["module", "OBSERVATION", 21, 27], ["layer", "OBSERVATION_MODIFIER", 42, 47]]], ["These functions have their independent runtimes, i.e., block Rk (k = 1 4).", [["k", "TEST", 65, 66]]], ["Each combination of blocks Ak, Dk and Rk respectively constitutes a software release Fk for business feature Bk.", [["Ak", "GENE_OR_GENE_PRODUCT", 27, 29], ["Dk", "GENE_OR_GENE_PRODUCT", 31, 33], ["Dk", "PROTEIN", 31, 33], ["Rk", "PROTEIN", 38, 40], ["Fk", "PROTEIN", 85, 87]]], ["In the serverless model, users will no longer have to invest in creating, maintaining, or managing the underlying infrastructure.", [["infrastructure", "OBSERVATION", 114, 128]]], ["Establishing the business service on the serverless architecture is just like erecting a building with Lego bricks.Function-as-a-ServiceFunction-as-a-Service (FaaS) is an implementation of \"serverless computing\" via serverless architecture.", [["Lego bricks", "TREATMENT", 103, 114]]], ["It has become dominating in serverless realization [19] and therefore widely regarded as a synonym of \"serverless computing\" [20, 21] .", [["dominating", "OBSERVATION_MODIFIER", 14, 24]]], ["Following the lead of AWS Lambda, corresponding services such as Azure Functions, Google Cloud Functions, OpenWhisk are introduced by Microsoft, Google, IBM respectively to enrich the options for FaaS implementation [17] .Features and benefitsServerless computing, or FaaS, is usually characterized by a number of attributes listed below [17, 18] .Event-drivenFaaS executes the business logic in response to user requests.", [["FaaS", "DNA", 360, 364]]], ["Anything that triggers the execution of the function is regarded as an event, e.g., message publishing, file upload.Low costServerless is a new way of offloading IT overhead.", [["Low costServerless", "PROBLEM", 116, 134], ["new", "OBSERVATION_MODIFIER", 140, 143]]], ["A serverless architecture eliminates the responsibility of managing servers, databases, and even application logic, lowering the setup and maintenance costs.", [["lowering the setup", "TREATMENT", 116, 134], ["maintenance costs", "TREATMENT", 139, 156]]], ["They never need to pay for the idle resources.Inherently scalableLike other cloud computing models, serverless offers inherent scalability.", [["cloud", "OBSERVATION_MODIFIER", 76, 81]]], ["The ability to scale down to zero instance is one of the key differentiators of a serverless platform.Business focused and productivity centricServerless allows developers to focus on business logic instead of infrastructure so they can improve their productivity of turning ideas to real products or services.Built-in availability and fault toleranceDisaster recovery is integrated into Cloud Service Provider (CSP) offerings.", [["fault tolerance", "OBSERVATION", 336, 351]]], ["Your applications are highly available on serverless architecture because they are built on fault-tolerant functions.StatelessFunctions are stateless because they do not rely on internal memory, state-machines, stored files or mounted volumes.", [["Your applications", "TREATMENT", 0, 17]]], ["Subject to external services each call to a function should result in the same end-result.Use casesServerless computing has been utilized to support a wide range of applications including event processing, stream processing, Extract-Transform-Load (ETL), advanced analytics, Internet of Things (IoT) solutions, artificial intelligence solutions, web and mobile applications, etc.Emergency generation dispatch in case of loss of EMS or SCADAAs mentioned in the introduction part as well as in the preceding work [11] , system operators are required to perform dispatch using manually collected data when there is an EMS or SCADA failure as pursuant to the emergency operating guidelines by NERC and a variety of BAs.", [["SCADAAs", "DISEASE", 435, 442], ["EMS", "CHEMICAL", 428, 431], ["BAs", "CHEMICAL", 711, 714], ["BAs", "SIMPLE_CHEMICAL", 711, 714], ["Things (IoT) solutions", "TREATMENT", 287, 309], ["artificial intelligence solutions", "TREATMENT", 311, 344], ["mobile applications", "TREATMENT", 354, 373], ["loss of EMS or SCADAAs", "PROBLEM", 420, 442], ["SCADA failure", "PROBLEM", 622, 635]]], ["Although these guidelines vary from each other in specific procedures, all of them require significant human intervention during the dispatch process.Current operating practiceThe manual dispatch guidelines by different BAs share some common points.", [["human", "ORGANISM", 103, 108], ["BAs", "MULTI-TISSUE_STRUCTURE", 220, 223], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["significant human intervention", "TREATMENT", 91, 121], ["The manual dispatch guidelines", "TREATMENT", 176, 206]]], ["For a grid operator like ISO New England, a typical operating procedure in the event of loss of SCADA/EMS includes the following action steps.", [["SCADA", "DNA", 96, 101], ["a typical operating procedure", "TREATMENT", 42, 71], ["loss of SCADA", "PROBLEM", 88, 101], ["New", "OBSERVATION_MODIFIER", 29, 32]]], ["Select generators which are online and available for the dispatch as the participating units for the emergency dispatch.Current operating practiceActionCurrent operating practiceStep 3: determine the economic dispatch of the unit and estimate the amount of generation output changes to minimize current ACE and balance projected load change.Current operating practiceActionCurrent operating practiceStep 4: send the estimated DDPs to participating units either verbally via secure phone calls, or electronically through the dispatch communication system, if it is still available.Current operating practiceActionCurrent operating practiceStep 5: verify that the responsible units have acknowledged the DDPs that are sent to them.Current operating practiceAction Step 6: record and log all verbal communications with LCCs, neighboring BAs, and generators.Economic generation dispatch using PMU measurementsTo reduce the manual effort involved in the current operating procedure during the emergency of SCADA or EMS failure, the PMU measurements can be used as a backup of SCADA to re-acquire the ability of generator dispatch and monitoring.", [["DDPs", "GENE_OR_GENE_PRODUCT", 702, 706], ["BAs", "MULTI-TISSUE_STRUCTURE", 834, 837], ["generation output changes", "PROBLEM", 257, 282], ["current ACE", "TREATMENT", 295, 306], ["balance projected load change", "TREATMENT", 311, 340], ["the DDPs", "PROBLEM", 698, 706], ["PMU measurements", "TEST", 889, 905], ["the current operating procedure", "TREATMENT", 945, 976], ["SCADA", "PROBLEM", 1001, 1006], ["EMS failure", "PROBLEM", 1010, 1021], ["the PMU measurements", "TEST", 1023, 1043], ["a backup of SCADA", "TREATMENT", 1059, 1076], ["generator dispatch", "TREATMENT", 1106, 1124], ["monitoring", "TEST", 1129, 1139], ["amount", "OBSERVATION_MODIFIER", 247, 253], ["generation output", "OBSERVATION", 257, 274]]], ["Because the synchrophasor infrastructure is independent of the traditional SCADA system, a failure of SCADA does not necessarily indicate PMU unavailability.", [["PMU", "SIMPLE_CHEMICAL", 138, 141], ["the synchrophasor infrastructure", "PROBLEM", 8, 40], ["a failure of SCADA", "PROBLEM", 89, 107]]], ["Furthermore, unlike the SCADA data, PMU measurements are timealigned and can be streamed to the cloud either from the substations directly or from the ISO irrespective of network latency.", [["ISO", "CHEMICAL", 151, 154], ["SCADA", "DNA", 24, 29], ["the SCADA data", "TEST", 20, 34], ["PMU measurements", "TEST", 36, 52], ["network latency", "OBSERVATION", 171, 186]]], ["The PMUbased control scheme that proposed in [11] was designed specifically to meet the goal of emergency generation dispatch.", [["The PMUbased control scheme", "TREATMENT", 0, 27]]], ["With the primary objective of balancing the supply and demand using a cost optimization strategy, the PMU based emergency generation control scheme dispatches generation in response to variation in ACE and projected load change in a short-term look-ahead horizon.", [["a cost optimization strategy", "TREATMENT", 68, 96], ["the PMU based emergency generation control scheme", "TREATMENT", 98, 147], ["ACE and projected load change", "TREATMENT", 198, 227]]], ["The operating limits and ramp rates of dispatchable PMU-monitored generators are respected.", [["PMU", "CHEMICAL", 52, 55], ["PMU", "SIMPLE_CHEMICAL", 52, 55], ["dispatchable PMU", "TREATMENT", 39, 55]]], ["Besides, a feasibility check is also enforced to guarantee the LP problem does not end up with an infeasible solution.", [["a feasibility check", "TEST", 9, 28], ["an infeasible solution", "TREATMENT", 95, 117]]], ["The details of algorithm including mathematical equations can be found in [11] .", [["mathematical equations", "TEST", 35, 57]]], ["This dispatch scheme, which was validated on ISO New England system through near real-time closed loop simulations, demonstrates good balancing control performance that complies with NERC's reliability standard under the emergency when there is a complete loss of SCADA or EMS.Challenges due to unavailability and inaccessibility of the control center infrastructureDispatching PMU-monitored units to maintain system balancing during loss of SCADA or EMS emergency can alleviate the manual workload and reduce operators' mistakes; however, it only provides help to eliminate the human error in action steps 1 and 3 mentioned above.", [["SCADA", "CHEMICAL", 442, 447], ["human", "ORGANISM", 579, 584], ["human", "SPECIES", 579, 584], ["human", "SPECIES", 579, 584], ["closed loop simulations", "TREATMENT", 91, 114], ["a complete loss of SCADA", "PROBLEM", 245, 269], ["SCADA", "TREATMENT", 442, 447], ["good", "OBSERVATION_MODIFIER", 129, 133]]], ["As a matter of fact, the manual dispatch procedure will be triggered and step 2, 4, 5, 6 will be needed whenever there is a failure of the dispatch communication network regardless of the availability of SCADA and EMS.", [["EMS", "CHEMICAL", 214, 217], ["the manual dispatch procedure", "TREATMENT", 21, 50]]], ["As a result, the control may be stochastically lagged, uncorrelated and unfavorably offset due to delay in the human reaction.", [["human", "ORGANISM", 111, 116], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["the human reaction", "PROBLEM", 107, 125]]], ["Moreover, solely relying on verbal conversations to acknowledge DDPs is unreliable and slow, which could have an adverse impact on the decision-making for the subsequent dispatch intervals.Challenges due to unavailability and inaccessibility of the control center infrastructureThe current operation practice using manual verbal dispatch under emergency conditions cannot guarantee the control performance and could put system reliability in jeopardy.", [["DDPs", "GENE_OR_GENE_PRODUCT", 64, 68], ["The current operation practice", "TREATMENT", 278, 308], ["emergency conditions", "TREATMENT", 344, 364]]], ["It is also highly dependent on the control center infrastructure.", [["highly", "OBSERVATION_MODIFIER", 11, 17], ["dependent", "OBSERVATION_MODIFIER", 18, 27]]], ["Besides, there are situations when grid operators must work remotely away from the control room due to fire, gas leak and mandatory quarantine amid COVID-19, making on-premises facilities inaccessible.", [["gas leak", "PROBLEM", 109, 117], ["gas leak", "OBSERVATION", 109, 117]]], ["It is, therefore, worthwhile to develop an alternative emergency backup solution, which is independent of the control center infrastructure for computing and communication, to assist operators with system balancing.Cloud-hosted framework for emergency generation dispatchThe synchrophasor infrastructure can be used in lieu of SCADA system to reinstate the capability of data acquisition and system monitoring for utilities under \"Emergency\" situations [10] .", [["an alternative emergency backup solution", "TREATMENT", 40, 80], ["The synchrophasor infrastructure", "TREATMENT", 271, 303], ["data acquisition", "TEST", 371, 387], ["system monitoring", "TEST", 392, 409]]], ["The generation control algorithm based on the synchrophasor infrastructure can produce dispatch orders for system balancing while minimizing cost [11] .", [["The generation control algorithm", "TREATMENT", 0, 32]]], ["In simple words, the prior works have answered the questions on \"how to take in data automatically and fast\" and \"how to leverage these data for emergency dispatch\"; however, the additional question \"how to transfer data to other parties quickly and accurately\", especially when the control center infrastructure is unavailable, still remains unsolved.Cloud-hosted framework for emergency generation dispatchTo address this concern, we present a cloud-centric framework as shown in Fig. 3 .Cloud-hosted framework for emergency generation dispatchThe framework transforms the center of information processing, visualization and storage from the on-premises infrastructure to the cloud.", [["visualization", "TEST", 609, 622]]], ["The PMU-based control scheme is implemented in the cloud to perform emergency generation dispatch.", [["PMU", "CHEMICAL", 4, 7], ["PMU", "SIMPLE_CHEMICAL", 4, 7]]], ["This cloud framework also enables bi-directional information flow between the BA and generators via secured Internet connections.", [["BA", "SIMPLE_CHEMICAL", 78, 80]]], ["One of the major benefits is robustness of the data delivery and flexibility of accessing dispatch information from anywhere as long as there is an Internet connection.Serverless-based emergency dispatch solutionTo realize the cloud-hosted emergency generation dispatch framework, we present a serverless solution with its implementation on Amazon Web Services (AWS) described in detail.Why serverlessBefore FaaS emerges, a number of other cloud computing models have existed, e.g., Infrastructure-as-a-Service (IaaS), Platform-as-a-Service (PaaS) and Software-as-a-Service (SaaS).", [["FaaS", "PROTEIN", 408, 412], ["the data delivery", "TREATMENT", 43, 60], ["a serverless solution", "TREATMENT", 292, 313]]], ["Unlike normal system operation, emergency dispatch is not needed on a 24 \u00d7 7 basis.", [["normal system operation", "OBSERVATION", 7, 30]]], ["There is no need to provision resources such as servers, databases and I/O capacity for it during normal conditions.", [["I/O capacity", "TEST", 71, 83], ["no need to", "UNCERTAINTY", 9, 19]]], ["Secondly, the solution for the generation dispatch in the event of an \"Emergency\" should be made as a group of microservices in order to minimize the impact of any component (subtask) failure in the process.", [["the solution", "TREATMENT", 10, 22], ["a group of microservices", "TREATMENT", 100, 124], ["any component (subtask) failure in the process", "PROBLEM", 160, 206], ["failure", "OBSERVATION", 184, 191]]], ["The FaaS model, which provides the fine-grained services, is the right choice to utilize in this case.", [["FaaS model", "OBSERVATION", 4, 14], ["right", "ANATOMY_MODIFIER", 65, 70]]], ["Last but not least, we want to avoid the burden of the infrastructure management and maintenance because increasing the IT workload for occasional use case is really undesirable.Implementation of serverless emergency dispatchThe proposed serverless solution for emergency generation dispatch can be built using any large public cloud service provider like Amazon, Microsoft and Google, because they all have corresponding services for serverless computing that is seamlessly integrated with other services.", [["the infrastructure management", "TREATMENT", 51, 80], ["The proposed serverless solution", "TREATMENT", 225, 257], ["emergency generation dispatch", "TREATMENT", 262, 291]]], ["Having years of experience on running a production-scale cloud platform for power system planning studies on AWS [24] , we continued to implement the proposed serverless solution on AWS.", [["the proposed serverless solution", "TREATMENT", 146, 178]]], ["As shown in Fig. 4 , the entire platform is built upon AWS with its serverless service -Amazon Lambda as the cornerstone.", [["Amazon Lambda", "TREATMENT", 88, 101], ["Fig", "OBSERVATION", 12, 15]]], ["Surrounding Amazon Lambda, the implemented platform also integrates other Amazon services for data ingestion, storage and visualization.Implementation of serverless emergency dispatchThe implementation of the serverless emergency generation dispatch is described as follows.", [["visualization", "TEST", 122, 135], ["Amazon Lambda", "OBSERVATION", 12, 25]]], ["Whenever there is a loss of SCADA/EMS, dispatch communication system failure or control room evacuation, operators are required to send a notification according to the current operating procedure [7] .", [["a loss of SCADA", "PROBLEM", 18, 33], ["dispatch communication system failure", "TREATMENT", 39, 76], ["control room evacuation", "TREATMENT", 80, 103]]], ["This notification is used to trigger a periodic query at every 1 min to pull the latest (within 1 min) synchrophasor data, e.g., tie-line flows, frequencies on key buses, and active power outputs of the PMU-monitored generators, from the PMU database.", [["PMU", "PROTEIN", 203, 206], ["synchrophasor data", "TEST", 103, 121], ["tie-line flows", "TREATMENT", 129, 143], ["line flows", "OBSERVATION", 133, 143]]], ["The query also pulls generator offer parameters such as unit ramp rates, incremental energy offers, operating limits and regulation limits from the market database.", [["pulls generator offer parameters", "TREATMENT", 15, 47], ["unit ramp rates", "TREATMENT", 56, 71]]], ["The activity of putting a data object in the S3 bucket then triggers a Lambda function to retrieve the encrypted data file from the S3 bucket.", [["a Lambda function", "PROBLEM", 69, 86], ["activity", "OBSERVATION_MODIFIER", 4, 12]]], ["Once data is parsed from the uploaded file, the Lambda function start calculating ACE and DDPs using the dispatch algorithm described in Section 3.2.", [["ACE", "GENE_OR_GENE_PRODUCT", 82, 85], ["DDPs", "DNA", 90, 94], ["calculating ACE and DDPs", "TREATMENT", 70, 94], ["the dispatch algorithm", "TREATMENT", 101, 123]]], ["The calculation results, including ACE, frequency deviation, advised DDPs, are written to a flat file and saved in another S3 bucket where a static website is hosted using Data-Driven Document display technology (d3.js) [26] .", [["The calculation results", "TEST", 0, 23], ["ACE", "TEST", 35, 38]]], ["In the meanwhile, the historical results are written to a NoSQL database service on AWS, Dy-namoDB, for archiving purposes.Implementation of serverless emergency dispatchAlternatively, if the PMU data are directly streamed from the substations to the cloud from substations or from Phasor Data Concentrator (PDC) servers hosted at the BA through Amazon Direct Connect (a secure, dedicated connection from on-premises infrastructure into AWS) as shown in Fig. 3 , Amazon Kinesis [27] can be used to ingest the PMU data and deliver them to S3, which will trigger the Lambda function to perform emergency generation dispatch.", [["Amazon Kinesis", "TREATMENT", 463, 477]]], ["Currently, we are still working with the cloud provider to establish the dedicated connection to Amazon data centers.Implementation of serverless emergency dispatchThe operators at the BA and the generator side will open their respective webpages to visualize the dispatch information through secure HTTP links in terms of signed Uniform Resource Locators (URLs) after they authenticate themselves with a pre-defined user pool in Amazon Cognito [28] .", [["the generator side", "TREATMENT", 192, 210]]], ["Similarly, generator operators can initiate a request to change the UCM of a unit and BA can confirm this change.", [["BA", "SIMPLE_CHEMICAL", 86, 88], ["UCM", "DNA", 68, 71], ["a unit and BA", "TREATMENT", 75, 88]]], ["Such a design is helpful if the data files are uploaded at an interval much smaller than the processing time of Lambda functions.Data visualizationOne benefit of this cloud-centric platform is that it provides a shared platform for consistent data presentation, despite that grid operators and generators need to observe different portion of data due to their different roles in the emergency dispatch process.", [["Lambda", "GENE_OR_GENE_PRODUCT", 112, 118], ["the data files", "TEST", 28, 42], ["Data visualization", "TEST", 129, 147]]], ["For BA operators, they are mainly monitoring information related to system balancing performance e.g., ACE, frequency deviation, and Balancing Authority ACE Limit (BAAL) [30] , as well as dispatch-related information such as UCM, DDPs and actual outputs of all participating generators.", [["ACE, frequency deviation", "TREATMENT", 103, 127], ["Balancing Authority ACE Limit (BAAL)", "TREATMENT", 133, 169]]], ["For generators, they only care about the dispatch information for their responsible units, so only that portion of data is displayed to them.Data visualizationThe web-based displays are completely driven by the portion of data that each role desires to view using d3.js libraries.", [["d3", "DNA", 264, 266], ["Data visualization", "TEST", 141, 159], ["d3", "TREATMENT", 264, 266]]], ["The API calls trigger another Lambda which updates the data files in the website hosting S3 bucket and also writes these changes to DynamoDB.", [["Lambda", "DNA", 30, 36], ["DynamoDB", "PROTEIN", 132, 140]]], ["Although cloud computing has been widely used in many areas such as finance, healthcare, insurance, business analytics and even government agencies, it is still an emerging technology to the electric energy industry.", [["cloud", "OBSERVATION", 9, 14]]], ["In short, lack of understanding in the cloud technology and lack of confidence in cloud security are the major challenges of applying cloud solutions, including the serverless architecture proposed in this work, for power grid operation.", [["cloud solutions", "TREATMENT", 134, 149], ["the serverless architecture", "TREATMENT", 161, 188], ["power grid operation", "TREATMENT", 216, 236]]], ["To address such concerns, we developed a comprehensive cyber security mechanism, which includes data protection, identity management, key rotation and access authorization as per the instructions given in [33] , to secure our cloud solution.", [["identity management", "TREATMENT", 113, 132]]], ["In the cloud context, data protection refers to protecting data both in transit (as it travels to and from Amazon S3), and at rest (while it is stored in Amazon data centers).Data protectionTo protect data in transit, we enforce the standard Secure Socket Layer (SSL) encryption by using HTTPS protocol.", [["the standard Secure Socket Layer (SSL) encryption", "TREATMENT", 229, 278]]], ["As for protection of data at rest, we opt for the server-side other than client-side encryption because it saves us from the heavy lifting in the encryption/decryption process.", [["client-side encryption", "TREATMENT", 73, 95]]], ["There are three options for server-side encryption approach: 1, Use server-side encryption with Amazon S3 managed keys (SSE-S3); 2, use server-side encryption with AWS Key Management Service (KMS) managed keys (SSE-KMS); and 3, use server-side encryption with customer-provided keys (SSE-C).", [["server-side encryption approach", "TREATMENT", 28, 59], ["Amazon S3", "TREATMENT", 96, 105]]], ["Option 1 requires the minimum effort on key management and encryption process.", [["key management", "TREATMENT", 40, 54]]], ["Based on all considerations above as a whole, we decided to use a mixed mode of option 2 and option 3 in this design with the encryption key generated in-house and managed by the BA while imported to Amazon KMS so that it can be used by other AWS services with ease.", [["a mixed mode of option", "TREATMENT", 64, 86]]], ["The proposed encryption/ decryption process is shown in Fig. 5 .Access security checkIn addition to data protection, the access security is also of great importance.", [["The proposed encryption/ decryption process", "TREATMENT", 0, 43], ["data protection", "TREATMENT", 100, 115]]], ["The locations of green text in Fig. 4 have pointed out the places of access security checkpoints in the implementation.", [["green text", "OBSERVATION", 17, 27]]], ["The security check mechanisms include Identity Access Management (IAM) user (a permanent long-term credential for authorized user) for uploading the pulled data to S3, IAM role (an entity that defines a set of permissions for making AWS service requests) for Lambda functions interact with other AWS services, IP range control for limiting the cyber locations of workstations to access the generation dispatch results in S3, API key for sending user requests to API Gateway to acknowledge DDPs or confirm UCM change, signed URLs for serving the private content with sensitive data, and authentication for the viewer's identity through the Lambda@Edge function triggered by CloudFront.", [["CloudFront", "PROTEIN", 673, 683], ["a permanent long-term credential", "TREATMENT", 77, 109], ["IP range control", "TREATMENT", 310, 326], ["UCM change", "PROBLEM", 505, 515]]], ["The authentication process, which is marked by green double arrows and attached numbers in Fig. 4 , include 9 steps.CostAs emergency dispatch is event-driven, using serverless will just incur a very low cost.", [["green double arrows", "PROBLEM", 47, 66], ["marked", "OBSERVATION_MODIFIER", 37, 43], ["green", "OBSERVATION_MODIFIER", 47, 52], ["double arrows", "OBSERVATION", 53, 66], ["9 steps", "OBSERVATION_MODIFIER", 108, 115]]], ["The incurred cost surrounding serverless functions on this platform is given in Table 1 .CostAs analyzed in Table 1 , the cost of using AWS services for serverless emergency dispatch is literally negligible.", [["AWS services", "TREATMENT", 136, 148]]], ["By contrast, provisioning local servers in on-premises infrastructure or spinning up virtual machines through traditional IaaS cloud model will lead to inevitable upfront and/or operating costs.Resource configuration for serverless function Cost-Performance balanceChanging the resource settings by selecting memory or changing the timeout may impact the Lambda function performance and cost.", [["traditional IaaS cloud model", "TREATMENT", 110, 138], ["inevitable upfront", "TREATMENT", 152, 170]]], ["In this use case, the emergency generation control is a lightweight algorithm that requires no significant amount of memory or CPU time.", [["the emergency generation control", "TREATMENT", 18, 50], ["a lightweight algorithm", "TEST", 54, 77]]], ["For example, the time used for the Lambda function execution typically ranges between 400 ms and 800 ms, which is much smaller than the function invocation interval, when it is configured with an economy size of memory at 512 MB.", [["the Lambda function execution", "TEST", 31, 60], ["smaller", "OBSERVATION_MODIFIER", 119, 126], ["size", "OBSERVATION_MODIFIER", 204, 208]]], ["The corresponding cost for each request is only 0.5 * $0.0000166667 * mean (0.4, 0.8) + $0.0000002 = $0.000005Creation and management of signed URLsSigned URLs are used to restrict access to documents, business data or content that is intended for selected users.", [["mean", "TEST", 70, 74], ["management", "TREATMENT", 123, 133]]], ["The signed URLs are created using a custom CloudFront policy with the expiration date and time specified.", [["a custom CloudFront policy", "TREATMENT", 34, 60]]], ["The signature can be created in house by the IT department of BA using Base64-encoding tool like OpenSSL [35] .", [["BA", "CHEMICAL", 62, 64], ["Base64", "PROTEIN", 71, 77]]], ["Once created, the signed URLs can be sent to each power plant's point of contact via encrypted email periodically, e.g., once a week or once every other week, to rotate the expired hyperlink.Deployment for evaluation at ISO New EnglandThis serverless-based emergency generation dispatch solution was deployed on AWS and evaluated by ISO New England amid COVID-19 pandemic.", [["evaluation", "TEST", 206, 216], ["pandemic", "PROBLEM", 363, 371]]], ["It ran in parallel to the regular system balancing process and compared to the latter on several key metrics including ACE, CPS1 and BAAL [28] .", [["ACE", "GENE_OR_GENE_PRODUCT", 119, 122], ["CPS1", "GENE_OR_GENE_PRODUCT", 124, 128], ["ACE", "PROTEIN", 119, 122], ["CPS1", "PROTEIN", 124, 128], ["ACE", "TEST", 119, 122], ["CPS1", "TEST", 124, 128]]], ["For simplicity, the user authentication and URL signing process are removed on purpose.ConclusionThe event of loss of SCADA or EMS is usually regarded as an \"emergency\" by grid operators.", [["SCADA", "GENE_OR_GENE_PRODUCT", 118, 123], ["loss of SCADA", "PROBLEM", 110, 123]]], ["To maintain supply-demand balance in case of an emergency, system operators are required to perform manual dispatch by the current operating procedures.ConclusionThis work presents cloud-hosted serverless solution for emergency generation dispatch using PMU measurements.", [["PMU measurements", "TEST", 254, 270]]], ["The solution can not only run economic dispatch to maintain system balance, but also enable rapid, accurate and secure sharing of emergency dispatch information such as control signals, system balancing performance metrics and operator acknowledgements.", [["The solution", "TREATMENT", 0, 12]]], ["With an aid of this cloud-based solution, the potential human errors due to the use of phone conversations for manual verbal dispatch can be avoided.", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["this cloud-based solution", "TREATMENT", 15, 40], ["manual verbal dispatch", "TREATMENT", 111, 133]]], ["Each operation activity done through the platform is written to a database in a clearly defined data format which makes auditing and responsibility tracking much easier.", [["Each operation activity", "TEST", 0, 23]]], ["More importantly, the solution also enables the operators to monitor and control the grid even when they need to work remotely away from the control room as long as they have access to the Internet connection.ConclusionA comprehensive cyber security mechanism, including data protection, identity management, key rotation and access authorization, was also developed in this work to comply with critical infrastructure requirements for the power grid.", [["identity management", "TREATMENT", 288, 307]]], ["This security framework was created in the light of the vendor's official guide to support compliance with NERC CIP standards, which provides a reference for other grid operators to secure their cloud services.Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["NERC CIP standards", "TREATMENT", 107, 125]]]], "989dea380aa2a226bcfb3eba72573eb6d0047087": [["Dear Editor, The rapid emergence of COVID-19 in Wuhan city, Hubei Province, China, has resulted in thousands of deaths [1] .", [["COVID-19", "CHEMICAL", 36, 44], ["deaths", "DISEASE", 112, 118], ["COVID", "TEST", 36, 41], ["rapid", "OBSERVATION_MODIFIER", 17, 22]]], ["Many infected patients, however, presented mild flu-like symptoms and quickly recover [2] .", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["mild flu-like symptoms", "PROBLEM", 43, 65], ["infected", "OBSERVATION", 5, 13], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["flu-", "OBSERVATION", 48, 52]]], ["To effectively prioritize resources for patients with the highest risk, we identified clinical predictors of mild and severe patient outcomes.", [["patients", "ORGANISM", 40, 48], ["patient", "ORGANISM", 125, 132], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 125, 132], ["mild and severe patient outcomes", "PROBLEM", 109, 141], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["severe", "OBSERVATION_MODIFIER", 118, 124]]]], "a9e617934e8f5e0c46afc9b566f43df0c6f0b565": [["our results clearly showed that the distribution of the linear epitopes is not related to Nglycosylation, if any, subtle.", [["the linear epitopes", "PROBLEM", 52, 71], ["Nglycosylation", "TREATMENT", 90, 104], ["linear", "OBSERVATION_MODIFIER", 56, 62], ["epitopes", "OBSERVATION", 63, 71], ["not related to", "UNCERTAINTY", 75, 89]]]], "PMC7093460": [["IntroductionThe detection of antigen-specific antibodies in human specimens via serology remains an essential and fundamental necessity in laboratory medicine and therapeutic and vaccine development.", [["specimens", "ANATOMY", 66, 75], ["antigen", "GENE_OR_GENE_PRODUCT", 29, 36], ["human", "ORGANISM", 60, 65], ["specimens", "CANCER", 66, 75], ["antigen-specific antibodies", "PROTEIN", 29, 56], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["The detection of antigen", "TEST", 12, 36], ["specific antibodies in human specimens", "TEST", 37, 75], ["serology", "TEST", 80, 88], ["laboratory medicine", "TREATMENT", 139, 158], ["therapeutic and vaccine development", "TREATMENT", 163, 198]]], ["Antibody serology is used in the diagnosis of hundreds of infectious, allergic, and autoimmune diseases, and new biomarkers and tests continue to expand the utility of serology.", [["allergic", "DISEASE", 70, 78], ["autoimmune diseases", "DISEASE", 84, 103], ["Antibody serology", "TEST", 0, 17], ["infectious", "PROBLEM", 58, 68], ["allergic", "PROBLEM", 70, 78], ["autoimmune diseases", "PROBLEM", 84, 103], ["new biomarkers", "TEST", 109, 123], ["tests", "TEST", 128, 133], ["serology", "TEST", 168, 176], ["infectious", "OBSERVATION", 58, 68]]], ["Nevertheless, antibody serologic tests frequently exhibit suboptimal performance characteristics as measured by clinical sensitivity and specificity, require subjective interpretation1, and/or depend upon multi-step algorithms2,3.", [["antibody serologic tests", "TEST", 14, 38]]], ["Serologic assays using whole cell material and antigen mixtures can have high false positive rates, leading to unnecessary follow-up tests, inappropriate treatments, or misdiagnosis of patients.", [["cell", "ANATOMY", 29, 33], ["cell material", "CELL", 29, 42], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["Serologic assays", "TEST", 0, 16], ["whole cell material", "TEST", 23, 42], ["antigen mixtures", "TEST", 47, 63], ["high false positive rates", "PROBLEM", 73, 98], ["follow-up tests", "TEST", 123, 138], ["inappropriate treatments", "TREATMENT", 140, 164], ["positive rates", "OBSERVATION", 84, 98]]], ["Antibody serologic methods typically provide a narrow view of immunity towards a single, or small number of antigens or organisms, while an estimated 1400 pathogens may cause human disease4.", [["human", "ORGANISM", 175, 180], ["antigens", "PROTEIN", 108, 116], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["Antibody serologic methods", "TEST", 0, 26], ["small number of antigens", "PROBLEM", 92, 116], ["organisms", "PROBLEM", 120, 129], ["human disease4", "PROBLEM", 175, 189], ["small", "OBSERVATION_MODIFIER", 92, 97]]], ["And, many of these diseases lack effective serology tests altogether.", [["these diseases", "PROBLEM", 13, 27], ["serology tests", "TEST", 43, 57]]], ["Furthermore, many tests remain organism or antigen-based, even though knowledge of which antigen epitopes are targeted can be critical for inferring infection stage5, reactivation6, and immune protection7.IntroductionDespite biomedical need, methods have not emerged to broadly analyze antibody repertoire composition to enable multiplex serology for infection, allergy, or autoimmunity.", [["infection", "DISEASE", 149, 158], ["infection", "DISEASE", 351, 360], ["allergy", "DISEASE", 362, 369], ["autoimmunity", "DISEASE", 374, 386], ["antigen epitopes", "PROTEIN", 89, 105], ["many tests", "TEST", 13, 23], ["organism", "PROBLEM", 31, 39], ["antigen epitopes", "PROBLEM", 89, 105], ["inferring infection stage5", "PROBLEM", 139, 165], ["methods", "TREATMENT", 242, 249], ["multiplex serology", "TEST", 328, 346], ["infection", "PROBLEM", 351, 360], ["allergy", "PROBLEM", 362, 369], ["autoimmunity", "PROBLEM", 374, 386]]], ["Multiplex serology is typically limited to several organisms, and to only a small subset of their immunogenic epitopes8,9, even though infection or vaccination can give rise to hundreds of distinct antibody species10.", [["infection", "DISEASE", 135, 144], ["epitopes8,9", "CELL", 110, 121], ["antibody species10", "PROTEIN", 198, 216], ["Multiplex serology", "TEST", 0, 18], ["several organisms", "PROBLEM", 43, 60], ["their immunogenic epitopes8", "PROBLEM", 92, 119], ["infection", "PROBLEM", 135, 144], ["vaccination", "PROBLEM", 148, 159], ["distinct antibody species", "PROBLEM", 189, 214], ["small", "OBSERVATION_MODIFIER", 76, 81], ["infection", "OBSERVATION", 135, 144], ["distinct", "OBSERVATION_MODIFIER", 189, 197], ["antibody species", "OBSERVATION", 198, 214]]], ["To expand the breadth and information content of parallel immunoassays, pathogen-proteome derived phage display libraries and planar peptide arrays have been developed.", [["phage display libraries", "DNA", 98, 121], ["parallel immunoassays", "TEST", 49, 70], ["pathogen", "TEST", 72, 80], ["planar peptide arrays", "TREATMENT", 126, 147]]], ["For example, a phage display library of 93,904, 56-mer peptides spanning 208 human virus proteomes was constructed11,12.", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human virus", "SPECIES", 77, 88], ["a phage", "TEST", 13, 20], ["mer peptides", "TEST", 51, 63], ["human virus proteomes", "TEST", 77, 98]]], ["Following immunoprecipitation and DNA sequencing, seropositivity towards each virus was inferred.", [["DNA", "CELLULAR_COMPONENT", 34, 37], ["immunoprecipitation", "TEST", 10, 29], ["DNA sequencing", "TEST", 34, 48], ["seropositivity", "PROBLEM", 50, 64], ["each virus", "PROBLEM", 73, 83]]], ["However, comprehensive proteome tiling for many higher complexity organisms is currently impractical given their larger proteome size.", [["comprehensive proteome tiling", "PROBLEM", 9, 38], ["many higher complexity organisms", "PROBLEM", 43, 75], ["size", "OBSERVATION_MODIFIER", 129, 133]]], ["Similarly, the tiling of overlapping peptides from sets of a priori known antigens from eight tick-borne pathogens enabled construction of a planar peptide arrays with 170,000 features enabling detection of each infection2.", [["antigens", "PROTEIN", 74, 82], ["overlapping peptides", "PROBLEM", 25, 45], ["a priori known antigens", "PROBLEM", 59, 82], ["eight tick-borne pathogens", "PROBLEM", 88, 114], ["a planar peptide arrays", "TREATMENT", 139, 162], ["each infection2", "PROBLEM", 207, 222]]], ["In principle, this method could be expanded to include a larger number of pathogens but requires known antigens or epitopes, and does not provide sufficient peptide diversity to mimic diverse structural epitopes.", [["antigens", "PROTEIN", 103, 111], ["epitopes", "PROTEIN", 115, 123], ["structural epitopes", "PROTEIN", 192, 211], ["pathogens", "PROBLEM", 74, 83], ["epitopes", "PROBLEM", 115, 123], ["larger", "OBSERVATION_MODIFIER", 57, 63], ["number", "OBSERVATION_MODIFIER", 64, 70], ["pathogens", "OBSERVATION", 74, 83]]], ["Random peptide arrays of up to 330,000 members have proven effective to detect antibodies towards a range of organisms (i.e., viral, bacterial, fungal)13.", [["antibodies", "PROTEIN", 79, 89], ["Random peptide arrays", "TEST", 0, 21], ["antibodies", "TEST", 79, 89], ["organisms", "PROBLEM", 109, 118], ["viral, bacterial, fungal)", "PROBLEM", 126, 151]]], ["Yet, they lack the diversity required to effectively mimic arbitrary protein antigens, and thereby detect the corresponding antibodies.", [["protein antigens", "PROTEIN", 69, 85], ["antibodies", "PROTEIN", 124, 134], ["arbitrary protein antigens", "TEST", 59, 85], ["the corresponding antibodies", "PROBLEM", 106, 134]]], ["Thus, methods to analyze entire antibody repertoires to reveal the spectrum of antigenic epitopes are needed.IntroductionTo enable epitope resolution analysis of immune responses towards any organism, we applied parallel advancements in peptide display library technology14, next-generation sequencing (NGS), and computational discovery algorithms15.", [["antigenic epitopes", "PROTEIN", 79, 97], ["entire antibody repertoires", "TEST", 25, 52], ["antigenic epitopes", "PROBLEM", 79, 97], ["immune responses", "PROBLEM", 162, 178], ["any organism", "PROBLEM", 187, 199]]], ["We applied serum epitope repertoire analysis (SERA) to discover shared, but highly specific immunogenic epitope motifs associated with Chagas disease caused by the protozoan parasite Trypanosoma cruzi, and thereby develop a serological assay.", [["serum", "ANATOMY", 11, 16], ["Chagas disease", "DISEASE", 135, 149], ["Trypanosoma cruzi", "DISEASE", 183, 200], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["protozoan parasite", "ORGANISM", 164, 182], ["Trypanosoma cruzi", "ORGANISM", 183, 200], ["serum epitope repertoire", "PROTEIN", 11, 35], ["Trypanosoma cruzi", "SPECIES", 183, 200], ["Trypanosoma cruzi", "SPECIES", 183, 200], ["serum epitope repertoire analysis", "TEST", 11, 44], ["immunogenic epitope motifs", "PROBLEM", 92, 118], ["Chagas disease", "PROBLEM", 135, 149], ["the protozoan parasite Trypanosoma cruzi", "PROBLEM", 160, 200], ["a serological assay", "TEST", 222, 241]]], ["Chagas disease is estimated to impact more than 300,000 people in the United States and 8 million in Central and South America16.", [["Chagas disease", "DISEASE", 0, 14], ["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62], ["Chagas disease", "PROBLEM", 0, 14]]], ["Confirmatory testing currently requires the use of three serology tests - two parallel, independent tests, and a third \u201ctie-breaker\u201d test to achieve a specificity of >99%.", [["Confirmatory testing", "TEST", 0, 20], ["three serology tests", "TEST", 51, 71], ["independent tests", "TEST", 88, 105], ["a specificity", "TEST", 149, 162]]], ["Thus, a single test with high specificity could streamline confirmatory testing and screening in blood donors and at-risk groups17.", [["blood", "ANATOMY", 97, 102], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["a single test", "TEST", 6, 19], ["streamline confirmatory testing", "TEST", 48, 79], ["screening", "TEST", 84, 93], ["blood donors", "TEST", 97, 109]]], ["Our results indicate that NGS-based serology using SERA provides an effective approach to antigen and epitope discovery, and an assay format capable of achieving exceptional diagnostic specificity without multiplexing limitations.Discovery of Chagas disease-specific antigen motifs ::: ResultsBiospecimens seropositive for Chagas disease (n = 28) and negative controls (n = 30) were provided by the Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria (CDC-DPDM) Reference Lab (Table 1, Supplemental Table S1).", [["Chagas disease", "DISEASE", 243, 257], ["Chagas disease", "DISEASE", 323, 337], ["Parasitic Diseases and Malaria", "DISEASE", 455, 485], ["NGS", "PROTEIN", 26, 29], ["SERA", "PROTEIN", 51, 55], ["Chagas disease-specific antigen motifs", "DNA", 243, 281], ["NGS", "TEST", 26, 29], ["based serology", "TEST", 30, 44], ["SERA", "TREATMENT", 51, 55], ["an assay", "TEST", 125, 133], ["Chagas disease", "PROBLEM", 243, 257], ["ResultsBiospecimens", "TEST", 286, 305], ["Chagas disease", "PROBLEM", 323, 337], ["Disease Control", "TREATMENT", 411, 426], ["Parasitic Diseases", "PROBLEM", 455, 473], ["Malaria", "PROBLEM", 478, 485], ["Chagas disease", "OBSERVATION", 243, 257], ["Parasitic Diseases", "OBSERVATION", 455, 473]]], ["Specimens were from males and females, with a mean age of 42+/\u221217 years, and residing primarily in the southern United States.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["All disease specimens were seropositive for Chagas disease using the CDC two-test algorithm requiring seropositivity on both the Chagas Antigen ELISA, and a separate immunoblot.", [["specimens", "ANATOMY", 12, 21], ["Chagas disease", "DISEASE", 44, 58], ["All disease specimens", "TEST", 0, 21], ["Chagas disease", "PROBLEM", 44, 58], ["the CDC two-test algorithm", "TEST", 65, 91], ["seropositivity", "PROBLEM", 102, 116], ["the Chagas Antigen ELISA", "TEST", 125, 149], ["a separate immunoblot", "TEST", 155, 176]]], ["One of 28 specimens exhibited discordant ELISA/immunoblot results, and a second-tier IFA test was used to resolve the discordancy.", [["specimens", "ANATOMY", 10, 19], ["specimens", "CANCER", 10, 19], ["discordant ELISA/immunoblot results", "PROBLEM", 30, 65], ["a second-tier IFA test", "TEST", 71, 93], ["the discordancy", "PROBLEM", 114, 129]]], ["Additional presumed non-Chagas specimens (n = 170) were sourced from commercial vendors.Discovery of Chagas disease-specific antigen motifs ::: ResultsEach specimen was incubated with the peptide library and antibody binders were separated using Protein A/G-conjugated magnetic beads.", [["non-Chagas specimens", "ANATOMY", 20, 40], ["ResultsEach specimen", "ANATOMY", 144, 164], ["Chagas disease", "DISEASE", 101, 115], ["non-Chagas specimens", "CANCER", 20, 40], ["ResultsEach specimen", "CANCER", 144, 164], ["Chagas disease-specific antigen motifs", "DNA", 101, 139], ["Protein A/G", "PROTEIN", 246, 257], ["non-Chagas specimens", "TEST", 20, 40], ["Chagas disease", "PROBLEM", 101, 115], ["ResultsEach specimen", "TEST", 144, 164], ["the peptide library", "TREATMENT", 184, 203], ["antibody binders", "TREATMENT", 208, 224], ["Protein A/G-conjugated magnetic beads", "TREATMENT", 246, 283], ["Chagas disease", "OBSERVATION", 101, 115]]], ["After amplifying the selected population through growth, plasmids were prepared and the peptide-encoding regions were amplified via PCR with a unique oligonucleotide bar-code for each specimen.", [["plasmids", "ANATOMY", 57, 65], ["specimen", "ANATOMY", 184, 192], ["plasmids", "DNA", 57, 65], ["plasmids", "TREATMENT", 57, 65], ["the peptide-encoding regions", "TREATMENT", 84, 112], ["a unique oligonucleotide bar", "TREATMENT", 141, 169]]], ["The resulting amplicon libraries were pooled and the DNA sequences of the peptide encoding regions were determined using NGS.", [["DNA", "CELLULAR_COMPONENT", 53, 56], ["DNA sequences", "DNA", 53, 66], ["The resulting amplicon libraries", "TREATMENT", 0, 32], ["the DNA sequences", "TEST", 49, 66], ["NGS", "TEST", 121, 124], ["amplicon libraries", "OBSERVATION", 14, 32]]], ["On average, ~7 million total sequence reads and ~3 million unique reads were determined for each bar-code and corresponding specimen.", [["specimen", "ANATOMY", 124, 132]]], ["The set of unique antibody binding peptides for each specimen, or epitope repertoire, was inferred by translation of the DNA sequences into amino acid sequences, and unique sequences were archived for bioinformatic analysis.Discovery of Chagas disease-specific antigen motifs ::: ResultsTo identify antibody epitope motifs specific to Chagas disease, we applied the IMUNE motif discovery algorithm15 (see Methods for parameters) to epitope repertoires from 28 Chagas specimens and 30 non-Chagas sera, yielding 331 candidate motifs (Supplementary Table S2).", [["specimen", "ANATOMY", 53, 61], ["specimens", "ANATOMY", 467, 476], ["sera", "ANATOMY", 495, 499], ["amino acid", "CHEMICAL", 140, 150], ["Chagas disease", "DISEASE", 237, 251], ["Chagas disease", "DISEASE", 335, 349], ["amino acid", "CHEMICAL", 140, 150], ["antibody binding peptides", "GENE_OR_GENE_PRODUCT", 18, 43], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["amino acid", "AMINO_ACID", 140, 150], ["sera", "ORGANISM_SUBSTANCE", 495, 499], ["epitope repertoire", "PROTEIN", 66, 84], ["DNA sequences", "DNA", 121, 134], ["Chagas disease-specific antigen motifs", "DNA", 237, 275], ["antibody epitope motifs", "PROTEIN", 299, 322], ["IMUNE motif discovery algorithm15", "DNA", 366, 399], ["each specimen", "TEST", 48, 61], ["the DNA sequences", "TEST", 117, 134], ["amino acid sequences", "TEST", 140, 160], ["unique sequences", "TEST", 166, 182], ["bioinformatic analysis", "TEST", 201, 223], ["Chagas disease", "PROBLEM", 237, 251], ["antibody epitope motifs", "PROBLEM", 299, 322], ["Chagas disease", "PROBLEM", 335, 349], ["epitope repertoires", "TEST", 432, 451], ["Chagas specimens", "TEST", 460, 476], ["Chagas sera", "TEST", 488, 499], ["Chagas disease", "OBSERVATION", 237, 251]]], ["We then down-selected the full set of IMUNE output motifs by requiring a retained motif to be (i) significantly enriched (\u22654 standard deviations from mean of the controls) in at least 15% of Chagas specimens (n = 28) and (ii) absent from control repertoires (i.e., non-significantly enriched (<4 standard deviations from mean of controls) in 99% of control epitope repertoires (n = 200).", [["specimens", "ANATOMY", 198, 207], ["IMUNE output motifs", "DNA", 38, 57], ["IMUNE output motifs", "TREATMENT", 38, 57], ["a retained motif", "PROBLEM", 71, 87], ["Chagas specimens", "TEST", 191, 207], ["epitope repertoires", "TEST", 357, 376]]], ["Downselection yielded 194 motifs with sensitivities ranging from 18\u201380% (Supplementary Table S2).", [["Downselection", "TEST", 0, 13], ["sensitivities", "TEST", 38, 51]]], ["IMUNE identified overlapping groups of motifs that mapped to the same T. cruzi epitopes and occurred in the same subsets of epitope repertoires.", [["T. cruzi", "ORGANISM", 70, 78], ["T. cruzi epitopes", "PROTEIN", 70, 87], ["epitope repertoires", "PROTEIN", 124, 143], ["T. cruzi", "SPECIES", 70, 78], ["T. cruzi", "SPECIES", 70, 78], ["overlapping groups of motifs", "PROBLEM", 17, 45], ["epitope repertoires", "TREATMENT", 124, 143], ["cruzi epitopes", "OBSERVATION", 73, 87], ["epitope repertoires", "OBSERVATION", 124, 143]]], ["For example, [FW]KPWE and EGxKxWE shared three identities, and both occurred within a metacaspase 7-mer epitope EGFKPWE.", [["EGxKxWE", "PROTEIN", 26, 33], ["metacaspase 7-mer epitope", "PROTEIN", 86, 111], ["EGFKPWE", "PROTEIN", 112, 119], ["FW", "TEST", 14, 16], ["a metacaspase", "TEST", 84, 97]]], ["Motifs mapping to the same epitope were grouped and their equivalence was confirmed by clustering of motif seropositivity (Supplementary Table S3).", [["Motifs mapping", "TEST", 0, 14], ["motif seropositivity", "PROBLEM", 101, 121]]], ["Thus, IMUNE yielded more than 100 Chagas disease specific motifs (>99% specificity) with varying sensitivity (Fig. 2a).", [["IMUNE", "CHEMICAL", 6, 11], ["IMUNE", "PROTEIN", 6, 11], ["IMUNE", "TEST", 6, 11], ["100 Chagas disease specific motifs", "PROBLEM", 30, 64]]], ["Individual motifs were remarkably specific to Chagas disease, as determined by inspection of their corresponding Enrichment values (# observations/# expected) within the discovery set of 200 epitope repertoires (Fig. 2b).Construction of a chagas disease motif panel ::: ResultsMotifs within a given epitope group with the highest mean enrichment and sensitivity were selected for inclusion into a diagnostic motif panel.", [["Chagas disease", "DISEASE", 46, 60], ["Individual motifs", "TEST", 0, 17], ["Chagas disease", "PROBLEM", 46, 60], ["epitope group", "TREATMENT", 299, 312], ["a diagnostic motif panel", "TEST", 395, 419]]], ["In two cases, two motifs from the same group were included in the panel because their combination increased sensitivity.", [["increased sensitivity", "PROBLEM", 98, 119]]], ["Chagas-specific motifs exhibited variable enrichments of up to 150-fold and each motif was present in a different subset of disease repertoires (Figs.", [["Chagas", "TEST", 0, 6], ["variable enrichments", "PROBLEM", 33, 53], ["variable", "OBSERVATION_MODIFIER", 33, 41], ["enrichments", "OBSERVATION", 42, 53]]], ["Motif enrichment values were standardized using the mean and standard deviation of enrichments within non-Chagas repertoires.", [["Motif enrichment values", "TEST", 0, 23], ["the mean", "TEST", 48, 56]]], ["Individual Chagas motif \u201cz-scores\u201d were then summed to obtain a composite SERA score for each epitope repertoire.", [["SERA", "PROTEIN", 74, 78], ["epitope repertoire", "PROTEIN", 94, 112], ["Individual Chagas motif", "TEST", 0, 23], ["a composite SERA score", "TEST", 62, 84], ["each epitope repertoire", "TREATMENT", 89, 112]]], ["A composite score threshold of 50 readily captured 26/28 serologically defined Chagas specimens with 100% specificity (0/200 controls) (Fig. 3b).Motif panel performance in a randomized, blinded validation set ::: ResultsTo evaluate the performance of Chagas panel v1.0, a blinded and randomized set of 72 biospecimens (Table 1, Supplementary Table S1) was analyzed by SERA and composite scores were calculated (Fig. 4a,b).", [["specimens", "ANATOMY", 86, 95], ["Chagas specimens", "CANCER", 79, 95], ["SERA", "PROTEIN", 368, 372], ["A composite score threshold", "TEST", 0, 27], ["Chagas specimens", "TEST", 79, 95], ["Motif panel performance", "TEST", 145, 168], ["Chagas panel v", "TEST", 251, 265], ["Supplementary Table S1)", "TREATMENT", 328, 351]]], ["The set contained 12 Leishmania seropositive specimens, known to cause false positives in Chagas serology tests19, due to the relatedness of these organisms.", [["specimens", "ANATOMY", 45, 54], ["Chagas serology tests19", "DISEASE", 90, 113], ["Leishmania", "ORGANISM", 21, 31], ["12 Leishmania seropositive specimens", "PROBLEM", 18, 54], ["false positives", "PROBLEM", 71, 86], ["Chagas serology tests19", "TEST", 90, 113], ["these organisms", "PROBLEM", 141, 156], ["false positives", "OBSERVATION", 71, 86]]], ["Even so, the panel accurately classified all 30 Chagas as positive, as well as 30 non-Chagas controls and 11/12 Leishmania as negative (Fig. 4a,b).", [["the panel", "TEST", 9, 18], ["Chagas", "TEST", 48, 54], ["Chagas controls", "TEST", 86, 101], ["Leishmania", "PROBLEM", 112, 122]]], ["A second Leishmania seropositive epitope repertoire was similarly elevated on Chagas panel v1.0 but classified as negative (Fig. 4b).", [["Leishmania seropositive epitope repertoire", "PROTEIN", 9, 51], ["A second Leishmania seropositive epitope repertoire", "TEST", 0, 51], ["Chagas panel v", "TEST", 78, 92], ["Leishmania", "OBSERVATION", 9, 19], ["elevated", "OBSERVATION_MODIFIER", 66, 74], ["negative", "OBSERVATION", 114, 122]]], ["Inspection of the Leishmania motif enrichments revealed that the motif [ADP]GGFG was enriched in these two Leishmania specimens (Fig. 4a), and present in the proteomes of both T. cruzi and Leishmania.", [["specimens", "ANATOMY", 118, 127], ["ADP", "CHEMICAL", 72, 75], ["ADP", "CHEMICAL", 72, 75], ["T. cruzi", "ORGANISM", 176, 184], ["Leishmania", "ORGANISM", 189, 199], ["T. cruzi", "SPECIES", 176, 184], ["T. cruzi", "SPECIES", 176, 184], ["the Leishmania motif enrichments", "TEST", 14, 46], ["the motif [ADP]GGFG", "TEST", 61, 80], ["Leishmania", "PROBLEM", 189, 199], ["cruzi", "OBSERVATION", 179, 184], ["Leishmania", "OBSERVATION", 189, 199]]], ["Removal of this motif from the panel, yielded Chagas panel v1.1 which resulted in a sensitivity and specificity of 100% within the first validation set (Fig. 4c).Motif panel performance in a randomized, blinded validation set ::: ResultsTo further evaluate the performance of Chagas panel v1.1, we processed an additional 120 blinded and randomized validation sera from the CDC that contained sera from subjects with Chagas disease and three other parasitic diseases (Table 1).", [["sera", "ANATOMY", 360, 364], ["sera", "ANATOMY", 393, 397], ["Chagas disease", "DISEASE", 417, 431], ["parasitic diseases", "DISEASE", 448, 466], ["sera", "ORGANISM_SUBSTANCE", 360, 364], ["sera", "ORGANISM_SUBSTANCE", 393, 397], ["Removal", "TREATMENT", 0, 7], ["this motif from the panel", "TEST", 11, 36], ["Chagas panel v", "TEST", 46, 60], ["specificity", "TEST", 100, 111], ["Motif panel performance", "TEST", 162, 185], ["Chagas panel", "TEST", 276, 288], ["randomized validation sera", "TEST", 338, 364], ["Chagas disease", "PROBLEM", 417, 431], ["three other parasitic diseases", "PROBLEM", 436, 466], ["Chagas disease", "OBSERVATION", 417, 431], ["parasitic", "OBSERVATION_MODIFIER", 448, 457], ["diseases", "OBSERVATION", 458, 466]]], ["Panel scores were again calculated for this set.", [["Panel scores", "TEST", 0, 12]]], ["The panel was 100% sensitive and specific within this second, blinded validation set (Fig. 4d,c).", [["The panel", "TEST", 0, 9], ["blinded validation", "TEST", 62, 80]]], ["To further investigate the specificity SERA Chagas panel v1.1, 1000 epitope repertoires from individuals with unknown Chagas serostatus were analyzed.", [["Chagas serostatus", "DISEASE", 118, 135], ["the specificity", "TEST", 23, 38], ["Chagas panel v", "TEST", 44, 58], ["epitope repertoires", "TEST", 68, 87], ["Chagas serostatus", "TEST", 118, 135]]], ["Remarkably, just 2/1000 had composite scores above the threshold, thereby yielding an apparent lower bound of specificity of 99.8% (Fig. 4e).", [["specificity", "TEST", 110, 121]]], ["In summary, Chagas panel v1.1 exhibited 100% sensitivity (60/60) and \u226599.8% specificity within the validation cohorts.Identification of candidate antigens from Chagas-specific motifs ::: ResultsSERA Chagas panel v1.1 motifs were queried against the Trypanasoma cruzi proteome to identify candidate antigens and their antibody recognition epitopes.", [["Trypanasoma cruzi", "ORGANISM", 249, 266], ["candidate antigens", "PROTEIN", 136, 154], ["ResultsSERA Chagas panel v1.1 motifs", "DNA", 187, 223], ["candidate antigens", "PROTEIN", 288, 306], ["antibody recognition epitopes", "PROTEIN", 317, 346], ["Trypanasoma cruzi", "SPECIES", 249, 266], ["Trypanasoma cruzi", "SPECIES", 249, 266], ["Chagas panel v", "TEST", 12, 26], ["sensitivity", "TEST", 45, 56], ["\u2265", "TEST", 69, 70], ["ResultsSERA Chagas panel", "TEST", 187, 211], ["their antibody recognition epitopes", "PROBLEM", 311, 346]]], ["Several Chagas-specific motifs occurred as exact matches within established serological antigens, including trans-sialidase, MASP, and CA-2 (Table 2).", [["trans-sialidase", "GENE_OR_GENE_PRODUCT", 108, 123], ["MASP", "GENE_OR_GENE_PRODUCT", 125, 129], ["CA-2", "GENE_OR_GENE_PRODUCT", 135, 139], ["Table 2", "GENE_OR_GENE_PRODUCT", 141, 148], ["Chagas-specific motifs", "DNA", 8, 30], ["serological antigens", "PROTEIN", 76, 96], ["sialidase", "PROTEIN", 114, 123], ["MASP", "PROTEIN", 125, 129], ["CA", "PROTEIN", 135, 137], ["Several Chagas-specific motifs", "PROBLEM", 0, 30], ["trans-sialidase", "TEST", 108, 123], ["MASP", "TEST", 125, 129], ["CA", "TEST", 135, 137], ["Chagas", "OBSERVATION", 8, 14]]], ["Some motifs occurred multiple times within repeat regions of their corresponding candidate antigen.", [["Some motifs", "PROBLEM", 0, 11]]], ["For example, there were 11 instances of AGxKPx[AE] within the established antigen trans-sialidase, 51 copies of GxAAAxxK within Surface antigen 2 (CA-2), and 19 copies of Yx[AP]Vxxx[AS]Y within microtubule-associated protein (Table 2).", [["microtubule", "ANATOMY", 194, 205], ["AGxKPx", "GENE_OR_GENE_PRODUCT", 40, 46], ["antigen trans-sialidase", "GENE_OR_GENE_PRODUCT", 74, 97], ["Surface antigen 2", "GENE_OR_GENE_PRODUCT", 128, 145], ["CA-2", "GENE_OR_GENE_PRODUCT", 147, 151], ["AS]Y", "GENE_OR_GENE_PRODUCT", 182, 186], ["microtubule-associated protein (Table 2", "GENE_OR_GENE_PRODUCT", 194, 233], ["sialidase", "PROTEIN", 88, 97], ["GxAAAxxK", "PROTEIN", 112, 120], ["Surface antigen 2", "PROTEIN", 128, 145], ["CA", "PROTEIN", 147, 149], ["Yx[AP]Vxxx", "PROTEIN", 171, 181], ["microtubule-associated protein", "PROTEIN", 194, 224], ["Table 2", "PROTEIN", 226, 233], ["AGxKPx", "TEST", 40, 46], ["GxAAAxxK", "TEST", 112, 120], ["Surface antigen", "TEST", 128, 143], ["CA", "TEST", 147, 149], ["Yx", "TEST", 171, 173], ["AP]Vxxx", "TEST", 174, 181]]], ["A few candidate antigens harboring Chagas-specific motifs, including Metacaspase, and Kinetoplast DNA-associated protein have not been described previously as antigens (Table 2).", [["Metacaspase", "GENE_OR_GENE_PRODUCT", 69, 80], ["Kinetoplast", "GENE_OR_GENE_PRODUCT", 86, 97], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["Chagas-specific motifs", "DNA", 35, 57], ["Metacaspase", "PROTEIN", 69, 80], ["Kinetoplast DNA-associated protein", "PROTEIN", 86, 120], ["antigens", "PROTEIN", 159, 167], ["Metacaspase", "TEST", 69, 80], ["Kinetoplast DNA", "PROBLEM", 86, 101], ["associated protein", "PROBLEM", 102, 120]]], ["These results demonstrate that motifs frequently contain sufficient information content to identify their corresponding antigens and that SERA identifies bona fide pathogen antigens.DiscussionHere we present a general methodology for serum epitope repertoire analysis (SERA) to rapidly discover the immunogenic epitopes within an organism proteome, and to arbitrarily multiplex the detection of epitope-specific antibodies to develop high performance NGS-based serology assays.", [["serum", "ANATOMY", 234, 239], ["SERA", "GENE_OR_GENE_PRODUCT", 138, 142], ["bona fide pathogen antigens", "GENE_OR_GENE_PRODUCT", 154, 181], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["antigens", "PROTEIN", 120, 128], ["SERA", "PROTEIN", 138, 142], ["bona fide pathogen antigens", "PROTEIN", 154, 181], ["serum epitope repertoire", "PROTEIN", 234, 258], ["immunogenic epitopes", "PROTEIN", 299, 319], ["epitope-specific antibodies", "PROTEIN", 395, 422], ["serum epitope repertoire analysis", "TEST", 234, 267], ["the immunogenic epitopes", "PROBLEM", 295, 319], ["epitope-specific antibodies", "PROBLEM", 395, 422], ["high performance NGS", "PROBLEM", 434, 454], ["based serology assays", "TEST", 455, 476]]], ["Within Chagas disease sera, many conserved epitopes were identified as sequence motifs representing the shared amino acid preferences within established and putative candidate Trypanosoma cruzi antigens.", [["sera", "ANATOMY", 22, 26], ["Chagas disease", "DISEASE", 7, 21], ["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 111, 121], ["sera", "ORGANISM_SUBSTANCE", 22, 26], ["amino acid", "AMINO_ACID", 111, 121], ["Trypanosoma cruzi antigens", "ORGANISM", 176, 202], ["Trypanosoma cruzi antigens", "PROTEIN", 176, 202], ["Trypanosoma cruzi", "SPECIES", 176, 193], ["Trypanosoma cruzi", "SPECIES", 176, 193], ["Chagas disease sera", "PROBLEM", 7, 26], ["many conserved epitopes", "PROBLEM", 28, 51], ["sequence motifs", "TEST", 71, 86], ["the shared amino acid preferences", "PROBLEM", 100, 133], ["Trypanosoma cruzi antigens", "PROBLEM", 176, 202]]], ["Measurement of motif enrichments within the set of all Ig-binding peptides for a given specimen (the epitope repertoire) provided a quantitative measure of epitope-specific Ig binding activity that could be multiplexed as desired to detect any number of epitope-specific antibodies.", [["specimen", "ANATOMY", 87, 95], ["Ig-binding peptides", "GENE_OR_GENE_PRODUCT", 55, 74], ["Ig", "GENE_OR_GENE_PRODUCT", 173, 175], ["Ig", "PROTEIN", 55, 57], ["epitope repertoire", "PROTEIN", 101, 119], ["epitope-specific antibodies", "PROTEIN", 254, 281], ["motif enrichments", "TEST", 15, 32], ["Ig binding activity", "PROBLEM", 173, 192], ["epitope", "TEST", 254, 261], ["motif enrichments", "OBSERVATION", 15, 32]]], ["A random peptide library of 10 billion 12-mers provided sufficient diversity to represent all possible 6 amino acid motifs with 99% confidence, and all possible 7-mers with 98% confidence.", [["amino acid", "CHEMICAL", 105, 115], ["amino acid", "CHEMICAL", 105, 115], ["amino acid", "AMINO_ACID", 105, 115], ["6 amino acid motifs", "PROTEIN", 103, 122], ["A random peptide library", "TEST", 0, 24], ["6 amino acid motifs", "PROBLEM", 103, 122]]], ["This diversity is thus about 10,000\u2013100,000-fold greater than that represented by pathogen proteome peptide arrays (e.g., representing a specific pathogen)11 or random peptide arrays13.", [["pathogen proteome peptide arrays", "TREATMENT", 82, 114], ["a specific pathogen)", "PROBLEM", 135, 155], ["random peptide arrays", "TREATMENT", 161, 182]]], ["SERA differs from reported phage display library immunoprecipitation (PhIP) or VirScan11 approaches to antibody repertoire profiling, in that it makes no assumptions about which organisms, strains, or specific epitopes may be targeted by antibodies.", [["PhIP", "CHEMICAL", 70, 74], ["SERA", "GENE_OR_GENE_PRODUCT", 0, 4], ["PhIP", "SIMPLE_CHEMICAL", 70, 74], ["SERA", "PROTEIN", 0, 4], ["antibodies", "PROTEIN", 238, 248], ["library immunoprecipitation", "TEST", 41, 68], ["VirScan11 approaches", "TREATMENT", 79, 99], ["antibody repertoire profiling", "TEST", 103, 132], ["strains", "PROBLEM", 189, 196], ["specific epitopes", "PROBLEM", 201, 218]]], ["Consequently, SERA provides a universal approach that can be applied to analyze the immune response to virtually any biological organism or protein antigen - including pathogens, commensals, allergens, biologics and autoantigens.DiscussionThe diagnostic accuracy of SERA, measured by combined sensitivity and specificity, was superior to that reported for diagnostics in current use for Chagas disease confirmatory testing.", [["Chagas disease", "DISEASE", 387, 401], ["SERA", "PROTEIN", 14, 18], ["protein antigen", "PROTEIN", 140, 155], ["autoantigens", "PROTEIN", 216, 228], ["SERA", "PROTEIN", 266, 270], ["SERA", "TREATMENT", 14, 18], ["a universal approach", "TREATMENT", 28, 48], ["any biological organism", "PROBLEM", 113, 136], ["protein antigen", "TEST", 140, 155], ["pathogens", "PROBLEM", 168, 177], ["SERA", "TEST", 266, 270], ["Chagas disease confirmatory testing", "TEST", 387, 422]]], ["Chagas disease resulting from infection with the protozoan parasite T. cruzi may be asymptomatic, and chronic, untreated infection can lead to heart failure and death20.", [["heart", "ANATOMY", 143, 148], ["Chagas disease", "DISEASE", 0, 14], ["infection", "DISEASE", 30, 39], ["T. cruzi", "DISEASE", 68, 76], ["infection", "DISEASE", 121, 130], ["heart failure", "DISEASE", 143, 156], ["T. cruzi", "ORGANISM", 68, 76], ["heart", "ORGAN", 143, 148], ["T. cruzi", "SPECIES", 68, 76], ["T. cruzi", "SPECIES", 68, 76], ["Chagas disease", "PROBLEM", 0, 14], ["infection", "PROBLEM", 30, 39], ["the protozoan parasite T. cruzi", "PROBLEM", 45, 76], ["asymptomatic", "PROBLEM", 84, 96], ["chronic, untreated infection", "PROBLEM", 102, 130], ["heart failure", "PROBLEM", 143, 156], ["death20", "PROBLEM", 161, 168], ["infection", "OBSERVATION", 30, 39], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["untreated", "OBSERVATION_MODIFIER", 111, 120], ["infection", "OBSERVATION", 121, 130], ["heart", "ANATOMY", 143, 148], ["failure", "OBSERVATION", 149, 156]]], ["Transfusions from asymptomatic, infected donors may transmit the parasite to blood recipients.", [["blood", "ANATOMY", 77, 82], ["donors", "ORGANISM", 41, 47], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["Transfusions", "TREATMENT", 0, 12], ["asymptomatic", "PROBLEM", 18, 30], ["infected donors", "TREATMENT", 32, 47], ["infected", "OBSERVATION", 32, 40]]], ["Consequently, serologic testing for Chagas disease is included in routine blood bank testing of donors.", [["blood", "ANATOMY", 74, 79], ["Chagas disease", "DISEASE", 36, 50], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["donors", "ORGANISM", 96, 102], ["serologic testing", "TEST", 14, 31], ["Chagas disease", "PROBLEM", 36, 50], ["routine blood bank testing", "TEST", 66, 92]]], ["For confirmatory testing and screening, no single serological test achieves adequate specificity, necessitating the use of two or three independent serology tests.", [["confirmatory testing", "TEST", 4, 24], ["screening", "TEST", 29, 38], ["single serological test", "TEST", 43, 66], ["three independent serology tests", "TEST", 130, 162]]], ["Using Chagas disease seropositive specimens, a panel of 31 peptide motifs was identified that exhibited 100% sensitivity (60/60) and 100% specificity (120/120) in independent validation sets.", [["specimens", "ANATOMY", 34, 43], ["Chagas disease", "DISEASE", 6, 20], ["Chagas disease seropositive specimens", "TEST", 6, 43], ["a panel", "TEST", 45, 52], ["peptide motifs", "TEST", 59, 73]]], ["Remarkably, the Chagas SERA assay exhibited 99.8% specificity (998/1000) amongst sera without known Chagas serostatus, which compares favorably to the combined sensitivity and specificity of individual, FDA-cleared tests17.", [["sera", "ANATOMY", 81, 85], ["sera", "ORGANISM_SUBSTANCE", 81, 85], ["the Chagas SERA assay", "TEST", 12, 33], ["known Chagas serostatus", "PROBLEM", 94, 117], ["FDA", "TEST", 203, 206]]], ["The exceptional specificity of SERA could be expected to yield fewer false positive tests, a feature that may be useful in screening and surveillance studies21, particularly when multiple tests are performed in parallel.DiscussionSix genetic lineages of T. cruzi or DTUs (discrete typing units) have been described that infect humans.", [["DTUs", "ANATOMY", 266, 270], ["SERA", "GENE_OR_GENE_PRODUCT", 31, 35], ["T. cruzi", "ORGANISM", 254, 262], ["DTUs", "GENE_OR_GENE_PRODUCT", 266, 270], ["humans", "ORGANISM", 327, 333], ["SERA", "PROTEIN", 31, 35], ["T. cruzi", "SPECIES", 254, 262], ["humans", "SPECIES", 327, 333], ["T. cruzi", "SPECIES", 254, 262], ["humans", "SPECIES", 327, 333], ["fewer false positive tests", "PROBLEM", 63, 89], ["screening", "TEST", 123, 132], ["surveillance studies21", "TEST", 137, 159], ["multiple tests", "TEST", 179, 193], ["T. cruzi", "PROBLEM", 254, 262], ["DTUs", "PROBLEM", 266, 270]]], ["These DTUs show different geographic distributions and may generate strain specific immune responses22.", [["These DTUs", "TEST", 0, 10], ["different", "OBSERVATION_MODIFIER", 16, 25], ["geographic distributions", "OBSERVATION", 26, 50]]], ["The specimens in our study are from individuals receiving confirmatory testing at the CDC DPDRL, and are of undetermined DTU.", [["specimens", "ANATOMY", 4, 13], ["DTU", "CANCER", 121, 124], ["our study", "TEST", 17, 26], ["confirmatory testing", "TEST", 58, 78]]], ["However, the 28 specimens used for discovery were from subjects who had lived or travelled in multiple countries where different DTUs are prevalent including Bolivia, Brazil, El Salvador, Mexico, Ecuador, Costa Rica, Nicaragua and Argentina22 (Supplementary Table S1).", [["specimens", "ANATOMY", 16, 25], ["DTUs", "DISEASE", 129, 133]]], ["We were able to identify a set of epitope motifs that were conserved among these subjects, and independently validated with a sensitivity of 100% in a randomized, blinded set, demonstrating that the discovered motifs effectively captured the diversity in T. cruzi DTUs among the tested population.", [["T. cruzi DTUs", "ORGANISM", 255, 268], ["T. cruzi", "SPECIES", 255, 263], ["T. cruzi", "SPECIES", 255, 263], ["epitope motifs", "TREATMENT", 34, 48], ["a sensitivity", "TEST", 124, 137], ["cruzi DTUs", "OBSERVATION", 258, 268]]], ["Nevertheless, our discovery and validation specimens may not represent all DTUs, and thus, expanded validation amongst a larger cohort with known DTU may reveal whether all DTUs are detected with equivalent sensitivity.", [["specimens", "ANATOMY", 43, 52], ["DTU", "CANCER", 146, 149], ["DTUs", "CANCER", 173, 177], ["validation specimens", "TEST", 32, 52], ["all DTUs", "PROBLEM", 71, 79], ["all DTUs", "PROBLEM", 169, 177], ["may not represent", "UNCERTAINTY", 53, 70], ["all", "OBSERVATION_MODIFIER", 71, 74], ["DTUs", "OBSERVATION", 75, 79]]], ["Additionally, we do not know whether these individuals were in the acute or chronic phase of infection.", [["infection", "DISEASE", 93, 102], ["individuals", "ORGANISM", 43, 54], ["infection", "PROBLEM", 93, 102], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["phase", "OBSERVATION_MODIFIER", 84, 89], ["infection", "OBSERVATION", 93, 102]]], ["Testing of subjects in which the phase of infection is known is necessary to determine whether our test has differential sensitivity based on phase of infection.DiscussionThere are at least two likely reasons for the improved specificity observed with SERA.", [["infection", "DISEASE", 42, 51], ["infection", "DISEASE", 151, 160], ["SERA", "PROTEIN", 252, 256], ["infection", "PROBLEM", 42, 51], ["our test", "TEST", 95, 103], ["differential sensitivity", "PROBLEM", 108, 132], ["infection", "PROBLEM", 151, 160], ["SERA", "TREATMENT", 252, 256], ["infection", "OBSERVATION", 42, 51], ["infection", "OBSERVATION", 151, 160]]], ["First, panels are constructed using exclusively specific epitopes within protein antigens and those epitopes that that cross-react can easily be identified and removed.", [["epitopes", "PROTEIN", 57, 65], ["protein antigens", "PROTEIN", 73, 89], ["epitopes", "PROTEIN", 100, 108]]], ["Unlike conventional serology in which whole antigens or organism lysates are often used as detection reagents3, SERA excludes a large number of potentially cross-reactive epitopes introduced by using whole protein antigens.", [["lysates", "ANATOMY", 65, 72], ["SERA", "PROTEIN", 112, 116], ["cross-reactive epitopes", "PROTEIN", 156, 179], ["whole protein antigens", "PROTEIN", 200, 222], ["conventional serology", "TEST", 7, 28], ["organism lysates", "PROBLEM", 56, 72], ["detection reagents3", "TEST", 91, 110], ["SERA", "TEST", 112, 116], ["potentially cross-reactive epitopes", "TREATMENT", 144, 179], ["whole protein antigens", "TREATMENT", 200, 222], ["large", "OBSERVATION_MODIFIER", 128, 133], ["cross-reactive epitopes", "OBSERVATION", 156, 179]]], ["Second, computational discovery using epitope repertoires from other infectious diseases enabled optimization of motif combinations to minimize cross-reactivity in non-Chagas sera.", [["sera", "ANATOMY", 175, 179], ["infectious diseases", "DISEASE", 69, 88], ["sera", "ORGANISM_SUBSTANCE", 175, 179], ["epitope repertoires", "TREATMENT", 38, 57], ["other infectious diseases", "PROBLEM", 63, 88], ["motif combinations", "TREATMENT", 113, 131], ["cross-reactivity in non-Chagas sera", "PROBLEM", 144, 179], ["infectious", "OBSERVATION_MODIFIER", 69, 79]]], ["We discovered the motif [ADP]GGFG to be enriched in the epitope repertoires from specimens seropositive for either T. cruzi or Leishmania sp., (an organism known to generate false positive Chagas test results23).", [["specimens", "ANATOMY", 81, 90], ["ADP", "CHEMICAL", 25, 28], ["ADP", "CHEMICAL", 25, 28], ["T. cruzi", "ORGANISM", 115, 123], ["Leishmania sp.", "ORGANISM", 127, 141], ["T. cruzi", "SPECIES", 115, 123], ["Leishmania sp.", "SPECIES", 127, 141], ["T. cruzi", "SPECIES", 115, 123], ["Leishmania sp.", "SPECIES", 127, 141], ["the motif [ADP]GGFG", "TREATMENT", 14, 33], ["the epitope repertoires", "TEST", 52, 75], ["T. cruzi", "PROBLEM", 115, 123], ["Leishmania sp.", "PROBLEM", 127, 141], ["an organism", "PROBLEM", 144, 155]]], ["Identification and removal of the shared epitope did not adversely affect diagnostic panel performance.DiscussionSERA enabled rapid discovery and mapping of candidate proteome antigens targeted by antibodies associated with Chagas disease.", [["Chagas disease", "DISEASE", 224, 238], ["candidate proteome antigens", "PROTEIN", 157, 184], ["antibodies", "PROTEIN", 197, 207], ["Identification", "TEST", 0, 14], ["removal", "TREATMENT", 19, 26], ["proteome antigens", "TEST", 167, 184], ["Chagas disease", "PROBLEM", 224, 238], ["Chagas disease", "OBSERVATION", 224, 238]]], ["Many T. cruzi strains within seven recognized discrete typing units are known to cause Chagas disease24.", [["Chagas disease24", "DISEASE", 87, 103], ["T. cruzi strains", "ORGANISM", 5, 21], ["T. cruzi", "SPECIES", 5, 13], ["T. cruzi", "SPECIES", 5, 13], ["Many T. cruzi strains", "PROBLEM", 0, 21], ["Chagas disease24", "PROBLEM", 87, 103], ["cruzi strains", "OBSERVATION", 8, 21], ["discrete", "OBSERVATION_MODIFIER", 46, 54]]], ["Using a large library of 10 billion random 12-mer peptides, and computational motif analysis, SERA circumvents the challenge of identifying which particular species and strains should be represented for a given pathogen.", [["SERA", "PROTEIN", 94, 98], ["computational motif analysis", "TEST", 64, 92], ["SERA circumvents", "TREATMENT", 94, 110], ["strains", "PROBLEM", 169, 176], ["pathogen", "PROBLEM", 211, 219]]], ["Strain level variation, a recurrent problem in infectious disease diagnostics24, can be accommodated using motifs constructed from peptides enriched from a random library.", [["Strain level variation", "PROBLEM", 0, 22], ["a recurrent problem in infectious disease diagnostics24", "PROBLEM", 24, 79], ["a random library", "TREATMENT", 154, 170], ["recurrent", "OBSERVATION_MODIFIER", 26, 35], ["infectious", "OBSERVATION_MODIFIER", 47, 57]]], ["Here, Chagas-specific motifs mapped to distinct candidate antigens.", [["Chagas-specific motifs", "DNA", 6, 28], ["candidate antigens", "PROTEIN", 48, 66]]], ["Several of these antigens have been reported25, while others have not been described previously.", [["antigens", "PROTEIN", 17, 25]]], ["Approaches to antigen discovery from biospecimens often require laborious antigen cloning, expression, purification, and reactivity testing26.", [["antigen", "GENE_OR_GENE_PRODUCT", 14, 21], ["laborious antigen cloning", "TREATMENT", 64, 89]]], ["While feasible for small organisms such as viruses, this approach becomes difficult or impractical for organisms with large proteomes including bacteria, protozoans, fungi, and plants.DiscussionSERA could potentially be used without major modification within clinical testing laboratories.", [["small organisms", "PROBLEM", 19, 34], ["viruses", "PROBLEM", 43, 50], ["organisms", "PROBLEM", 103, 112], ["large proteomes", "PROBLEM", 118, 133], ["bacteria", "PROBLEM", 144, 152], ["protozoans", "PROBLEM", 154, 164], ["fungi", "PROBLEM", 166, 171], ["clinical testing laboratories", "TEST", 259, 288], ["small", "OBSERVATION_MODIFIER", 19, 24], ["organisms", "OBSERVATION", 25, 34], ["viruses", "OBSERVATION", 43, 50]]], ["The primary methodological steps of incubation, magnetic bead pull-down/immuno-precipitation, PCR, and NGS are already performed in infectious disease testing laboratories.", [["infectious disease", "DISEASE", 132, 150], ["incubation", "TEST", 36, 46], ["magnetic bead pull", "TEST", 48, 66], ["PCR", "TEST", 94, 97], ["NGS", "TEST", 103, 106]]], ["And, many laboratories are equipped for bacterial culture.", [["many laboratories", "TEST", 5, 22], ["bacterial culture", "TEST", 40, 57]]], ["Nevertheless, we anticipate that the assay might be offered initially from a centralized CLIA-certified, CAP-accredited clinical testing laboratory.", [["the assay", "TEST", 33, 42]]], ["Longer term, commercial testing labs, and state and federal labs could develop Laboratory-Developed Tests (LDTs) within their existing CLIA labs using peptide library reagent plates, and published motifs and methods.", [["commercial testing labs", "TEST", 13, 36], ["federal labs", "TEST", 52, 64], ["Tests", "TEST", 100, 105], ["LDTs", "TEST", 107, 111], ["peptide library reagent plates", "TREATMENT", 151, 181]]], ["In the authors\u2019 facilities, the assay is routinely performed in 96-well plates, using semi-automated commercial liquid-handling instrumentation, with a two day turn-around time.", [["the assay", "TEST", 28, 37], ["semi-automated commercial liquid-handling instrumentation", "TREATMENT", 86, 143]]], ["Finally, the bacterial display peptide library used here could be manufactured economically by conventional fed-batch fermentation, and quality control of the library reagent can be performed using NGS to measure the composition/diversity.", [["the bacterial display peptide library", "PROBLEM", 9, 46], ["conventional fed-batch fermentation", "TREATMENT", 95, 130], ["the library reagent", "TREATMENT", 155, 174], ["NGS", "TREATMENT", 198, 201]]], ["We typically sequence 400\u2013500 M library members to ensure maintenance of library diversity and lack of bias towards particular sequences.", [["library diversity", "PROBLEM", 73, 90]]], ["Thus, we have not identified any barriers to routine use of SERA in a clinical testing lab setting.DiscussionBecause a single SERA assay can detect an arbitrary number of motifs and thus an effectively unlimited number of pathogens, high-multiplex SERA may be useful for syndromic testing to identify unsuspected underlying causes of disease.", [["SERA", "CHEMICAL", 60, 64], ["SERA", "SIMPLE_CHEMICAL", 60, 64], ["SERA", "GENE_OR_GENE_PRODUCT", 248, 252], ["SERA", "TREATMENT", 60, 64], ["a single SERA assay", "TEST", 117, 136], ["pathogens", "PROBLEM", 222, 231], ["syndromic testing", "TEST", 271, 288], ["disease", "PROBLEM", 334, 341], ["disease", "OBSERVATION", 334, 341]]], ["Similarly, SERA may be a useful tool for epidemiology studies of associations between organisms, antigens, or epitopes and diseases or syndromes.", [["SERA", "GENE_OR_GENE_PRODUCT", 11, 15], ["SERA", "PROTEIN", 11, 15], ["antigens", "PROTEIN", 97, 105], ["epitopes", "PROTEIN", 110, 118], ["epidemiology studies", "TEST", 41, 61], ["organisms", "PROBLEM", 86, 95], ["epitopes", "PROBLEM", 110, 118], ["diseases", "PROBLEM", 123, 131], ["syndromes", "PROBLEM", 135, 144]]], ["At present, 15% of cancers globally are associated with bacterial, viral, and parasitic infections and this number will likely rise as new associations are discovered27.", [["cancers", "ANATOMY", 19, 26], ["cancers", "DISEASE", 19, 26], ["bacterial, viral, and parasitic infections", "DISEASE", 56, 98], ["cancers", "CANCER", 19, 26], ["cancers", "PROBLEM", 19, 26], ["bacterial, viral, and parasitic infections", "PROBLEM", 56, 98], ["cancers", "OBSERVATION", 19, 26], ["viral", "OBSERVATION", 67, 72], ["parasitic", "OBSERVATION_MODIFIER", 78, 87], ["infections", "OBSERVATION", 88, 98]]], ["Similarly, autoimmune and neurodegenerative diseases have long been suspected to be triggered or driven by infections or other environmental factors27,28.", [["autoimmune and neurodegenerative diseases", "DISEASE", 11, 52], ["infections", "DISEASE", 107, 117], ["autoimmune and neurodegenerative diseases", "PROBLEM", 11, 52], ["autoimmune", "OBSERVATION", 11, 21], ["neurodegenerative", "OBSERVATION_MODIFIER", 26, 43], ["diseases", "OBSERVATION", 44, 52], ["infections", "OBSERVATION", 107, 117]]], ["Identification and removal of environmental drivers of these diseases, as with gluten in Celiac disease, may lead to effective interventions29.", [["gluten", "DISEASE", 79, 85], ["Celiac disease", "DISEASE", 89, 103], ["Identification", "TEST", 0, 14], ["removal", "TREATMENT", 19, 26], ["these diseases", "PROBLEM", 55, 69], ["gluten in Celiac disease", "PROBLEM", 79, 103], ["effective interventions", "TREATMENT", 117, 140], ["diseases", "OBSERVATION", 61, 69], ["Celiac", "ANATOMY", 89, 95]]], ["However, the ability to identify associations has been hampered by the limitations of available serologic approaches, including the requirement to predefine a small set of organisms/strains to investigate, and the inability to differentiate epitope-level immune responses.", [["a small set of organisms/strains", "PROBLEM", 157, 189]]], ["SERA provides a potential means to overcome these serology platform limitations and provide a broad, high-resolution view of humoral immunity.Biospecimens ::: Materials and MethodsDe-identified specimens along with geographical and associated clinical testing data in this study are described (Table 1, Supplementary Table S1).", [["specimens", "ANATOMY", 194, 203], ["specimens", "CELL", 194, 203], ["SERA", "PROTEIN", 0, 4], ["specimens", "TEST", 194, 203], ["clinical testing data", "TEST", 243, 264], ["this study", "TEST", 268, 278]]], ["Specimens from the CDC-DPDM Reference Lab and commercial vendors include the following cohorts: discovery Chagas (n = 28), confirmed negative discovery controls (n = 30), specificity controls (n = 170) from apparently healthy donors (n = 100) and non-Chagas controls from a similar geographical distribution as the Chagas disease cohort (n = 70), blinded validation 1 (n = 72), and blinded validation 2 (n = 120).Epitope repertoire capture and NGS ::: Materials and MethodsSpecimens were incubated with a fully random 12-mer peptide library having estimated diversity of 1010, expressed on the surface of E. coli in a 96-well, deep-well plate format.", [["Specimens", "ANATOMY", 0, 9], ["surface", "ANATOMY", 594, 601], ["Chagas", "DISEASE", 106, 112], ["Chagas disease", "DISEASE", 315, 329], ["donors", "ORGANISM", 226, 232], ["surface", "CELLULAR_COMPONENT", 594, 601], ["E. coli", "ORGANISM", 605, 612], ["E. coli", "SPECIES", 605, 612], ["E. coli", "SPECIES", 605, 612], ["Specimens", "TEST", 0, 9], ["the CDC", "TEST", 15, 22], ["discovery Chagas", "TEST", 96, 112], ["non-Chagas controls", "PROBLEM", 247, 266], ["the Chagas disease cohort", "PROBLEM", 311, 336], ["blinded validation", "TEST", 347, 365], ["blinded validation", "TEST", 382, 400], ["E. coli", "PROBLEM", 605, 612], ["Chagas disease", "OBSERVATION", 315, 329], ["E. coli", "OBSERVATION", 605, 612], ["well plate", "OBSERVATION_MODIFIER", 632, 642]]], ["Each well contained 1011 cells for a 10-fold oversampling of the library.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["1011 cells", "CELL_LINE", 20, 30], ["the library", "TREATMENT", 61, 72]]], ["Library preparation, binder selection using magnetic-activated cell sorting (MACS), sample-specific amplicon preparation, and next-generation sequencing (NGS) methods were performed as described (see Supplementary Methods).Generation of antibody epitope repertoires ::: Materials and MethodsSequencing data from each sample was processed to generate a non-redundant peptide list of antibody binding epitopes using publicly available software as described30.", [["cell", "ANATOMY", 63, 67], ["cell", "CELL", 63, 67], ["antibody epitope repertoires", "PROTEIN", 237, 265], ["antibody binding epitopes", "PROTEIN", 382, 407], ["Library preparation", "TREATMENT", 0, 19], ["binder selection", "TREATMENT", 21, 37], ["sample", "TEST", 84, 90], ["specific amplicon preparation", "TREATMENT", 91, 120], ["MethodsSequencing data", "TEST", 284, 306], ["antibody binding epitopes", "PROBLEM", 382, 407], ["antibody epitope", "OBSERVATION", 237, 253]]], ["FASTQ DNA sequencing files were deposited into the NCBI Sequence Read Archive (SRA) for public access.", [["DNA", "CELLULAR_COMPONENT", 6, 9], ["NCBI Sequence Read Archive", "DNA", 51, 77], ["FASTQ DNA sequencing files", "TEST", 0, 26], ["public access", "TREATMENT", 88, 101]]], ["Sequence processing occurred in the following steps: (1) FASTQ DNA sequencing data were read, filtered, and trimmed.", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["Sequence processing", "TEST", 0, 19], ["FASTQ DNA sequencing data", "TEST", 57, 82]]], ["Filtering removed sequences greater than or less than lengths of 36 bases, sequences with four or more mis-matches or base pair insertions in the regions flanking the peptide region, or sequences with in-frame stop codons.", [["base pair insertions", "DNA", 118, 138], ["in-frame stop codons", "DNA", 201, 221], ["Filtering removed sequences", "TEST", 0, 27], ["base pair insertions", "TREATMENT", 118, 138], ["greater", "OBSERVATION_MODIFIER", 28, 35], ["base", "ANATOMY_MODIFIER", 118, 122], ["pair insertions", "OBSERVATION", 123, 138], ["regions", "ANATOMY_MODIFIER", 146, 153]]], ["Trimming removed the flanking sequences so that only the library peptide encoding sequences remained.", [["flanking sequences", "DNA", 21, 39], ["the flanking sequences", "TEST", 17, 39], ["the library peptide encoding sequences", "TEST", 53, 91]]], ["(2) The DNA sequences were translated into peptide sequences of 12 amino acids.", [["amino acids", "CHEMICAL", 67, 78], ["amino acids", "CHEMICAL", 67, 78], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["amino acids", "AMINO_ACID", 67, 78], ["DNA sequences", "DNA", 8, 21], ["The DNA sequences", "TEST", 4, 21], ["peptide sequences", "TEST", 43, 60], ["amino acids", "TREATMENT", 67, 78]]], ["(3) Peptide sequences were collapsed into a single sequence if they had nine or more shared identities.", [["Peptide sequences", "TEST", 4, 21]]], ["Processing thus yielded a unique peptide list (each with a count of one) for each specimen representing an antibody epitope repertoire.Chagas disease diagnostic motif panel creation ::: Materials and MethodsFollowing NGS and processing of sequencing data, Chagas specific motifs were discovered using the IMUNE computational algorithm.", [["specimen", "ANATOMY", 82, 90], ["Chagas disease", "DISEASE", 135, 149], ["antibody epitope repertoire", "PROTEIN", 107, 134], ["Chagas specific motifs", "DNA", 256, 278], ["a unique peptide list", "TREATMENT", 24, 45], ["a count", "TEST", 57, 64], ["each specimen", "TEST", 77, 90], ["an antibody epitope repertoire", "TREATMENT", 104, 134], ["NGS", "TEST", 217, 220], ["sequencing data", "TEST", 239, 254], ["Chagas specific motifs", "TEST", 256, 278], ["the IMUNE computational algorithm", "TEST", 301, 334], ["antibody epitope", "OBSERVATION", 107, 123]]], ["Motifs were down-selected based on sensitivity, specificity and mean enrichment in disease.", [["Motifs", "TEST", 0, 6], ["sensitivity", "TEST", 35, 46], ["specificity", "TEST", 48, 59], ["mean enrichment in disease", "PROBLEM", 64, 90]]], ["The resulting Chagas motif panel v1.0 was then tested against the blinded validation cohort 1 and refined to generate the final diagnostic panel v1.1.", [["The resulting Chagas motif panel v", "TEST", 0, 34]]], ["The methods used to select Chagas-specific motifs for inclusion in the panel are described in detail below.Chagas disease motif discovery using IMUNE ::: Materials and MethodsChagas-specific motifs were discovered by comparing the epitope repertoires from the discovery Chagas cohort (n = 28) with those from discovery controls (n = 30) using IMUNE as previously described15.", [["Chagas disease", "DISEASE", 107, 121], ["Chagas-specific motifs", "DNA", 27, 49], ["The methods", "TREATMENT", 0, 11], ["inclusion in the panel", "TEST", 54, 76], ["MethodsChagas", "TEST", 168, 181]]], ["IMUNE identified patterns, defined as three to five amino acids interspersed with undefined residues (\u201cX\u201d) within a 10-amino acid window, that were significantly (Poisson p < 0.0001) enriched in 25% of Chagas samples but not enriched in any discovery control samples (100% specificity).", [["samples", "ANATOMY", 209, 216], ["samples", "ANATOMY", 259, 266], ["amino acids", "CHEMICAL", 52, 63], ["amino acids", "CHEMICAL", 52, 63], ["amino acid", "CHEMICAL", 119, 129], ["amino acids", "AMINO_ACID", 52, 63], ["amino acid", "AMINO_ACID", 119, 129], ["Chagas samples", "CANCER", 202, 216], ["five amino acids", "TEST", 47, 63], ["undefined residues", "PROBLEM", 82, 100], ["a 10-amino acid window", "TREATMENT", 114, 136], ["Chagas samples", "TEST", 202, 216], ["residues", "OBSERVATION_MODIFIER", 92, 100]]], ["Pattern enrichment was quantified as the ratio of pattern observations in a sample to the expected observations taking into account the amino acid frequencies in the peptide library and total number of sequences for that sample as described15.", [["amino acid", "CHEMICAL", 136, 146], ["amino acid", "CHEMICAL", 136, 146], ["amino acid", "AMINO_ACID", 136, 146], ["Pattern enrichment", "PROBLEM", 0, 18], ["the amino acid frequencies", "TREATMENT", 132, 158]]], ["The Poisson statistic selected patterns if they were statistically enriched (p < 0.0001) in disease repertoires but not enriched in controls.", [["disease repertoires", "PROBLEM", 92, 111]]], ["The standard deviation method identified patterns enriched in disease repertoires relative to those of controls.", [["The standard deviation method", "TREATMENT", 0, 29], ["disease repertoires", "PROBLEM", 62, 81]]], ["For the standard deviation method, patterns could be present or enriched in controls but were enriched by >3\u20134 standard deviations above the controls in disease data sets.", [["the standard deviation method", "TEST", 4, 33]]], ["Significantly enriched patterns were aligned and scored using a PAM30 substitution matrix and IMUNE15, to generate motifs that could include positions where multiple amino acids are observed, indicated by brackets (e.g., [IVL] or [KRQ].", [["amino acids", "CHEMICAL", 166, 177], ["amino acids", "CHEMICAL", 166, 177], ["matrix", "CELLULAR_COMPONENT", 83, 89], ["amino acids", "AMINO_ACID", 166, 177], ["PAM30 substitution matrix", "DNA", 64, 89], ["IMUNE15", "DNA", 94, 101], ["a PAM30 substitution matrix", "TREATMENT", 62, 89], ["IMUNE15", "TREATMENT", 94, 101], ["multiple amino acids", "TREATMENT", 157, 177], ["amino acids", "OBSERVATION", 166, 177]]], ["Pattern clustering with IMUNE generated 331 motifs (Supplementary Table S2).", [["IMUNE", "DNA", 24, 29], ["331 motifs", "DNA", 40, 50]]], ["To identify the most sensitive and specific motifs for inclusion into a Chagas diagnostic panel, motif enrichment values were standardized using,", [["a Chagas diagnostic panel", "TEST", 70, 95], ["motif enrichment values", "TEST", 97, 120]]]], "PMC1899505": [["BackgroundSevere acute respiratory syndrome (SARS) is an infectious disease caused by SARS coronavirus [1] with >8000 cases and 774 deaths reported in 2003 [2].", [["BackgroundSevere acute respiratory syndrome", "DISEASE", 0, 43], ["SARS", "DISEASE", 45, 49], ["infectious disease", "DISEASE", 57, 75], ["SARS coronavirus", "DISEASE", 86, 102], ["deaths", "DISEASE", 132, 138], ["SARS coronavirus", "ORGANISM", 86, 102], ["BackgroundSevere acute respiratory syndrome (SARS)", "SPECIES", 0, 50], ["SARS coronavirus", "SPECIES", 86, 102], ["BackgroundSevere acute respiratory syndrome", "PROBLEM", 0, 43], ["an infectious disease", "PROBLEM", 54, 75], ["SARS coronavirus", "PROBLEM", 86, 102], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["infectious", "OBSERVATION_MODIFIER", 57, 67]]], ["Pathogenesis of SARS is complex and host genetic background is one of the factors in determining susceptibility and outcome [3].", [["SARS", "DISEASE", 16, 20], ["SARS", "PROBLEM", 16, 20], ["SARS", "OBSERVATION", 16, 20]]], ["We have demonstrated that genetic haplotypes associated with low serum mannose-binding lectin (MBL) are associated with SARS[4] and our findings were confirmed in another independent study [5].", [["serum", "ANATOMY", 65, 70], ["mannose", "CHEMICAL", 71, 78], ["SARS", "DISEASE", 120, 124], ["mannose", "CHEMICAL", 71, 78], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 71, 93], ["MBL", "GENE_OR_GENE_PRODUCT", 95, 98], ["serum mannose-binding lectin", "PROTEIN", 65, 93], ["MBL", "PROTEIN", 95, 98], ["genetic haplotypes", "PROBLEM", 26, 44], ["low serum mannose-binding lectin (MBL)", "PROBLEM", 61, 99], ["SARS", "PROBLEM", 120, 124]]], ["We furthermore showed that the interferon gamma gene polymorphism, +874 A/T, is associated with SARS [6].", [["SARS", "DISEASE", 96, 100], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 31, 47], ["+874 A/T", "GENE_OR_GENE_PRODUCT", 67, 75], ["interferon gamma gene polymorphism", "DNA", 31, 65], ["the interferon gamma gene polymorphism", "PROBLEM", 27, 65], ["SARS", "PROBLEM", 96, 100]]], ["Other susceptibility genes, such as liver/lymph node-specific ICAM-3-grabbing nonintegrin (L-SIGN) which is encoded by CLEC4M, 2',5'-oligoadenylate synthetase 1 gene (OAS-1) and myxovirus resistance 1 (MxA) were also identified [7,8].BackgroundChemokines play important role in cells trafficking during immune responses.", [["liver", "ANATOMY", 36, 41], ["lymph node", "ANATOMY", 42, 52], ["cells", "ANATOMY", 278, 283], ["liver", "ORGAN", 36, 41], ["lymph node", "MULTI-TISSUE_STRUCTURE", 42, 52], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 62, 68], ["grabbing nonintegrin", "GENE_OR_GENE_PRODUCT", 69, 89], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 91, 97], ["CLEC4M", "GENE_OR_GENE_PRODUCT", 119, 125], ["5'-oligoadenylate synthetase 1", "GENE_OR_GENE_PRODUCT", 130, 160], ["OAS-1", "GENE_OR_GENE_PRODUCT", 167, 172], ["myxovirus resistance 1", "GENE_OR_GENE_PRODUCT", 178, 200], ["MxA", "GENE_OR_GENE_PRODUCT", 202, 205], ["cells", "CELL", 278, 283], ["susceptibility genes", "DNA", 6, 26], ["ICAM-3", "DNA", 62, 68], ["grabbing nonintegrin", "DNA", 69, 89], ["L", "DNA", 91, 92], ["SIGN", "DNA", 93, 97], ["CLEC4M, 2',5'-oligoadenylate synthetase 1 gene", "DNA", 119, 165], ["OAS-1", "DNA", 167, 172], ["myxovirus resistance 1", "DNA", 178, 200], ["MxA", "DNA", 202, 205], ["Chemokines", "PROTEIN", 244, 254], ["Other susceptibility genes", "PROBLEM", 0, 26], ["liver/lymph node", "TEST", 36, 52], ["specific ICAM", "TEST", 53, 66], ["oligoadenylate synthetase", "TEST", 133, 158], ["OAS", "TEST", 167, 170], ["myxovirus resistance", "TEST", 178, 198], ["susceptibility genes", "OBSERVATION", 6, 26], ["liver", "ANATOMY", 36, 41], ["lymph node", "OBSERVATION", 42, 52], ["Chemokines", "OBSERVATION", 244, 254]]], ["Acute respiratory viruses commonly induce inflammatory chemokines in local tissue [9].", [["respiratory", "ANATOMY", 6, 17], ["tissue", "ANATOMY", 75, 81], ["tissue", "TISSUE", 75, 81], ["inflammatory chemokines", "PROTEIN", 42, 65], ["Acute respiratory viruses", "PROBLEM", 0, 25], ["inflammatory chemokines in local tissue", "PROBLEM", 42, 81], ["respiratory viruses", "OBSERVATION", 6, 25], ["inflammatory", "OBSERVATION_MODIFIER", 42, 54]]], ["In the case of SARS, our previous study confirmed that SARS coronavirus induces upregulation of a number of inflammatoemokines, i.e. Regulated upon Activation, Normal T cell-Expressed and Secreted (RANTES), interferon-gamma inducible protein 10 (IP-10) and Monocyte Chemoattractant Protein-1 (MCP-1) [10].", [["T cell", "ANATOMY", 167, 173], ["SARS", "DISEASE", 15, 19], ["SARS coronavirus", "DISEASE", 55, 71], ["SARS coronavirus", "ORGANISM", 55, 71], ["inflammatoemokines", "GENE_OR_GENE_PRODUCT", 108, 126], ["T cell", "CELL", 167, 173], ["RANTES", "GENE_OR_GENE_PRODUCT", 198, 204], ["interferon-gamma inducible protein 10", "GENE_OR_GENE_PRODUCT", 207, 244], ["IP-10", "GENE_OR_GENE_PRODUCT", 246, 251], ["Monocyte Chemoattractant Protein-1", "GENE_OR_GENE_PRODUCT", 257, 291], ["MCP-1", "GENE_OR_GENE_PRODUCT", 293, 298], ["inflammatoemokines", "PROTEIN", 108, 126], ["RANTES", "PROTEIN", 198, 204], ["interferon-gamma inducible protein 10 (IP-10", "PROTEIN", 207, 251], ["Monocyte Chemoattractant Protein-1 (MCP-1", "PROTEIN", 257, 298], ["SARS coronavirus", "SPECIES", 55, 71], ["SARS", "PROBLEM", 15, 19], ["our previous study", "TEST", 21, 39], ["SARS coronavirus", "PROBLEM", 55, 71], ["inflammatoemokines", "TREATMENT", 108, 126], ["interferon-gamma inducible protein", "TREATMENT", 207, 241], ["IP", "TEST", 246, 248], ["Monocyte Chemoattractant Protein", "TEST", 257, 289], ["MCP", "TEST", 293, 296]]], ["The upregulation of these chemokines recruit inflammatory cells and leukocytes into the tissue [11].", [["inflammatory cells", "ANATOMY", 45, 63], ["leukocytes", "ANATOMY", 68, 78], ["tissue", "ANATOMY", 88, 94], ["inflammatory cells", "CELL", 45, 63], ["leukocytes", "CELL", 68, 78], ["tissue", "TISSUE", 88, 94], ["chemokines", "PROTEIN", 26, 36], ["inflammatory cells", "CELL_TYPE", 45, 63], ["leukocytes", "CELL_TYPE", 68, 78], ["inflammatory cells", "PROBLEM", 45, 63], ["leukocytes into the tissue", "PROBLEM", 68, 94], ["inflammatory cells", "OBSERVATION", 45, 63], ["leukocytes", "OBSERVATION_MODIFIER", 68, 78], ["tissue", "ANATOMY", 88, 94]]], ["Therefore, we hypothesized that the polymorphisms of inflammatory chemokine genes might be associated with SARS.BackgroundIn this study, we investigated the single nucleotide polymorphisms (SNPs) of inflammatory chemokine genes, i.e. RANTES, IP-10 and monokine induced by gamma interferon gene (Mig) in two Chinese cohorts from Hong Kong and Beijing and found that the RANTES -28 G allele was associated with disease susceptibility and severity of SARS.Patients ::: MethodsThe study included 495 Hong Kong Chinese patients with SARS.", [["SARS", "DISEASE", 107, 111], ["SARS", "DISEASE", 448, 452], ["SARS", "DISEASE", 528, 532], ["RANTES", "GENE_OR_GENE_PRODUCT", 234, 240], ["IP-10", "GENE_OR_GENE_PRODUCT", 242, 247], ["gamma interferon", "GENE_OR_GENE_PRODUCT", 272, 288], ["Mig", "GENE_OR_GENE_PRODUCT", 295, 298], ["RANTES -28 G", "GENE_OR_GENE_PRODUCT", 369, 381], ["Patients", "ORGANISM", 453, 461], ["patients", "ORGANISM", 514, 522], ["inflammatory chemokine genes", "DNA", 53, 81], ["inflammatory chemokine genes", "DNA", 199, 227], ["RANTES", "PROTEIN", 234, 240], ["IP-10", "DNA", 242, 247], ["monokine", "PROTEIN", 252, 260], ["gamma interferon gene", "DNA", 272, 293], ["Mig", "DNA", 295, 298], ["RANTES -28 G allele", "DNA", 369, 388], ["Patients", "SPECIES", 453, 461], ["patients", "SPECIES", 514, 522], ["the polymorphisms of inflammatory chemokine genes", "PROBLEM", 32, 81], ["SARS", "PROBLEM", 107, 111], ["this study", "TEST", 125, 135], ["the single nucleotide polymorphisms (SNPs", "PROBLEM", 153, 194], ["inflammatory chemokine genes", "TREATMENT", 199, 227], ["IP", "TEST", 242, 244], ["monokine", "TREATMENT", 252, 260], ["gamma interferon gene", "TREATMENT", 272, 293], ["the RANTES", "TEST", 365, 375], ["disease susceptibility", "PROBLEM", 409, 431], ["severity of SARS", "PROBLEM", 436, 452], ["Methods", "TREATMENT", 466, 473], ["The study", "TEST", 473, 482], ["SARS", "PROBLEM", 528, 532], ["inflammatory", "OBSERVATION_MODIFIER", 53, 65], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211]]], ["At least 95% of the patients were documented with SARS-CoV antibody seroconversion and/or detectable SARS-CoV RNA in respiratory secretions by RT-PCR as described previously in our studies [4,6].", [["respiratory secretions", "ANATOMY", 117, 139], ["patients", "ORGANISM", 20, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["SARS-CoV RNA", "RNA", 101, 113], ["patients", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 101, 109], ["SARS", "PROBLEM", 50, 54], ["CoV antibody seroconversion", "PROBLEM", 55, 82], ["detectable SARS", "PROBLEM", 90, 105], ["CoV RNA in respiratory secretions", "PROBLEM", 106, 139], ["RT-PCR", "TEST", 143, 149], ["our studies", "TEST", 177, 188], ["respiratory secretions", "ANATOMY", 117, 139]]], ["Approval for the study was granted by the Clinical Research Ethics Committee of the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.", [["the study", "TEST", 13, 22]]], ["The patients were further divided into two groups, the death group and the survival group.", [["death", "DISEASE", 55, 60], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["The death group consisted of 57 patients who died from SARS and their mean \u00b1 SD age was 56.2 \u00b1 15.3 years, with 33 males and 24 females.", [["death", "DISEASE", 4, 9], ["SARS", "DISEASE", 55, 59], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["SARS", "PROBLEM", 55, 59]]], ["The survival group consisted of 438 patients and their mean \u00b1 SD age was 38.7 \u00b1 14.6 years, with 178 males and 260 females.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["A population of Hong Kong Chinese comprising 578 healthy Red Cross blood donors served as the control subjects.", [["blood", "ANATOMY", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["donors", "ORGANISM", 73, 79], ["Red Cross blood donors", "TREATMENT", 57, 79]]], ["Their mean \u00b1 SD age was 30.05 \u00b1 9.49 years, with 343 males and 235 females (Table 1).Patients ::: MethodsThree hundred and fifty six Beijing Chinese patients with SARS were recruited as described previously (mean \u00b1 SD age = 34.85 \u00b1 13.5, 200 male and 156 female) (Table 1) [5].", [["SARS", "DISEASE", 163, 167], ["Patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 149, 157], ["Patients", "SPECIES", 85, 93], ["patients", "SPECIES", 149, 157], ["SARS", "PROBLEM", 163, 167]]], ["Among them, 20 patients were classified as severe group, which were identified by their admissions to intensive care units or deaths from SARS (mean \u00b1 SD age = 39.45 \u00b1 12.8, 11 male and 9 female).", [["deaths", "DISEASE", 126, 132], ["SARS", "DISEASE", 138, 142], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["SARS", "PROBLEM", 138, 142]]], ["The remaining 336 patients were classified as mild group (mean \u00b1 SD age = 34.57 \u00b1 13.5, 189 male and 147 female).", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["mild", "OBSERVATION_MODIFIER", 46, 50]]], ["A total of 367 ethnically matched healthy individuals (mean age \u00b1 SD = 32.98 \u00b1 12.8, 200 male and 167 female) served as controls (Table 1).Genotyping ::: MethodsRANTES -28C/G (rs2107538) was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) as described previously [12].Genotyping ::: MethodsRANTES -403A/G (rs2107538), RANTES In1.1T/C (rs2280789), IP-10 nt1811A/G (rs8878), IP-10 nt2867C/A (rs4859587) and Mig nt367A/G (rs10336) were genotyped by the MassARRAY system (Sequenom, San Diego, CA).", [["individuals", "ORGANISM", 42, 53], ["MethodsRANTES -28C/G (rs2107538", "GENE_OR_GENE_PRODUCT", 154, 185], ["RANTES In1.1T/C", "GENE_OR_GENE_PRODUCT", 361, 376], ["IP-10", "GENE_OR_GENE_PRODUCT", 390, 395], ["IP-10", "GENE_OR_GENE_PRODUCT", 416, 421], ["Mig nt367A/G", "GENE_OR_GENE_PRODUCT", 448, 460], ["RFLP", "DNA", 276, 280], ["RANTES", "PROTEIN", 361, 367], ["Mig nt367A", "DNA", 448, 458], ["rs10336", "DNA", 462, 469], ["SD", "TEST", 66, 68], ["Genotyping", "TEST", 139, 149], ["MethodsRANTES", "TEST", 154, 167], ["polymerase chain reaction", "PROBLEM", 204, 229], ["restriction fragment length polymorphism", "PROBLEM", 230, 270], ["PCR", "TEST", 272, 275], ["Genotyping", "TEST", 311, 321], ["MethodsRANTES", "TEST", 326, 339], ["RANTES", "TEST", 361, 367], ["rs", "TEST", 378, 380], ["IP", "TEST", 390, 392], ["nt", "TEST", 396, 398], ["G", "TEST", 404, 405], ["rs", "TEST", 407, 409], ["IP", "TEST", 416, 418], ["rs", "TEST", 433, 435], ["Mig nt367A/G", "TEST", 448, 460], ["the MassARRAY system", "TEST", 489, 509]]], ["In brief, the samples were amplified in a 6 \u03bcL reaction mixture, containing 5 ng genomic DNA, 0.3 pmol each of specific forward and reverse primers, 200 \u03bcL of each dNTP, 3.25 mM MgCl2 and 0.2 units of HotStarTaq polymerase (Qiagen, Valencia, CA).", [["samples", "ANATOMY", 14, 21], ["dNTP", "CHEMICAL", 164, 168], ["MgCl2", "CHEMICAL", 178, 183], ["dNTP", "CHEMICAL", 164, 168], ["MgCl2", "CHEMICAL", 178, 183], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["dNTP", "SIMPLE_CHEMICAL", 164, 168], ["genomic DNA", "DNA", 81, 92], ["HotStarTaq polymerase", "PROTEIN", 201, 222], ["the samples", "TEST", 10, 21], ["a 6 \u03bcL reaction mixture", "TREATMENT", 40, 63], ["5 ng genomic DNA", "TREATMENT", 76, 92], ["reverse primers", "TREATMENT", 132, 147], ["dNTP", "TREATMENT", 164, 168], ["3.25 mM MgCl2", "TREATMENT", 170, 183], ["HotStarTaq polymerase", "TREATMENT", 201, 222]]], ["PCR conditions included initial hot-start for 15 min at 95\u00b0C, 45 cycles of amplification (20 sec at 95\u00b0C, 30 sec at 56\u00b0C and 1 min at 72\u00b0C) and final extension for 3 min at 72\u00b0C. The PCR products were treated with alkaline phosphatase to dephosphorylate residual amplification nucleotides.", [["nucleotides", "CHEMICAL", 277, 288], ["alkaline phosphatase", "PROTEIN", 214, 234], ["PCR conditions", "TEST", 0, 14], ["amplification", "TREATMENT", 75, 88], ["The PCR products", "TREATMENT", 179, 195], ["alkaline phosphatase", "TREATMENT", 214, 234], ["dephosphorylate residual amplification nucleotides", "PROBLEM", 238, 288], ["residual amplification nucleotides", "OBSERVATION", 254, 288]]], ["A mixture of 0.2 \u03bcL of hME buffer, 0.3 \u03bcL of shrimp alkaline phosphatase (1 unit/\u03bcL, Sequenom) and 1.5 \u03bcL of ddH2O was added to the PCR products.", [["hME", "CHEMICAL", 23, 26], ["hME", "CHEMICAL", 23, 26], ["ddH2O", "CHEMICAL", 109, 114], ["hME", "SIMPLE_CHEMICAL", 23, 26], ["ddH2O", "SIMPLE_CHEMICAL", 109, 114], ["shrimp alkaline phosphatase", "PROTEIN", 45, 72], ["hME buffer", "TREATMENT", 23, 33], ["shrimp alkaline phosphatase", "TREATMENT", 45, 72], ["ddH2O", "TREATMENT", 109, 114], ["the PCR products", "TREATMENT", 128, 144]]], ["The reaction solutions were incubated for 20 min at 37\u00b0C, followed by 5 min at 85\u00b0C to inactivate the enzyme.", [["enzyme", "PROTEIN", 102, 108], ["The reaction solutions", "TREATMENT", 0, 22], ["the enzyme", "TEST", 98, 108]]], ["Mass-extend reactions to determine genotypes were performed in four groups of different terminations according to the design rationale (ddACG, ddACT, ddAGT and ddCGT, respectively).", [["ddACG", "PROTEIN", 136, 141], ["ddACT", "PROTEIN", 143, 148], ["ddAGT", "PROTEIN", 150, 155], ["ddCGT", "PROTEIN", 160, 165], ["Mass", "PROBLEM", 0, 4], ["ddACG", "TEST", 136, 141], ["ddACT", "TEST", 143, 148]]], ["The reaction volume was 10 \u03bcL including 1 unit of Thermosequenase (Sequenom), 50 \u03bcM of the respective termination mix, and 0.6 pmol of each assay specific extension primer (Table 2).", [["Thermosequenase", "PROTEIN", 50, 65], ["The reaction volume", "TEST", 0, 19], ["Thermosequenase (Sequenom)", "TREATMENT", 50, 76], ["the respective termination mix", "TREATMENT", 87, 117]]], ["All assays were run with the same thermal cycle conditions: initial denaturation for 2 min at 94\u00b0C followed by 55 cycles of extension (5 sec at 94\u00b0C, 5 sec at 52\u00b0C and 5 sec at 72\u00b0C).", [["All assays", "TEST", 0, 10], ["initial denaturation", "PROBLEM", 60, 80], ["extension", "TEST", 124, 133]]], ["Products of the mass-extend reactions were desalted and transferred onto a SpectroCHIP by a nanoliter dispenser according to the manufacturer's instructions (Sequenom).Genotyping ::: MethodsGenotype determination was performed on a MALDI-TOF mass spectrometer (Sequenom).", [["SpectroCHIP", "CHEMICAL", 75, 86], ["SpectroCHIP", "SIMPLE_CHEMICAL", 75, 86], ["the mass", "PROBLEM", 12, 20], ["extend reactions", "PROBLEM", 21, 37], ["a nanoliter dispenser", "TREATMENT", 90, 111], ["MethodsGenotype determination", "TEST", 183, 212], ["a MALDI", "TEST", 230, 237], ["mass", "OBSERVATION", 16, 20]]], ["Mass spectrometric data were automatically imported into the SpectroTYPER (Sequenom) database for data analysis including noise normalization and peak area analysis.", [["SpectroTYPER", "DNA", 61, 73], ["Mass spectrometric data", "TEST", 0, 23], ["data analysis", "TEST", 98, 111], ["noise normalization", "TEST", 122, 141], ["peak area analysis", "TEST", 146, 164]]], ["The expected molecular weights of all relevant peaks were calculated by the MassARRAY AssayDesign Software (Sequenom) before the analysis and identified from the mass spectrum.", [["the analysis", "TEST", 125, 137], ["molecular", "OBSERVATION_MODIFIER", 13, 22], ["weights", "OBSERVATION_MODIFIER", 23, 30], ["mass", "OBSERVATION", 162, 166]]], ["In every 96-well plate for assay, there is one well for blank control and five wells for duplicate check on five samples for internal quality control.Statistical Analysis ::: MethodsA two-step analysis was used to determine the association of polymorphisms with SARS.", [["samples", "ANATOMY", 113, 120], ["SARS", "DISEASE", 262, 266], ["assay", "TEST", 27, 32], ["blank control", "TREATMENT", 56, 69], ["duplicate check", "TEST", 89, 104], ["internal quality control", "TREATMENT", 125, 149], ["MethodsA two-step analysis", "TEST", 175, 201], ["polymorphisms", "PROBLEM", 243, 256], ["SARS", "PROBLEM", 262, 266]]], ["The genotype frequencies and allele frequencies of all the genes were compared between SARS patients and controls by a 3 \u00d7 2 chi-square test and a 2 \u00d7 2 chi-square test respectively, then logistic regression was used for calculating odds ratios (95% confidence interval) and corresponding P-values of different genotype frequencies among SARS patients and controls by adjusting for age, sex and all significant single nucleotide polymorphisms (SNPs).", [["SARS", "DISEASE", 87, 91], ["SARS", "DISEASE", 338, 342], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 343, 351], ["The genotype frequencies", "TREATMENT", 0, 24], ["different genotype frequencies", "PROBLEM", 301, 331], ["all significant single nucleotide polymorphisms (SNPs)", "PROBLEM", 395, 449]]], ["Association with the outcomes of SARS infection (death vs survival) was then tested by comparing the genotype frequencies and allele frequencies of all the genes between the death group and the survival group of SARS patients by a 3 \u00d7 2 chi-square test and a 2 \u00d7 2 chi-square test respectively.", [["SARS infection", "DISEASE", 33, 47], ["death", "DISEASE", 49, 54], ["death", "DISEASE", 174, 179], ["SARS", "DISEASE", 212, 216], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["SARS infection", "PROBLEM", 33, 47]]], ["The genotype frequencies of all the SNPs were tested for Hardy-Weinberg equilibrium (HWE) separately in SARS patients and controls by chi-square test.", [["SARS", "DISEASE", 104, 108], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["chi-square test", "TEST", 134, 149]]], ["Significant P-value for multiple testing was adjusted with Bonferroni's correction and all statistical analysis was performed by SAS, version 8.02 and SAS/Genetics (SAS Institute Inc., NC, USA).RANTES -28C/G associated with SARS susceptibility in Hong Kong Chinese ::: ResultsRANTES -28C/G,RANTES -403A/G, RANTES In1.1T/C, IP-10 nt1811A/G, IP-10 nt2867C/A and Mig nt367A/G were genotyped in all 495 SARS patients and 578 controls from Hong Kong.", [["SARS", "DISEASE", 224, 228], ["SARS", "DISEASE", 399, 403], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 194, 207], ["ResultsRANTES -28C/G", "GENE_OR_GENE_PRODUCT", 269, 289], ["RANTES -403A", "GENE_OR_GENE_PRODUCT", 290, 302], ["RANTES In1.1T/C", "GENE_OR_GENE_PRODUCT", 306, 321], ["IP-10", "GENE_OR_GENE_PRODUCT", 323, 328], ["IP-10", "GENE_OR_GENE_PRODUCT", 340, 345], ["Mig nt367A/G", "GENE_OR_GENE_PRODUCT", 360, 372], ["patients", "ORGANISM", 404, 412], ["RANTES", "PROTEIN", 194, 200], ["RANTES", "PROTEIN", 290, 296], ["RANTES", "PROTEIN", 306, 312], ["Mig nt367A/G", "DNA", 360, 372], ["patients", "SPECIES", 404, 412], ["multiple testing", "TEST", 24, 40], ["Bonferroni's correction", "TREATMENT", 59, 82], ["all statistical analysis", "TEST", 87, 111], ["version", "TEST", 134, 141], ["SAS", "TEST", 151, 154], ["RANTES", "TEST", 194, 200], ["SARS susceptibility", "PROBLEM", 224, 243], ["ResultsRANTES", "TEST", 269, 282], ["RANTES", "TEST", 290, 296], ["G", "TEST", 303, 304], ["RANTES", "TEST", 306, 312], [".1T", "TEST", 316, 319], ["C", "TEST", 320, 321], ["IP", "TEST", 323, 325], ["nt", "TEST", 329, 331], ["G", "TEST", 337, 338], ["IP", "TEST", 340, 342], ["A", "TEST", 354, 355], ["Mig", "TEST", 360, 363], ["G", "TEST", 371, 372]]], ["Their genotype and allele frequencies were shown in Table 3 and 4 respectively.RANTES -28C/G associated with SARS susceptibility in Hong Kong Chinese ::: ResultsRANTES -28 CG and GG genotypes were significantly associated with SARS susceptibility with OR of 3.28 (95% CI: 2.32\u20134.64) and 3.06 (95% CI: 1.47\u20136.39) respectively (P < 0.0001) (Table 3).", [["SARS", "DISEASE", 109, 113], ["SARS", "DISEASE", 227, 231], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 79, 92], ["ResultsRANTES -28 CG", "GENE_OR_GENE_PRODUCT", 154, 174], ["RANTES", "PROTEIN", 79, 85], ["allele frequencies", "TEST", 19, 37], ["RANTES", "TEST", 79, 85], ["SARS susceptibility", "PROBLEM", 109, 128], ["ResultsRANTES", "TEST", 154, 167], ["CG and GG genotypes", "TEST", 172, 191], ["SARS susceptibility", "PROBLEM", 227, 246], ["CI", "TEST", 268, 270], ["CI", "TEST", 297, 299], ["P", "TEST", 326, 327]]], ["RANTES -28 G allele was also significantly increased in the patients (P < 0.0001, OR = 2.80, 95%CI: 2.11\u20133.71) (Table 4).", [["G", "GENE_OR_GENE_PRODUCT", 11, 12], ["patients", "ORGANISM", 60, 68], ["RANTES", "PROTEIN", 0, 6], ["G allele", "DNA", 11, 19], ["patients", "SPECIES", 60, 68], ["RANTES", "TEST", 0, 6], ["CI", "TEST", 96, 98], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["increased", "OBSERVATION_MODIFIER", 43, 52]]], ["After correction by Bonferroni method, the significant P value should be less than 0.007, the association of RANTES -28C/G to SARS susceptibility remained to have significance.RANTES -28C/G associated with SARS susceptibility in Hong Kong Chinese ::: ResultsAll genotype frequencies of the six polymorphisms in SARS patients and controls were in HWE except for the RANTES -28C/G in controls.", [["SARS", "DISEASE", 126, 130], ["SARS", "DISEASE", 206, 210], ["SARS", "DISEASE", 311, 315], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 109, 122], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 176, 189], ["patients", "ORGANISM", 316, 324], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 365, 378], ["RANTES", "PROTEIN", 109, 115], ["RANTES", "PROTEIN", 176, 182], ["RANTES", "PROTEIN", 365, 371], ["patients", "SPECIES", 316, 324], ["Bonferroni method", "TEST", 20, 37], ["RANTES", "TEST", 109, 115], ["SARS susceptibility", "PROBLEM", 126, 145], ["RANTES", "TEST", 176, 182], ["the RANTES", "TEST", 361, 371], ["significant", "OBSERVATION_MODIFIER", 43, 54]]], ["To confirm that there is no genotyping error that may contribute to the observation in HWE, direct DNA sequencing was performed in 20\u201330 samples for each SNP and no ambiguous results were obtained.RANTES -28C/G associated with death of Hong Kong Chinese patients ::: ResultsWe then compared the genotype and allele frequencies of the RANTES -28C/G between the death group and survival group of the SARS patients.", [["20\u201330 samples", "ANATOMY", 131, 144], ["SNP", "CHEMICAL", 154, 157], ["death", "DISEASE", 227, 232], ["death", "DISEASE", 360, 365], ["SARS", "DISEASE", 398, 402], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 197, 210], ["patients", "ORGANISM", 254, 262], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 334, 347], ["patients", "ORGANISM", 403, 411], ["RANTES", "PROTEIN", 197, 203], ["RANTES", "PROTEIN", 334, 340], ["patients", "SPECIES", 254, 262], ["patients", "SPECIES", 403, 411], ["genotyping error", "PROBLEM", 28, 44], ["direct DNA sequencing", "TEST", 92, 113], ["each SNP", "TEST", 149, 157], ["the RANTES", "TEST", 330, 340], ["no", "UNCERTAINTY", 25, 27]]], ["RANTES -28 G allele associated with death from SARS in a gene-dosage dependent manner (P = 0.014), with -28 CG and GG individuals having a 2.12-fold (95% CI: 1.11\u20134.06) and 4.01-fold (95% CI: 1.30:12.4) increased risk of death from SARS respectively (Table 5).Association of RANTES -28 C/G with SARS in Beijing Chinese ::: ResultsTo further confirm the association of RANTES with SARS, we studied the three RANTES SNPs in a Beijing Chinese cohort [14].", [["death", "DISEASE", 36, 41], ["SARS", "DISEASE", 47, 51], ["death", "DISEASE", 221, 226], ["SARS", "DISEASE", 232, 236], ["SARS", "DISEASE", 295, 299], ["SARS", "DISEASE", 380, 384], ["G", "GENE_OR_GENE_PRODUCT", 11, 12], ["RANTES", "GENE_OR_GENE_PRODUCT", 275, 281], ["RANTES", "GENE_OR_GENE_PRODUCT", 368, 374], ["RANTES", "GENE_OR_GENE_PRODUCT", 407, 413], ["RANTES", "PROTEIN", 0, 6], ["G allele", "DNA", 11, 19], ["RANTES", "PROTEIN", 275, 281], ["RANTES", "PROTEIN", 368, 374], ["RANTES SNPs", "DNA", 407, 418], ["RANTES", "TEST", 0, 6], ["death", "PROBLEM", 36, 41], ["SARS", "PROBLEM", 47, 51], ["CI", "TEST", 154, 156], ["CI", "TEST", 188, 190], ["death", "PROBLEM", 221, 226], ["SARS", "PROBLEM", 232, 236], ["RANTES", "TEST", 275, 281], ["SARS", "PROBLEM", 380, 384], ["RANTES", "OBSERVATION", 275, 281]]], ["Three hundred and fifty six SARS patients and 367 healthy controls were genotyped and their genotype and allele frequencies were shown in (Table 6).", [["SARS", "DISEASE", 28, 32], ["patients", "ORGANISM", 33, 41], ["controls", "ORGANISM", 58, 66], ["patients", "SPECIES", 33, 41]]], ["All genotype distributions of the two groups were in HWE.", [["genotype", "OBSERVATION_MODIFIER", 4, 12], ["distributions", "OBSERVATION_MODIFIER", 13, 26]]], ["No significant difference was observed between the frequencies in the SNPs between patients and controls.Association of RANTES -28 C/G with SARS in Beijing Chinese ::: ResultsNext, we investigated the association of RANTES -28C/G with SARS severity.", [["SARS", "DISEASE", 140, 144], ["SARS", "DISEASE", 235, 239], ["patients", "ORGANISM", 83, 91], ["RANTES", "GENE_OR_GENE_PRODUCT", 120, 126], ["RANTES -28C/G", "GENE_OR_GENE_PRODUCT", 216, 229], ["RANTES", "PROTEIN", 120, 126], ["RANTES", "PROTEIN", 216, 222], ["patients", "SPECIES", 83, 91], ["RANTES", "TEST", 120, 126], ["RANTES", "TEST", 216, 222], ["SARS severity", "PROBLEM", 235, 248], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["RANTES", "OBSERVATION", 120, 126]]], ["Twenty patients were classified as severe group as defined by their admissions to intensive care units or deaths due to SARS [5].", [["deaths", "DISEASE", 106, 112], ["SARS", "DISEASE", 120, 124], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["SARS", "PROBLEM", 120, 124]]], ["The genotype and allele frequencies of this SNP in severe and mild patients were shown in Table 7.", [["SNP", "CHEMICAL", 44, 47], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["The genotype and allele frequencies", "TREATMENT", 0, 35], ["this SNP", "TREATMENT", 39, 47], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["mild", "OBSERVATION_MODIFIER", 62, 66]]], ["The genotype distribution among the two groups were significantly different (P = 0.011).", [["genotype", "OBSERVATION_MODIFIER", 4, 12], ["distribution", "OBSERVATION_MODIFIER", 13, 25], ["significantly", "OBSERVATION_MODIFIER", 52, 65], ["different", "OBSERVATION_MODIFIER", 66, 75]]], ["The frequencies of CG and GG genotypes were over-represented in the severe group (CG: OR = 4.27, 95%CI: 1.64\u201311.1; GG: OR = 3.34, 95%CI: 0.37\u201330.7).", [["CG and GG genotypes", "TEST", 19, 38], ["CI", "TEST", 100, 102], ["\u2013", "TEST", 108, 109], ["GG", "TEST", 115, 117], ["CI", "TEST", 133, 135]]], ["The frequency of G allele was also significantly increased in the severe group (OR = 2.78, 95%CI: 1.37\u20135.63, P = 0.005).DiscussionWe described here that Hong Kong Chinese with RANTES -28CG and GG genotypes had a 3.28-fold (95% CI: 2.32\u20134.64) and 3.06-fold (95% CI: 1.47\u20136.39) increased risk of developing SARS respectively (P < 0.0001) (Table 3).", [["SARS", "DISEASE", 305, 309], ["G", "GENE_OR_GENE_PRODUCT", 17, 18], ["RANTES -28CG", "GENE_OR_GENE_PRODUCT", 176, 188], ["G allele", "DNA", 17, 25], ["RANTES", "PROTEIN", 176, 182], ["G allele", "TEST", 17, 25], ["CI", "TEST", 94, 96], ["P", "TEST", 109, 110], ["RANTES", "TEST", 176, 182], ["GG genotypes", "TEST", 193, 205], ["CI", "TEST", 227, 229], ["CI", "TEST", 261, 263], ["developing SARS", "PROBLEM", 294, 309], ["significantly", "OBSERVATION_MODIFIER", 35, 48], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["severe", "OBSERVATION_MODIFIER", 66, 72]]], ["This -28 G allele also increased the risk of death of Hong Kong Chinese patients with SARS in a gene-dosage dependent manner (P = 0.014) that -28 CG and GG individuals had a 2.12-fold (95% CI: 1.11\u20134.06) and 4.01-fold (95% CI: 1.30:12.4) increased risk (Table 5).", [["death", "DISEASE", 45, 50], ["SARS", "DISEASE", 86, 90], ["G", "GENE_OR_GENE_PRODUCT", 9, 10], ["patients", "ORGANISM", 72, 80], ["G allele", "DNA", 9, 17], ["patients", "SPECIES", 72, 80], ["SARS", "PROBLEM", 86, 90], ["GG individuals", "TEST", 153, 167], ["CI", "TEST", 189, 191], ["CI", "TEST", 223, 225], ["increased", "OBSERVATION_MODIFIER", 23, 32]]], ["More importantly, we further confirmed the association of RANTES -28 C/G with the severity of SARS by studying the Beijing Chinese cohort and found that Beijing Chinese patients with CG (OR = 4.27, 95%CI: 1.64\u201311.1) and GG (OR = 3.34, 95%CI: 0.37\u201330.7) genotype were more severe, as defined by admission to intensive care units or deaths due to SARS.", [["SARS", "DISEASE", 94, 98], ["deaths", "DISEASE", 331, 337], ["SARS", "DISEASE", 345, 349], ["RANTES", "GENE_OR_GENE_PRODUCT", 58, 64], ["C/G", "GENE_OR_GENE_PRODUCT", 69, 72], ["patients", "ORGANISM", 169, 177], ["RANTES", "PROTEIN", 58, 64], ["patients", "SPECIES", 169, 177], ["RANTES", "TEST", 58, 64], ["SARS", "PROBLEM", 94, 98], ["CG", "TEST", 183, 185], ["CI", "TEST", 201, 203], ["GG", "TEST", 220, 222], ["CI", "TEST", 238, 240], ["genotype", "TEST", 253, 261], ["SARS", "PROBLEM", 345, 349]]], ["To further investigate the association of RANTES with SARS, we have also performed haplotype analysis using the 3 studied SNPs of RANTES, i.e. -403A/G, -28C/G and In1.1T/C, for constructing the haplotypes.", [["SARS", "DISEASE", 54, 58], ["RANTES", "GENE_OR_GENE_PRODUCT", 42, 48], ["RANTES", "GENE_OR_GENE_PRODUCT", 130, 136], ["G", "GENE_OR_GENE_PRODUCT", 149, 150], ["In1.1T/C", "GENE_OR_GENE_PRODUCT", 163, 171], ["RANTES", "PROTEIN", 42, 48], ["RANTES", "PROTEIN", 130, 136], ["SARS", "PROBLEM", 54, 58], ["haplotype analysis", "TEST", 83, 101], ["RANTES", "TEST", 130, 136]]], ["However, the major effect of the haplotypes was due to the SNP RANTES -28 only (data not shown).DiscussionRANTES is responsible for the recruitment of eosinophils, lymphocytes, monocytes and basophils at the site of inflammation and is involved in many viral infections [13,14].", [["eosinophils", "ANATOMY", 151, 162], ["lymphocytes", "ANATOMY", 164, 175], ["monocytes", "ANATOMY", 177, 186], ["basophils", "ANATOMY", 191, 200], ["SNP", "CHEMICAL", 59, 62], ["inflammation", "DISEASE", 216, 228], ["viral infections", "DISEASE", 253, 269], ["eosinophils", "CELL", 151, 162], ["lymphocytes", "CELL", 164, 175], ["monocytes", "CELL", 177, 186], ["basophils", "CELL", 191, 200], ["RANTES", "PROTEIN", 63, 69], ["eosinophils", "CELL_TYPE", 151, 162], ["lymphocytes", "CELL_TYPE", 164, 175], ["monocytes", "CELL_TYPE", 177, 186], ["basophils", "CELL_TYPE", 191, 200], ["the haplotypes", "PROBLEM", 29, 43], ["the SNP RANTES", "TEST", 55, 69], ["eosinophils", "TEST", 151, 162], ["lymphocytes", "TEST", 164, 175], ["monocytes", "TEST", 177, 186], ["basophils", "TEST", 191, 200], ["inflammation", "PROBLEM", 216, 228], ["many viral infections", "PROBLEM", 248, 269], ["major", "OBSERVATION_MODIFIER", 13, 18], ["effect", "OBSERVATION_MODIFIER", 19, 25], ["responsible for", "UNCERTAINTY", 116, 131], ["inflammation", "OBSERVATION", 216, 228], ["viral", "OBSERVATION_MODIFIER", 253, 258], ["infections", "OBSERVATION", 259, 269]]], ["We found that -28 G allele of RANTES associated with the susceptibility to and death from SARS.", [["death", "DISEASE", 79, 84], ["SARS", "DISEASE", 90, 94], ["RANTES", "GENE_OR_GENE_PRODUCT", 30, 36], ["-28 G allele", "DNA", 14, 26], ["RANTES", "PROTEIN", 30, 36], ["SARS", "PROBLEM", 90, 94]]], ["Indeed, RANTES -28C/G is located at the NF-\u03baB binding site, which is confirmed by gel-mobility shift assays [15], meaning that this SNP may be involved in the regulation of RANTES expression.", [["SNP", "CHEMICAL", 132, 135], ["RANTES -28C", "GENE_OR_GENE_PRODUCT", 8, 19], ["G", "GENE_OR_GENE_PRODUCT", 20, 21], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 40, 44], ["B", "GENE_OR_GENE_PRODUCT", 44, 45], ["RANTES", "GENE_OR_GENE_PRODUCT", 173, 179], ["RANTES", "PROTEIN", 8, 14], ["28C", "PROTEIN", 16, 19], ["NF-\u03ba", "PROTEIN", 40, 44], ["B binding site", "DNA", 44, 58], ["RANTES", "PROTEIN", 173, 179], ["RANTES", "TEST", 8, 14], ["B binding site", "PROBLEM", 44, 58], ["this SNP", "TREATMENT", 127, 135]]], ["Further in vitro studies show that RANTES -28 G allele enhances NF-\u03baB binding that leads to elevation of promoter activity and increases RANTES expression in CD8+ T cells, CD4+ T cells and monocytes/macrophages [15,16].", [["CD8+ T cells", "ANATOMY", 158, 170], ["CD4+ T cells", "ANATOMY", 172, 184], ["monocytes", "ANATOMY", 189, 198], ["macrophages", "ANATOMY", 199, 210], ["RANTES -28 G", "GENE_OR_GENE_PRODUCT", 35, 47], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 64, 69], ["RANTES", "GENE_OR_GENE_PRODUCT", 137, 143], ["CD8", "GENE_OR_GENE_PRODUCT", 158, 161], ["CD4", "GENE_OR_GENE_PRODUCT", 172, 175], ["monocytes", "CELL", 189, 198], ["RANTES -28 G allele", "DNA", 35, 54], ["NF-\u03baB", "PROTEIN", 64, 69], ["RANTES", "PROTEIN", 137, 143], ["CD8+ T cells", "CELL_TYPE", 158, 170], ["CD4+ T cells", "CELL_TYPE", 172, 184], ["monocytes", "CELL_TYPE", 189, 198], ["macrophages", "CELL_TYPE", 199, 210], ["Further in vitro studies", "TEST", 0, 24], ["RANTES", "TEST", 35, 41], ["B binding", "PROBLEM", 68, 77], ["elevation of promoter activity", "PROBLEM", 92, 122], ["RANTES expression", "TEST", 137, 154], ["CD8", "TEST", 158, 161], ["T cells", "TEST", 163, 170], ["CD4", "TEST", 172, 175], ["T cells", "TEST", 177, 184], ["monocytes", "TEST", 189, 198], ["macrophages", "TEST", 199, 210], ["macrophages", "ANATOMY", 199, 210]]], ["Therefore, together with our observation that -28 G allele associated with SARS, we conclude a high level of RANTES may predispose to developing SARS.DiscussionThis study showed that RANTES -28 G allele was a risk factor that associated with severe clinical outcomes in both Hong Kong and Beijing Chinese SARS patients.", [["SARS", "DISEASE", 75, 79], ["SARS", "DISEASE", 145, 149], ["SARS", "DISEASE", 305, 309], ["-28 G", "GENE_OR_GENE_PRODUCT", 46, 51], ["RANTES", "GENE_OR_GENE_PRODUCT", 109, 115], ["RANTES -28 G", "GENE_OR_GENE_PRODUCT", 183, 195], ["patients", "ORGANISM", 310, 318], ["-28 G allele", "DNA", 46, 58], ["RANTES", "PROTEIN", 109, 115], ["RANTES -28 G allele", "DNA", 183, 202], ["patients", "SPECIES", 310, 318], ["our observation", "TEST", 25, 40], ["SARS", "PROBLEM", 75, 79], ["SARS", "PROBLEM", 145, 149], ["This study", "TEST", 160, 170], ["RANTES", "TEST", 183, 189], ["a risk factor", "PROBLEM", 207, 220], ["SARS", "OBSERVATION", 145, 149]]], ["It has to be noted that many cytokines/chemokines released from activated immune cells not only take part in the process of anti-viral immune response, but are also involved in cell damage and organ dysfunction [17].", [["immune cells", "ANATOMY", 74, 86], ["cell", "ANATOMY", 177, 181], ["organ", "ANATOMY", 193, 198], ["organ dysfunction", "DISEASE", 193, 210], ["immune cells", "CELL", 74, 86], ["cell", "CELL", 177, 181], ["organ", "ORGAN", 193, 198], ["cytokines", "PROTEIN", 29, 38], ["chemokines", "PROTEIN", 39, 49], ["activated immune cells", "CELL_TYPE", 64, 86], ["many cytokines/chemokines", "TREATMENT", 24, 49], ["activated immune cells", "TREATMENT", 64, 86], ["anti-viral immune response", "TREATMENT", 124, 150], ["cell damage", "PROBLEM", 177, 188], ["organ dysfunction", "PROBLEM", 193, 210], ["cytokines", "OBSERVATION", 29, 38], ["anti-viral immune", "OBSERVATION", 124, 141], ["cell damage", "OBSERVATION", 177, 188]]], ["Apart from the chemokine receptor signaling pathway, RANTES could activate T cells through herbimycin A-sensitive protein tyrosine kinase (PTK)-mediated pathway at high concentration [18].", [["T cells", "ANATOMY", 75, 82], ["herbimycin", "CHEMICAL", 91, 101], ["tyrosine", "CHEMICAL", 122, 130], ["herbimycin", "CHEMICAL", 91, 101], ["tyrosine", "CHEMICAL", 122, 130], ["RANTES", "GENE_OR_GENE_PRODUCT", 53, 59], ["T cells", "CELL", 75, 82], ["herbimycin A-sensitive protein tyrosine kinase", "GENE_OR_GENE_PRODUCT", 91, 137], ["PTK", "GENE_OR_GENE_PRODUCT", 139, 142], ["chemokine receptor", "PROTEIN", 15, 33], ["RANTES", "PROTEIN", 53, 59], ["T cells", "CELL_TYPE", 75, 82], ["herbimycin A-sensitive protein tyrosine kinase", "PROTEIN", 91, 137], ["PTK", "PROTEIN", 139, 142], ["RANTES", "TEST", 53, 59], ["herbimycin A-sensitive protein tyrosine kinase", "TREATMENT", 91, 137], ["PTK", "TEST", 139, 142]]], ["This triggers the release of inflammatory cytokines and chemokines such as IL-2, IL-5, IFN-\u03b3 and MIP1-\u03b2 [18].", [["IL-2", "GENE_OR_GENE_PRODUCT", 75, 79], ["IL-5", "GENE_OR_GENE_PRODUCT", 81, 85], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 87, 92], ["MIP1-\u03b2", "GENE_OR_GENE_PRODUCT", 97, 103], ["inflammatory cytokines", "PROTEIN", 29, 51], ["chemokines", "PROTEIN", 56, 66], ["IL-2, IL-5", "PROTEIN", 75, 85], ["IFN", "PROTEIN", 87, 90], ["MIP1", "PROTEIN", 97, 101], ["\u03b2", "PROTEIN", 102, 103], ["inflammatory cytokines", "PROBLEM", 29, 51], ["chemokines", "TEST", 56, 66], ["IL", "TEST", 75, 77], ["IL", "TEST", 81, 83], ["IFN", "TEST", 87, 90], ["MIP1", "TEST", 97, 101], ["inflammatory", "OBSERVATION_MODIFIER", 29, 41]]], ["We have recently demonstrated SARS coronavirus can induce high level of expression of chemokines from human dendritic cells [10].", [["dendritic cells", "ANATOMY", 108, 123], ["SARS coronavirus", "DISEASE", 30, 46], ["SARS coronavirus", "ORGANISM", 30, 46], ["human", "ORGANISM", 102, 107], ["dendritic cells", "CELL", 108, 123], ["chemokines", "PROTEIN", 86, 96], ["human dendritic cells", "CELL_TYPE", 102, 123], ["human", "SPECIES", 102, 107], ["SARS coronavirus", "SPECIES", 30, 46], ["human", "SPECIES", 102, 107], ["SARS coronavirus", "PROBLEM", 30, 46], ["chemokines from human dendritic cells", "TREATMENT", 86, 123]]], ["Too high a level of RANTES may intensify lung inflammation and lead to lymphopenia, increasing the chance of secondary infection and hence death rate among SARS patients [18,19].", [["lung", "ANATOMY", 41, 45], ["lung inflammation", "DISEASE", 41, 58], ["lymphopenia", "DISEASE", 71, 82], ["infection", "DISEASE", 119, 128], ["death", "DISEASE", 139, 144], ["SARS", "DISEASE", 156, 160], ["RANTES", "GENE_OR_GENE_PRODUCT", 20, 26], ["lung", "ORGAN", 41, 45], ["patients", "ORGANISM", 161, 169], ["RANTES", "PROTEIN", 20, 26], ["patients", "SPECIES", 161, 169], ["lung inflammation", "PROBLEM", 41, 58], ["lymphopenia", "PROBLEM", 71, 82], ["secondary infection", "PROBLEM", 109, 128], ["lung", "ANATOMY", 41, 45], ["inflammation", "OBSERVATION", 46, 58], ["lymphopenia", "OBSERVATION", 71, 82], ["secondary", "OBSERVATION_MODIFIER", 109, 118], ["infection", "OBSERVATION", 119, 128]]], ["Therefore, we speculate that the -28 G allele that associates with the higher level of RANTES may enhance the inflammation and lead to severe clinical outcomes of SARS.", [["inflammation", "DISEASE", 110, 122], ["SARS", "DISEASE", 163, 167], ["G", "GENE_OR_GENE_PRODUCT", 37, 38], ["RANTES", "GENE_OR_GENE_PRODUCT", 87, 93], ["G allele", "DNA", 37, 45], ["RANTES", "PROTEIN", 87, 93], ["the inflammation", "PROBLEM", 106, 122], ["SARS", "PROBLEM", 163, 167], ["inflammation", "OBSERVATION", 110, 122]]], ["Indeed, RANTES -28 G allele did show a strong association with death in Hong Kong Chinese patients with SARS (Table 5) and this observation was confirmed in Beijing Chinese that the RANTES -28 G allele was associated with admission to intensive care units or deaths due to SARS (Table 7).DiscussionIn the case of SARS susceptibility, the RANTES -28 G allele was associated with Hong Kong Chinese patients only but not in Beijing Chinese patients.", [["death", "DISEASE", 63, 68], ["SARS", "DISEASE", 104, 108], ["deaths", "DISEASE", 259, 265], ["SARS", "DISEASE", 273, 277], ["SARS", "DISEASE", 313, 317], ["RANTES -28", "GENE_OR_GENE_PRODUCT", 8, 18], ["G", "GENE_OR_GENE_PRODUCT", 19, 20], ["patients", "ORGANISM", 90, 98], ["RANTES -28 G", "GENE_OR_GENE_PRODUCT", 182, 194], ["RANTES -28 G", "GENE_OR_GENE_PRODUCT", 338, 350], ["patients", "ORGANISM", 396, 404], ["patients", "ORGANISM", 437, 445], ["RANTES", "PROTEIN", 8, 14], ["G allele", "DNA", 19, 27], ["RANTES -28 G allele", "DNA", 182, 201], ["RANTES -28 G allele", "DNA", 338, 357], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 396, 404], ["patients", "SPECIES", 437, 445], ["RANTES", "TEST", 8, 14], ["SARS", "PROBLEM", 273, 277], ["SARS susceptibility", "PROBLEM", 313, 332]]], ["It has been suggested that Chinese in southern and northern China may be genetically distinct [20,21], accounting for the different observations with regard to SARS susceptibility.ConclusionWe demonstrated that the RANTES -28 G allele, which correlates with high RANTES production, was associated with SARS susceptibility in Hong Kong Chinese.", [["SARS", "DISEASE", 160, 164], ["SARS", "DISEASE", 302, 306], ["RANTES -28 G", "GENE_OR_GENE_PRODUCT", 215, 227], ["RANTES", "GENE_OR_GENE_PRODUCT", 263, 269], ["RANTES -28 G allele", "DNA", 215, 234], ["RANTES", "PROTEIN", 263, 269], ["SARS susceptibility", "PROBLEM", 160, 179], ["the RANTES", "TEST", 211, 221], ["high RANTES production", "PROBLEM", 258, 280], ["SARS susceptibility", "PROBLEM", 302, 321], ["high RANTES", "OBSERVATION_MODIFIER", 258, 269]]], ["It was also associated with adverse outcomes from SARS in both Hong Kong and Beijing Chinese.", [["SARS", "DISEASE", 50, 54], ["SARS", "PROBLEM", 50, 54]]], ["These suggest that a high RANTES level may play a role in the pathogenesis of SARS.Competing interestsThe authors do not have any commercial or other association that might pose a conflict of interest.Authors' contributionsMWN and GZ: Genotyping, data analyses, drafting the manuscriptAuthors' contributionsWPC: Data analyses, drafting the manuscriptAuthors' contributionsLWYL, HZ, SFSF, YZ: genotypingAuthors' contributionsHKWL, RWHY, EYC, KLA, EYTC: Sample collection, revising for medical contentAuthors' contributionsWL and JSMP: Sample collection, providing virological dataAuthors' contributionsYLL: Study design, conception and co-ordination, drafting the manuscriptAuthors' contributionsAll authors contributed to writing of the final manuscriptAuthors' contributionsAll authors read and approved the final manuscriptPre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication history", [["SARS", "DISEASE", 78, 82], ["HZ", "DISEASE", 378, 380], ["pre-publication", "DISEASE", 852, 867], ["Pre-publication", "DISEASE", 912, 927], ["RANTES", "GENE_OR_GENE_PRODUCT", 26, 32], ["RANTES", "PROTEIN", 26, 32], ["a high RANTES level", "PROBLEM", 19, 38], ["SARS", "PROBLEM", 78, 82], ["data analyses", "TEST", 247, 260], ["medical content", "PROBLEM", 484, 499], ["Sample collection", "PROBLEM", 534, 551], ["high RANTES", "OBSERVATION", 21, 32], ["KLA", "ANATOMY", 441, 444]]]], "aee4a6925ec8360192f9fee45ce7f86c98875636": [["IntroductionUp to 25% of critically ill patients experience difficulties in weaning from invasive mechanical ventilation (IMV), burdening the intensive care unit (ICU) with long lengths-of-stay, prolonged mechanical ventilation (IMV), and increased morbidity and mortality [1] .", [["critically ill", "DISEASE", 25, 39], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["IntroductionUp", "TREATMENT", 0, 14], ["invasive mechanical ventilation", "TREATMENT", 89, 120], ["prolonged mechanical ventilation", "TREATMENT", 195, 227], ["IMV", "TREATMENT", 229, 232], ["increased morbidity", "PROBLEM", 239, 258], ["mechanical ventilation", "OBSERVATION", 205, 227], ["increased", "OBSERVATION_MODIFIER", 239, 248], ["morbidity", "OBSERVATION", 249, 258]]], ["Weaning failure is commonly described as a failed spontaneous breathing trial (SBT) or the reinstitution of mechanical ventilation within 2 to 7 days after extubation [2] .", [["Weaning failure", "DISEASE", 0, 15], ["Weaning failure", "PROBLEM", 0, 15], ["spontaneous breathing trial", "TREATMENT", 50, 77], ["SBT", "TREATMENT", 79, 82], ["mechanical ventilation", "TREATMENT", 108, 130], ["failure", "OBSERVATION", 8, 15], ["mechanical ventilation", "OBSERVATION", 108, 130]]], ["Failed extubation complicates up to 30% of successful spontaneous breathing trials [3] and correlates with higher morbidity and mortality rates [4, 5] .IntroductionDetermining the optimal time to extubate a patient continues to be a challenge.", [["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["successful spontaneous breathing trials", "TREATMENT", 43, 82], ["higher morbidity", "PROBLEM", 107, 123], ["mortality rates", "TEST", 128, 143]]], ["Prolonged mechanical ventilation is associated with a series of adverse effects (e.g., tracheal lesions, ventilator-associated pneumonia, ventilator-induced lung injury, and ventilator-induced diaphragm injury) [6, 7] , whereas premature extubation exposes the patient to cardiovascular stress due to spontaneous breathing, often requiring the reinstitution of ventilatory support [8] .", [["tracheal lesions", "ANATOMY", 87, 103], ["lung", "ANATOMY", 157, 161], ["diaphragm", "ANATOMY", 193, 202], ["cardiovascular", "ANATOMY", 272, 286], ["tracheal lesions", "DISEASE", 87, 103], ["pneumonia", "DISEASE", 127, 136], ["ventilator-induced lung injury", "DISEASE", 138, 168], ["ventilator-induced diaphragm injury", "DISEASE", 174, 209], ["cardiovascular stress", "DISEASE", 272, 293], ["tracheal lesions", "PATHOLOGICAL_FORMATION", 87, 103], ["lung", "ORGAN", 157, 161], ["diaphragm", "ORGAN", 193, 202], ["patient", "ORGANISM", 261, 268], ["patient", "SPECIES", 261, 268], ["Prolonged mechanical ventilation", "TREATMENT", 0, 32], ["adverse effects", "PROBLEM", 64, 79], ["tracheal lesions", "PROBLEM", 87, 103], ["pneumonia", "PROBLEM", 127, 136], ["ventilator", "TREATMENT", 138, 148], ["lung injury", "PROBLEM", 157, 168], ["ventilator", "TREATMENT", 174, 184], ["diaphragm injury", "PROBLEM", 193, 209], ["premature extubation", "PROBLEM", 228, 248], ["cardiovascular stress", "PROBLEM", 272, 293], ["spontaneous breathing", "PROBLEM", 301, 322], ["ventilatory support", "TREATMENT", 361, 380], ["mechanical ventilation", "OBSERVATION", 10, 32], ["tracheal", "ANATOMY", 87, 95], ["lesions", "OBSERVATION", 96, 103], ["pneumonia", "OBSERVATION", 127, 136], ["lung", "ANATOMY", 157, 161], ["injury", "OBSERVATION", 162, 168], ["diaphragm", "ANATOMY", 193, 202], ["injury", "OBSERVATION", 203, 209]]], ["Although international guidelines recommend the implementation of spontaneous breathing trials [9] , used alone this practice is ineffective in predicting weaning failure and reintubation [10] [11] [12] [13] .", [["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 188, 207], ["spontaneous breathing trials", "TREATMENT", 66, 94], ["weaning failure", "PROBLEM", 155, 170], ["reintubation", "TREATMENT", 175, 187]]], ["A number of studies have investigated and proposed Vetrugno et al. Ultrasound J (2020) 12:9 different parameters as outcome predictors of weaning from mechanical ventilation; however, a clear understanding of the ideal time to proceed with extubation for a successful outcome continues to elude us [14, 15] .", [["studies", "TEST", 12, 19], ["mechanical ventilation", "TREATMENT", 151, 173], ["extubation", "TREATMENT", 240, 250]]], ["Cardiac failure, diaphragmatic dysfunction and acute respiratory illness (lung parenchyma disease, or upper or lower airway obstructions), neurological status, and intraabdominal issues are among the known leading causes of failed weaning [3, 16] .IntroductionSignificant advancements have been achieved in ultrasound technology over the last 20 years, most notably in bringing these techniques to the bedside, with all the advantages that this conveys.", [["Cardiac", "ANATOMY", 0, 7], ["diaphragmatic", "ANATOMY", 17, 30], ["respiratory", "ANATOMY", 53, 64], ["lung parenchyma", "ANATOMY", 74, 89], ["lower airway", "ANATOMY", 111, 123], ["neurological", "ANATOMY", 139, 151], ["intraabdominal", "ANATOMY", 164, 178], ["Cardiac failure", "DISEASE", 0, 15], ["diaphragmatic dysfunction", "DISEASE", 17, 42], ["acute respiratory illness", "DISEASE", 47, 72], ["lung parenchyma disease", "DISEASE", 74, 97], ["airway obstructions", "DISEASE", 117, 136], ["Cardiac", "ORGAN", 0, 7], ["diaphragmatic", "ORGAN", 17, 30], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 74, 89], ["upper", "ORGANISM_SUBDIVISION", 102, 107], ["lower airway", "ORGANISM_SUBDIVISION", 111, 123], ["Cardiac failure", "PROBLEM", 0, 15], ["diaphragmatic dysfunction", "PROBLEM", 17, 42], ["acute respiratory illness", "PROBLEM", 47, 72], ["lung parenchyma disease", "PROBLEM", 74, 97], ["upper or lower airway obstructions", "PROBLEM", 102, 136], ["neurological status", "PROBLEM", 139, 158], ["intraabdominal issues", "PROBLEM", 164, 185], ["failure", "OBSERVATION", 8, 15], ["diaphragmatic", "ANATOMY", 17, 30], ["dysfunction", "OBSERVATION", 31, 42], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["respiratory illness", "OBSERVATION", 53, 72], ["lung", "ANATOMY", 74, 78], ["parenchyma", "ANATOMY_MODIFIER", 79, 89], ["disease", "OBSERVATION", 90, 97], ["upper", "ANATOMY_MODIFIER", 102, 107], ["lower", "ANATOMY_MODIFIER", 111, 116], ["airway", "ANATOMY", 117, 123], ["obstructions", "OBSERVATION", 124, 136], ["intraabdominal", "ANATOMY", 164, 178]]], ["In fact, our capacity to study the individual organs ultrasonographically has become so finely tuned and specialized that physicians risk overlooking a more integrated examination of the patient.", [["organs", "ANATOMY", 46, 52], ["organs", "ORGAN", 46, 52], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194], ["a more integrated examination", "TEST", 150, 179]]], ["A comprehensive approach to invasive mechanical ventilation should include an extensive ultrasonographic assessment of cardiac function, diaphragmatic activity, and lung parenchyma.", [["cardiac", "ANATOMY", 119, 126], ["diaphragmatic", "ANATOMY", 137, 150], ["lung parenchyma", "ANATOMY", 165, 180], ["cardiac", "ORGAN", 119, 126], ["diaphragmatic", "ORGAN", 137, 150], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 165, 180], ["A comprehensive approach", "TREATMENT", 0, 24], ["invasive mechanical ventilation", "TREATMENT", 28, 59], ["an extensive ultrasonographic assessment", "TEST", 75, 115], ["cardiac", "ANATOMY", 119, 126], ["function", "OBSERVATION", 127, 135], ["diaphragmatic", "ANATOMY", 137, 150], ["activity", "OBSERVATION", 151, 159], ["lung", "ANATOMY", 165, 169], ["parenchyma", "ANATOMY_MODIFIER", 170, 180]]], ["In particular, much light has been shone on the use of ultrasonographic assessment of diaphragmatic dysfunction as a predictor of weaning failure.", [["diaphragmatic", "ANATOMY", 86, 99], ["diaphragmatic dysfunction", "DISEASE", 86, 111], ["weaning failure", "DISEASE", 130, 145], ["diaphragmatic", "ORGAN", 86, 99], ["ultrasonographic assessment", "TEST", 55, 82], ["diaphragmatic dysfunction", "PROBLEM", 86, 111], ["weaning failure", "PROBLEM", 130, 145], ["diaphragmatic", "ANATOMY", 86, 99], ["dysfunction", "OBSERVATION", 100, 111]]], ["That said, it is fundamental that the diaphragm does not receive excessive attention at the expense of other predictive factors.", [["diaphragm", "ANATOMY", 38, 47], ["diaphragm", "ORGAN", 38, 47], ["diaphragm", "ANATOMY", 38, 47]]], ["A simultaneous and comprehensive ultrasound examination of the cardiopulmonary-diaphragmatic district may confer valuable predictive information regarding successful weaning from mechanical ventilation, although literature in this regard is still limited [17] .", [["cardiopulmonary", "ANATOMY", 63, 78], ["A simultaneous and comprehensive ultrasound examination", "TEST", 0, 55], ["successful weaning", "TREATMENT", 155, 173], ["mechanical ventilation", "TREATMENT", 179, 201], ["cardiopulmonary", "ANATOMY", 63, 78], ["diaphragmatic", "ANATOMY", 79, 92], ["mechanical ventilation", "OBSERVATION", 179, 201]]], ["It is also important to bear in mind that other factors able to negatively influence the weaning outcome exist outside the cardio-pulmonarydiaphragmatic area (i.e., the neurological status and intra-abdominal hypertension) that cannot be evaluated with ultrasound [18, 19] .IntroductionMechanical ventilation can negatively affect the actors involved in respiratory function; for example, ventilatorinduced lung injury, impaired cardiac performance, and ventilator-induced diaphragmatic dysfunction are all possible consequences.", [["cardio-pulmonarydiaphragmatic area", "ANATOMY", 123, 157], ["neurological", "ANATOMY", 169, 181], ["intra-abdominal", "ANATOMY", 193, 208], ["respiratory", "ANATOMY", 354, 365], ["lung", "ANATOMY", 407, 411], ["cardiac", "ANATOMY", 429, 436], ["diaphragmatic", "ANATOMY", 473, 486], ["hypertension", "DISEASE", 209, 221], ["lung injury", "DISEASE", 407, 418], ["impaired cardiac performance", "DISEASE", 420, 448], ["diaphragmatic dysfunction", "DISEASE", 473, 498], ["pulmonarydiaphragmatic area", "TISSUE", 130, 157], ["intra-abdominal", "ORGANISM_SUBDIVISION", 193, 208], ["lung", "ORGAN", 407, 411], ["cardiac", "ORGAN", 429, 436], ["diaphragmatic", "ORGAN", 473, 486], ["intra-abdominal hypertension", "PROBLEM", 193, 221], ["ultrasound", "TEST", 253, 263], ["Mechanical ventilation", "TREATMENT", 286, 308], ["ventilatorinduced lung injury", "PROBLEM", 389, 418], ["impaired cardiac performance", "PROBLEM", 420, 448], ["ventilator", "TREATMENT", 454, 464], ["diaphragmatic dysfunction", "PROBLEM", 473, 498], ["cardio", "ANATOMY", 123, 129], ["intra-abdominal", "ANATOMY", 193, 208], ["hypertension", "OBSERVATION", 209, 221], ["Mechanical ventilation", "OBSERVATION", 286, 308], ["respiratory function", "OBSERVATION", 354, 374], ["lung", "ANATOMY", 407, 411], ["injury", "OBSERVATION", 412, 418], ["impaired", "OBSERVATION_MODIFIER", 420, 428], ["cardiac", "ANATOMY", 429, 436], ["diaphragmatic", "ANATOMY", 473, 486], ["dysfunction", "OBSERVATION", 487, 498]]], ["Although the concept of 'lung protection' during mechanical ventilation is well established, a more precise definition of a 'protective modality' to help preserve all the elements involved in the respiratory function is also desirable.IntroductionThe purpose of this two-part review is to illustrate the main causes of unsuccessful weaning and recent advancements on the application of bedside ultrasound evaluation in these topics.The weaning pathWeaning from mechanical ventilation starts with the institution of mechanical ventilation; from the outset, the physician assesses the patient on a daily basis to determine when they might be ready to wean.", [["lung", "ANATOMY", 25, 29], ["respiratory", "ANATOMY", 196, 207], ["lung", "ORGAN", 25, 29], ["patient", "ORGANISM", 583, 590], ["patient", "SPECIES", 583, 590], ["'lung protection", "TREATMENT", 24, 40], ["mechanical ventilation", "TREATMENT", 49, 71], ["a 'protective modality", "TREATMENT", 122, 144], ["unsuccessful weaning", "TREATMENT", 319, 339], ["bedside ultrasound evaluation", "TEST", 386, 415], ["The weaning pathWeaning", "TREATMENT", 432, 455], ["mechanical ventilation", "TREATMENT", 461, 483], ["mechanical ventilation", "TREATMENT", 515, 537], ["lung", "ANATOMY", 25, 29], ["protection", "OBSERVATION", 30, 40], ["respiratory function", "OBSERVATION", 196, 216], ["unsuccessful weaning", "OBSERVATION", 319, 339], ["mechanical ventilation", "OBSERVATION", 461, 483], ["mechanical ventilation", "OBSERVATION", 515, 537]]], ["Invasive mechanical ventilation is a risky journey for a critically ill patient admitted to the intensive care unit because of acute illness, IMV itself, or a failed weaning attempt.", [["critically ill", "DISEASE", 57, 71], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["Invasive mechanical ventilation", "TREATMENT", 0, 31], ["acute illness", "PROBLEM", 127, 140], ["a failed weaning attempt", "TREATMENT", 157, 181], ["mechanical ventilation", "OBSERVATION", 9, 31], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["illness", "OBSERVATION", 133, 140]]], ["Weaning is the process in which the breathing effort is progressively returned from the machine to the patient.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["This process consists of 3 key steps, Fig. 1 : first, when the patient's clinical conditions permit it, ventilation supports are progressively decreased (Ready, weaning!); second, a spontaneous breathing trial (SBT) assesses the patient's capability to breathe autonomously (Ready, breathing!); and third, the patient is liberated from mechanical ventilation (Ready, extubation!) [20, 21] .", [["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 229, 236], ["patient", "ORGANISM", 310, 317], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 229, 236], ["patient", "SPECIES", 310, 317], ["ventilation supports", "TREATMENT", 104, 124], ["a spontaneous breathing trial", "TREATMENT", 180, 209], ["mechanical ventilation", "TREATMENT", 336, 358], ["progressively", "OBSERVATION_MODIFIER", 129, 142], ["decreased", "OBSERVATION_MODIFIER", 143, 152], ["mechanical ventilation", "OBSERVATION", 336, 358]]], ["Three main SBT strategies are described in the literature: the T-piece trial; the continuous positive airway pressure (CPAP) trial-in which the CPAP applied is equal to the previously applied positive end-expiratory pressure (PEEP); and positive support ventilation, which uses a low level of pressure support (5-8 cmH 2 O).The weaning pathNo standardized SBT method has been identified to date in terms of type or duration (30-120 min) that can ensure a higher rate of successful weaning.", [["airway", "ANATOMY", 102, 108], ["airway", "MULTI-TISSUE_STRUCTURE", 102, 108], ["the T-piece trial", "TREATMENT", 59, 76], ["the continuous positive airway pressure (CPAP", "TREATMENT", 78, 123], ["the CPAP", "TREATMENT", 140, 148], ["PEEP", "TREATMENT", 226, 230], ["positive support ventilation", "TREATMENT", 237, 265], ["a low level of pressure support", "TREATMENT", 278, 309], ["The weaning pathNo", "TREATMENT", 324, 342], ["successful weaning", "TREATMENT", 470, 488], ["main", "OBSERVATION_MODIFIER", 6, 10], ["SBT strategies", "OBSERVATION", 11, 25], ["airway pressure", "OBSERVATION", 102, 117], ["support ventilation", "OBSERVATION", 246, 265]]], ["However, strong evidence does exist supporting the employment of a short-term (30 min) breathing trail and low-level pressure support (8 cmH 2 O) [22] .", [["cmH 2 O", "CHEMICAL", 137, 144], ["breathing trail", "TEST", 87, 102], ["low-level pressure support", "TREATMENT", 107, 133]]], ["If the SBT is accompanied by patient discomfort (i.e., anxiety or fatigue) and/or cardio-respiratory distress (i.e., RR \u2265 35 bpm, SpO 2 < 90%, HR variability > 20%, hemodynamic instability) [23] , then it is considered to have failed.", [["respiratory", "ANATOMY", 89, 100], ["anxiety", "DISEASE", 55, 62], ["fatigue", "DISEASE", 66, 73], ["cardio-respiratory distress", "DISEASE", 82, 109], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["the SBT", "TEST", 3, 10], ["patient discomfort", "PROBLEM", 29, 47], ["anxiety", "PROBLEM", 55, 62], ["fatigue", "PROBLEM", 66, 73], ["cardio-respiratory distress", "PROBLEM", 82, 109], ["RR", "TEST", 117, 119], ["SpO", "TEST", 130, 133], ["HR variability", "TEST", 143, 157], ["hemodynamic instability", "PROBLEM", 165, 188], ["cardio", "ANATOMY", 82, 88], ["respiratory", "ANATOMY", 89, 100], ["distress", "OBSERVATION", 101, 109]]], ["In the absence of such responses, the SBT is deemed successful and the patient can be considered for airway removal (Ready, extubing!).", [["airway", "ANATOMY", 101, 107], ["patient", "ORGANISM", 71, 78], ["airway", "MULTI-TISSUE_STRUCTURE", 101, 107], ["patient", "SPECIES", 71, 78], ["the SBT", "TREATMENT", 34, 41], ["airway removal", "TREATMENT", 101, 115]]], ["Although heterogeneity exists in the definition of successful weaning, it is generally taken as the patient's capacity to maintain spontaneous breathing for at least 48 h following extubation [3] .", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["successful weaning", "TREATMENT", 51, 69], ["spontaneous breathing", "PROBLEM", 131, 152], ["heterogeneity", "OBSERVATION", 9, 22]]], ["As mentioned above, despite international guidelines recommending the implementation of spontaneous breathing trials [3, 9] , used alone SBTs are ineffective in predicting weaning failure and reintubation [10] [11] [12] [13] .", [["SBTs", "SIMPLE_CHEMICAL", 137, 141], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 205, 224], ["spontaneous breathing trials", "TREATMENT", 88, 116], ["weaning failure", "PROBLEM", 172, 187], ["reintubation", "TREATMENT", 192, 204]]], ["One possible solution to this may be the implementation of integrated cardiopulmonary-diaphragmatic assessments for the detection of predictive indicators of weaning failure.The (he)art of weaning from mechanical ventilationIn the case of shock patients admitted to intensive care, most are resuscitated with the use of mechanical ventilation and intravenous fluid for respiratory and circulatory support.", [["diaphragmatic", "ANATOMY", 86, 99], ["intravenous", "ANATOMY", 347, 358], ["respiratory", "ANATOMY", 369, 380], ["circulatory", "ANATOMY", 385, 396], ["weaning failure", "DISEASE", 158, 173], ["shock", "DISEASE", 239, 244], ["diaphragmatic", "ORGAN", 86, 99], ["patients", "ORGANISM", 245, 253], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 347, 358], ["fluid", "ORGANISM_SUBSTANCE", 359, 364], ["patients", "SPECIES", 245, 253], ["diaphragmatic assessments", "TEST", 86, 111], ["weaning failure", "PROBLEM", 158, 173], ["mechanical ventilation", "TREATMENT", 202, 224], ["shock", "PROBLEM", 239, 244], ["mechanical ventilation", "TREATMENT", 320, 342], ["intravenous fluid", "TREATMENT", 347, 364], ["respiratory and circulatory support", "TREATMENT", 369, 404], ["diaphragmatic", "ANATOMY", 86, 99], ["weaning failure", "OBSERVATION", 158, 173], ["mechanical ventilation", "OBSERVATION", 202, 224], ["shock", "OBSERVATION", 239, 244], ["mechanical ventilation", "OBSERVATION", 320, 342], ["circulatory support", "OBSERVATION", 385, 404]]], ["Regarding fluid management procedures in shock patients, recent literature has schematized its practice into four different phases, adopting the acronym ROSE: resuscitation (R), optimization (O), stabilization (S), and evacuation (E) [24] .", [["fluid", "ANATOMY", 10, 15], ["shock", "DISEASE", 41, 46], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["fluid management", "TREATMENT", 10, 26]]], ["Resuscitation, in some cases, could be too aggressive with the risk of fluid-overload, whereas evacuation could be too fast with the risk of hypovolemia and low cardiac output state (see below).", [["cardiac", "ANATOMY", 161, 168], ["fluid-overload", "DISEASE", 71, 85], ["hypovolemia", "DISEASE", 141, 152], ["low cardiac output", "DISEASE", 157, 175], ["fluid", "ORGANISM_SUBSTANCE", 71, 76], ["cardiac", "ORGAN", 161, 168], ["Resuscitation", "TREATMENT", 0, 13], ["fluid-overload", "PROBLEM", 71, 85], ["evacuation", "TREATMENT", 95, 105], ["hypovolemia", "PROBLEM", 141, 152], ["low cardiac output state", "PROBLEM", 157, 181], ["fluid", "OBSERVATION", 71, 76], ["overload", "OBSERVATION", 77, 85], ["hypovolemia", "OBSERVATION", 141, 152]]], ["In the first case, previous over-hydration with a positive fluid balance has been associated with death and an increased risk of failed weaning from mechanical ventilation in surviving patients [25, 26] .", [["fluid", "ANATOMY", 59, 64], ["death", "DISEASE", 98, 103], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["previous over-hydration", "TREATMENT", 19, 42], ["a positive fluid balance", "PROBLEM", 48, 72], ["death", "PROBLEM", 98, 103], ["mechanical ventilation", "TREATMENT", 149, 171], ["fluid balance", "OBSERVATION", 59, 72], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["mechanical ventilation", "OBSERVATION", 149, 171]]], ["This could be explained by the fact that shifting the patient from mechanical ventilation (positive airway pressure) to a T-piece trial (negative airway pressure) can increase cardiac preload and unmask an underlying cardiac problem.", [["airway", "ANATOMY", 100, 106], ["airway", "ANATOMY", 146, 152], ["cardiac", "ANATOMY", 176, 183], ["cardiac", "ANATOMY", 217, 224], ["patient", "ORGANISM", 54, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 100, 106], ["airway", "MULTI-TISSUE_STRUCTURE", 146, 152], ["cardiac", "ORGAN", 176, 183], ["cardiac", "ORGAN", 217, 224], ["patient", "SPECIES", 54, 61], ["mechanical ventilation", "TREATMENT", 67, 89], ["positive airway pressure", "TREATMENT", 91, 115], ["a T-piece trial", "TREATMENT", 120, 135], ["cardiac preload", "TEST", 176, 191], ["an underlying cardiac problem", "PROBLEM", 203, 232], ["cardiac", "ANATOMY", 217, 224], ["problem", "OBSERVATION", 225, 232]]], ["Potential cardiac complications can be monitored in 3 main ways: one is direct but invasive-measurement of the cardiac filing pressure by pulmonary arterial catheter (PAC); the remaining two are indirect and un-invasiveone entails the use of heart or lung ultrasound, and the other the rapid measurement of natriuretic peptide for the diagnosis of acute heart failure [27, 28] .The (he)art of weaning from mechanical ventilationMonitoring for cardiac complications is necessary because the sensitivity and specificity of clinical signs of acute heart failure in intensive care patients are poor [29] .", [["cardiac", "ANATOMY", 10, 17], ["cardiac", "ANATOMY", 111, 118], ["pulmonary arterial", "ANATOMY", 138, 156], ["heart", "ANATOMY", 242, 247], ["lung", "ANATOMY", 251, 255], ["heart", "ANATOMY", 354, 359], ["cardiac", "ANATOMY", 443, 450], ["heart", "ANATOMY", 545, 550], ["cardiac complications", "DISEASE", 10, 31], ["heart failure", "DISEASE", 354, 367], ["cardiac complications", "DISEASE", 443, 464], ["heart failure", "DISEASE", 545, 558], ["cardiac", "ORGAN", 10, 17], ["cardiac", "ORGAN", 111, 118], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 138, 156], ["heart", "ORGAN", 242, 247], ["lung", "ORGAN", 251, 255], ["natriuretic peptide", "GENE_OR_GENE_PRODUCT", 307, 326], ["heart", "ORGAN", 354, 359], ["cardiac", "ORGAN", 443, 450], ["heart", "ORGAN", 545, 550], ["patients", "ORGANISM", 577, 585], ["patients", "SPECIES", 577, 585], ["Potential cardiac complications", "PROBLEM", 0, 31], ["pulmonary arterial catheter (PAC", "TREATMENT", 138, 170], ["heart or lung ultrasound", "TEST", 242, 266], ["natriuretic peptide", "TREATMENT", 307, 326], ["acute heart failure", "PROBLEM", 348, 367], ["mechanical ventilation", "TREATMENT", 406, 428], ["cardiac complications", "PROBLEM", 443, 464], ["the sensitivity", "TEST", 486, 501], ["acute heart failure", "PROBLEM", 539, 558], ["cardiac", "ANATOMY", 10, 17], ["complications", "OBSERVATION", 18, 31], ["invasive", "OBSERVATION", 83, 91], ["cardiac", "ANATOMY", 111, 118], ["pulmonary arterial", "ANATOMY", 138, 156], ["catheter", "OBSERVATION", 157, 165], ["heart", "ANATOMY", 242, 247], ["lung", "ANATOMY", 251, 255], ["acute", "OBSERVATION_MODIFIER", 348, 353], ["heart", "ANATOMY", 354, 359], ["failure", "OBSERVATION", 360, 367], ["acute", "OBSERVATION_MODIFIER", 539, 544], ["heart", "ANATOMY", 545, 550], ["failure", "OBSERVATION", 551, 558]]], ["PAC is reserved for specific severe cases.", [["PAC", "CHEMICAL", 0, 3], ["PAC", "CHEMICAL", 0, 3], ["PAC", "TREATMENT", 0, 3], ["specific severe cases", "PROBLEM", 20, 41]]], ["It is used for the diagnosis and treatment of pulmonary arterial hypertension and to guide fluid and catecholamine management; however, its routine use has been abandoned globally due to the lack of any outcome benefits [30, 31] .", [["pulmonary arterial", "ANATOMY", 46, 64], ["fluid", "ANATOMY", 91, 96], ["pulmonary arterial hypertension", "DISEASE", 46, 77], ["catecholamine", "CHEMICAL", 101, 114], ["catecholamine", "CHEMICAL", 101, 114], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 46, 64], ["catecholamine", "SIMPLE_CHEMICAL", 101, 114], ["treatment", "TREATMENT", 33, 42], ["pulmonary arterial hypertension", "PROBLEM", 46, 77], ["fluid and catecholamine management", "TREATMENT", 91, 125], ["pulmonary arterial", "ANATOMY", 46, 64], ["hypertension", "OBSERVATION", 65, 77]]], ["Ultrasound, on the other hand, has become an invaluable tool in the ICU thanks to its widespread availability at the patient's bedside and the absence of any known side effects [28] .", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["Ultrasound", "TEST", 0, 10], ["any known side effects", "PROBLEM", 154, 176]]], ["Moreover, the role of echocardiography in the detection of cardiac origins of weaning failure has grown significantly over the last 15 years.", [["cardiac", "ANATOMY", 59, 66], ["weaning failure", "DISEASE", 78, 93], ["cardiac", "ORGAN", 59, 66], ["echocardiography", "TEST", 22, 38], ["weaning failure", "PROBLEM", 78, 93], ["cardiac", "ANATOMY", 59, 66], ["weaning failure", "OBSERVATION", 78, 93]]], ["In particular, we now know that impaired systolic function (i.e., a small left ventricular ejection fraction [LVEF]) is less frequently associated with weaning failure in patients who failed the SBT (33% of cases) than left ventricular diastolic dysfunction (67% of cases) [28, 32, 33] .", [["left ventricular", "ANATOMY", 74, 90], ["left ventricular", "ANATOMY", 219, 235], ["impaired systolic function", "DISEASE", 32, 58], ["weaning failure", "DISEASE", 152, 167], ["ventricular diastolic dysfunction", "DISEASE", 224, 257], ["ventricular", "MULTI-TISSUE_STRUCTURE", 79, 90], ["patients", "ORGANISM", 171, 179], ["ventricular", "MULTI-TISSUE_STRUCTURE", 224, 235], ["patients", "SPECIES", 171, 179], ["impaired systolic function", "PROBLEM", 32, 58], ["a small left ventricular ejection fraction", "PROBLEM", 66, 108], ["LVEF", "TEST", 110, 114], ["weaning failure", "PROBLEM", 152, 167], ["the SBT", "TEST", 191, 198], ["left ventricular diastolic dysfunction", "PROBLEM", 219, 257], ["impaired", "OBSERVATION", 32, 40], ["systolic function", "OBSERVATION", 41, 58], ["small", "OBSERVATION_MODIFIER", 68, 73], ["left ventricular", "ANATOMY", 74, 90], ["ejection fraction", "OBSERVATION", 91, 108], ["left ventricular diastolic", "ANATOMY", 219, 245], ["dysfunction", "OBSERVATION", 246, 257]]], ["To investigate this latter condition, trans-mitral flow is interrogated using a pulse wave Doppler placed over the mitral valve in an apical four-chamber view.", [["mitral", "ANATOMY", 44, 50], ["mitral valve", "ANATOMY", 115, 127], ["mitral", "MULTI-TISSUE_STRUCTURE", 44, 50], ["mitral valve", "PATHOLOGICAL_FORMATION", 115, 127], ["a pulse wave Doppler", "TEST", 78, 98], ["mitral", "ANATOMY", 44, 50], ["flow", "OBSERVATION", 51, 55], ["mitral valve", "ANATOMY", 115, 127], ["apical", "ANATOMY_MODIFIER", 134, 140]]], ["An early wave (E wave) is displayed on the monitor, Fig. 2a , that represents the first phase of the diastole as a passive phenomenon, limited only by the stiffness of the left ventricle or by interventricular interdependence-right ventricular push over the left ventricle via the septum.", [["left ventricle", "ANATOMY", 172, 186], ["interventricular", "ANATOMY", 193, 209], ["right ventricular", "ANATOMY", 226, 243], ["left ventricle", "ANATOMY", 258, 272], ["septum", "ANATOMY", 281, 287], ["ventricle", "MULTI-TISSUE_STRUCTURE", 177, 186], ["interventricular", "MULTI-TISSUE_STRUCTURE", 193, 209], ["ventricular", "MULTI-TISSUE_STRUCTURE", 232, 243], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 258, 272], ["septum", "MULTI-TISSUE_STRUCTURE", 281, 287], ["An early wave (E wave)", "PROBLEM", 0, 22], ["the monitor", "TEST", 39, 50], ["a passive phenomenon", "PROBLEM", 113, 133], ["interventricular interdependence", "PROBLEM", 193, 225], ["early", "OBSERVATION_MODIFIER", 3, 8], ["wave", "OBSERVATION_MODIFIER", 9, 13], ["diastole", "OBSERVATION", 101, 109], ["passive phenomenon", "OBSERVATION", 115, 133], ["stiffness", "OBSERVATION", 155, 164], ["left ventricle", "ANATOMY", 172, 186], ["interventricular", "ANATOMY_MODIFIER", 193, 209], ["interdependence", "OBSERVATION", 210, 225], ["right ventricular", "ANATOMY", 226, 243], ["push", "ANATOMY_MODIFIER", 244, 248], ["left ventricle", "ANATOMY", 258, 272], ["septum", "OBSERVATION", 281, 287]]], ["A stiff ventricle generates an elevated filling pressure, leading to pulmonary edema.", [["ventricle", "ANATOMY", 8, 17], ["pulmonary", "ANATOMY", 69, 78], ["pulmonary edema", "DISEASE", 69, 84], ["ventricle", "MULTI-TISSUE_STRUCTURE", 8, 17], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 69, 84], ["an elevated filling pressure", "PROBLEM", 28, 56], ["pulmonary edema", "PROBLEM", 69, 84], ["stiff ventricle", "ANATOMY", 2, 17], ["elevated", "OBSERVATION", 31, 39], ["filling pressure", "OBSERVATION", 40, 56], ["pulmonary", "ANATOMY", 69, 78], ["edema", "OBSERVATION", 79, 84]]], ["In addition to trans-mitral Doppler, an E wave inpatient with sinus rhythm is followed by atrial contraction (A wave, Fig. 2a) .", [["atrial", "ANATOMY", 90, 96], ["atrial", "MULTI-TISSUE_STRUCTURE", 90, 96], ["trans-mitral Doppler", "TEST", 15, 35], ["sinus rhythm", "PROBLEM", 62, 74], ["atrial contraction", "PROBLEM", 90, 108], ["mitral", "ANATOMY", 21, 27], ["sinus rhythm", "OBSERVATION", 62, 74], ["atrial contraction", "OBSERVATION", 90, 108]]], ["The left ventricular preload is the sum of the E and A waves at a price of low or average left ventricular end-diastolic pressure (LVEDP) less than 12-14 mmHg.", [["left ventricular", "ANATOMY", 4, 20], ["left ventricular", "ANATOMY", 90, 106], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 4, 20], ["ventricular", "MULTI-TISSUE_STRUCTURE", 95, 106], ["The left ventricular preload", "TEST", 0, 28], ["LVEDP", "TEST", 131, 136], ["left ventricular", "ANATOMY", 4, 20], ["preload", "OBSERVATION", 21, 28], ["left ventricular", "ANATOMY", 90, 106], ["diastolic pressure", "OBSERVATION", 111, 129]]], ["However, to estimate the LVEDP non-invasively, the E/A ratio has shown to be preload dependent and insufficient [34] .", [["E/A", "GENE_OR_GENE_PRODUCT", 51, 54], ["the LVEDP non-invasively", "TEST", 21, 45], ["the E/A ratio", "TEST", 47, 60], ["preload dependent", "PROBLEM", 77, 94], ["LVEDP", "OBSERVATION", 25, 30], ["preload dependent", "OBSERVATION", 77, 94]]], ["On the other hand, tissue Doppler directly measures myocardial velocities by means of the E\u02b9 wave in a load-independent way, Fig. 2b .", [["tissue", "ANATOMY", 19, 25], ["myocardial", "ANATOMY", 52, 62], ["tissue", "TISSUE", 19, 25], ["myocardial", "MULTI-TISSUE_STRUCTURE", 52, 62], ["tissue Doppler", "TEST", 19, 33], ["myocardial velocities", "TEST", 52, 73]]], ["The combination of the trans-mitral Doppler E wave, the tissue Doppler E\u02b9 wave, and the E/E\u02b9 ratio at the end of an SBT also seems to be Fig. 1 The weaning path.", [["tissue", "ANATOMY", 56, 62], ["tissue", "TISSUE", 56, 62], ["the tissue Doppler", "TEST", 52, 70], ["the E/E\u02b9 ratio", "TEST", 84, 98], ["an SBT", "TEST", 113, 119], ["The weaning path", "TREATMENT", 144, 160], ["mitral", "OBSERVATION", 29, 35]]], ["GCS Glasgow Coma Scale, RR respiratory rate, PEEP positive end-expiratory pressure, RSBI rapid shallow breathing index, SBT spontaneous breathing trial capable of predicting weaning failure from diastolic dysfunction in patients with arrhythmia, immediately after and 10 min after extubation, with an area under the curve (AUC) of 0.75 and 0.86, respectively [33] .", [["Coma", "DISEASE", 12, 16], ["diastolic dysfunction", "DISEASE", 195, 216], ["arrhythmia", "DISEASE", 234, 244], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["GCS", "TEST", 0, 3], ["Coma Scale", "TEST", 12, 22], ["RR", "TEST", 24, 26], ["respiratory rate", "TEST", 27, 43], ["PEEP", "TEST", 45, 49], ["end", "TEST", 59, 62], ["expiratory pressure", "TEST", 63, 82], ["RSBI", "TEST", 84, 88], ["shallow breathing index", "PROBLEM", 95, 118], ["SBT spontaneous breathing trial", "TREATMENT", 120, 151], ["weaning failure", "PROBLEM", 174, 189], ["diastolic dysfunction", "PROBLEM", 195, 216], ["arrhythmia", "PROBLEM", 234, 244], ["extubation", "TREATMENT", 281, 291], ["AUC", "TEST", 323, 326], ["expiratory pressure", "OBSERVATION", 63, 82], ["diastolic dysfunction", "OBSERVATION", 195, 216]]], ["However, two main limitations of these methods need to be recognized.", [["these methods", "TREATMENT", 33, 46], ["main", "OBSERVATION_MODIFIER", 13, 17]]], ["First, although an E/E\u02b9 value < 8 can accurately identify patients with a normal LVEDP, and an E/E\u02b9 value > 15 can identify those with an elevated LVEDP, a gray zone exists between the values of 8 and 15 [33] [34] [35] ; second, not all intensive care clinicians possess advanced echocardiography skills; and third, LVEDP may also be elevated in cases of increased intra-abdominal pressure (see below).The (he)art of weaning from mechanical ventilationIn a very recent study, lung ultrasound evaluating the delta-B-lines before and after SBT in the four anterior chest wall regions was shown to provide excellent correlation with successful weaning [36] .", [["intra-abdominal", "ANATOMY", 365, 380], ["lung", "ANATOMY", 476, 480], ["delta-B-lines", "ANATOMY", 507, 520], ["anterior chest wall", "ANATOMY", 554, 573], ["patients", "ORGANISM", 58, 66], ["intra-abdominal", "ORGANISM_SUBDIVISION", 365, 380], ["lung", "ORGAN", 476, 480], ["B-lines", "CELL", 513, 520], ["anterior chest wall", "MULTI-TISSUE_STRUCTURE", 554, 573], ["delta-B-lines", "CELL_LINE", 507, 520], ["patients", "SPECIES", 58, 66], ["an E/E\u02b9 value", "TEST", 16, 29], ["an E/E\u02b9 value", "TEST", 92, 105], ["an elevated LVEDP", "PROBLEM", 135, 152], ["a gray zone", "TEST", 154, 165], ["the values", "TEST", 181, 191], ["advanced echocardiography skills", "TEST", 271, 303], ["LVEDP", "TEST", 316, 321], ["increased intra-abdominal pressure", "PROBLEM", 355, 389], ["mechanical ventilation", "TREATMENT", 430, 452], ["a very recent study", "TEST", 455, 474], ["lung ultrasound", "TEST", 476, 491], ["the delta-B-lines", "TREATMENT", 503, 520], ["SBT", "TREATMENT", 538, 541], ["LVEDP", "OBSERVATION", 81, 86], ["elevated", "OBSERVATION_MODIFIER", 138, 146], ["LVEDP", "OBSERVATION", 147, 152], ["LVEDP", "OBSERVATION", 316, 321], ["may also be", "UNCERTAINTY", 322, 333], ["elevated", "OBSERVATION", 334, 342], ["increased", "OBSERVATION_MODIFIER", 355, 364], ["intra-abdominal", "ANATOMY", 365, 380], ["pressure", "OBSERVATION_MODIFIER", 381, 389], ["mechanical ventilation", "OBSERVATION", 430, 452], ["lung", "ANATOMY", 476, 480], ["anterior", "ANATOMY_MODIFIER", 554, 562], ["chest", "ANATOMY", 563, 568], ["wall", "ANATOMY_MODIFIER", 569, 573]]], ["However, the shift from mechanical to spontaneous ventilation may alone justify the appearance of such artifacts.", [["mechanical to spontaneous ventilation", "TREATMENT", 24, 61], ["such artifacts", "PROBLEM", 98, 112]]], ["Furthermore, distinguishing between cardiogenic and inflammatory causes of delta-B-lines may be a challenge.The (he)art of weaning from mechanical ventilationLastly, natriuretic peptides, and in particular brain natriuretic peptide (BNP), have been studied for their potential to predict weaning failure.", [["delta-B-lines", "ANATOMY", 75, 88], ["cardiogenic", "DISEASE", 36, 47], ["natriuretic peptides", "GENE_OR_GENE_PRODUCT", 166, 186], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 206, 231], ["BNP", "GENE_OR_GENE_PRODUCT", 233, 236], ["delta-B-lines", "CELL_LINE", 75, 88], ["cardiogenic", "PROBLEM", 36, 47], ["inflammatory causes", "PROBLEM", 52, 71], ["delta-B-lines", "TREATMENT", 75, 88], ["mechanical ventilationLastly", "TREATMENT", 136, 164], ["natriuretic peptides", "TREATMENT", 166, 186], ["BNP", "TEST", 233, 236], ["weaning failure", "PROBLEM", 288, 303], ["cardiogenic", "OBSERVATION", 36, 47], ["inflammatory", "OBSERVATION_MODIFIER", 52, 64]]], ["In their study, Mekontso-Dessap et al. reported the outcome of two weaning strategies, one of which was driven by BNP level, whereas the other followed no explicit protocol [37] .", [["BNP", "GENE_OR_GENE_PRODUCT", 114, 117], ["BNP", "PROTEIN", 114, 117], ["their study", "TEST", 3, 14], ["two weaning strategies", "TREATMENT", 63, 85], ["BNP level", "TEST", 114, 123]]], ["They found that the BNP-guided fluid strategy was associated with increased use of diuretics, more negative fluid balance leading to a shorter mechanical ventilation time, and more ventilator-free days, but no change in ICU length-of-stay, morbidity, or mortality.", [["fluid", "ANATOMY", 108, 113], ["BNP", "GENE_OR_GENE_PRODUCT", 20, 23], ["the BNP", "TEST", 16, 23], ["fluid strategy", "TREATMENT", 31, 45], ["diuretics", "TREATMENT", 83, 92], ["fluid balance", "TEST", 108, 121], ["a shorter mechanical ventilation time", "TREATMENT", 133, 170], ["morbidity", "PROBLEM", 240, 249], ["mortality", "PROBLEM", 254, 263], ["fluid", "OBSERVATION", 31, 36], ["no", "UNCERTAINTY", 207, 209], ["change", "OBSERVATION_MODIFIER", 210, 216]]], ["The authors suggest that the changes in BNP that occur in the ICU are relatively slow and may be influenced by renal insufficiency or by the use of extracorporeal renal replacement therapy.The (he)art of weaning from mechanical ventilationAs previously mentioned, one-third of weaning failures with a cardiac origin depend on systolic dysfunction.", [["renal", "ANATOMY", 111, 116], ["renal", "ANATOMY", 163, 168], ["cardiac", "ANATOMY", 301, 308], ["renal insufficiency", "DISEASE", 111, 130], ["systolic dysfunction", "DISEASE", 326, 346], ["BNP", "GENE_OR_GENE_PRODUCT", 40, 43], ["renal", "ORGAN", 111, 116], ["renal", "ORGAN", 163, 168], ["cardiac", "ORGAN", 301, 308], ["systolic", "ORGANISM_SUBDIVISION", 326, 334], ["BNP", "PROTEIN", 40, 43], ["the changes in BNP", "PROBLEM", 25, 43], ["renal insufficiency", "PROBLEM", 111, 130], ["extracorporeal renal replacement therapy", "TREATMENT", 148, 188], ["mechanical ventilation", "TREATMENT", 217, 239], ["weaning failures", "PROBLEM", 277, 293], ["systolic dysfunction", "PROBLEM", 326, 346], ["renal", "ANATOMY", 111, 116], ["insufficiency", "OBSERVATION", 117, 130], ["renal", "ANATOMY", 163, 168], ["replacement", "OBSERVATION", 169, 180], ["mechanical ventilation", "OBSERVATION", 217, 239], ["failures", "OBSERVATION", 285, 293], ["cardiac", "ANATOMY", 301, 308], ["origin", "OBSERVATION", 309, 315], ["systolic dysfunction", "OBSERVATION", 326, 346]]], ["In the case of cardiogenic shock, the diaphragmatic blood flow decreases and diaphragm muscular function can become compromised.", [["diaphragmatic blood", "ANATOMY", 38, 57], ["diaphragm muscular", "ANATOMY", 77, 95], ["cardiogenic shock", "DISEASE", 15, 32], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["diaphragm muscular", "MULTI-TISSUE_STRUCTURE", 77, 95], ["cardiogenic shock", "PROBLEM", 15, 32], ["the diaphragmatic blood flow", "TEST", 34, 62], ["cardiogenic shock", "OBSERVATION", 15, 32], ["diaphragmatic", "ANATOMY", 38, 51], ["blood flow", "OBSERVATION", 52, 62], ["diaphragm muscular", "ANATOMY", 77, 95]]], ["In normal conditions, the diaphragmatic blood flow significantly increases with a high level of muscle contraction [38] .", [["diaphragmatic blood", "ANATOMY", 26, 45], ["muscle", "ANATOMY", 96, 102], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["muscle", "ORGAN", 96, 102], ["the diaphragmatic blood flow", "TEST", 22, 50], ["normal conditions", "OBSERVATION", 3, 20], ["diaphragmatic", "ANATOMY", 26, 39], ["muscle", "ANATOMY", 96, 102]]], ["Indeed, the diaphragmatic blood flow is strictly dependent on cardiac output in both individuals at rest and with increased muscular activity [39] .", [["diaphragmatic blood", "ANATOMY", 12, 31], ["cardiac", "ANATOMY", 62, 69], ["muscular", "ANATOMY", 124, 132], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["cardiac", "ORGAN", 62, 69], ["the diaphragmatic blood flow", "TEST", 8, 36], ["cardiac output", "TEST", 62, 76], ["increased muscular activity", "PROBLEM", 114, 141], ["diaphragmatic", "ANATOMY", 12, 25], ["blood flow", "OBSERVATION", 26, 36], ["dependent", "OBSERVATION_MODIFIER", 49, 58], ["output", "OBSERVATION_MODIFIER", 70, 76], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["muscular activity", "OBSERVATION", 124, 141]]], ["Thus, since the diaphragm requires a high blood flow-in fact it is the skeletal muscle receiving the largest volume of blood per gram of tissue-diaphragm function may be impaired by a reduction in blood flow [40] .The (he)art of weaning from mechanical ventilationIn patients with cardiogenic shock, respiratory muscles, which are the only muscles working during low cardiac output, shift to anaerobic metabolism resulting in lactate production even though they may be receiving a large fraction of the cardiac output [41] .", [["diaphragm", "ANATOMY", 16, 25], ["blood", "ANATOMY", 42, 47], ["skeletal muscle", "ANATOMY", 71, 86], ["blood", "ANATOMY", 119, 124], ["tissue", "ANATOMY", 137, 143], ["diaphragm", "ANATOMY", 144, 153], ["blood", "ANATOMY", 197, 202], ["respiratory muscles", "ANATOMY", 300, 319], ["muscles", "ANATOMY", 340, 347], ["cardiac", "ANATOMY", 367, 374], ["cardiac", "ANATOMY", 503, 510], ["cardiogenic shock", "DISEASE", 281, 298], ["low cardiac output", "DISEASE", 363, 381], ["lactate", "CHEMICAL", 426, 433], ["lactate", "CHEMICAL", 426, 433], ["diaphragm", "ORGAN", 16, 25], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["skeletal muscle", "TISSUE", 71, 86], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["tissue", "TISSUE", 137, 143], ["diaphragm", "ORGAN", 144, 153], ["blood", "ORGANISM_SUBSTANCE", 197, 202], ["patients", "ORGANISM", 267, 275], ["muscles", "ORGAN", 312, 319], ["muscles", "ORGANISM_SUBDIVISION", 340, 347], ["cardiac", "ORGAN", 367, 374], ["lactate", "SIMPLE_CHEMICAL", 426, 433], ["cardiac", "ORGAN", 503, 510], ["patients", "SPECIES", 267, 275], ["a high blood flow", "PROBLEM", 35, 52], ["blood flow", "TEST", 197, 207], ["mechanical ventilation", "TREATMENT", 242, 264], ["cardiogenic shock", "PROBLEM", 281, 298], ["respiratory muscles", "PROBLEM", 300, 319], ["low cardiac output", "PROBLEM", 363, 381], ["anaerobic metabolism", "PROBLEM", 392, 412], ["lactate production", "PROBLEM", 426, 444], ["the cardiac output", "TEST", 499, 517], ["diaphragm", "ANATOMY", 16, 25], ["skeletal muscle", "ANATOMY", 71, 86], ["largest", "OBSERVATION_MODIFIER", 101, 108], ["volume", "OBSERVATION_MODIFIER", 109, 115], ["diaphragm", "ANATOMY", 144, 153], ["may be", "UNCERTAINTY", 163, 169], ["impaired", "OBSERVATION_MODIFIER", 170, 178], ["reduction", "OBSERVATION_MODIFIER", 184, 193], ["mechanical ventilation", "OBSERVATION", 242, 264], ["cardiogenic shock", "OBSERVATION", 281, 298], ["respiratory muscles", "ANATOMY", 300, 319], ["cardiac", "ANATOMY", 503, 510]]], ["As a consequence, skeletal muscles and vital organs receive less blood flow, contributing to an increased production and impaired removal of lactate [41] .", [["skeletal muscles", "ANATOMY", 18, 34], ["organs", "ANATOMY", 45, 51], ["blood", "ANATOMY", 65, 70], ["lactate", "CHEMICAL", 141, 148], ["lactate", "CHEMICAL", 141, 148], ["skeletal muscles", "ORGAN", 18, 34], ["organs", "ORGAN", 45, 51], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["lactate", "SIMPLE_CHEMICAL", 141, 148], ["blood flow", "TEST", 65, 75], ["an increased production", "PROBLEM", 93, 116], ["impaired removal of lactate", "TREATMENT", 121, 148], ["skeletal muscles", "ANATOMY", 18, 34], ["increased", "OBSERVATION_MODIFIER", 96, 105]]], ["The onset of acidemia and hypoxemia then leads to an increase in the work of breathing due to induced compensatory hyperventilation.", [["acidemia", "DISEASE", 13, 21], ["hypoxemia", "DISEASE", 26, 35], ["hyperventilation", "DISEASE", 115, 131], ["acidemia", "PROBLEM", 13, 21], ["hypoxemia", "PROBLEM", 26, 35], ["an increase", "PROBLEM", 50, 61], ["the work of breathing", "PROBLEM", 65, 86], ["induced compensatory hyperventilation", "PROBLEM", 94, 131], ["acidemia", "OBSERVATION", 13, 21], ["hypoxemia", "OBSERVATION", 26, 35], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["compensatory hyperventilation", "OBSERVATION", 102, 131]]], ["Of note, whenever the muscle oxygen and nutrient demands exceed the supply, the diaphragm's ability to generate and sustain force decreases and muscle failure ensues [42] .", [["muscle", "ANATOMY", 22, 28], ["diaphragm", "ANATOMY", 80, 89], ["muscle", "ANATOMY", 144, 150], ["oxygen", "CHEMICAL", 29, 35], ["muscle failure", "DISEASE", 144, 158], ["oxygen", "CHEMICAL", 29, 35], ["muscle", "ORGAN", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["diaphragm", "ORGAN", 80, 89], ["muscle", "ORGAN", 144, 150], ["the muscle oxygen", "TREATMENT", 18, 35], ["muscle failure ensues", "PROBLEM", 144, 165], ["muscle", "ANATOMY", 22, 28], ["diaphragm", "ANATOMY", 80, 89], ["muscle", "ANATOMY", 144, 150], ["failure", "OBSERVATION", 151, 158]]], ["During cardiogenic shock, the imbalance between demand and supply is facilitated by the reduced cardiac output and diaphragmatic blood flow (see Fig. 3 ).The (he)art of weaning from mechanical ventilationIn 1982, Aubier and colleagues investigated the influence of respiratory muscle activity on lactic acidosis and survival time in a cardiogenic shock canine model [41] .", [["cardiac", "ANATOMY", 96, 103], ["diaphragmatic blood", "ANATOMY", 115, 134], ["respiratory muscle", "ANATOMY", 265, 283], ["cardiogenic shock", "DISEASE", 7, 24], ["lactic acidosis", "DISEASE", 296, 311], ["cardiogenic shock", "DISEASE", 335, 352], ["cardiac", "ORGAN", 96, 103], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["muscle", "ORGAN", 277, 283], ["cardiogenic shock", "PROBLEM", 7, 24], ["the reduced cardiac output", "PROBLEM", 84, 110], ["diaphragmatic blood flow", "TEST", 115, 139], ["mechanical ventilationIn", "TREATMENT", 182, 206], ["respiratory muscle activity", "PROBLEM", 265, 292], ["lactic acidosis", "PROBLEM", 296, 311], ["survival time", "TREATMENT", 316, 329], ["a cardiogenic shock canine model", "TREATMENT", 333, 365], ["cardiogenic", "OBSERVATION_MODIFIER", 7, 18], ["shock", "OBSERVATION", 19, 24], ["reduced", "OBSERVATION_MODIFIER", 88, 95], ["cardiac output", "OBSERVATION", 96, 110], ["diaphragmatic", "ANATOMY", 115, 128], ["blood flow", "OBSERVATION", 129, 139], ["respiratory muscle", "ANATOMY", 265, 283], ["lactic acidosis", "OBSERVATION", 296, 311]]], ["Pulse wave Doppler and tissue Doppler. a Trans-mitralic Doppler; an early wave (E wave) is displayed on the monitor that represents the first phase of the diastole as a passive phenomenon, limited only by the stiffness of the left ventricle or by interventricular interdependence-right ventricular push over the left ventricle via the septum.", [["tissue", "ANATOMY", 23, 29], ["left ventricle", "ANATOMY", 226, 240], ["interventricular", "ANATOMY", 247, 263], ["right ventricular", "ANATOMY", 280, 297], ["left ventricle", "ANATOMY", 312, 326], ["septum", "ANATOMY", 335, 341], ["tissue", "TISSUE", 23, 29], ["ventricle", "MULTI-TISSUE_STRUCTURE", 231, 240], ["interventricular", "MULTI-TISSUE_STRUCTURE", 247, 263], ["ventricular", "MULTI-TISSUE_STRUCTURE", 286, 297], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 312, 326], ["septum", "MULTI-TISSUE_STRUCTURE", 335, 341], ["Pulse wave Doppler", "TEST", 0, 18], ["tissue Doppler", "TEST", 23, 37], ["a Trans-mitralic Doppler", "TEST", 39, 63], ["an early wave (E wave", "TEST", 65, 86], ["the monitor", "TEST", 104, 115], ["a passive phenomenon", "PROBLEM", 167, 187], ["interventricular interdependence", "PROBLEM", 247, 279], ["diastole", "OBSERVATION", 155, 163], ["passive phenomenon", "OBSERVATION", 169, 187], ["stiffness", "OBSERVATION", 209, 218], ["left ventricle", "ANATOMY", 226, 240], ["interventricular", "ANATOMY_MODIFIER", 247, 263], ["interdependence", "OBSERVATION", 264, 279], ["right ventricular", "ANATOMY", 280, 297], ["push", "ANATOMY_MODIFIER", 298, 302], ["left ventricle", "ANATOMY", 312, 326], ["septum", "OBSERVATION", 335, 341]]], ["The E wave in patient with sinus rhythm is followed by atrial contraction (A wave). b Septal tissue Doppler; tissue Doppler directly measures myocardial velocities by means of the E\u02b9 wave in a load-independent way.", [["sinus", "ANATOMY", 27, 32], ["atrial", "ANATOMY", 55, 61], ["tissue", "ANATOMY", 93, 99], ["tissue", "ANATOMY", 109, 115], ["myocardial", "ANATOMY", 142, 152], ["patient", "ORGANISM", 14, 21], ["sinus", "ORGAN", 27, 32], ["atrial", "MULTI-TISSUE_STRUCTURE", 55, 61], ["Septal tissue", "TISSUE", 86, 99], ["tissue", "TISSUE", 109, 115], ["myocardial", "MULTI-TISSUE_STRUCTURE", 142, 152], ["patient", "SPECIES", 14, 21], ["The E wave", "TEST", 0, 10], ["sinus rhythm", "PROBLEM", 27, 39], ["atrial contraction", "PROBLEM", 55, 73], ["Septal tissue Doppler", "TEST", 86, 107], ["tissue Doppler", "TEST", 109, 123], ["myocardial velocities", "TEST", 142, 163], ["E wave", "OBSERVATION", 4, 10], ["sinus rhythm", "ANATOMY", 27, 39], ["atrial contraction", "OBSERVATION", 55, 73], ["tissue", "OBSERVATION", 93, 99], ["velocities", "OBSERVATION_MODIFIER", 153, 163]]], ["The combination of the trans-mitral Doppler E wave, the tissue Doppler E\u02b9 wave, and the E/E\u02b9 ratio at the end of an SBT also seems to be capable of predicting weaning failure from diastolic dysfunction As opposed to mechanically ventilated dogs, the spontaneously breathing ones showed higher lactate levels and lower glycogen concentration due to the increased minute ventilation and respiratory workload occurring in the first hour after the onset of cardiogenic shock; afterward, minute ventilation rapidly decreased, due to diaphragmatic fatigue, till the death of the animal [41] .", [["tissue", "ANATOMY", 56, 62], ["respiratory", "ANATOMY", 385, 396], ["diaphragmatic", "ANATOMY", 528, 541], ["diastolic dysfunction", "DISEASE", 180, 201], ["lactate", "CHEMICAL", 293, 300], ["glycogen", "CHEMICAL", 318, 326], ["cardiogenic shock", "DISEASE", 453, 470], ["diaphragmatic fatigue", "DISEASE", 528, 549], ["death", "DISEASE", 560, 565], ["lactate", "CHEMICAL", 293, 300], ["tissue", "TISSUE", 56, 62], ["dogs", "ORGANISM", 240, 244], ["lactate", "SIMPLE_CHEMICAL", 293, 300], ["glycogen", "SIMPLE_CHEMICAL", 318, 326], ["dogs", "SPECIES", 240, 244], ["the trans-mitral Doppler E wave", "TEST", 19, 50], ["the tissue Doppler", "TEST", 52, 70], ["the E/E\u02b9 ratio", "TEST", 84, 98], ["an SBT", "TEST", 113, 119], ["weaning failure", "PROBLEM", 159, 174], ["diastolic dysfunction", "PROBLEM", 180, 201], ["mechanically ventilated dogs", "TREATMENT", 216, 244], ["higher lactate levels", "PROBLEM", 286, 307], ["lower glycogen concentration", "PROBLEM", 312, 340], ["the increased minute ventilation", "PROBLEM", 348, 380], ["respiratory workload", "PROBLEM", 385, 405], ["cardiogenic shock", "PROBLEM", 453, 470], ["minute ventilation", "TEST", 483, 501], ["diaphragmatic fatigue", "PROBLEM", 528, 549], ["diastolic dysfunction", "OBSERVATION", 180, 201], ["increased", "OBSERVATION_MODIFIER", 352, 361], ["minute ventilation", "OBSERVATION", 362, 380], ["respiratory workload", "OBSERVATION", 385, 405], ["cardiogenic shock", "OBSERVATION", 453, 470], ["diaphragmatic", "ANATOMY", 528, 541], ["fatigue", "OBSERVATION", 542, 549]]], ["Furthermore, the use of neuromuscular blocking agents in mechanically ventilated dogs may have reduced lactate production due to the absence of diaphragmatic activity [41] .", [["neuromuscular", "ANATOMY", 24, 37], ["diaphragmatic", "ANATOMY", 144, 157], ["lactate", "CHEMICAL", 103, 110], ["lactate", "CHEMICAL", 103, 110], ["dogs", "ORGANISM", 81, 85], ["lactate", "SIMPLE_CHEMICAL", 103, 110], ["diaphragmatic", "ORGAN", 144, 157], ["neuromuscular blocking agents", "TREATMENT", 24, 53], ["mechanically ventilated dogs", "TREATMENT", 57, 85], ["reduced lactate production", "PROBLEM", 95, 121], ["diaphragmatic activity", "PROBLEM", 144, 166], ["diaphragmatic", "ANATOMY", 144, 157]]], ["Impairment of the diaphragmatic contraction process during cardiogenic shock may be the underlying mechanism responsible for ventilatory failure (see below) [43] .", [["diaphragmatic", "ANATOMY", 18, 31], ["cardiogenic shock", "DISEASE", 59, 76], ["ventilatory failure", "DISEASE", 125, 144], ["diaphragmatic", "ORGAN", 18, 31], ["the diaphragmatic contraction process", "PROBLEM", 14, 51], ["cardiogenic shock", "PROBLEM", 59, 76], ["ventilatory failure", "PROBLEM", 125, 144], ["diaphragmatic", "ANATOMY", 18, 31], ["contraction", "OBSERVATION", 32, 43], ["cardiogenic shock", "OBSERVATION", 59, 76], ["ventilatory failure", "OBSERVATION", 125, 144]]], ["No studies have so far evaluated the ultrasonographic modifications of the diaphragm during the course of or after cardiogenic shock, or their impact on short-and long-term outcomes.Diaphragm ultrasound (DUS)The diaphragm, being the primary respiratory muscle, performs the majority of the work entailed in breathing.", [["diaphragm", "ANATOMY", 75, 84], ["diaphragm", "ANATOMY", 212, 221], ["respiratory muscle", "ANATOMY", 241, 259], ["cardiogenic shock", "DISEASE", 115, 132], ["diaphragm", "ORGAN", 75, 84], ["diaphragm", "ORGAN", 212, 221], ["muscle", "ORGAN", 253, 259], ["cardiogenic shock", "PROBLEM", 115, 132], ["Diaphragm ultrasound", "TEST", 182, 202], ["diaphragm", "ANATOMY", 75, 84], ["shock", "OBSERVATION", 127, 132], ["diaphragm", "ANATOMY", 212, 221], ["respiratory muscle", "ANATOMY", 241, 259]]], ["Diaphragm dysfunction, defined as the inability of the diaphragm to generate reasonable levels of maximal force, is an under-recognized pathological condition in critically ill patients and can render weaning from mechanical ventilation extremely difficult, resulting in protracted mechanical ventilation and prolonged intensive care unit length-of-stay [44] .", [["Diaphragm", "ANATOMY", 0, 9], ["diaphragm", "ANATOMY", 55, 64], ["Diaphragm dysfunction", "DISEASE", 0, 21], ["critically ill", "DISEASE", 162, 176], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["diaphragm", "ORGAN", 55, 64], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["Diaphragm dysfunction", "PROBLEM", 0, 21], ["mechanical ventilation", "TREATMENT", 214, 236], ["protracted mechanical ventilation", "TREATMENT", 271, 304], ["dysfunction", "OBSERVATION", 10, 21], ["diaphragm", "ANATOMY", 55, 64], ["protracted", "OBSERVATION_MODIFIER", 271, 281], ["mechanical ventilation", "OBSERVATION", 282, 304]]], ["The prevalence of diaphragm dysfunction in critically ill patients admitted to the intensive care unit and requiring IMV is over 60%, reaching 80% in patients requiring prolonged IMV and experiencing difficult weaning [45] .Diaphragm ultrasound (DUS)Considerable research attention has been focused on diagnosing diaphragm dysfunction over recent years, and there is strong evidence to sustain an association/ correlation between diaphragm dysfunction and weaning failure [45] [46] [47] .", [["diaphragm", "ANATOMY", 18, 27], ["diaphragm", "ANATOMY", 313, 322], ["diaphragm", "ANATOMY", 430, 439], ["diaphragm dysfunction", "DISEASE", 18, 39], ["critically ill", "DISEASE", 43, 57], ["diaphragm dysfunction", "DISEASE", 313, 334], ["diaphragm dysfunction", "DISEASE", 430, 451], ["weaning failure", "DISEASE", 456, 471], ["diaphragm", "ORGAN", 18, 27], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 150, 158], ["diaphragm", "ORGAN", 313, 322], ["diaphragm", "ORGAN", 430, 439], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 150, 158], ["diaphragm dysfunction", "PROBLEM", 18, 39], ["IMV", "TREATMENT", 117, 120], ["prolonged IMV", "TREATMENT", 169, 182], ["Diaphragm ultrasound", "TEST", 224, 244], ["diaphragm dysfunction", "PROBLEM", 313, 334], ["diaphragm dysfunction", "PROBLEM", 430, 451], ["weaning failure", "PROBLEM", 456, 471], ["diaphragm", "ANATOMY", 18, 27], ["dysfunction", "OBSERVATION", 28, 39], ["diaphragm", "ANATOMY", 313, 322], ["dysfunction", "OBSERVATION", 323, 334], ["diaphragm", "ANATOMY", 430, 439], ["dysfunction", "OBSERVATION", 440, 451]]], ["The gold standard for evaluating diaphragm force is the measurement of trans-diaphragmatic pressure (Pdi) [48] .", [["diaphragm", "ANATOMY", 33, 42], ["diaphragmatic", "ANATOMY", 77, 90], ["diaphragm", "ORGAN", 33, 42], ["diaphragmatic", "ORGAN", 77, 90], ["diaphragm", "ANATOMY", 33, 42], ["diaphragmatic", "ANATOMY", 77, 90], ["pressure", "OBSERVATION_MODIFIER", 91, 99]]], ["This test entails the insertion of a dedicated catheter with two balloons that measure the esophageal and gastric pressures, respectively.", [["esophageal", "ANATOMY", 91, 101], ["gastric", "ANATOMY", 106, 113], ["esophageal", "MULTI-TISSUE_STRUCTURE", 91, 101], ["gastric", "ORGAN", 106, 113], ["This test", "TEST", 0, 9], ["a dedicated catheter", "TREATMENT", 35, 55], ["two balloons", "TREATMENT", 61, 73], ["catheter", "OBSERVATION", 47, 55], ["balloons", "OBSERVATION", 65, 73], ["esophageal", "ANATOMY", 91, 101], ["gastric", "ANATOMY", 106, 113], ["pressures", "ANATOMY_MODIFIER", 114, 123]]], ["Diaphragm dysfunction occurs when Pdi < 11 cmH 2 O [48] .Diaphragm ultrasound (DUS)Another adjunctive test to assess diaphragm activity is the electrical activity of the diaphragm (EAdi) test.", [["Diaphragm", "ANATOMY", 0, 9], ["diaphragm", "ANATOMY", 117, 126], ["diaphragm", "ANATOMY", 170, 179], ["Diaphragm dysfunction", "DISEASE", 0, 21], ["cmH 2 O", "CHEMICAL", 43, 50], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 117, 126], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 170, 179], ["Diaphragm dysfunction", "PROBLEM", 0, 21], ["Diaphragm ultrasound", "TEST", 57, 77], ["Another adjunctive test", "TEST", 83, 106], ["dysfunction", "OBSERVATION", 10, 21], ["diaphragm", "ANATOMY", 117, 126], ["diaphragm", "ANATOMY", 170, 179]]], ["EAdi is performed using a dedicated esophageal catheter that has four couples of electrodes at its distal end.", [["esophageal", "ANATOMY", 36, 46], ["esophageal", "ORGAN", 36, 46], ["a dedicated esophageal catheter", "TREATMENT", 24, 55], ["electrodes at its distal end", "TREATMENT", 81, 109], ["esophageal", "ANATOMY", 36, 46], ["catheter", "OBSERVATION", 47, 55], ["distal", "OBSERVATION_MODIFIER", 99, 105], ["end", "OBSERVATION_MODIFIER", 106, 109]]], ["Besides monitoring the diaphragm, EAdi is also used to drive the ventilator with a proportional mode of ventilation, the so-called neutrally adjusted ventilator assist (NAVA).", [["diaphragm", "ANATOMY", 23, 32], ["diaphragm", "ORGAN", 23, 32], ["EAdi", "SIMPLE_CHEMICAL", 34, 38], ["the ventilator", "TREATMENT", 61, 75], ["a proportional mode of ventilation", "TREATMENT", 81, 115], ["diaphragm", "ANATOMY", 23, 32]]], ["Thus, EAdi can be used to monitor the diaphragm at the bedside, whereas NAVA can exert a rehabilitative role in the case of diaphragm dysfunction.Diaphragm ultrasound (DUS)Bedside ultrasound assessment of the diaphragm in critically ill patients can also be used to detect diaphragm dysfunction (diaphragm activity is classified as: usual, reduced, or loss of function) [49] .", [["diaphragm", "ANATOMY", 38, 47], ["diaphragm", "ANATOMY", 124, 133], ["diaphragm", "ANATOMY", 209, 218], ["diaphragm", "ANATOMY", 273, 282], ["diaphragm", "ANATOMY", 296, 305], ["NAVA", "CHEMICAL", 72, 76], ["diaphragm dysfunction", "DISEASE", 124, 145], ["critically ill", "DISEASE", 222, 236], ["diaphragm dysfunction", "DISEASE", 273, 294], ["EAdi", "SIMPLE_CHEMICAL", 6, 10], ["diaphragm", "ORGAN", 38, 47], ["diaphragm", "ORGAN", 124, 133], ["diaphragm", "ORGAN", 209, 218], ["patients", "ORGANISM", 237, 245], ["diaphragm", "ORGAN", 273, 282], ["diaphragm", "ORGAN", 296, 305], ["EAdi", "PROTEIN", 6, 10], ["patients", "SPECIES", 237, 245], ["NAVA", "TREATMENT", 72, 76], ["diaphragm dysfunction", "PROBLEM", 124, 145], ["Diaphragm ultrasound", "TEST", 146, 166], ["Bedside ultrasound assessment", "TEST", 172, 201], ["diaphragm dysfunction", "PROBLEM", 273, 294], ["diaphragm", "ANATOMY", 38, 47], ["diaphragm", "ANATOMY", 124, 133], ["dysfunction", "OBSERVATION", 134, 145], ["diaphragm", "ANATOMY", 209, 218], ["diaphragm", "ANATOMY", 273, 282], ["dysfunction", "OBSERVATION", 283, 294], ["diaphragm", "ANATOMY", 296, 305]]], ["Although it may help the clinician make therapeutic decisions, a possible role in ventilation and weaning from mechanical ventilation has yet to be fully determined [49] [50] [51] [52] .Diaphragm ultrasound (DUS)Two diaphragm sonographic predictors of successful weaning have been proposed [45, [49] [50] [51] [52] [53] [54] [55] [56] :Diaphragm ultrasound (DUS)\u2022 Diaphragmatic excursion (DE, cm)-defined as the maximum displacement of the hemidiaphragm during breathing (Fig. 4) ; \u2022 Diaphragmatic thickening fraction (DTF, %)-defined as the difference between the end-inspiration thickness (Te-Insp) and end-expiration thickness (Te-exp) divided by the end-expiration thickness (Fig. 5) .", [["diaphragm", "ANATOMY", 216, 225], ["Diaphragmatic", "ANATOMY", 364, 377], ["hemidiaphragm", "ANATOMY", 440, 453], ["Diaphragmatic", "ANATOMY", 484, 497], ["[49] [50] [51]", "CHEMICAL", 165, 179], ["[45, [49] [50] [51] [52] [53] [54] [55] [56]", "CHEMICAL", 290, 334], ["[49] [50] [51] [52]", "SIMPLE_CHEMICAL", 165, 184], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 216, 225], ["[49] [50] [51] [52] [53] [54] [55] [56]", "SIMPLE_CHEMICAL", 295, 334], ["hemidiaphragm", "ORGAN", 440, 453], ["ventilation", "TREATMENT", 82, 93], ["mechanical ventilation", "TREATMENT", 111, 133], ["Diaphragm ultrasound", "TEST", 186, 206], ["successful weaning", "TREATMENT", 252, 270], ["Diaphragm ultrasound", "TEST", 336, 356], ["Diaphragmatic excursion (DE, cm)", "PROBLEM", 364, 396], ["the maximum displacement of the hemidiaphragm", "PROBLEM", 408, 453], ["Diaphragmatic thickening fraction", "PROBLEM", 484, 517], ["DTF", "TEST", 519, 522], ["the end-inspiration thickness", "TEST", 561, 590], ["end-expiration thickness (Te-exp)", "TREATMENT", 605, 638], ["diaphragm", "ANATOMY", 216, 225], ["Diaphragm", "ANATOMY", 336, 345], ["Diaphragmatic", "ANATOMY", 364, 377], ["excursion", "OBSERVATION", 378, 387], ["maximum", "OBSERVATION_MODIFIER", 412, 419], ["displacement", "OBSERVATION_MODIFIER", 420, 432], ["hemidiaphragm", "ANATOMY", 440, 453], ["thickening", "OBSERVATION", 498, 508]]], ["Some studies have hypothesized that diaphragmatic excursion or liver/spleen movements could predict extubation failure.", [["diaphragmatic", "ANATOMY", 36, 49], ["liver", "ANATOMY", 63, 68], ["spleen", "ANATOMY", 69, 75], ["liver/spleen movements", "DISEASE", 63, 85], ["extubation failure", "DISEASE", 100, 118], ["diaphragmatic", "ORGAN", 36, 49], ["liver", "ORGAN", 63, 68], ["spleen", "ORGAN", 69, 75], ["Some studies", "TEST", 0, 12], ["diaphragmatic excursion", "PROBLEM", 36, 59], ["liver/spleen movements", "PROBLEM", 63, 85], ["extubation failure", "PROBLEM", 100, 118], ["diaphragmatic", "ANATOMY", 36, 49], ["excursion", "OBSERVATION", 50, 59], ["liver", "ANATOMY", 63, 68], ["spleen", "ANATOMY", 69, 75]]], ["DE reflects the sum of the patient's inspiratory activity and mechanical ventilatory support, so it only has real value when assessed during a spontaneous breathing trial.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["mechanical ventilatory support", "TREATMENT", 62, 92], ["a spontaneous breathing trial", "TREATMENT", 141, 170], ["mechanical", "OBSERVATION", 62, 72], ["ventilatory support", "OBSERVATION", 73, 92]]], ["Diaphragm displacement is associated with lung volume during the inspiratory phase [57] , but it does not correlate with and does not quantify the patient's inspiratory effort [58] ; furthermore, its assessment is influenced by numerous factors (see Table 1 ) [45] .", [["Diaphragm", "ANATOMY", 0, 9], ["lung", "ANATOMY", 42, 46], ["Diaphragm", "MULTI-TISSUE_STRUCTURE", 0, 9], ["lung", "ORGAN", 42, 46], ["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["Diaphragm displacement", "PROBLEM", 0, 22], ["lung volume", "PROBLEM", 42, 53], ["the inspiratory phase", "TEST", 61, 82], ["its assessment", "TEST", 196, 210], ["displacement", "OBSERVATION", 10, 22], ["lung", "ANATOMY", 42, 46], ["volume", "OBSERVATION", 47, 53]]], ["It should also be noted that diaphragmatic excursion can be influenced by PEEP and levels of ventilator support during mechanical ventilation [55] : by increasing lung expiratory volumes, higher levels of PEEP lower the diaphragmatic domes, resulting in a decreased diaphragmatic excursion; during assisted ventilation, diaphragmatic excursion results from ventilator support plus the patient's inspiratory efforts [56] .", [["diaphragmatic", "ANATOMY", 29, 42], ["lung", "ANATOMY", 163, 167], ["diaphragmatic domes", "ANATOMY", 220, 239], ["diaphragmatic", "ANATOMY", 266, 279], ["diaphragmatic", "ANATOMY", 320, 333], ["diaphragmatic excursion", "DISEASE", 29, 52], ["diaphragmatic", "ORGAN", 29, 42], ["lung", "ORGAN", 163, 167], ["diaphragmatic", "ORGAN", 266, 279], ["diaphragmatic", "ORGAN", 320, 333], ["patient", "ORGANISM", 385, 392], ["patient", "SPECIES", 385, 392], ["diaphragmatic excursion", "PROBLEM", 29, 52], ["PEEP", "TREATMENT", 74, 78], ["ventilator support", "TREATMENT", 93, 111], ["mechanical ventilation", "TREATMENT", 119, 141], ["increasing lung expiratory volumes", "PROBLEM", 152, 186], ["PEEP", "TREATMENT", 205, 209], ["a decreased diaphragmatic excursion", "PROBLEM", 254, 289], ["assisted ventilation", "TREATMENT", 298, 318], ["diaphragmatic excursion", "TEST", 320, 343], ["ventilator support", "TREATMENT", 357, 375], ["diaphragmatic", "ANATOMY", 29, 42], ["excursion", "OBSERVATION", 43, 52], ["lung", "ANATOMY", 163, 167], ["expiratory volumes", "OBSERVATION", 168, 186], ["diaphragmatic", "ANATOMY", 220, 233], ["domes", "ANATOMY_MODIFIER", 234, 239], ["decreased", "OBSERVATION_MODIFIER", 256, 265], ["diaphragmatic excursion", "OBSERVATION", 266, 289], ["diaphragmatic", "ANATOMY", 320, 333]]], ["Therefore, only diaphragm thickening can provide a reliable indicator of diaphragm function during assisted mechanical ventilation [57] .", [["diaphragm", "ANATOMY", 16, 25], ["diaphragm", "ANATOMY", 73, 82], ["diaphragm", "ORGAN", 16, 25], ["diaphragm", "ORGAN", 73, 82], ["diaphragm thickening", "PROBLEM", 16, 36], ["assisted mechanical ventilation", "TREATMENT", 99, 130], ["diaphragm", "ANATOMY", 16, 25], ["thickening", "OBSERVATION", 26, 36], ["diaphragm", "ANATOMY", 73, 82]]], ["DTF, also known as the \"ejection fraction\" of the diaphragm, reflects active diaphragm contraction and inspiratory effort [59, 60] .", [["diaphragm", "ANATOMY", 50, 59], ["diaphragm", "ANATOMY", 77, 86], ["DTF", "GENE_OR_GENE_PRODUCT", 0, 3], ["diaphragm", "ORGAN", 50, 59], ["diaphragm", "ORGAN", 77, 86], ["DTF", "PROTEIN", 0, 3], ["active diaphragm contraction", "PROBLEM", 70, 98], ["diaphragm", "ANATOMY", 50, 59], ["active", "OBSERVATION_MODIFIER", 70, 76], ["diaphragm contraction", "OBSERVATION", 77, 98], ["inspiratory effort", "OBSERVATION", 103, 121]]], ["It is associated with ICU length-of-stay, the duration of mechanical ventilation, and mortality [59, 60] .", [["mechanical ventilation", "TREATMENT", 58, 80], ["mechanical ventilation", "OBSERVATION", 58, 80]]], ["Whereas diaphragmatic excursion is not able to evaluate the degree of contractile activity of the diaphragm, DTF, on the other hand, has this capacity and can be used both in IMV (assisted or supported) and during an SBT [45] .Diaphragm ultrasound (DUS)A number of studies have investigated these two parameters, either individually or in combination, with the aim of identifying cut-off values as predictors of successful weaning (see Table 2 ) [43, 53, [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] .", [["diaphragmatic", "ANATOMY", 8, 21], ["diaphragm", "ANATOMY", 98, 107], ["43, 53, [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71]", "CHEMICAL", 447, 509], ["diaphragmatic", "ORGAN", 8, 21], ["diaphragm", "ORGAN", 98, 107], ["[61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73]", "SIMPLE_CHEMICAL", 455, 519], ["contractile activity of the diaphragm", "PROBLEM", 70, 107], ["IMV", "TREATMENT", 175, 178], ["an SBT", "TEST", 214, 220], ["Diaphragm ultrasound", "TEST", 227, 247], ["studies", "TEST", 265, 272], ["diaphragmatic", "ANATOMY", 8, 21], ["excursion", "OBSERVATION", 22, 31], ["contractile activity", "OBSERVATION", 70, 90], ["diaphragm", "ANATOMY", 98, 107]]], ["However, the results have been heterogeneous in terms of outcome results and cut-off values due to differences in study protocol design and outcome designation.Diaphragm ultrasound (DUS)Although bilateral anterior magnetic stimulation of the phrenic nerves is considered the gold standard for the assessment of diaphragm function [48] , it requires high expertise and expensive machines.", [["phrenic nerves", "ANATOMY", 242, 256], ["diaphragm", "ANATOMY", 311, 320], ["phrenic nerves", "MULTI-TISSUE_STRUCTURE", 242, 256], ["diaphragm", "ORGAN", 311, 320], ["study protocol", "TEST", 114, 128], ["Diaphragm ultrasound", "TEST", 160, 180], ["DUS", "TEST", 182, 185], ["bilateral anterior magnetic stimulation of the phrenic nerves", "PROBLEM", 195, 256], ["the assessment of diaphragm function", "TEST", 293, 329], ["expensive machines", "TREATMENT", 368, 386], ["heterogeneous", "OBSERVATION_MODIFIER", 31, 44], ["bilateral", "ANATOMY_MODIFIER", 195, 204], ["anterior", "ANATOMY_MODIFIER", 205, 213], ["phrenic nerves", "ANATOMY", 242, 256], ["diaphragm", "ANATOMY", 311, 320]]], ["By contrast, ultrasonography is a widely available non-invasive tool that provides both structural and functional information about the muscle.", [["muscle", "ANATOMY", 136, 142], ["muscle", "ORGAN", 136, 142], ["ultrasonography", "TEST", 13, 28], ["non-invasive tool", "TEST", 51, 68], ["muscle", "ANATOMY", 136, 142]]], ["Regarding diaphragm evaluation by ultrasonography and the therapeutic and prognostic implications of this measure, more studies are needed to evaluate the accuracy of ultrasound measures of the diaphragm and their therapeutic and prognostic implications and applicability in mechanical ventilation (i.e., diaphragm-protective ventilation and weaning from IMV).", [["diaphragm", "ANATOMY", 10, 19], ["diaphragm", "ANATOMY", 194, 203], ["diaphragm", "ANATOMY", 305, 314], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 10, 19], ["diaphragm", "ORGAN", 194, 203], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 305, 314], ["diaphragm evaluation", "TEST", 10, 30], ["ultrasonography", "TEST", 34, 49], ["ultrasound measures", "TEST", 167, 186], ["mechanical ventilation", "TREATMENT", 275, 297], ["diaphragm-protective ventilation", "TREATMENT", 305, 337], ["IMV", "TREATMENT", 355, 358], ["diaphragm", "ANATOMY", 10, 19], ["diaphragm", "ANATOMY", 194, 203], ["mechanical ventilation", "OBSERVATION", 275, 297], ["diaphragm", "ANATOMY", 305, 314]]], ["Further research is also required to standardize the measurement techniques and teaching programs [74] .ConclusionsIn the first section of this review, two of the five factors involved in successful weaning from mechanical ventilation were addressed.", [["the measurement techniques", "TEST", 49, 75], ["successful weaning", "TREATMENT", 188, 206], ["mechanical ventilation", "TREATMENT", 212, 234], ["mechanical ventilation", "OBSERVATION", 212, 234]]], ["The remaining components will be discussed in the second section of this review entitled: \"Mechanical ventilation weaning issues can be counted on the fingers of just one hand: part 2\".", [["hand", "ANATOMY", 171, 175], ["fingers", "ORGANISM_SUBDIVISION", 151, 158], ["Mechanical ventilation weaning issues", "TREATMENT", 91, 128]]]], "411ab3cd9e131c20a912cc5a3e477f133c1a47b0": [["Introduction\u00abNo contact tracing, no lockdown lifting \u00bb said Dr V\u00e9ran, the French government Health Minister, on May 6th at the Senate debate on the \"stop-covid\" app.", [["contact tracing", "TEST", 16, 31]]], ["The power of this crisp formula seemed clear: the app is a means to the end of reconquering our freedom of movement.", [["power", "OBSERVATION_MODIFIER", 4, 9], ["clear", "OBSERVATION", 39, 44]]], ["Yet it was ambiguous and senators rejected it then before approving it on may 27th.", [["senators", "TREATMENT", 25, 33]]], ["The ambiguity resorts to a debate on values where individual privacy is at risk of being crushed and where surveillance is looming, an important issue in a country who puts liberty first on its motto.", [["The ambiguity", "PROBLEM", 0, 13]]], ["In France, as in many countries, the idea of building a mobile app that would inform a smartphone user if she/he crossed the way of contagious individuals has led the French government to add this protection method to the traditional contact tracing method by human investigation that is generally used when an epidemic develops.", [["human", "ORGANISM", 260, 265], ["human", "SPECIES", 260, 265], ["human", "SPECIES", 260, 265], ["this protection method", "TREATMENT", 192, 214]]], ["In general, contact tracing methods enable the State to identify contagious individuals, notably presymptomatic and asymptomatic ones, and isolate them before they spread the pandemic further.", [["presymptomatic and asymptomatic ones", "PROBLEM", 97, 133]]], ["They can be informed up to 15 days after the encounter as the disease may take time to develop.", [["the disease", "PROBLEM", 58, 69]]], ["Such contacts happen in many situations, especially in public transportation or with relatives or good friends who may ignore for a moment that they have Covid-19.IntroductionThe app potentially offers several advantages over the traditional method for contact tracing.", [["Covid", "TEST", 154, 159], ["contact tracing", "TEST", 253, 268]]], ["The latter rests on traditional snowballing interviews with infected people to identify who they interacted with in the past days.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75]]], ["Specifically, tracing cost is much lower if individuals are automatically detected as prospective cases.", [["tracing cost", "TEST", 14, 26]]], ["Most importantly, an app can help identify more quickly and more comprehensively the infected individuals who were in contact with a person if both were carrying their smartphones with the app.", [["person", "SPECIES", 133, 139]]], ["These advantages are key when an epidemic moves fast and has severe consequences, such as a potentially huge death toll and social and economic crisis (Ferretti et al., 2020) .", [["death", "DISEASE", 109, 114]]], ["At the time we write France has had nearly 30,000 deaths due to covid-19 and 22 other countries have started develop a similar app.", [["deaths", "DISEASE", 50, 56], ["covid", "TEST", 64, 69]]], ["For example Austria and Australia launched their apps a couple of months before but despite the benefits the launch was considered a failure.", [["a failure", "PROBLEM", 131, 140], ["failure", "OBSERVATION", 133, 140]]], ["Beyond technical reasons that may explain this negative outcome, and from which France and other following countries could learn, concerns for privacy may still prevail in France where a culture on data privacy has been built for more than 40 years and prevent this identification and preventative method to be a success.IntroductionIn this opinion paper we will first present conditions for the app to be effective.", [["a culture", "TEST", 185, 194]]], ["We then highlight the value dilemmas.", [["the value dilemmas", "PROBLEM", 18, 36]]], ["The French government and people value privacy, but in the current crisis, they may prefer immediate benefits.", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32], ["people value privacy", "TREATMENT", 26, 46]]], ["Consequently they expose themselves to hacking risks and surveillance related to technology vulnerability and monitoring.", [["surveillance", "TEST", 57, 69], ["technology vulnerability", "TEST", 81, 105], ["monitoring", "TEST", 110, 120]]], ["We then highlight that this calculus is influenced by the public debate at institutional level and interpret technology and responsibility in a Foucauldian perspective as a technology of self in a neo-liberal world.", [["calculus", "DISEASE", 28, 36], ["this calculus", "PROBLEM", 23, 36], ["calculus", "OBSERVATION", 28, 36]]], ["In the fourth section we then give our opinion which largely overlaps with that of La Quadrature du Net, a French organization similar to Freedom on The Net.", [["a French organization", "TREATMENT", 105, 126]]], ["We highlight that not only privacy would be harmed, but risks such as potential surveillance and habituation to security policies, discrimination, distrust and generate other health problems in the long-term may develop.", [["potential surveillance", "TEST", 70, 92]]], ["We conclude with practical and research implications.Critical conditions for the effectiveness of the appNumerous conditions are critical to predict that the mobile app method of infected individuals identification will be effective.", [["Critical conditions", "PROBLEM", 53, 72], ["the appNumerous conditions", "PROBLEM", 98, 124], ["infected individuals identification", "PROBLEM", 179, 214]]], ["Notably: 1) Correct information qualifying individuals as infected and contagious requires that population be tested and that tests are not error-prone, 2) High likelihood that when a contagious person meets or crosses another person an infected person both parties have a smartphone, 3) A very high proportion of smartphone users download the app.Critical conditions for the effectiveness of the appThat these conditions be all met is very unlikely.", [["person", "SPECIES", 195, 201], ["person", "SPECIES", 227, 233], ["person", "SPECIES", 246, 252], ["infected", "PROBLEM", 58, 66], ["tests", "TEST", 126, 131], ["Critical conditions", "PROBLEM", 348, 367], ["very unlikely", "UNCERTAINTY", 436, 449]]], ["The first condition would require a testing capacity that France did not have before mid-may.", [["a testing capacity", "TEST", 34, 52]]], ["With testing capacity clearly below one million per week how can we control at individual level the infection and/or contagious level of a 67 million population?", [["infection", "DISEASE", 100, 109], ["testing capacity", "TEST", 5, 21], ["the infection", "PROBLEM", 96, 109], ["infection", "OBSERVATION", 100, 109]]], ["On May 27,th at parliament, Dr V\u00e9ran presented findings of a recent study indicating that 46 % of presystematic individuals contribute to the reproduction of the disease as an argument in favor of the app (Ferretti et al., 2020) .", [["individuals", "ORGANISM", 112, 123], ["a recent study", "TEST", 59, 73], ["presystematic individuals", "PROBLEM", 98, 123], ["the disease", "PROBLEM", 158, 169], ["disease", "OBSERVATION", 162, 169]]], ["But the effectiveness of the app presupposes that the health system and a corresponding IS records who is infected and when infection occurred.", [["infection", "DISEASE", 124, 133], ["infection", "PROBLEM", 124, 133], ["infected", "OBSERVATION", 106, 114]]], ["We can still cross the way of people who are contagious and have not been tested precisely because a large share of infected individuals are still asymptomatic and ignore it.", [["people", "ORGANISM", 30, 36], ["individuals", "ORGANISM", 125, 136], ["people", "SPECIES", 30, 36], ["infected individuals", "PROBLEM", 116, 136], ["large", "OBSERVATION_MODIFIER", 101, 106], ["infected", "OBSERVATION", 116, 124]]], ["This is unlikely even if in France 77 % of the population is equipped with a smartphone (La Quadrature du Net, 2020a).", [["unlikely even", "UNCERTAINTY", 8, 21]]], ["In fact, while when people travel, they take their phone with them in order to face any uncertainty related to traffic jam or delays on public transportation, when at destination, at their office or at their relatives they may keep their phone in a jacket or a bag and visit people or colleagues or go to meetings without them.", [["people", "ORGANISM", 20, 26], ["people", "ORGANISM", 275, 281], ["people", "SPECIES", 20, 26], ["people", "SPECIES", 275, 281]]], ["Thus, people do not always carry their smartphones with them and this makes the traditional method of contact tracing still necessary.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["contact tracing", "TEST", 102, 117]]], ["However wishing to limit these issues, in France, unlike other countries (e.g. Norway), government chose Bluetooth against geolocation by GPS.Critical conditions for the effectiveness of the appBeing more cost efficient and, if effective, of interest as a complementary means for isolating contagious people and increasing individual and public health, the app does not come without short-term and long-term risks of privacy and surveillance.", [["people", "ORGANISM", 301, 307], ["people", "SPECIES", 301, 307], ["Critical conditions", "PROBLEM", 142, 161], ["privacy", "TREATMENT", 417, 424], ["surveillance", "TEST", 429, 441]]], ["In sum, for those, private life has gone public with the internet.Critical conditions for the effectiveness of the appLike cell phones, the tracing app offers both positive externalities (any individual is better protected from a health viewpoint when others also have it if they keep their phones with them) and negative externalities (the more others activate Bluetooth in high population density areas such as malls or public transportation, the greater the risk of malevolent action for those who have bad intentions have it on already).", [["cell", "ANATOMY", 123, 127], ["appLike cell", "CELL", 115, 127], ["Critical conditions", "PROBLEM", 66, 85], ["the tracing app", "TEST", 136, 151]]], ["However from a public policy viewpoint the value of positive externalities grows exponentially only when a very large share of the population has adopted the app and claim has been made at Parliament on May 27th by C\u00e9dric O, Secretary of State that a threshold of 56 % of the population is sufficient, absent of masks, lockdown and tests to curb the pandemics.", [["positive externalities", "PROBLEM", 52, 74], ["tests", "TEST", 332, 337]]], ["1 Contrary to what Dr V\u00e9ran and Mr O claimed, the conclusions from one of the most advanced epidemiological study taking into account the benefit of a contact tracing smartphone app (Ferretti et al., 2020) neither meant that, without the app, lock-down would continue, nor that other preventative measures should be dropped but that an app similar to what was proposed by the Oxford team would help control the disease.", [["the disease", "PROBLEM", 407, 418], ["disease", "OBSERVATION", 411, 418]]], ["However the team noted that \"The app should be one tool among many general preventative population measures such as physical distancing, enhanced hand and respiratory hygiene, and regular decontamination. \u00bb (ibidem).A privacy paradox: data privacy vs freedom and healthThe dilemma(s) we face are about the values that we choose (Rowe, 2018) .", [["hand", "ANATOMY", 146, 150], ["respiratory", "ANATOMY", 155, 166], ["hand", "ORGANISM_SUBDIVISION", 146, 150], ["general preventative population measures", "TREATMENT", 67, 107], ["respiratory hygiene", "TREATMENT", 155, 174], ["regular decontamination", "TREATMENT", 180, 203], ["respiratory", "ANATOMY", 155, 166]]], ["Most of the time these dilemmas are treated within an organization or a profession (e.g. RFID tags for librarians in various management processes concern efficiency and security vs privacy , but they are rarely exposed at the level of a nation with impact on everyone's life.", [["librarians in various management", "TREATMENT", 103, 135], ["dilemmas", "OBSERVATION", 23, 31]]], ["While privacy is a fundamental human right, freedom to move and safety are also fundamental.", [["human", "ORGANISM", 31, 36], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["right", "ANATOMY_MODIFIER", 37, 42]]], ["Contact tracing apps may bring higher health safety for others, and particularly for the elderly (since mortality of those infected by covid-19 essentially affects people over 65), and would contribute to allow the economy to restart, as emphasized by Dr V\u00e9ran, for the risk of overwhelming the health system would diminish.", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["Contact tracing apps", "TEST", 0, 20]]], ["Under the circumstances health professionals would also reduce their own risk of becoming infected.", [["infected", "PROBLEM", 90, 98], ["infected", "OBSERVATION", 90, 98]]], ["Otherwise put the covid crisis may be a nice illustration of the privacy paradox which states that we generally value privacy, but when we have an opportunity we are ready to trade it for something else (Kokolakis, 2017) .A privacy paradox: data privacy vs freedom and healthThis feeling may be even confirmed when one looks at the public debate on privacy issues and the efforts apparently made to surface privacy issues and mitigate corresponding risks.", [["the covid crisis", "PROBLEM", 14, 30]]], ["Technically and from an IS viewpoint, while many countries around the world have developed mobile apps for contact tracing, the design features have fueled heated typical IS debates regarding whether stored data should be decentralized or centralized, which data should be stored and more largely, about data governance.", [["contact tracing", "TEST", 107, 122]]], ["Regarding governance, the French government rejected the idea that the algorithm for identification of an infected contact be developed by Apple or Google or any foreign company.", [["the algorithm", "TEST", 67, 80], ["infected", "OBSERVATION", 106, 114]]], ["Furthermore the right to be forgotten was applied in France long before GDPR (2010).", [["right", "ANATOMY_MODIFIER", 16, 21], ["forgotten", "OBSERVATION", 28, 37]]], ["Despite the declared State of Urgency/ Emergency the government chose to bring the debate in front of parliament and could not proceed without the legal advice (although not binding) of CNIL who finally gave a favorable recommendation for the stop-covid app on May 26th and for the Information Systems that were set up also for contact tracing when following the traditional method.", [["Urgency", "PROBLEM", 30, 37], ["contact tracing", "TEST", 328, 343]]], ["It did so after considering that: 1) no personal data would be collected from the app without being encrypted and anonymized, 2) the exchange protocol named Robert would not be based on Apple or Google technology but developed by INRIA, the National Research Institute that specializes on computing and automation.Who is morally responsible?The French government and people value privacy, but in the face of human suffering and losses due to health, they may opt for the immediate benefits of the app: freedom to move and not having to feel morally responsible and looking guilty of as politicians rejecting a technique that could save lives.", [["people", "ORGANISM", 367, 373], ["human", "ORGANISM", 408, 413], ["people", "SPECIES", 367, 373], ["human", "SPECIES", 408, 413], ["human", "SPECIES", 408, 413], ["the exchange protocol", "TREATMENT", 129, 150]]], ["The privacy paradox is more multifarious and complex than it seems (Kokolakis, 2017) .", [["more multifarious", "OBSERVATION_MODIFIER", 23, 40]]], ["Here it is not exactly a calculus between the expected loss of privacy and the immediate gain of information disclosure (Dinev & Hart, 2006; Xu, Luo, Carroll, & Rosson, 2011 ) that the government think people will make, but a calculus taking into account their need for freedom to move and their feelings about moral responsibility and guilt due to the evolution of the pandemics.", [["people", "ORGANISM", 202, 208], ["people", "SPECIES", 202, 208], ["a calculus", "PROBLEM", 23, 33], ["a calculus", "PROBLEM", 224, 234], ["the pandemics", "PROBLEM", 366, 379], ["calculus", "OBSERVATION", 25, 33], ["loss", "OBSERVATION_MODIFIER", 55, 59], ["calculus", "OBSERVATION", 226, 234], ["pandemics", "OBSERVATION", 370, 379]]], ["For government and parliament representatives themselves the calculus may be a between reducing their risk of looking inactive and bearing similar moral responsibility (with higher social pressure since their decisions are public) if the pandemics is less controlled than in countries where the app has been adopted on the one hand; and being attacked for pursuing a surveillance policy and infringing upon data privacy on the other hand.A technology of the self in a neo-liberal worldHowever, even if taking account stakeholders' interest we may still at this stage conclude that the two sides of the dilemma do not weigh equally.", [["calculus", "DISEASE", 61, 69], ["hand", "ORGANISM_SUBDIVISION", 433, 437], ["the calculus", "PROBLEM", 57, 69], ["the pandemics", "PROBLEM", 234, 247], ["calculus", "OBSERVATION", 61, 69]]], ["Isn't it over with the dilemma?", [["dilemma", "OBSERVATION", 23, 30]]], ["To control the pandemics with this app people would voluntarily request to be tested and would self quarantine.", [["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45]]], ["Because it is necessary to carry smartphones close to our body to make the detection process and calculation of distance more effective, we argue that this contact tracing app can be interpreted as a technology of the self in a neoliberal thinking, included in governmentality (Foucault, 1993; Lemke, 2001) , a biopower self-disciplining our bodily behavior and reinforcing self-discipline in a Foucauldian sense (Leclercq-Vandelannoitte, 2014), but also creating long-term risks including for society and for our health.An opinion informed by a LA Quadrature du Net and longerterm concernsMy humble opinion is very similar to that of La Quadrature du Net (LQdN), an independent association that generally defends privacy and fights against trends towards the advent of a surveillance society, but also goes further in that it considers other long term negative consequences such as health and exclusion/discrimination consequences related to more intense smartphone use.An opinion informed by a LA Quadrature du Net and longerterm concernsIn its opinion LQdN approves the position of CNIL who expressly demanded that government demonstrate the practical utility of stopcovid, while regretting that, given its illusory benefits, CNIL did not purely and simply asked the French government \u00ab to stop this dangerous and useless project and gets lost in the false debate about deceptive warrants to delineate the use of the app \u00bb (La Quadrature du Net, 2020b).", [["body", "ANATOMY", 58, 62], ["LA", "CHEMICAL", 546, 548], ["LA", "CHEMICAL", 996, 998], ["body", "ORGANISM_SUBDIVISION", 58, 62]]], ["The main argument is that we can very cautiously agree to limit our freedoms ONLY when there are strong proven benefits, which is not currently the case and will not be, because, as we explained above, stop-covid effectiveness is very uncertain essentially due to a) too low predicted app and smartphone use 2 and b) too low data quality related to false positives (i.e. being informed that someone we crossed was contagious when this person was not (to reduce this risk people will have to enter a QR code in the app) or when the person (e.g. a doctor) was already informed prior to the encounter and protected herself and false negatives (e.g. not identifying the risk in the absence of sufficient disease testing capacity and due to not detecting beyond one meter as in France).", [["people", "ORGANISM", 471, 477], ["person", "SPECIES", 435, 441], ["people", "SPECIES", 471, 477], ["person", "SPECIES", 531, 537], ["too low data quality", "PROBLEM", 317, 337], ["false positives", "PROBLEM", 349, 364], ["sufficient disease testing capacity", "PROBLEM", 689, 724], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Data minimisation means that data collection should be adequate, relevant and limited to what is necessary in relation to the purposes for which they are processed.", [["Data minimisation means", "TEST", 0, 23]]], ["However, given our previous remark, we would argue that data minimisation is not met for multiple reasons: there will be multiple false positive/negative (relevance), the scope of data collection is too large and too loosely defined (purpose) 3 , the analysis and future use of biometric data are not 2 Detection of cases have still not been reported after four days its launch on june 2 nd and one million app downloads -a situation comparable to Australia who launched its app a month before France.", [["multiple false positive", "PROBLEM", 121, 144], ["the scope of data collection", "TEST", 167, 195], ["the analysis", "TEST", 247, 259], ["biometric data", "TEST", 278, 292], ["too large", "OBSERVATION_MODIFIER", 199, 208]]], ["2) \u00ab SI-DEP \u00bb (Syst\u00e8me d'Informations de DEPistage) that records all the results of labs who test COVID-19 and whose purpose is to make sure that all positive cases are taken care of.", [["labs", "TEST", 84, 88], ["test COVID", "TEST", 93, 103]]], ["In this respect little is known about how contact-covid is operated.An opinion informed by a LA Quadrature du Net and longerterm concerns2) It remains that increased surveillance, habituation to security policy, health issues related to more permanent carrying of smartphone and addiction are serious risks specifically related to stop-covid with little predicted effectiveness if we examine the conditions for its success.", [["LA", "CHEMICAL", 93, 95], ["increased", "OBSERVATION_MODIFIER", 156, 165]]], ["Source : https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladiesinfectieuses/coronavirus/tout-savoir-sur-le-covid-19/article/contact-covid-etsi-dep-les-outils-numeriques-du-depistage-covid-19.An opinion informed by a LA Quadrature du Net and longerterm concernsproperly addressed (adequation) 4 .", [["LA", "CHEMICAL", 231, 233]]], ["With regards to health safety LQdN adds that the stop-covid app may even prove counter-effective either with people feeling safe when they are not and stop behaving cautiously 5 or with people hiding their symptoms in fear that they be discriminated.An opinion informed by a LA Quadrature du Net and longerterm concernsInterestingly, not only short-term benefits are illusory, but negative long term risks abound, not only for privacy.", [["LA", "CHEMICAL", 275, 277], ["people", "ORGANISM", 109, 115], ["people", "ORGANISM", 186, 192], ["people", "SPECIES", 109, 115], ["people", "SPECIES", 186, 192], ["their symptoms", "PROBLEM", 200, 214]]], ["LQdN (La Quadrature du Net, 2020a) notes three types of risks for our freedom:An opinion informed by a LA Quadrature du Net and longerterm concerns-People could be discriminated if the app was to be compulsory or if social pressure towards adoption becomes too high; a particular case of discrimination being access to blood testing being conditioned by its adoption (On this first type of risk CNIL felt that government had taken appropriate measures hence its final favorable recommendation); -Increased surveillance will be facilitated if the app is adopted by a large share of the population; and anonymity is simply impossible as it runs counter to the very objective of the app which is to inform targeted persons.", [["blood", "ANATOMY", 319, 324], ["LQdN", "CHEMICAL", 0, 4], ["LA", "CHEMICAL", 103, 105], ["LQdN", "SIMPLE_CHEMICAL", 0, 4], ["People", "ORGANISM", 148, 154], ["blood", "ORGANISM_SUBSTANCE", 319, 324], ["persons", "ORGANISM", 712, 719], ["People", "SPECIES", 148, 154], ["persons", "SPECIES", 712, 719], ["blood testing", "TEST", 319, 332]]], ["Hence the need for pseudonyms which can not be very effective against malevolent action (Bonnetain et al., 2020) and individual surveillance. -Habituation to security policies that curtail our freedoms and social acceptability of digital surveillance based on the blind belief of technology as solutions to social problems.An opinion informed by a LA Quadrature du Net and longerterm concernsI do not wish to paint a bleak picture of the situation but the very last argument can be completed in two ways.", [["LA", "CHEMICAL", 348, 350], ["pseudonyms", "PROBLEM", 19, 29], ["individual surveillance", "TEST", 117, 140], ["digital surveillance", "TEST", 230, 250]]], ["As La Quadrature du Net (2020a) notes this is sad because there are much more important actions for government to undertake including to fight pandemics and its consequences.An opinion informed by a LA Quadrature du Net and longerterm concernsSecond, such smartphones tracing apps would inevitably reinforce the ubiquitous use of smartphones in the population who is not educated to the complexity of the dark side of IT (D'Arcy, Gupta, Tarafdar, & Turel, 2014) , pushing them to carry them permanently on the body.", [["body", "ANATOMY", 510, 514], ["LA", "CHEMICAL", 199, 201], ["body", "ORGANISM_SUBDIVISION", 510, 514], ["body", "ANATOMY", 510, 514]]], ["It is notorious that adolescents are already prone to some forms of problematic smartphone dependency (Gentina & Rowe, 2020) .", [["adolescents", "ORGANISM", 21, 32], ["adolescents", "SPECIES", 21, 32], ["notorious", "OBSERVATION_MODIFIER", 6, 15]]], ["More importantly adolescents are unaware about privacy issues and such apps reinforce the message that personal data do not belong to you, that tracking trips is not problematic and legitimizes that this can be done by any government.Implications for research and practiceAs academics in our multiple activities we have an important role to play to contribute to better public project decisions like these who are critical both on the short-term and on the long-term.", [["adolescents", "ORGANISM", 17, 28], ["adolescents", "SPECIES", 17, 28]]], ["Then, it is to act more directly to contribute to relevant efforts by teaching and research in a way which is suited to the evolving situation.Implications for research and practiceContact tracing apps may become an emblematic case for digital transformation and value changes in the western world.", [["research and practiceContact tracing apps", "TEST", 160, 201], ["digital transformation", "PROBLEM", 236, 258]]], ["We see the contact tracing as an original if not extreme case of the privacy paradox (Kokolakis, 2017) because in studies of the informational privacy paradox a) smartphones apps, or b) location data have rarely been studied ( (Egelman, Felt, & Wagner, 2012) and (Zafeiropoulou, Millard, Webber, & O'Hara, 2013) being exceptions) and because here the dilemma is not at the level of an executive, an organization or a profession, but at the level of all countries who are launching such apps and potentially to the world!", [["the contact tracing", "TEST", 7, 26]]], ["In such context no active personal information disclosure is used contrary to the vast majority of the privacy paradox literature; only metadata about our location and having been in contact or not with an infected person is monitored.", [["person", "SPECIES", 215, 221], ["active", "OBSERVATION_MODIFIER", 19, 25], ["infected", "OBSERVATION", 206, 214]]], ["What is activated through self-discipline are the opening of Bluetooth and the consent to be tested and to self-quarantine if the person crossed someone infected.", [["person", "ORGANISM", 130, 136], ["person", "SPECIES", 130, 136]]], ["However it is voluntary and at all the stages of the process citizens are made responsible for their health and public safety, an important issue in governmentality: if this stop-covid preventative method for avoiding to spread the disease is not effective government won't be to blame, people will be responsible.", [["people", "ORGANISM", 287, 293], ["people", "SPECIES", 287, 293], ["preventative method", "TREATMENT", 185, 204], ["the disease", "PROBLEM", 228, 239]]], ["For our academic community, fighting solutionism in this context requires developing awareness of ethical concerns and calls for future research on the ethics of digital governance (Markus, 2016 ) (e.g. on conditions where data sharing would be really useful (and there are plenty such as the project of health data hub which is about the sharing of health data to help discover new treatments for all sorts of deadly and rare disease).", [["new treatments", "TREATMENT", 379, 393], ["rare disease)", "PROBLEM", 422, 435]]], ["Normally those who have high temperature should then have their temperature confirmed and be tested if necessary.", [["high temperature", "PROBLEM", 24, 40], ["their temperature", "TEST", 58, 75]]], ["If positive this information will be added to SI-DEP.", [["DEP", "CHEMICAL", 49, 52]]], ["It does not say much about the myriad of sub-contactors who work on such a centralized system albeit the three apps are separate and who could also lead to data leaks.", [["data leaks", "PROBLEM", 156, 166], ["leaks", "OBSERVATION", 161, 166]]], ["5 This argument has also been used by the French government for masks.Implications for research and practiceHowever people are not stupid: it is not because they put their seat belt on that they speed up.F. RoweInternational Journal of Information Management xxx (xxxx) xxxx for the app development.", [["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122]]], ["However it is our task to also educate them to defend their privacy and be critical when receiving appealing commercial offers and invited to participate to local and national governments projects.ConclusionAs IS specialists our temptation, and sometimes our trap, is to contribute to the main ongoing and visible debate about what design feature is best and there are always pros and cons for any application and needs in our changing world.", [["any application", "TREATMENT", 394, 409]]], ["The world we build with technologies incorporates irreversible trends that are part of the digital transformation.", [["irreversible trends", "PROBLEM", 50, 69]]], ["Although hardly hit by covid-19 Belgium decided all the more courageously to only use the traditional contact tracing method.ConclusionAs INRIA researchers team note (Bonnetain et al., 2020) , the first article of CNIL has not aged a bit: \"IT must serve each citizen [.. .] .", [["CNIL", "CANCER", 214, 218]]], ["It must undermine neither human identity, nor human rights, nor private life, nor individual or public freedoms \u00bb.", [["human", "ORGANISM", 26, 31], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 46, 51]]]], "PMC5039805": [["BackgroundHuman hookworm infection remains one of the leading neglected tropical diseases (NTDs), affecting more than 400 million people living in developing countries and causing the loss of about 3.2 million disability adjusted life years (DALYs) [1, 2].", [["hookworm infection", "DISEASE", 16, 34], ["NTDs", "DISEASE", 91, 95], ["BackgroundHuman hookworm", "ORGANISM", 0, 24], ["people", "ORGANISM", 130, 136], ["people", "SPECIES", 130, 136], ["BackgroundHuman hookworm infection", "PROBLEM", 0, 34], ["the leading neglected tropical diseases (NTDs)", "PROBLEM", 50, 96], ["hookworm", "OBSERVATION_MODIFIER", 16, 24], ["infection", "OBSERVATION", 25, 34], ["neglected", "OBSERVATION_MODIFIER", 62, 71], ["tropical", "OBSERVATION_MODIFIER", 72, 80], ["diseases", "OBSERVATION", 81, 89]]], ["Hookworm is a blood-feeding nematode that hooks onto the host intestinal mucosa using sharp teeth or cutting plates, causing significant host blood loss.", [["blood", "ANATOMY", 14, 19], ["intestinal mucosa", "ANATOMY", 62, 79], ["teeth", "ANATOMY", 92, 97], ["blood", "ANATOMY", 142, 147], ["Hookworm", "CHEMICAL", 0, 8], ["host blood loss", "DISEASE", 137, 152], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 62, 79], ["teeth", "ORGAN", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["a blood-feeding nematode", "TREATMENT", 12, 36], ["sharp teeth", "PROBLEM", 86, 97], ["cutting plates", "TREATMENT", 101, 115], ["significant host blood loss", "PROBLEM", 125, 152], ["host", "ANATOMY_MODIFIER", 57, 61], ["intestinal mucosa", "ANATOMY", 62, 79], ["sharp teeth", "OBSERVATION", 86, 97], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["host blood loss", "OBSERVATION", 137, 152]]], ["As a consequence, hookworm infection is the major cause of iron-deficiency anemia in endemic regions [3].", [["hookworm infection", "DISEASE", 18, 36], ["iron-deficiency anemia", "DISEASE", 59, 81], ["hookworm", "ORGANISM", 18, 26], ["hookworm infection", "PROBLEM", 18, 36], ["iron-deficiency anemia in endemic regions", "PROBLEM", 59, 100], ["hookworm", "OBSERVATION_MODIFIER", 18, 26], ["infection", "OBSERVATION", 27, 36], ["iron-deficiency anemia", "OBSERVATION", 59, 81]]], ["Current control of hookworm infection mainly relies on mass drug administration with a single annual dose of an anthelmintic such as albendazole or mebendazole.", [["hookworm infection", "DISEASE", 19, 37], ["albendazole", "CHEMICAL", 133, 144], ["mebendazole", "CHEMICAL", 148, 159], ["albendazole", "CHEMICAL", 133, 144], ["mebendazole", "CHEMICAL", 148, 159], ["hookworm", "ORGANISM", 19, 27], ["albendazole", "SIMPLE_CHEMICAL", 133, 144], ["mebendazole", "SIMPLE_CHEMICAL", 148, 159], ["hookworm infection", "PROBLEM", 19, 37], ["mass drug administration", "TREATMENT", 55, 79], ["an anthelmintic", "TREATMENT", 109, 124], ["albendazole", "TREATMENT", 133, 144], ["mebendazole", "TREATMENT", 148, 159], ["hookworm", "OBSERVATION_MODIFIER", 19, 27], ["infection", "OBSERVATION", 28, 37]]], ["However, a recent systematic analysis revealed that anthelmintic treatment with mebendazole had no impact on the improvement of anemia in hookworm-infected regions [4] and is associated with a low cure rate overall [5, 6], while the cure rates with albendazole were highly variable [7].", [["mebendazole", "CHEMICAL", 80, 91], ["anemia", "DISEASE", 128, 134], ["hookworm-infected", "DISEASE", 138, 155], ["albendazole", "CHEMICAL", 249, 260], ["mebendazole", "CHEMICAL", 80, 91], ["albendazole", "CHEMICAL", 249, 260], ["mebendazole", "SIMPLE_CHEMICAL", 80, 91], ["albendazole", "SIMPLE_CHEMICAL", 249, 260], ["a recent systematic analysis", "TEST", 9, 37], ["anthelmintic treatment", "TREATMENT", 52, 74], ["mebendazole", "TREATMENT", 80, 91], ["anemia in hookworm-infected regions", "PROBLEM", 128, 163], ["albendazole", "TREATMENT", 249, 260], ["anemia", "OBSERVATION", 128, 134], ["infected", "OBSERVATION", 147, 155]]], ["Therefore, development of a vaccine has emerged as a practical and feasible alternative technology to control hookworm infection or complement anthelmintic drug treatment [1, 8].", [["hookworm infection", "DISEASE", 110, 128], ["hookworm", "ORGANISM", 110, 118], ["hookworm", "SPECIES", 110, 118], ["a vaccine", "TREATMENT", 26, 35], ["a practical and feasible alternative technology", "TREATMENT", 51, 98], ["hookworm infection", "PROBLEM", 110, 128], ["complement anthelmintic drug treatment", "TREATMENT", 132, 170]]], ["A human hookworm vaccine is considered both cost-effective and cost-saving relative to mass drug administration [9].BackgroundHookworm infection begins when infective larvae penetrate the skin of the host and migrate through the circulatory system and the lungs before reaching the intestine, where they develop into adult worms and start blood-feeding [3].", [["larvae", "ANATOMY", 167, 173], ["skin", "ANATOMY", 188, 192], ["circulatory system", "ANATOMY", 229, 247], ["lungs", "ANATOMY", 256, 261], ["intestine", "ANATOMY", 282, 291], ["worms", "ANATOMY", 323, 328], ["blood", "ANATOMY", 339, 344], ["infection", "DISEASE", 135, 144], ["human", "ORGANISM", 2, 7], ["skin", "ORGAN", 188, 192], ["circulatory system", "ANATOMICAL_SYSTEM", 229, 247], ["lungs", "ORGAN", 256, 261], ["intestine", "ORGAN", 282, 291], ["blood", "ORGANISM_SUBSTANCE", 339, 344], ["human", "SPECIES", 2, 7], ["worms", "SPECIES", 323, 328], ["human", "SPECIES", 2, 7], ["A human hookworm vaccine", "TREATMENT", 0, 24], ["mass drug administration", "TREATMENT", 87, 111], ["BackgroundHookworm infection", "PROBLEM", 116, 144], ["infective larvae", "PROBLEM", 157, 173], ["Hookworm", "OBSERVATION_MODIFIER", 126, 134], ["infection", "OBSERVATION", 135, 144], ["skin", "ANATOMY", 188, 192], ["circulatory system", "ANATOMY", 229, 247], ["lungs", "ANATOMY", 256, 261], ["intestine", "ANATOMY", 282, 291]]], ["The hookworm\u2019s survival exclusively depends on blood-feeding and the digestion of blood proteins including hemoglobin and serum proteins as a major source of nutrition [10].", [["blood", "ANATOMY", 47, 52], ["blood", "ANATOMY", 82, 87], ["serum", "ANATOMY", 122, 127], ["hookworm", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 107, 117], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["blood proteins", "PROTEIN", 82, 96], ["hemoglobin", "PROTEIN", 107, 117], ["serum proteins", "PROTEIN", 122, 136], ["blood-feeding", "TREATMENT", 47, 60], ["the digestion of blood proteins", "PROBLEM", 65, 96], ["hemoglobin", "TEST", 107, 117], ["serum proteins", "TEST", 122, 136]]], ["During the past decade, the molecular basis of this blood-feeding process and the digestion has been partially identified as a cascade of hemoglobinases [11].", [["blood", "ANATOMY", 52, 57], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["this blood-feeding process", "PROBLEM", 47, 73], ["the digestion", "PROBLEM", 78, 91], ["a cascade of hemoglobinases", "PROBLEM", 125, 152], ["feeding process", "OBSERVATION", 58, 73]]], ["After the worm takes up blood into the intestine, the red blood cells are lysed by hemolysin and hemoglobin is released.", [["worm", "ANATOMY", 10, 14], ["blood", "ANATOMY", 24, 29], ["intestine", "ANATOMY", 39, 48], ["red blood cells", "ANATOMY", 54, 69], ["worm", "ORGANISM", 10, 14], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["intestine", "ORGAN", 39, 48], ["red blood cells", "CELL", 54, 69], ["hemolysin", "GENE_OR_GENE_PRODUCT", 83, 92], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 97, 107], ["red blood cells", "CELL_TYPE", 54, 69], ["hemolysin", "PROTEIN", 83, 92], ["hemoglobin", "PROTEIN", 97, 107], ["the red blood cells", "TEST", 50, 69], ["hemolysin", "TEST", 83, 92], ["hemoglobin", "TEST", 97, 107], ["intestine", "ANATOMY", 39, 48]]], ["The released hemoglobin is degraded and digested by a series of hemoglobinases, initiating cleavage of the hemoglobin molecule by an aspartic protease (APR) [12, 13], followed by further digestion with several cysteine proteases [10, 14] and metalloproteinases [15].", [["cysteine", "CHEMICAL", 210, 218], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 13, 23], ["hemoglobinases", "GENE_OR_GENE_PRODUCT", 64, 78], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 107, 117], ["cysteine proteases [10, 14]", "SIMPLE_CHEMICAL", 210, 237], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 242, 260], ["hemoglobin", "PROTEIN", 13, 23], ["hemoglobin molecule", "PROTEIN", 107, 126], ["aspartic protease", "PROTEIN", 133, 150], ["APR", "PROTEIN", 152, 155], ["cysteine proteases", "PROTEIN", 210, 228], ["metalloproteinases", "PROTEIN", 242, 260], ["The released hemoglobin", "TEST", 0, 23], ["hemoglobinases", "TEST", 64, 78], ["the hemoglobin molecule", "TEST", 103, 126], ["an aspartic protease (APR", "TREATMENT", 130, 155], ["several cysteine proteases", "TREATMENT", 202, 228], ["metalloproteinases", "TEST", 242, 260], ["hemoglobin", "OBSERVATION_MODIFIER", 13, 23]]], ["These proteases are expressed in the brush border membrane of the parasite's intestine [10, 15, 16].", [["brush border membrane", "ANATOMY", 37, 58], ["intestine", "ANATOMY", 77, 86], ["brush border membrane", "CELLULAR_COMPONENT", 37, 58], ["intestine", "ORGAN", 77, 86], ["proteases", "PROTEIN", 6, 15], ["These proteases", "TREATMENT", 0, 15], ["intestine", "ANATOMY", 77, 86]]], ["A vaccine development strategy is in process that focuses on interfering with the blood-feeding process of the hookworm.", [["blood", "ANATOMY", 82, 87], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["hookworm", "ORGANISM", 111, 119], ["A vaccine development strategy", "TREATMENT", 0, 30], ["the blood-feeding process", "TREATMENT", 78, 103], ["the hookworm", "PROBLEM", 107, 119], ["hookworm", "OBSERVATION", 111, 119]]], ["It targets proteins, including enzymes, found in the gut of the major human hookworm, Necator americanus, and involved in the degradation of hemoglobin and the detoxification of breakdown products of the process [1].", [["gut", "ANATOMY", 53, 56], ["gut", "ORGANISM_SUBDIVISION", 53, 56], ["human", "ORGANISM", 70, 75], ["hookworm", "ORGANISM", 76, 84], ["Necator americanus", "ORGANISM", 86, 104], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 141, 151], ["enzymes", "PROTEIN", 31, 38], ["hemoglobin", "PROTEIN", 141, 151], ["human", "SPECIES", 70, 75], ["Necator americanus", "SPECIES", 86, 104], ["human hookworm", "SPECIES", 70, 84], ["Necator americanus", "SPECIES", 86, 104], ["enzymes", "TEST", 31, 38], ["hemoglobin", "TREATMENT", 141, 151]]], ["Vaccination elicits anti-enzyme antibodies that can reach the hookworm intestine through blood feeding and subsequently inactivate their target enzymes in the hookworm\u2019s digestive tract and other organs.", [["intestine", "ANATOMY", 71, 80], ["blood", "ANATOMY", 89, 94], ["digestive tract", "ANATOMY", 170, 185], ["organs", "ANATOMY", 196, 202], ["anti-enzyme antibodies", "GENE_OR_GENE_PRODUCT", 20, 42], ["intestine", "ORGAN", 71, 80], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["hookworm", "ORGANISM", 159, 167], ["digestive tract", "ORGAN", 170, 185], ["organs", "ORGAN", 196, 202], ["anti-enzyme antibodies", "PROTEIN", 20, 42], ["Vaccination", "TREATMENT", 0, 11], ["anti-enzyme antibodies", "PROBLEM", 20, 42], ["blood feeding", "TREATMENT", 89, 102], ["their target enzymes", "TEST", 131, 151], ["digestive tract", "ANATOMY", 170, 185]]], ["Among the lead candidate antigens are Na-APR-1, a cathepsin-D aspartic protease required for hemoglobin digestion and Na-GST-1, a glutathione-S transferase involved in detoxification of toxic heme derived from hemoglobin digestion \u2013 both molecules induce significant protective immunity in vaccinated animals against hookworm infection [16, 17].", [["glutathione", "CHEMICAL", 130, 141], ["hookworm infection", "DISEASE", 317, 335], ["glutathione", "CHEMICAL", 130, 141], ["S", "CHEMICAL", 142, 143], ["heme", "CHEMICAL", 192, 196], ["Na-APR-1", "GENE_OR_GENE_PRODUCT", 38, 46], ["cathepsin-D", "GENE_OR_GENE_PRODUCT", 50, 61], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 93, 103], ["Na-GST-1", "GENE_OR_GENE_PRODUCT", 118, 126], ["glutathione-S transferase", "GENE_OR_GENE_PRODUCT", 130, 155], ["heme", "SIMPLE_CHEMICAL", 192, 196], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 210, 220], ["hookworm", "ORGANISM", 317, 325], ["Na-APR-1", "PROTEIN", 38, 46], ["cathepsin-D aspartic protease", "PROTEIN", 50, 79], ["hemoglobin", "PROTEIN", 93, 103], ["Na-GST", "PROTEIN", 118, 124], ["glutathione-S transferase", "PROTEIN", 130, 155], ["heme", "PROTEIN", 192, 196], ["hemoglobin", "PROTEIN", 210, 220], ["hookworm", "SPECIES", 317, 325], ["Na-APR", "TEST", 38, 44], ["a cathepsin-D aspartic protease", "TREATMENT", 48, 79], ["hemoglobin digestion", "PROBLEM", 93, 113], ["Na-GST", "TEST", 118, 124], ["a glutathione", "TEST", 128, 141], ["toxic heme derived", "PROBLEM", 186, 204], ["hemoglobin digestion", "PROBLEM", 210, 230], ["significant protective immunity", "TREATMENT", 255, 286], ["hookworm infection", "PROBLEM", 317, 335]]], ["These two antigens have been selected as the leading hookworm vaccine antigens for product development and are currently in phase 1 clinical trials [1, 8].", [["the leading hookworm vaccine antigens", "TREATMENT", 41, 78]]], ["Ac-CP-2, another cysteine protease of the canine hookworm Ancylostoma caninum, was also determined to be expressed on the intestine brush-border membrane.", [["intestine brush-border membrane", "ANATOMY", 122, 153], ["Ac-CP-2", "CHEMICAL", 0, 7], ["Ancylostoma caninum", "DISEASE", 58, 77], ["cysteine", "CHEMICAL", 17, 25], ["Ac-CP-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["cysteine", "AMINO_ACID", 17, 25], ["canine hookworm", "ORGANISM", 42, 57], ["Ancylostoma caninum", "ORGANISM", 58, 77], ["intestine brush", "MULTI-TISSUE_STRUCTURE", 122, 137], ["border membrane", "CELLULAR_COMPONENT", 138, 153], ["cysteine protease", "PROTEIN", 17, 34], ["canine", "SPECIES", 42, 48], ["Ancylostoma caninum", "SPECIES", 58, 77], ["Ancylostoma caninum", "SPECIES", 58, 77], ["CP", "PROBLEM", 3, 5], ["another cysteine protease", "TREATMENT", 9, 34], ["the canine hookworm Ancylostoma caninum", "TREATMENT", 38, 77], ["Ancylostoma caninum", "OBSERVATION", 58, 77], ["intestine", "ANATOMY", 122, 131], ["brush", "ANATOMY_MODIFIER", 132, 137], ["border membrane", "ANATOMY", 138, 153]]], ["Like Na-APR-1, laboratory animals vaccinated with recombinant Ac-CP-2 also produced antibodies that stunted worm development and reduced egg count after being challenged with hookworm larvae [18].", [["worm", "ANATOMY", 108, 112], ["egg", "ANATOMY", 137, 140], ["Na-APR-1", "GENE_OR_GENE_PRODUCT", 5, 13], ["animals", "ORGANISM", 26, 33], ["Ac-CP-2", "GENE_OR_GENE_PRODUCT", 62, 69], ["worm", "ORGANISM_SUBDIVISION", 108, 112], ["egg", "ORGANISM_SUBSTANCE", 137, 140], ["Na-APR", "PROTEIN", 5, 11], ["recombinant Ac-CP-2", "DNA", 50, 69], ["antibodies", "PROTEIN", 84, 94], ["Na-APR", "TEST", 5, 11], ["laboratory animals", "TEST", 15, 33], ["recombinant Ac", "TREATMENT", 50, 64], ["CP", "PROBLEM", 65, 67], ["antibodies", "PROBLEM", 84, 94], ["stunted worm development", "PROBLEM", 100, 124], ["reduced egg count", "PROBLEM", 129, 146], ["hookworm larvae", "PROBLEM", 175, 190]]], ["In addition to their efficacy in preclinical studies, a second rationale for choosing hookworm gut antigens is that antigens from the hookworm intestine are not directly exposed to the host immune system during natural infection, thereby reducing the likelihood of eliciting host IgE responses and allergic antibodies.", [["intestine", "ANATOMY", 143, 152], ["infection", "DISEASE", 219, 228], ["allergic antibodies", "DISEASE", 298, 317], ["hookworm", "ORGANISM", 86, 94], ["gut antigens", "GENE_OR_GENE_PRODUCT", 95, 107], ["hookworm", "ORGANISM", 134, 142], ["intestine", "ORGAN", 143, 152], ["immune system", "ANATOMICAL_SYSTEM", 190, 203], ["IgE", "GENE_OR_GENE_PRODUCT", 280, 283], ["hookworm gut antigens", "PROTEIN", 86, 107], ["IgE", "PROTEIN", 280, 283], ["allergic antibodies", "PROTEIN", 298, 317], ["preclinical studies", "TEST", 33, 52], ["choosing hookworm gut antigens", "PROBLEM", 77, 107], ["natural infection", "PROBLEM", 211, 228], ["eliciting host IgE responses", "PROBLEM", 265, 293], ["allergic antibodies", "PROBLEM", 298, 317], ["infection", "OBSERVATION", 219, 228]]], ["This issue had previously thwarted other vaccine development efforts for infective larval stage-derived antigens [19].BackgroundIn an effort to identify additional antigens in the hookworm intestine that might be suitable for the development of novel vaccine antigens and therapeutics, we undertook an antigen discovery program.", [["intestine", "ANATOMY", 189, 198], ["hookworm", "ORGANISM", 180, 188], ["intestine", "ORGAN", 189, 198], ["infective larval stage", "PROBLEM", 73, 95], ["additional antigens in the hookworm intestine", "PROBLEM", 153, 198], ["novel vaccine antigens", "TREATMENT", 245, 267]]], ["Based on the success of previous reverse vaccinology programs for selecting bacterial vaccine antigens [20], we are interested in initiating a similar approach for the human hookworm vaccine based on the gut transcriptome.", [["gut", "ANATOMY", 204, 207], ["human", "ORGANISM", 168, 173], ["gut", "ORGANISM_SUBDIVISION", 204, 207], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["previous reverse vaccinology programs", "TREATMENT", 24, 61], ["selecting bacterial vaccine antigens", "TREATMENT", 66, 102], ["a similar approach", "TREATMENT", 141, 159], ["the human hookworm vaccine", "TREATMENT", 164, 190]]], ["We believe that the complete profile of the hookworm intestine\u2019s gene expression pattern could significantly facilitate this selection process.", [["intestine", "ANATOMY", 53, 62], ["hookworm", "ORGANISM", 44, 52], ["intestine", "ORGAN", 53, 62], ["intestine", "ANATOMY", 53, 62]]], ["For this study we used Ancylostoma ceylanicum as a model, a hookworm that infects both animals (e.g. dogs, hamsters) and humans (in focal areas of Malaysia and elsewhere in Southeast Asia) and expresses proteins sharing high homology with the two major human hookworms N. americanus and A. duodenale [21] which only infect humans and cannot properly infect laboratory animals without the use of immunosuppressant [22].", [["Ancylostoma ceylanicum", "DISEASE", 23, 45], ["Ancylostoma ceylanicum", "ORGANISM", 23, 45], ["hookworm", "ORGANISM", 60, 68], ["dogs", "ORGANISM", 101, 105], ["hamsters", "ORGANISM", 107, 115], ["humans", "ORGANISM", 121, 127], ["human", "ORGANISM", 253, 258], ["hookworms", "ORGANISM", 259, 268], ["N. americanus", "ORGANISM", 269, 282], ["A. duodenale [21]", "ORGANISM", 287, 304], ["humans", "ORGANISM", 323, 329], ["Ancylostoma ceylanicum", "SPECIES", 23, 45], ["dogs", "SPECIES", 101, 105], ["hamsters", "SPECIES", 107, 115], ["humans", "SPECIES", 121, 127], ["human", "SPECIES", 253, 258], ["N. americanus", "SPECIES", 269, 282], ["A. duodenale", "SPECIES", 287, 299], ["humans", "SPECIES", 323, 329], ["Ancylostoma ceylanicum", "SPECIES", 23, 45], ["hamsters", "SPECIES", 107, 115], ["humans", "SPECIES", 121, 127], ["human", "SPECIES", 253, 258], ["N. americanus", "SPECIES", 269, 282], ["A. duodenale", "SPECIES", 287, 299], ["humans", "SPECIES", 323, 329], ["this study", "TEST", 4, 14], ["Ancylostoma ceylanicum", "TREATMENT", 23, 45], ["immunosuppressant", "TREATMENT", 395, 412], ["focal", "OBSERVATION_MODIFIER", 132, 137]]], ["The full transcriptome of the A. ceylanicum adult intestine was sequenced and analyzed.", [["adult intestine", "ANATOMY", 44, 59], ["A. ceylanicum", "ORGANISM", 30, 43], ["adult intestine", "ORGAN", 44, 59], ["A. ceylanicum", "SPECIES", 30, 43], ["A. ceylanicum", "SPECIES", 30, 43], ["intestine", "ANATOMY", 50, 59]]], ["The results reveal some new macromolecules likely involved in parasite survival in the mammalian host with the potential to serve as future vaccine candidates or drug targets for controlling hookworm infections.Preparation of A. ceylanicum intestinal RNA ::: MethodsHookworm A. ceylanicum was maintained in hamsters according to protocol AN-5762 approved by Baylor College of Medicine\u2019s Institutional Animal Care and Use Committee (IACUC).", [["hookworm infections", "DISEASE", 191, 210], ["AN-5762", "CHEMICAL", 338, 345], ["hookworm", "ORGANISM", 191, 199], ["A. ceylanicum", "ORGANISM", 226, 239], ["intestinal", "ORGAN", 240, 250], ["Hookworm A. ceylanicum", "ORGANISM", 266, 288], ["hamsters", "ORGANISM", 307, 315], ["A. ceylanicum", "SPECIES", 226, 239], ["A. ceylanicum", "SPECIES", 275, 288], ["hookworm", "SPECIES", 191, 199], ["A. ceylanicum", "SPECIES", 226, 239], ["A. ceylanicum", "SPECIES", 275, 288], ["hamsters", "SPECIES", 307, 315], ["some new macromolecules", "PROBLEM", 19, 42], ["future vaccine candidates", "TREATMENT", 133, 158], ["drug targets", "TREATMENT", 162, 174], ["controlling hookworm infections", "PROBLEM", 179, 210], ["some", "OBSERVATION_MODIFIER", 19, 23], ["new", "OBSERVATION_MODIFIER", 24, 27], ["macromolecules", "OBSERVATION", 28, 42], ["ceylanicum intestinal RNA", "OBSERVATION", 229, 254]]], ["Fresh A. ceylanicum adult worms were recovered from the intestines of hamsters 21 days after infection with A. ceylanicum larvae [23].", [["intestines", "ANATOMY", 56, 66], ["infection", "DISEASE", 93, 102], ["A. ceylanicum adult worms", "ORGANISM", 6, 31], ["intestines", "ORGAN", 56, 66], ["hamsters", "ORGANISM", 70, 78], ["A. ceylanicum", "ORGANISM", 108, 121], ["A. ceylanicum", "SPECIES", 6, 19], ["worms", "SPECIES", 26, 31], ["hamsters", "SPECIES", 70, 78], ["A. ceylanicum", "SPECIES", 108, 121], ["A. ceylanicum", "SPECIES", 6, 19], ["hamsters", "SPECIES", 70, 78], ["A. ceylanicum", "SPECIES", 108, 121], ["infection", "PROBLEM", 93, 102], ["A. ceylanicum larvae", "TREATMENT", 108, 128], ["ceylanicum adult worms", "OBSERVATION", 9, 31], ["intestines", "ANATOMY", 56, 66]]], ["In order to avoid contamination from the worm\u2019s reproductive organs and eggs, only male worms were collected.", [["organs", "ANATOMY", 61, 67], ["worm", "ORGANISM_SUBDIVISION", 41, 45], ["reproductive organs", "MULTI-TISSUE_STRUCTURE", 48, 67], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 76], ["worms", "ORGANISM", 88, 93], ["worms", "SPECIES", 88, 93], ["contamination", "PROBLEM", 18, 31], ["the worm", "PROBLEM", 37, 45]]], ["Total hookworm intestinal tissue was isolated from 50 male adult worms.", [["intestinal tissue", "ANATOMY", 15, 32], ["intestinal tissue", "TISSUE", 15, 32], ["worms", "ORGANISM", 65, 70], ["worms", "SPECIES", 65, 70], ["Total hookworm intestinal tissue", "PROBLEM", 0, 32], ["hookworm", "OBSERVATION", 6, 14], ["intestinal tissue", "ANATOMY", 15, 32]]], ["The anterior esophagus and any contaminating reproductive organs were removed.", [["anterior esophagus", "ANATOMY", 4, 22], ["organs", "ANATOMY", 58, 64], ["anterior esophagus", "ORGAN", 4, 22], ["reproductive", "ORGAN", 45, 57], ["organs", "ORGAN", 58, 64], ["anterior", "ANATOMY_MODIFIER", 4, 12], ["esophagus", "ANATOMY", 13, 22]]], ["The isolated intestines were preserved immediately in RNAlater (Qiagen, Hilden, Germany) to prevent degradation of RNA.", [["intestines", "ANATOMY", 13, 23], ["intestines", "ORGAN", 13, 23], ["RNA", "RNA", 115, 118], ["degradation of RNA", "PROBLEM", 100, 118], ["intestines", "ANATOMY", 13, 23], ["RNA", "OBSERVATION", 115, 118]]], ["Total RNA was extracted from the hookworm intestines using Trizol reagent (Invitrogen, Carlsbad, CA, USA), then digested with Ambion Turbo DNase (Ambion/Applied Biosystems, Austin, TX, USA) to remove any contaminated chromosomal DNA.", [["intestines", "ANATOMY", 42, 52], ["chromosomal", "ANATOMY", 217, 228], ["hookworm", "ORGANISM", 33, 41], ["intestines", "ORGAN", 42, 52], ["DNase", "GENE_OR_GENE_PRODUCT", 139, 144], ["chromosomal", "CELLULAR_COMPONENT", 217, 228], ["DNA", "CELLULAR_COMPONENT", 229, 232], ["contaminated chromosomal DNA", "DNA", 204, 232], ["Total RNA", "PROBLEM", 0, 9], ["Trizol reagent", "TREATMENT", 59, 73], ["Invitrogen", "TREATMENT", 75, 85], ["Ambion Turbo DNase", "TREATMENT", 126, 144], ["any contaminated chromosomal DNA", "PROBLEM", 200, 232], ["intestines", "ANATOMY", 42, 52]]], ["The quality and yield of the purified RNA were assessed using an Agilent 2100 bioanalyzer (Agilent Technologies, Cedar Creek, TX, USA) using the ratio of 28S/18S rRNA and a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).", [["purified RNA", "RNA", 29, 41], ["28S", "DNA", 154, 157], ["the ratio", "TEST", 141, 150], ["a NanoDrop ND", "TREATMENT", 171, 184]]], ["The integrity of the purified RNA was determined using the RNA Integrity Number [24].RNA-seq library construction and Illumina sequencing ::: MethodsMessenger RNA (mRNA) was prepared from the purified total RNA using the MicroPoly(A)Purist\u2122 Kit (Ambion/Applied Biosystems, Austin, TX, USA), and then converted to cDNA using Ovation\u00ae\u2019s RNA-Seq V2 kit (NuGen Technologies, Inc., San Carlos, CA, USA) with both a poly-A and a random primer.", [["poly-A", "SIMPLE_CHEMICAL", 410, 416], ["purified RNA", "RNA", 21, 33], ["MethodsMessenger RNA", "RNA", 142, 162], ["mRNA", "RNA", 164, 168], ["cDNA", "DNA", 313, 317], ["the purified RNA", "TREATMENT", 17, 33], ["RNA", "TEST", 85, 88], ["Ovation\u00ae", "TEST", 324, 332], ["RNA", "TEST", 335, 338], ["a random primer", "TREATMENT", 421, 436], ["integrity", "OBSERVATION_MODIFIER", 4, 13]]], ["An Illumina sequencing library was constructed according to the manufacturer's instructions (Illumina Inc., San Diego, CA, USA).", [["Illumina sequencing library", "DNA", 3, 30], ["An Illumina sequencing library", "TEST", 0, 30]]], ["Briefly, 1 \u03bcg cDNA was sheared using a Covaris S220 DNA Sonicator (Covaris Inc., Woburn, MA, USA) and fragments with a size range of 200\u2013400 bp were collected.", [["1 \u03bcg cDNA", "DNA", 9, 18], ["1 \u03bcg cDNA", "TREATMENT", 9, 18], ["a Covaris S220 DNA Sonicator (Covaris Inc.", "TREATMENT", 37, 79], ["Woburn, MA", "TREATMENT", 81, 91], ["bp", "TEST", 141, 143], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["Single Primer Isothermal Amplification (SPIA) adapters were added to those fragments, followed by PCR amplification to enrich adaptor-ligated fragments.", [["fragments", "ANATOMY", 75, 84], ["fragments", "ANATOMY", 142, 151], ["Primer Isothermal Amplification (SPIA) adapters", "DNA", 7, 54], ["adaptor-ligated fragments", "DNA", 126, 151], ["Single Primer Isothermal Amplification (SPIA) adapters", "TREATMENT", 0, 54], ["those fragments", "PROBLEM", 69, 84], ["PCR amplification", "TREATMENT", 98, 115], ["ligated fragments", "PROBLEM", 134, 151], ["ligated", "OBSERVATION_MODIFIER", 134, 141], ["fragments", "OBSERVATION", 142, 151]]], ["Quantitative PCR (Kapa Biosystems Inc., Woburn, MA, USA) was used to determine the concentration of the resulting library and to produce the cluster counts appropriate for the Illumina platform.", [["Quantitative PCR", "TEST", 0, 16], ["the cluster counts", "PROBLEM", 137, 155], ["the Illumina platform", "TEST", 172, 193]]], ["The library was finally loaded into the flow cells of the HiSeq2000 sequencer to generate paired end reads of approximately 100 bp in length [21].RNA-seq library construction and Illumina sequencing ::: MethodsThe mRNA-sequence reads were processed using an in-house Perl script to remove adaptor sequences as well as those with low complexity or derived from non-target sources (golden hamster genome database, GCF_000349665.1, and GenBank Bacterial Sequences database, GBBCT).", [["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50], ["flow cells", "CELL_TYPE", 40, 50], ["HiSeq2000 sequencer", "DNA", 58, 77], ["adaptor sequences", "DNA", 289, 306], ["golden hamster genome database", "DNA", 380, 410], ["GCF_000349665.1", "DNA", 412, 427], ["golden hamster", "SPECIES", 380, 394], ["RNA", "TEST", 146, 149], ["Methods", "TREATMENT", 203, 210], ["adaptor sequences", "TREATMENT", 289, 306], ["GCF_", "TEST", 412, 416], ["GenBank Bacterial Sequences database", "TEST", 433, 469], ["flow cells", "OBSERVATION", 40, 50]]], ["The processed reads were mapped to the unpublished A. ceylanicum genome (available at http: nematode.net [25]), using Tophat 2.0.8 [26] with the parameter mate-inner-distance set to 300.", [["A. ceylanicum", "ORGANISM", 51, 64], ["A. ceylanicum genome", "DNA", 51, 71], ["A. ceylanicum", "SPECIES", 51, 64], ["A. ceylanicum", "SPECIES", 51, 64], ["Tophat", "TEST", 118, 124]]], ["Breadth of coverage and read count of individual A. ceylanicum gene transcripts were calculated using Refcov, version 0.3 (http://gmt.genome.wustl.edu/packages/refcov/) [27] and HTSeq-count (http://www-huber.embl.de/users/anders/HTSeq/doc/count.html) [28], respectively.", [["A. ceylanicum", "ORGANISM", 49, 62], ["A. ceylanicum", "SPECIES", 49, 62], ["A. ceylanicum", "SPECIES", 49, 62], ["Breadth of coverage", "TREATMENT", 0, 19], ["read count", "TEST", 24, 34], ["individual A. ceylanicum gene transcripts", "TREATMENT", 38, 79], ["version", "TEST", 110, 117], ["HTSeq", "TEST", 178, 183]]], ["Genes with at least 50 % breadth of coverage were considered to be expressed in the male A. ceylanicum intestine.", [["intestine", "ANATOMY", 103, 112], ["A. ceylanicum", "ORGANISM", 89, 102], ["intestine", "ORGAN", 103, 112], ["A. ceylanicum", "SPECIES", 89, 102], ["A. ceylanicum", "SPECIES", 89, 102], ["ceylanicum intestine", "ANATOMY", 92, 112]]], ["The corresponding counts were used to represent the expression abundances of those genes.", [["The corresponding counts", "TEST", 0, 24]]], ["The significantly abundant gene transcripts in A. ceylanicum intestine were identified with the Fisher\u2019s exact test in Bioconductor package edgeR on the basis of comparison of the gene transcript counts in the intestinal transcriptome with the whole male worm transcriptome.", [["ceylanicum intestine", "ANATOMY", 50, 70], ["intestinal", "ANATOMY", 210, 220], ["A. ceylanicum intestine", "ORGAN", 47, 70], ["intestinal", "ORGAN", 210, 220], ["Bioconductor package edgeR", "DNA", 119, 145], ["A. ceylanicum", "SPECIES", 47, 60], ["A. ceylanicum", "SPECIES", 47, 60], ["significantly", "OBSERVATION_MODIFIER", 4, 17], ["abundant", "OBSERVATION_MODIFIER", 18, 26], ["gene transcripts", "OBSERVATION", 27, 43], ["intestine", "ANATOMY", 61, 70], ["transcript counts", "OBSERVATION", 185, 202], ["intestinal transcriptome", "ANATOMY", 210, 234]]], ["A corrected false discovery rate (FDR) cutoff of 0.05 was used.Quantitative reverse transcription PCR (qRT-PCR) ::: MethodsTo validate the results from the RNA-seq experiments, five genes with higher expression levels in the intestine than in the whole worm were chosen for quantitative reverse transcription PCR (qRT-PCR).", [["intestine", "ANATOMY", 225, 234], ["worm", "ANATOMY", 253, 257], ["intestine", "ORGAN", 225, 234], ["worm", "ORGAN", 253, 257], ["Quantitative reverse transcription PCR", "TEST", 63, 101], ["qRT", "TEST", 103, 106], ["the RNA", "TEST", 152, 159], ["higher expression levels in the intestine", "PROBLEM", 193, 234], ["quantitative reverse transcription PCR", "TEST", 274, 312], ["intestine", "ANATOMY", 225, 234]]], ["Total RNA was freshly extracted from whole worms and isolated intestines of A. ceylanicum.", [["worms", "ANATOMY", 43, 48], ["intestines", "ANATOMY", 62, 72], ["worms", "ORGANISM_SUBDIVISION", 43, 48], ["intestines", "ORGAN", 62, 72], ["A. ceylanicum", "ORGANISM", 76, 89], ["worms", "SPECIES", 43, 48], ["A. ceylanicum", "SPECIES", 76, 89], ["A. ceylanicum", "SPECIES", 76, 89], ["Total RNA", "PROBLEM", 0, 9], ["whole worms", "PROBLEM", 37, 48], ["A. ceylanicum", "PROBLEM", 76, 89], ["intestines", "ANATOMY", 62, 72], ["ceylanicum", "OBSERVATION", 79, 89]]], ["Total cDNA was reverse-transcribed using the SuperScript III First-Strand Synthesis System per the manufacturer\u2019s protocol (Invitrogen, Waltham, USA).", [["cDNA", "DNA", 6, 10], ["Total cDNA", "TREATMENT", 0, 10], ["the SuperScript III", "TREATMENT", 41, 60], ["Strand Synthesis System", "TREATMENT", 67, 90]]], ["Quantitative PCR was performed using a PowerUp\u2122 SYBR\u00ae Green (Life Technologies, Carlsbad, USA) cocktail in a ViiA7 real-time PCR detection system (Applied Biosystems).", [["Quantitative PCR", "TEST", 0, 16]]], ["The PCR conditions were 95 \u00b0C for 1 min, followed by 35 cycles of 95 \u00b0C for 25 s, 55 \u00b0C for 20 s, 72 \u00b0C for 1 min, and concluded by a 10 min incubation step at 72 \u00b0C. The 18S rRNA of A. ceylanicum (DQ464371.1) was selected as a standard comparison control gene.Bioinformatics analysis ::: MethodsThe functional annotations based on primary sequence level was done using Interproscan (https://www.ebi.ac.uk/interpro/), and further classified into different Gene Ontologies (GO).", [["18S", "GENE_OR_GENE_PRODUCT", 171, 174], ["rRNA", "CELLULAR_COMPONENT", 175, 179], ["A. ceylanicum", "ORGANISM", 183, 196], ["18S rRNA", "DNA", 171, 179], ["standard comparison control gene", "DNA", 228, 260], ["Gene Ontologies", "DNA", 456, 471], ["GO", "DNA", 473, 475], ["A. ceylanicum", "SPECIES", 183, 196], ["A. ceylanicum", "SPECIES", 183, 196], ["The PCR conditions", "TEST", 0, 18], ["The 18S rRNA", "TEST", 167, 179], ["a standard comparison control gene", "TREATMENT", 226, 260], ["Bioinformatics analysis", "TEST", 261, 284], ["Methods", "TREATMENT", 289, 296], ["primary sequence level", "TEST", 332, 354], ["18S rRNA", "OBSERVATION", 171, 179]]], ["We further added various sub-categories within each GO-ontology and weighted them with FPKM (Fragments Per Kilobase of transcript per Million mapped reads, a measure of the relative expression of an individual transcript) values for each gene.", [["various sub-categories", "TREATMENT", 17, 39]]], ["Those transcripts highly expressed in the worm\u2019s intestine were determined through comparison with data from the whole adult male transcripts available from the SRA for A. ceylanicum (accession numbers: SRX1116908 and SRX1116915) downloaded and employed in this study.", [["worm\u2019s intestine", "ANATOMY", 42, 58], ["worm", "ORGAN", 42, 46], ["intestine", "ORGAN", 49, 58], ["A. ceylanicum", "ORGANISM", 169, 182], ["SRA", "PROTEIN", 161, 164], ["A. ceylanicum", "SPECIES", 169, 182], ["A. ceylanicum", "SPECIES", 169, 182], ["SRX", "TEST", 218, 221], ["this study", "TEST", 257, 267], ["intestine", "ANATOMY", 49, 58]]], ["The Merops database (https://merops.sanger.ac.uk/), a manually curated peptidase and inhibitor database, was used to annotate and classify peptidases in order to identify which proteases or peptidases are highly expressed in the hookworm intestine.", [["intestine", "ANATOMY", 238, 247], ["hookworm", "ORGANISM", 229, 237], ["intestine", "ORGAN", 238, 247], ["peptidase", "PROTEIN", 71, 80], ["peptidases", "PROTEIN", 139, 149], ["proteases", "PROTEIN", 177, 186], ["peptidases", "PROTEIN", 190, 200], ["a manually curated peptidase and inhibitor database", "TREATMENT", 52, 103], ["peptidases", "TEST", 139, 149], ["peptidases", "PROBLEM", 190, 200], ["hookworm", "OBSERVATION", 229, 237], ["intestine", "ANATOMY", 238, 247]]], ["Pepunit.lib sequences from release 9.12 were downloaded from the website (http://merops.sanger.ac.uk/download/) and used to create a custom Blastp database using BLAST command line tools and an e-value of less than 10-6.", [["Pepunit.lib sequences", "DNA", 0, 21], ["Blastp database", "DNA", 140, 155], ["Pepunit.lib sequences", "TEST", 0, 21], ["BLAST command line tools", "TEST", 162, 186], ["an e-value", "TEST", 191, 201]]], ["The hits were weighted by using their FPKM values and then summed to plot using proportional values.", [["their FPKM values", "TEST", 32, 49], ["proportional values", "TEST", 80, 99]]], ["Molecules involved in transmembrane transport were identified using the TrSSP dataset (http://bioinfo.noble.org/TrSSP/?dowhat=Datasets).", [["transmembrane", "ANATOMY", 22, 35], ["transmembrane", "CELLULAR_COMPONENT", 22, 35], ["TrSSP dataset", "DNA", 72, 85], ["transmembrane transport", "TEST", 22, 45]]], ["The transporter sequences were downloaded from the Transporter Substrate Specificity Prediction Server (TrSSP) and used for BlastP searches against the hookworm intestinal RNA-Seq genes obtained in this study by setting an e-value of less than 10-6.", [["intestinal", "ORGAN", 161, 171], ["hookworm intestinal RNA-Seq genes", "DNA", 152, 185], ["The transporter sequences", "TEST", 0, 25], ["BlastP searches", "TEST", 124, 139], ["the hookworm intestinal RNA", "PROBLEM", 148, 175], ["this study", "TEST", 198, 208], ["an e-value", "TEST", 220, 230]]], ["Phylogenetic trees were generated for those functional protein homologues identified in this study using Phylogeny.fr [29] (http://www.phylogeny.fr/index.cgi).", [["functional protein homologues", "PROTEIN", 44, 73], ["Phylogenetic trees", "PROBLEM", 0, 18], ["those functional protein homologues", "PROBLEM", 38, 73], ["this study", "TEST", 88, 98]]], ["Signal peptides were predicted using Phobius Server (http://phobius.sbc.su.se/) [30].", [["Signal peptides", "TEST", 0, 15]]], ["The transmembrane domains were predicted using TMHMM (http://www.cbs.dtu.dk/services/TMHMM/) [31].Isolation of hookworm intestines ::: Results and discussionThe intestines of hookworms were isolated from living adult male A. ceylanicum worms collected from infected hamsters under microscopy (Fig. 1a).", [["transmembrane", "ANATOMY", 4, 17], ["intestines", "ANATOMY", 120, 130], ["intestines", "ANATOMY", 161, 171], ["hookworm", "ORGANISM", 111, 119], ["intestines", "ORGAN", 120, 130], ["intestines", "ORGAN", 161, 171], ["hookworms", "ORGANISM", 175, 184], ["A. ceylanicum worms", "ORGANISM", 222, 241], ["hamsters", "ORGANISM", 266, 274], ["transmembrane domains", "PROTEIN", 4, 25], ["A. ceylanicum", "SPECIES", 222, 235], ["worms", "SPECIES", 236, 241], ["A. ceylanicum", "SPECIES", 222, 235], ["hamsters", "SPECIES", 266, 274], ["The transmembrane domains", "TEST", 0, 25], ["TMHMM", "TEST", 47, 52], ["hookworms", "PROBLEM", 175, 184], ["ceylanicum worms", "PROBLEM", 225, 241], ["hookworm intestines", "OBSERVATION", 111, 130], ["intestines", "ANATOMY", 161, 171]]], ["Total RNA was extracted from the isolated intestine and the total RIN for the hookworm intestinal RNA was 8.6 on a scale that extends from 10 (intact) to 2 (degraded), indicating that most of the RNA had remained intact throughout the purification process (Fig. 1b).", [["intestine", "ANATOMY", 42, 51], ["intestinal", "ANATOMY", 87, 97], ["intestine", "ORGAN", 42, 51], ["intestinal", "ORGAN", 87, 97], ["hookworm intestinal RNA", "RNA", 78, 101], ["Total RNA", "PROBLEM", 0, 9], ["the total RIN", "TREATMENT", 56, 69], ["the hookworm intestinal RNA", "TEST", 74, 101], ["the RNA", "PROBLEM", 192, 199], ["RNA", "OBSERVATION", 6, 9], ["isolated", "ANATOMY_MODIFIER", 33, 41], ["intestine", "ANATOMY", 42, 51], ["total RIN", "OBSERVATION_MODIFIER", 60, 69], ["hookworm", "OBSERVATION", 78, 86], ["intestinal RNA", "ANATOMY", 87, 101], ["RNA", "OBSERVATION", 196, 199], ["intact", "OBSERVATION", 213, 219]]]], "669da38cd7c61d4b4564749995b5a743a1254bee": [["IntroductionFeline infectious peritonitis (FIP) is one of the major infectious cause of mortality in kitten (Cave et al., 2002) .", [["infectious peritonitis", "DISEASE", 19, 41], ["FIP", "DISEASE", 43, 46], ["IntroductionFeline infectious peritonitis", "PROBLEM", 0, 41], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["peritonitis", "OBSERVATION", 30, 41], ["major", "OBSERVATION_MODIFIER", 62, 67], ["infectious", "OBSERVATION", 68, 78]]], ["The causative agent, feline coronavirus (FCoV), is an enveloped, positive-sense, single-stranded RNA virus belonging to family Coronaviridae within the order Nidovirales (Lai et al., 2007) .", [["feline coronavirus", "DISEASE", 21, 39], ["feline coronavirus", "ORGANISM", 21, 39], ["FCoV", "CANCER", 41, 45], ["feline coronavirus", "SPECIES", 21, 39], ["feline coronavirus", "SPECIES", 21, 39], ["FCoV", "SPECIES", 41, 45], ["The causative agent", "TREATMENT", 0, 19], ["feline coronavirus (FCoV", "PROBLEM", 21, 45], ["Coronaviridae", "TREATMENT", 127, 140]]], ["FCoVs are also associated with mild or subclinical enteric infections (Pedersen et al., 1981) .", [["enteric infections", "DISEASE", 51, 69], ["FCoVs", "GENE_OR_GENE_PRODUCT", 0, 5], ["mild or subclinical enteric infections", "PROBLEM", 31, 69], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["subclinical", "OBSERVATION_MODIFIER", 39, 50], ["enteric", "OBSERVATION_MODIFIER", 51, 58], ["infections", "OBSERVATION", 59, 69]]], ["Despite the high prevalence of FCoVs in feline populations around the world (Bell et al., 2006; Horzinek and Osterhaus, 1979; Kiss et al., 2000; Pedersen, 1976; Sparkes et al., 1992) , only 5-12% of seropositive cats develop FIP (Addie and Jarrett, 1992; Addie et al., 1995) .IntroductionFCoVs are further classified into two serotypes that differ in their growth characteristics in cell culture and antigenicity relative to canine coronaviruses (CCoVs) (Pedersen et al., 1984) .", [["cell", "ANATOMY", 383, 387], ["FCoVs", "DISEASE", 31, 36], ["FIP", "DISEASE", 225, 228], ["feline", "ORGANISM", 40, 46], ["cats", "ORGANISM", 212, 216], ["cell", "CELL", 383, 387], ["canine coronaviruses", "ORGANISM", 425, 445], ["feline", "SPECIES", 40, 46], ["cats", "SPECIES", 212, 216], ["canine", "SPECIES", 425, 431], ["canine coronaviruses", "SPECIES", 425, 445], ["IntroductionFCoVs", "TREATMENT", 276, 293], ["cell culture", "TEST", 383, 395], ["high prevalence", "OBSERVATION_MODIFIER", 12, 27]]], ["Type II FCoVs are the result of recombination between a type I FCoV and CCoV (Herrewegh et al., 1998) .", [["Type II FCoVs", "GENE_OR_GENE_PRODUCT", 0, 13], ["Type II FCoVs", "PROTEIN", 0, 13], ["Type II FCoVs", "PROBLEM", 0, 13]]], ["Both types of FCoV can cause FIP (Pedersen et al., 1984) .", [["FCoV", "CHEMICAL", 14, 18], ["FIP", "DISEASE", 29, 32], ["FCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["FIP", "PROBLEM", 29, 32], ["FCoV", "OBSERVATION", 14, 18]]], ["Type I and II FCoVs have different cell tropisms that can be explained by differences in the binding specificity of their respective spike proteins (Hohdatsu et al., 1998) .", [["cell", "ANATOMY", 35, 39], ["Type I and II FCoVs", "GENE_OR_GENE_PRODUCT", 0, 19], ["cell", "CELL", 35, 39], ["Type I and II FCoVs", "PROTEIN", 0, 19], ["spike proteins", "PROTEIN", 133, 147], ["Type I and II FCoVs", "PROBLEM", 0, 19], ["different cell tropisms", "PROBLEM", 25, 48], ["different cell tropisms", "OBSERVATION", 25, 48]]], ["Based upon recognized differences in the spike genes of these two virus types, reverse transcription-polymerase chain reaction (RT-PCR) analyses has been employed as an alternative method to distinguish between type I and II viruses (Addie et al., 2003; Benetka et al., 2004) .", [["type I and II viruses", "DISEASE", 211, 232], ["spike genes", "DNA", 41, 52], ["type I", "SPECIES", 211, 217], ["these two virus types", "PROBLEM", 56, 77], ["reverse transcription-polymerase chain reaction", "PROBLEM", 79, 126], ["RT-PCR", "TEST", 128, 134]]], ["The prevalence of type I and II FCoV has been surveyed in many countries, including the The outcomes of feline coronavirus (FCoV) infection vary greatly from asymptomatic or mild enteric infection to fatal feline infectious peritonitis (FIP).", [["feline coronavirus (FCoV) infection", "DISEASE", 104, 139], ["enteric infection", "DISEASE", 179, 196], ["feline infectious peritonitis", "DISEASE", 206, 235], ["FIP", "DISEASE", 237, 240], ["feline coronavirus", "ORGANISM", 104, 122], ["FCoV", "ORGANISM", 124, 128], ["feline", "ORGANISM", 206, 212], ["feline coronavirus", "SPECIES", 104, 122], ["feline", "SPECIES", 206, 212], ["feline coronavirus", "SPECIES", 104, 122], ["FCoV", "SPECIES", 124, 128], ["type I and II FCoV", "PROBLEM", 18, 36], ["feline coronavirus (FCoV) infection", "PROBLEM", 104, 139], ["asymptomatic", "PROBLEM", 158, 170], ["mild enteric infection", "PROBLEM", 174, 196], ["fatal feline infectious peritonitis", "PROBLEM", 200, 235], ["mild", "OBSERVATION_MODIFIER", 174, 178], ["enteric", "ANATOMY", 179, 186], ["infection", "OBSERVATION", 187, 196], ["fatal", "OBSERVATION_MODIFIER", 200, 205], ["feline", "OBSERVATION_MODIFIER", 206, 212], ["infectious", "OBSERVATION_MODIFIER", 213, 223], ["peritonitis", "OBSERVATION", 224, 235]]], ["On the basis of in vitro neutralization tests, FCoVs can be divided into two serotypes.", [["FCoVs", "SIMPLE_CHEMICAL", 47, 52], ["FCoVs", "PROTEIN", 47, 52], ["vitro neutralization tests", "TEST", 19, 45], ["FCoVs", "TREATMENT", 47, 52]]], ["To explore the correlation between different types of FCoV and FIP, clinical specimens collected from 363 naturally infected cats during 2003-2007 were analyzed.", [["specimens", "ANATOMY", 77, 86], ["FCoV", "GENE_OR_GENE_PRODUCT", 54, 58], ["cats", "ORGANISM", 125, 129], ["cats", "SPECIES", 125, 129], ["clinical specimens", "TEST", 68, 86]]], ["Amplification of a portion of the S gene from the FCoV was performed and a total of 222 cases were differentiated.", [["FCoV", "CANCER", 50, 54], ["S gene", "DNA", 34, 40], ["FCoV", "DNA", 50, 54]]], ["Among them, 197 (88.7%) cats were type I-positive, 13 (5.9%) were type II-positive, and 12 (5.4%) were positive for both types.", [["cats", "ORGANISM", 24, 28], ["cats", "SPECIES", 24, 28], ["cats", "TEST", 24, 28], ["type I", "TEST", 34, 40], ["type II", "TEST", 66, 73]]], ["Irrespective of the predominance of type I FCoV infection in Taiwan, type II FCoV demonstrated a significantly higher correlation with FIP (p < 0.01).", [["infection", "DISEASE", 48, 57], ["FIP", "DISEASE", 135, 138], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 36, 47], ["type I FCoV", "SPECIES", 36, 47], ["type I FCoV infection", "PROBLEM", 36, 57], ["type II FCoV", "PROBLEM", 69, 81], ["FIP", "TEST", 135, 138], ["type I", "OBSERVATION_MODIFIER", 36, 42], ["FCoV", "OBSERVATION_MODIFIER", 43, 47], ["infection", "OBSERVATION", 48, 57]]], ["Analysis of partial S gene sequences of the local type I and II FCoVs strains revealed that type I viruses were more genetically divergent (6.2-11.7%) than type II viruses (0.6-3.2%) within the 5-year study period.", [["type I viruses", "DISEASE", 92, 106], ["type II viruses", "DISEASE", 156, 171], ["type I viruses", "ORGANISM", 92, 106], ["partial S gene sequences", "DNA", 12, 36], ["type I viruses", "SPECIES", 92, 106], ["type II viruses", "SPECIES", 156, 171], ["partial S gene sequences", "PROBLEM", 12, 36], ["II FCoVs strains", "TEST", 61, 77], ["type I viruses", "PROBLEM", 92, 106], ["type II viruses", "PROBLEM", 156, 171]]], ["The higher genetic diversity of type I FCoVs might be due to the larger infected cat population and to the long period of viral persistence in asymptomatic cats in comparison to type II viruses.Introduction\u00df 2008 Elsevier B.V. All rights reserved.IntroductionUSA (Vennema, 1999) , UK (Addie et al., 2003) , Japan (Hohdatsu et al., 1992; Shiba et al., 2007) , Austria (Benetka et al., 2004) , and Switzerland (Kummrow et al., 2005) .", [["type I FCoVs", "GENE_OR_GENE_PRODUCT", 32, 44], ["cat", "ORGANISM", 81, 84], ["cats", "ORGANISM", 156, 160], ["type II viruses", "ORGANISM", 178, 193], ["cats", "SPECIES", 156, 160], ["type II viruses", "SPECIES", 178, 193], ["type I FCoVs", "PROBLEM", 32, 44], ["the larger infected cat population", "PROBLEM", 61, 95], ["viral persistence in asymptomatic cats", "PROBLEM", 122, 160], ["type II viruses", "PROBLEM", 178, 193], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["genetic", "OBSERVATION_MODIFIER", 11, 18], ["diversity", "OBSERVATION_MODIFIER", 19, 28], ["might be due to", "UNCERTAINTY", 45, 60], ["larger", "OBSERVATION_MODIFIER", 65, 71], ["infected", "OBSERVATION", 72, 80], ["cat population", "OBSERVATION", 81, 95], ["viral", "OBSERVATION_MODIFIER", 122, 127], ["persistence", "OBSERVATION_MODIFIER", 128, 139]]], ["Regardless of which assays were used, the majority of infections were attributed to type I FCoV.", [["infections", "DISEASE", 54, 64], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 84, 95], ["type I FCoV", "SPECIES", 84, 95], ["assays", "TEST", 20, 26], ["infections", "PROBLEM", 54, 64], ["type I FCoV", "PROBLEM", 84, 95], ["infections", "OBSERVATION", 54, 64], ["FCoV", "OBSERVATION", 91, 95]]], ["Although both type I and II FCoV can cause FIP, their likelihood of association with FIP was controversial in different studies (Kummrow et al., 2005; Hohdatsu et al., 1992) .", [["FIP", "DISEASE", 43, 46], ["FIP", "DISEASE", 85, 88], ["type I and II FCoV", "GENE_OR_GENE_PRODUCT", 14, 32], ["FIP", "PROBLEM", 43, 46], ["FIP", "PROBLEM", 85, 88]]], ["Coronaviruses (CoVs) have been identified in a variety of host species, including birds, humans, livestock, and other mammals (Lai et al., 2007) .", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["CoVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["humans", "ORGANISM", 89, 95], ["Coronaviruses", "PROTEIN", 0, 13], ["CoVs", "PROTEIN", 15, 19], ["humans", "SPECIES", 89, 95], ["humans", "SPECIES", 89, 95], ["Coronaviruses (CoVs", "PROBLEM", 0, 19], ["host species", "OBSERVATION", 58, 70]]], ["Recently, the evolution of CoVs has been extensively studied (Dong et al., 2007; Vijaykrishna et al., 2007; Woo et al., 2007) and the prototype FCoV strain 79-1146 was placed in group 1a together with transmissible gastroenteritis virus (TGEV) and two wild animal CoVs .", [["CoVs", "CHEMICAL", 27, 31], ["FCoV strain 79-1146", "CHEMICAL", 144, 163], ["transmissible gastroenteritis virus", "DISEASE", 201, 236], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["79-1146", "CELL", 156, 163], ["transmissible gastroenteritis virus", "ORGANISM", 201, 236], ["TGEV", "ORGANISM", 238, 242], ["CoVs", "CANCER", 264, 268], ["CoVs", "DNA", 27, 31], ["transmissible gastroenteritis virus", "SPECIES", 201, 236], ["FCoV strain 79-1146", "SPECIES", 144, 163], ["transmissible gastroenteritis virus", "SPECIES", 201, 236], ["TGEV", "SPECIES", 238, 242], ["CoVs", "PROBLEM", 27, 31], ["the prototype FCoV strain", "TEST", 130, 155], ["transmissible gastroenteritis virus", "PROBLEM", 201, 236], ["CoVs", "OBSERVATION", 27, 31], ["gastroenteritis", "OBSERVATION", 215, 230], ["animal CoVs", "OBSERVATION", 257, 268]]], ["As strain 79-1146 is a type II virus isolated long time ago (McKeirnan et al., 1981) , the genetic information carrying in current FCoVs might be quite different.", [["79-1146", "CHEMICAL", 10, 17], ["strain 79-1146", "ORGANISM", 3, 17], ["FCoVs", "CANCER", 131, 136], ["type II virus", "SPECIES", 23, 36], ["a type II virus", "PROBLEM", 21, 36]]], ["To explore the relationship between FIP and different FCoV serotypes and to better understand the prevalence and genetic diversity of the recent type I and II viruses, naturally infected cases collected over the past 5 years from our teaching hospital were investigated.", [["FIP", "DISEASE", 36, 39], ["naturally infected", "DISEASE", 168, 186], ["FIP", "PROBLEM", 36, 39], ["different FCoV serotypes", "TREATMENT", 44, 68], ["II viruses", "PROBLEM", 156, 166], ["naturally infected cases", "PROBLEM", 168, 192], ["FCoV serotypes", "OBSERVATION", 54, 68]]], ["Despite the higher prevalence and genetic diversity of type I FCoV, infection with type II FCoV appears to be highly significantly correlated with FIP.Animal and specimen collectionClinical specimens including body effusions, whole blood, rectal swabs, and conjunctival swabs were collected from cats presenting at the Animal Hospital of National Taiwan University over a 5-year period (2003) (2004) (2005) (2006) (2007) .", [["specimen", "ANATOMY", 162, 170], ["specimens", "ANATOMY", 190, 199], ["body effusions", "ANATOMY", 210, 224], ["whole blood", "ANATOMY", 226, 237], ["rectal swabs", "ANATOMY", 239, 251], ["conjunctival swabs", "ANATOMY", 257, 275], ["type I FCoV", "DISEASE", 55, 66], ["infection", "DISEASE", 68, 77], ["FIP", "DISEASE", 147, 150], ["effusions", "DISEASE", 215, 224], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 55, 66], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 83, 95], ["body", "ORGANISM_SUBDIVISION", 210, 214], ["blood", "ORGANISM_SUBSTANCE", 232, 237], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 239, 251], ["conjunctival swabs", "ORGANISM_SUBSTANCE", 257, 275], ["cats", "ORGANISM", 296, 300], ["cats", "SPECIES", 296, 300], ["type I FCoV", "SPECIES", 55, 66], ["type II FCoV", "SPECIES", 83, 95], ["type I FCoV", "PROBLEM", 55, 66], ["infection", "PROBLEM", 68, 77], ["type II FCoV", "PROBLEM", 83, 95], ["FIP", "PROBLEM", 147, 150], ["specimen collection", "TEST", 162, 181], ["Clinical specimens", "TEST", 181, 199], ["body effusions", "PROBLEM", 210, 224], ["whole blood", "TEST", 226, 237], ["rectal swabs", "TEST", 239, 251], ["conjunctival swabs", "TEST", 257, 275], ["type I", "OBSERVATION_MODIFIER", 55, 61], ["FCoV", "OBSERVATION", 62, 66], ["infection", "OBSERVATION", 68, 77], ["FCoV", "OBSERVATION", 91, 95], ["FIP", "OBSERVATION", 147, 150], ["body", "ANATOMY", 210, 214], ["effusions", "OBSERVATION", 215, 224], ["rectal swabs", "ANATOMY", 239, 251], ["conjunctival", "ANATOMY", 257, 269]]], ["All specimens were screened for FCoV by RT-PCR, as described by Herrewegh et al. (1995) .", [["specimens", "ANATOMY", 4, 13], ["FCoV", "SIMPLE_CHEMICAL", 32, 36], ["FCoV", "DNA", 32, 36], ["All specimens", "TEST", 0, 13], ["FCoV", "PROBLEM", 32, 36], ["PCR", "TEST", 43, 46]]], ["A total of 363 cases that showed positive RT-PCR from either one of the specimens were enrolled in this study.", [["specimens", "ANATOMY", 72, 81], ["specimens", "CANCER", 72, 81], ["A total of 363 cases", "TEST", 0, 20], ["positive RT-PCR", "PROBLEM", 33, 48], ["this study", "TEST", 99, 109]]], ["These include 127 healthy cats (83 admitted for routine health check and 44 FIPcohabitated cats) together with 236 clinically FIP-suspected cats that showed either a clinical history of anorexia, weight loss, lethargy, icterus, mild antibioticunresponsive fever, abdominal distension and/or thoracic effusion with a low albumin to globulin ratio.", [["abdominal", "ANATOMY", 263, 272], ["thoracic", "ANATOMY", 291, 299], ["FIP", "DISEASE", 126, 129], ["anorexia", "DISEASE", 186, 194], ["weight loss", "DISEASE", 196, 207], ["lethargy", "DISEASE", 209, 217], ["icterus", "DISEASE", 219, 226], ["fever", "DISEASE", 256, 261], ["abdominal distension", "DISEASE", 263, 283], ["thoracic effusion", "DISEASE", 291, 308], ["cats", "ORGANISM", 26, 30], ["cats", "ORGANISM", 91, 95], ["cats", "ORGANISM", 140, 144], ["abdominal", "ORGANISM_SUBDIVISION", 263, 272], ["albumin", "GENE_OR_GENE_PRODUCT", 320, 327], ["globulin", "GENE_OR_GENE_PRODUCT", 331, 339], ["cats", "SPECIES", 26, 30], ["cats", "SPECIES", 91, 95], ["cats", "SPECIES", 140, 144], ["routine health check", "TEST", 48, 68], ["anorexia", "PROBLEM", 186, 194], ["weight loss", "PROBLEM", 196, 207], ["lethargy", "PROBLEM", 209, 217], ["icterus", "PROBLEM", 219, 226], ["mild antibioticunresponsive fever", "PROBLEM", 228, 261], ["abdominal distension", "PROBLEM", 263, 283], ["thoracic effusion", "PROBLEM", 291, 308], ["a low albumin to globulin ratio", "PROBLEM", 314, 345], ["anorexia", "OBSERVATION", 186, 194], ["icterus", "OBSERVATION", 219, 226], ["mild", "OBSERVATION_MODIFIER", 228, 232], ["antibioticunresponsive", "OBSERVATION_MODIFIER", 233, 255], ["fever", "OBSERVATION", 256, 261], ["abdominal", "ANATOMY", 263, 272], ["distension", "OBSERVATION", 273, 283], ["thoracic", "ANATOMY", 291, 299], ["effusion", "OBSERVATION", 300, 308]]], ["The specimens that tested positively were subsequently subjected to FCoV typing.Sample preparation and reverse transcriptionRectal swab samples were suspended in 1 ml of 0.1% DEPC-treated water.", [["specimens", "ANATOMY", 4, 13], ["swab samples", "ANATOMY", 131, 143], ["DEPC", "CHEMICAL", 175, 179], ["DEPC", "CHEMICAL", 175, 179], ["specimens", "CANCER", 4, 13], ["DEPC", "SIMPLE_CHEMICAL", 175, 179], ["The specimens", "TEST", 0, 13], ["FCoV typing", "TEST", 68, 79], ["Sample preparation", "TREATMENT", 80, 98], ["reverse transcriptionRectal swab samples", "TEST", 103, 143]]], ["Total RNA was extracted from 300 ml of whole blood, body effusion, or rectal swab suspension using Trizol (Chomczynski and Sacchi, 1987) .", [["whole blood", "ANATOMY", 39, 50], ["body", "ANATOMY", 52, 56], ["rectal swab", "ANATOMY", 70, 81], ["effusion", "DISEASE", 57, 65], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["rectal swab", "ORGANISM_SUBSTANCE", 70, 81], ["Total RNA", "PROBLEM", 0, 9], ["whole blood, body effusion", "PROBLEM", 39, 65], ["rectal swab suspension", "TREATMENT", 70, 92], ["Trizol", "TREATMENT", 99, 105], ["body", "ANATOMY", 52, 56], ["effusion", "OBSERVATION", 57, 65], ["rectal", "ANATOMY", 70, 76]]], ["Eleven microlitre of isolated RNA were added to the premix, consisting of 4 ml of 5\u00c2 RT buffer, 1 ml of 2.5 mM dNTPs (GeneTeks Bioscience, Inc., Taipei), 1 ml of 50 mM oligo dT, 2 ml of 0.1 M dithiothreitol, and 1 ml containing 200 U Moloney murine leukemia virus reverse transcriptase (Invitrogen, CA, USA) in a 0.6 ml reaction tube.", [["dNTPs", "CHEMICAL", 111, 116], ["oligo dT", "CHEMICAL", 168, 176], ["dithiothreitol", "CHEMICAL", 192, 206], ["dNTPs", "CHEMICAL", 111, 116], ["dithiothreitol", "CHEMICAL", 192, 206], ["dithiothreitol", "SIMPLE_CHEMICAL", 192, 206], ["Moloney murine leukemia virus", "ORGANISM", 234, 263], ["reverse transcriptase", "PROTEIN", 264, 285], ["murine", "SPECIES", 242, 248], ["isolated RNA", "TREATMENT", 21, 33], ["the premix", "TREATMENT", 48, 58], ["5\u00c2 RT buffer", "TREATMENT", 82, 94], ["2.5 mM dNTPs", "TREATMENT", 104, 116], ["50 mM oligo dT", "TREATMENT", 162, 176], ["0.1 M dithiothreitol", "TREATMENT", 186, 206], ["U Moloney murine leukemia virus", "TREATMENT", 232, 263], ["a 0.6 ml reaction tube", "TREATMENT", 311, 333], ["isolated RNA", "OBSERVATION", 21, 33]]], ["This reac-tion mixture was incubated at 37 8C for 60 min, then at 72 8C for 15 min, and finally at 94 8C for 5 min.Multiplex-nested PCR amplification of the S geneFor typing of FCoV, multiplex-nested PCR was performed according to the procedures outlined in Addie et al. (2003) with slight modifications.", [["S gene", "DNA", 157, 163], ["FCoV", "DNA", 177, 181], ["FCoV", "SPECIES", 177, 181], ["This reac-tion mixture", "TREATMENT", 0, 22], ["Multiplex-nested PCR amplification", "TREATMENT", 115, 149], ["FCoV", "PROBLEM", 177, 181], ["multiplex-nested PCR", "TEST", 183, 203], ["slight modifications", "TREATMENT", 283, 303]]], ["Following reverse transcription, 2 ml of the product was added to 28 ml of the PCR mixture.", [["the product", "TREATMENT", 41, 52], ["the PCR mixture", "TREATMENT", 75, 90]]], ["The PCR mixture consisted of 3 ml of 10\u00c2 Taq buffer, 0.5 ml of each primer (10 mM) (S1: 5 Multiplex-nested PCR was performed on 2 ml of the first PCR product using nested primers (Addie et al., 2003) .", [["The PCR mixture", "TREATMENT", 0, 15], ["10\u00c2 Taq buffer", "TREATMENT", 37, 51], ["Multiplex-nested PCR", "TREATMENT", 90, 110], ["the first PCR product", "TREATMENT", 136, 157], ["nested primers", "TREATMENT", 164, 178]]], ["The temperature cycling protocol consisted of 3 min of preheating at 94 8C, 35 cycles of denaturation at 94 8C for 30 s, annealing at 47 8C for 30 s, and extension at 72 8C for 30 s, with a final extension at 72 8C for 5 min.", [["The temperature cycling protocol", "TEST", 0, 32], ["denaturation", "TEST", 89, 101], ["extension", "TEST", 154, 163]]], ["The expected size of the product from the first PCR was 702 bp.", [["the first PCR", "TEST", 38, 51], ["bp", "TEST", 60, 62], ["size", "OBSERVATION_MODIFIER", 13, 17]]], ["The second PCR yielded the expected products for type I and II FCoV: 360 and 218 bp, respectively.Sequencing and analysis of PCR-amplified productsA 10 ml aliquot of each PCR product was analyzed by electrophoresis through a 1.5% agarose gel (Viogene, Taipei).", [["type I and II FCoV", "GENE_OR_GENE_PRODUCT", 49, 67], ["agarose", "SIMPLE_CHEMICAL", 230, 237], ["The second PCR", "TEST", 0, 14], ["bp", "TEST", 81, 83], ["Sequencing", "TEST", 98, 108], ["analysis", "TEST", 113, 121], ["PCR", "TEST", 125, 128], ["amplified productsA", "TREATMENT", 129, 148], ["each PCR product", "TREATMENT", 166, 182], ["a 1.5% agarose gel", "TREATMENT", 223, 241]]], ["Amplification products were visualized using UV illumination after ethidium bromide staining.", [["ethidium bromide", "CHEMICAL", 67, 83], ["ethidium bromide", "CHEMICAL", 67, 83], ["ethidium bromide", "SIMPLE_CHEMICAL", 67, 83], ["Amplification products", "TREATMENT", 0, 22], ["UV illumination", "TREATMENT", 45, 60], ["ethidium bromide staining", "TREATMENT", 67, 92]]], ["The targeted DNA fragments were purified (Geneaid Biotech, Ltd., Taipei), and the nucleic acid sequences were determined from both orientations, sense and antisense, using an automated DNA sequencer (ABI 3730XL, USA).", [["fragments", "ANATOMY", 17, 26], ["nucleic acid", "CHEMICAL", 82, 94], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["targeted DNA fragments", "DNA", 4, 26], ["The targeted DNA fragments", "PROBLEM", 0, 26], ["the nucleic acid sequences", "TEST", 78, 104], ["an automated DNA sequencer", "TEST", 172, 198], ["ABI", "TEST", 200, 203], ["DNA fragments", "OBSERVATION", 13, 26]]], ["The cDNA sequences of a region of the S gene were then compared with those of reference FCoVs, CCoV, and wild animal CoVs.", [["FCoVs", "GENE_OR_GENE_PRODUCT", 88, 93], ["CCoV", "GENE_OR_GENE_PRODUCT", 95, 99], ["CoVs", "GENE_OR_GENE_PRODUCT", 117, 121], ["cDNA sequences", "DNA", 4, 18], ["S gene", "DNA", 38, 44], ["CCoV", "SPECIES", 95, 99], ["The cDNA sequences", "TEST", 0, 18], ["animal CoVs", "OBSERVATION", 110, 121]]], ["Multiple alignments of nucleic acid sequences were performed by the Clustal W method using the MegAlign program (DNASTAR Inc., WI, USA).Statistical analysisAll cases were divided into three groups, namely FIP, ill, and healthy, according to the laboratory findings.", [["nucleic acid", "CHEMICAL", 23, 35], ["FIP", "DISEASE", 205, 208], ["nucleic acid sequences", "TEST", 23, 45], ["the MegAlign program", "TREATMENT", 91, 111], ["Statistical analysis", "TEST", 136, 156], ["FIP", "OBSERVATION", 205, 208]]], ["A definitive diagnosis of FIP was made by a postmortem histopathological examination with typical pyogranulomatous lesions (Hartmann et al., 2003) .", [["pyogranulomatous lesions", "ANATOMY", 98, 122], ["FIP", "DISEASE", 26, 29], ["FIP", "CANCER", 26, 29], ["pyogranulomatous lesions", "CANCER", 98, 122], ["FIP", "PROBLEM", 26, 29], ["a postmortem histopathological examination", "TEST", 42, 84], ["typical pyogranulomatous lesions", "PROBLEM", 90, 122], ["FIP", "OBSERVATION", 26, 29], ["pyogranulomatous", "OBSERVATION_MODIFIER", 98, 114], ["lesions", "OBSERVATION", 115, 122]]], ["The grouping criteria for ill were made for cases lacking the final histopathological confirmation irrespective of how strong their clinical and/or laboratory evidences of FIP may be.", [["FIP", "DISEASE", 172, 175], ["FIP", "ORGANISM", 172, 175], ["FIP", "PROBLEM", 172, 175], ["FIP", "OBSERVATION", 172, 175]]], ["Healthy cats refer to those that were first presented to our hospital either for a routine health check or cohabitated with a FIP-diagnosed cat, and have never been readmitted for FIP during the past years.", [["FIP", "DISEASE", 126, 129], ["FIP", "DISEASE", 180, 183], ["cats", "ORGANISM", 8, 12], ["cat", "ORGANISM", 140, 143], ["cats", "SPECIES", 8, 12], ["FIP", "PROBLEM", 180, 183]]], ["Correlation of virus genotypes with FIP disease was made by analyzing cases from FIP and healthy groups but not ill ones.", [["FIP disease", "DISEASE", 36, 47], ["virus genotypes", "PROBLEM", 15, 30], ["FIP disease", "PROBLEM", 36, 47]]], ["The statistical evaluation was carried out with the chi-square test with Yate's correction.", [["The statistical evaluation", "TEST", 0, 26], ["the chi-square test", "TEST", 48, 67], ["Yate's correction", "TREATMENT", 73, 90]]], ["The difference in values was considered statistically significant and highly significant if the associated p value was <0.05 and <0.01, respectively.Prevalence of FCoV typesOf the 363 cases, 197 (54.3%) tested positively for type I, 13 (3.6%) for type II, and 12 (3.3%) for both types; however, there were 141 cases (38.8%) for which differentiation was not possible by our RT-nPCR (Table 1) .", [["type I", "SPECIES", 225, 231], ["p value", "TEST", 107, 114], ["FCoV typesOf", "TEST", 163, 175], ["type I", "TEST", 225, 231], ["type II", "TEST", 247, 254], ["FCoV", "OBSERVATION", 163, 167]]], ["Among the 222 differentiable cases, type I appeared to be the main type (88.7%, 197/222), type II accounted for 5.9% (13/222), and cats infected with both types of virus made up the rest 5.4% (12/222).", [["cats infected", "DISEASE", 131, 144], ["cats", "ORGANISM", 131, 135], ["cats", "SPECIES", 131, 135], ["type II", "PROBLEM", 90, 97], ["cats infected", "PROBLEM", 131, 144], ["virus", "PROBLEM", 164, 169], ["main", "OBSERVATION_MODIFIER", 62, 66], ["virus", "OBSERVATION", 164, 169]]], ["Only the differentiable cases were subjected to further analysis.Correlation of FCoV type with FIP diseaseAccording to the grouping criteria given above, 110 FIPsuspected cats of which necropsy were unavailable after death were excluded from our analysis and were put into ill group (Table 1) .", [["FIP diseaseAccording", "DISEASE", 95, 115], ["death", "DISEASE", 217, 222], ["cats", "ORGANISM", 171, 175], ["further analysis", "TEST", 48, 64], ["FIP diseaseAccording", "PROBLEM", 95, 115], ["the grouping criteria", "TEST", 119, 140], ["our analysis", "TEST", 242, 254], ["FCoV type", "OBSERVATION_MODIFIER", 80, 89]]], ["Among the 74 FCoV strains from healthy cats, 71 (95.9%) were type I and 3 (4.1%) were type II.", [["cats", "ORGANISM", 39, 43], ["cats", "SPECIES", 39, 43], ["healthy cats", "TEST", 31, 43]]], ["For the 38 cats with definite diagnosis of FIP, 28 (73.7%) were type I, 4 (10.5%) were type II, and 6 (15.8%) had both types of FCoVs (Table 1) .", [["FIP", "DISEASE", 43, 46], ["FCoVs", "DISEASE", 128, 133], ["cats", "ORGANISM", 11, 15], ["cats", "SPECIES", 11, 15], ["FIP", "TEST", 43, 46], ["FIP", "OBSERVATION", 43, 46]]], ["Surprisingly, among the 13 cats infected with type II viruses, 10 (76.9%) were associated with FIP whereas only 32.4% (34/105) of type I FCoV-infected cats succumbed to FIP.", [["type II viruses", "DISEASE", 46, 61], ["FIP", "DISEASE", 95, 98], ["FIP", "DISEASE", 169, 172], ["cats", "ORGANISM", 27, 31], ["type II viruses", "ORGANISM", 46, 61], ["type I FCoV", "ORGANISM", 130, 141], ["cats", "ORGANISM", 151, 155], ["cats", "SPECIES", 27, 31], ["cats", "SPECIES", 151, 155], ["type II viruses", "SPECIES", 46, 61], ["type II viruses", "PROBLEM", 46, 61], ["FIP", "TEST", 95, 98], ["type I FCoV", "PROBLEM", 130, 141], ["type II", "OBSERVATION_MODIFIER", 46, 53], ["viruses", "OBSERVATION", 54, 61], ["FIP", "OBSERVATION", 169, 172]]], ["Using a chi-square test the correlation of FCoV type with FIP disease was calculated.", [["FIP disease", "DISEASE", 58, 69], ["a chi-square test", "TEST", 6, 23], ["FIP disease", "PROBLEM", 58, 69], ["FIP disease", "OBSERVATION", 58, 69]]], ["Among the 118 FCoV strains (105 type I and 13 type II) analyzed, type II virus appeared to be highly significantly correlated with the disease (p = 0.0046) ( Table 2) .Genetic comparison and phylogenetic analysis of the local type I and II FCoVsFCoV originated from 10 different households were chosen to further understand the evolutionary track of our local type I and II FCoVs (Table 3) , a region of the S gene from local strains that were circulating yearly from 2003 to 2007 were sequenced and compared with that of reference FCoV, CCoV and wild animal CoV strains.", [["type II virus", "ORGANISM", 65, 78], ["II FCoVs (Table 3", "GENE_OR_GENE_PRODUCT", 371, 388], ["FCoV", "GENE_OR_GENE_PRODUCT", 532, 536], ["animal CoV strains", "ORGANISM", 552, 570], ["local type I and II FCoVsFCoV", "DNA", 220, 249], ["local type I and II FCoVs", "DNA", 354, 379], ["S gene", "DNA", 408, 414], ["type II virus", "SPECIES", 65, 78], ["FCoV", "SPECIES", 532, 536], ["CCoV", "SPECIES", 538, 542], ["FCoV strains", "TEST", 14, 26], ["type I", "TEST", 32, 38], ["type II virus", "PROBLEM", 65, 78], ["the disease", "PROBLEM", 131, 142], ["Genetic comparison", "TEST", 168, 186], ["phylogenetic analysis", "TEST", 191, 212], ["local strains", "PROBLEM", 420, 433], ["wild animal CoV strains", "PROBLEM", 547, 570]]], ["In comparison to the low nucleotide sequence similarity between type I and II FCoV (56.2-63.6%), homology within all analyzed type I viruses (83.3-95.2%) and within all type II viruses (91.7-99.4%) appeared to be much higher ( Figs.", [["nucleotide", "CHEMICAL", 25, 35], ["nucleotide", "CHEMICAL", 25, 35], ["type I viruses", "SPECIES", 126, 140], ["type II viruses", "SPECIES", 169, 184], ["II FCoV", "TEST", 75, 82], ["type I viruses", "PROBLEM", 126, 140], ["higher", "OBSERVATION_MODIFIER", 218, 224]]], ["The nucleotide divergence between local FCoVs was between 6.2% and 11.7% for five type I viruses (Table 4 ) and between 0.6% and 3.1% for five type II viruses (Table 5 ).", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["FCoVs", "PATHOLOGICAL_FORMATION", 40, 45], ["type I viruses", "SPECIES", 82, 96], ["type II viruses", "SPECIES", 143, 158], ["local FCoVs", "TEST", 34, 45], ["divergence", "OBSERVATION_MODIFIER", 15, 25]]], ["These findings revealed that, within the time frame of this study, type I FCoVs displayed more genetic diversity than type II viruses.", [["type I FCoVs", "GENE_OR_GENE_PRODUCT", 67, 79], ["type II viruses", "ORGANISM", 118, 133], ["type I FCoVs", "PROTEIN", 67, 79], ["type II viruses", "SPECIES", 118, 133], ["this study", "TEST", 55, 65], ["type I FCoVs", "PROBLEM", 67, 79], ["type II viruses", "PROBLEM", 118, 133]]], ["The phylogenetic trees constructed using the partial S gene sequences are shown in Fig. 3 .", [["partial S gene sequences", "DNA", 45, 69], ["the partial S gene sequences", "TREATMENT", 41, 69], ["phylogenetic trees", "OBSERVATION", 4, 22]]], ["Apart from one local type I virus (NTU2R) and local CCoVs (NTU2 and 9) that originated from the same lineage, other type I viruses displayed divergence.", [["type I virus", "ORGANISM", 21, 33], ["NTU2R", "GENE_OR_GENE_PRODUCT", 35, 40], ["CCoVs", "GENE_OR_GENE_PRODUCT", 52, 57], ["type I virus", "SPECIES", 21, 33], ["one local type I virus (NTU2R)", "PROBLEM", 11, 41], ["local CCoVs (NTU2", "TREATMENT", 46, 63], ["one", "OBSERVATION_MODIFIER", 11, 14], ["local", "OBSERVATION_MODIFIER", 15, 20], ["type I", "OBSERVATION_MODIFIER", 21, 27], ["virus", "OBSERVATION", 28, 33], ["local", "OBSERVATION_MODIFIER", 46, 51], ["CCoVs", "OBSERVATION_MODIFIER", 52, 57], ["viruses", "OBSERVATION", 123, 130]]], ["Surprisingly, four of our local type II viruses (NTU30A, 39A, 46Ce and 205C) and a Japanese FCoV (F21-1) clustered with two wild animal CoVs from China (raccoon dog CoV/GZ43/03 and Chinese ferret badger CoV/DM95/03), and they were distinct from the reference type II FCoVs strains 79-1146 and 79-1683.DiscussionThe prevalence of type I and II FCoVs has been surveyed in many countries using serological and molecular assays (Addie et al., 2003; Benetka et al., 2004; Hohdatsu et al., 1992; Kummrow et al., 2005; Shiba et al., 2007; Vennema, 1999) .", [["type II viruses", "ORGANISM", 32, 47], ["F21-1", "GENE_OR_GENE_PRODUCT", 98, 103], ["raccoon dog CoV", "ORGANISM", 153, 168], ["ferret badger CoV", "ORGANISM", 189, 206], ["dog", "SPECIES", 161, 164], ["ferret", "SPECIES", 189, 195], ["type II viruses", "SPECIES", 32, 47], ["Japanese FCoV (F21-1", "SPECIES", 83, 103], ["raccoon dog CoV/GZ43/03", "SPECIES", 153, 176], ["Chinese ferret badger CoV/DM95/03", "SPECIES", 181, 214], ["a Japanese FCoV", "TEST", 81, 96], ["GZ43/03", "TREATMENT", 169, 176], ["type II", "OBSERVATION_MODIFIER", 32, 39], ["viruses", "OBSERVATION", 40, 47], ["animal CoVs", "OBSERVATION", 129, 140]]], ["In concordance with others findings, our results indicate that the majority of FCoV infection in Taiwan is due to type I viruses (88.7%).", [["FCoV infection", "DISEASE", 79, 93], ["type I viruses", "DISEASE", 114, 128], ["FCoV", "CANCER", 79, 83], ["FCoV", "SPECIES", 79, 83], ["type I viruses", "SPECIES", 114, 128], ["FCoV infection", "PROBLEM", 79, 93], ["type I viruses", "PROBLEM", 114, 128], ["FCoV", "OBSERVATION_MODIFIER", 79, 83], ["infection", "OBSERVATION", 84, 93]]], ["Our sequence analyses revealed that the type I virus is more genetically diverse than type II virus, a phenomenon that might be due to the large type I-infected population around the world and the possibility of a lengthy persistence of the virus in the asymptomatic cats (Addie et al., 2003; Herrewegh et al., 1997) .", [["type I virus", "ORGANISM", 40, 52], ["type II virus", "ORGANISM", 86, 99], ["cats", "ORGANISM", 267, 271], ["cats", "SPECIES", 267, 271], ["type I virus", "SPECIES", 40, 52], ["type II virus", "SPECIES", 86, 99], ["Our sequence analyses", "TEST", 0, 21], ["the type I virus", "PROBLEM", 36, 52], ["type II virus", "PROBLEM", 86, 99], ["a phenomenon", "PROBLEM", 101, 113], ["the large type I-infected population", "PROBLEM", 135, 171], ["the virus", "PROBLEM", 237, 246], ["more genetically", "OBSERVATION_MODIFIER", 56, 72], ["diverse", "OBSERVATION_MODIFIER", 73, 80], ["large", "OBSERVATION_MODIFIER", 139, 144], ["-infected", "OBSERVATION_MODIFIER", 151, 160], ["population", "OBSERVATION", 161, 171], ["virus", "OBSERVATION", 241, 246]]], ["Cats that are co-infected with both type I and II viruses were detected at a rather high frequency in this study (15.8%, 6 among a total of 38 FIP cases) (Table 1) .", [["FIP", "DISEASE", 143, 146], ["Cats", "ORGANISM", 0, 4], ["type I", "SPECIES", 36, 42], ["co-infected", "PROBLEM", 14, 25], ["both type I and II viruses", "PROBLEM", 31, 57], ["this study", "TEST", 102, 112], ["co-infected", "OBSERVATION", 14, 25]]], ["Similar findings (6.8%, 5/74) were reported in a study that employed RT-PCR to type FCoV using organ pools from cats with FIP in Austria (Benetka et al., 2004) .", [["organ", "ANATOMY", 95, 100], ["FIP", "DISEASE", 122, 125], ["organ", "ORGAN", 95, 100], ["cats", "ORGANISM", 112, 116], ["cats", "SPECIES", 112, 116], ["FCoV", "SPECIES", 84, 88], ["a study", "TEST", 47, 54], ["6.8%", "OBSERVATION_MODIFIER", 18, 22]]], ["Did both types of viruses participate equally in the pathogenesis of FIP in these co-infected cats?", [["FIP", "DISEASE", 69, 72], ["FIP", "ORGANISM", 69, 72], ["cats", "ORGANISM", 94, 98], ["cats", "SPECIES", 94, 98], ["viruses", "OBSERVATION", 18, 25], ["FIP", "OBSERVATION", 69, 72]]], ["The question is currently under investigation.DiscussionA study conducted in Swiss cats using an IFA assay reported that infection with type I FCoV was more frequently associated with clinical signs and/or FIP (Kummrow et al., 2005) .", [["infection", "DISEASE", 121, 130], ["FIP", "DISEASE", 206, 209], ["cats", "ORGANISM", 83, 87], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 136, 147], ["cats", "SPECIES", 83, 87], ["type I FCoV", "SPECIES", 136, 147], ["DiscussionA study", "TEST", 46, 63], ["an IFA assay", "TEST", 94, 106], ["infection", "PROBLEM", 121, 130], ["type I FCoV", "PROBLEM", 136, 147], ["clinical signs", "TEST", 184, 198], ["FIP", "PROBLEM", 206, 209], ["infection", "OBSERVATION", 121, 130]]], ["In contrast, using a different assay (RT-PCR), our results revealed that it is type II virus that significantly correlated with FIP (p = 0.0046).", [["FIP", "DISEASE", 128, 131], ["a different assay (RT-PCR", "TEST", 19, 44], ["type II virus", "PROBLEM", 79, 92], ["FIP", "TEST", 128, 131]]], ["A previous seroprevalence study conducted by Hohdatsu et al. (1992) in Japan also concluded that FIP due to type II FCoV might be higher than type I viruses.", [["FIP", "DISEASE", 97, 100], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 108, 120], ["type I viruses", "SPECIES", 142, 156], ["A previous seroprevalence study", "TEST", 0, 31], ["FIP", "PROBLEM", 97, 100], ["type II FCoV", "PROBLEM", 108, 120], ["type I viruses", "PROBLEM", 142, 156], ["FIP", "OBSERVATION", 97, 100], ["FCoV", "OBSERVATION", 116, 120]]], ["In our study, type II FCoV was detected on the rectal swabs from three healthy cats using RT-PCR.", [["rectal swabs", "ANATOMY", 47, 59], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 14, 26], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 47, 59], ["cats", "ORGANISM", 79, 83], ["type II FCoV", "PROTEIN", 14, 26], ["cats", "SPECIES", 79, 83], ["our study", "TEST", 3, 12], ["type II FCoV", "PROBLEM", 14, 26], ["the rectal swabs", "TEST", 43, 59], ["RT-PCR", "TREATMENT", 90, 96], ["FCoV", "OBSERVATION", 22, 26], ["rectal", "ANATOMY", 47, 53]]], ["Follow-ups were possible for two of these three cats.", [["cats", "ORGANISM", 48, 52], ["cats", "SPECIES", 48, 52]]], ["None of the rectal swabs collected during the past 3 years for these two cats were positive for FCoV (data not shown).", [["rectal swabs", "ANATOMY", 12, 24], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 12, 24], ["cats", "ORGANISM", 73, 77], ["FCoV", "PROTEIN", 96, 100], ["FCoV", "SPECIES", 96, 100], ["the rectal swabs", "TEST", 8, 24], ["these two cats", "TEST", 63, 77], ["FCoV (data", "TEST", 96, 106], ["rectal", "ANATOMY", 12, 18], ["swabs", "OBSERVATION", 19, 24]]], ["Similar finding was observed from one specific pathogen-free cat experimentally infected with a type II virus (strain Wellcome) (Stoddart et al., 1988) .", [["cat", "ORGANISM", 61, 64], ["type II virus", "ORGANISM", 96, 109], ["type II virus", "SPECIES", 96, 109], ["a type II virus", "PROBLEM", 94, 109]]], ["Unlike other seven cats that died from the infection, this cat did not develop clinical signs of FIP and the viral shedding ceased at day 14 post-infection.", [["infection", "DISEASE", 43, 52], ["FIP", "DISEASE", 97, 100], ["infection", "DISEASE", 146, 155], ["cats", "ORGANISM", 19, 23], ["cat", "ORGANISM", 59, 62], ["cats", "SPECIES", 19, 23], ["the infection", "PROBLEM", 39, 52], ["FIP", "PROBLEM", 97, 100], ["the viral shedding", "PROBLEM", 105, 123], ["infection", "PROBLEM", 146, 155], ["infection", "OBSERVATION", 43, 52], ["FIP", "OBSERVATION", 97, 100], ["infection", "OBSERVATION", 146, 155]]], ["Taken together with the observations from the aforementioned studies, infection with type II FCoV seems to follow a different course than infection with type I virus.", [["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 138, 147], ["type I virus", "DISEASE", 153, 165], ["type II FCoV", "ORGANISM", 85, 97], ["type I virus", "ORGANISM", 153, 165], ["type II FCoV", "SPECIES", 85, 97], ["type I virus", "SPECIES", 153, 165], ["the aforementioned studies", "TEST", 42, 68], ["infection", "PROBLEM", 70, 79], ["type II FCoV", "PROBLEM", 85, 97], ["infection", "PROBLEM", 138, 147], ["type I virus", "PROBLEM", 153, 165], ["infection", "OBSERVATION", 70, 79]]], ["Type I virus was demonstrated to be able to persist in cats living in multi-cat households for more than 6 years (Addie et al., 2003) and for at least 7 months in a single experimentally infected cat (Herrewegh et al., 1997) .", [["Type I virus", "ORGANISM", 0, 12], ["cats", "ORGANISM", 55, 59], ["cat", "ORGANISM", 76, 79], ["cat", "ORGANISM", 196, 199], ["cats", "SPECIES", 55, 59], ["cat", "SPECIES", 196, 199], ["Type I virus", "SPECIES", 0, 12], ["Type I virus", "PROBLEM", 0, 12], ["virus", "OBSERVATION", 7, 12]]], ["To our knowledge none of the similar finding has been reported in the naturally occurring type II FCoV infection.", [["infection", "DISEASE", 103, 112], ["type II FCoV", "CANCER", 90, 102], ["type II FCoV infection", "PROBLEM", 90, 112], ["FCoV", "OBSERVATION_MODIFIER", 98, 102], ["infection", "OBSERVATION", 103, 112]]], ["Type II virus is more likely to cause acute infections that result in either FIP or recovery without persistence.", [["infections", "DISEASE", 44, 54], ["FIP", "DISEASE", 77, 80], ["Type II virus", "ORGANISM", 0, 13], ["Type II virus", "SPECIES", 0, 13], ["Type II virus", "PROBLEM", 0, 13], ["acute infections", "PROBLEM", 38, 54], ["FIP", "PROBLEM", 77, 80], ["virus", "OBSERVATION", 8, 13], ["more likely to cause", "UNCERTAINTY", 17, 37], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["infections", "OBSERVATION", 44, 54], ["FIP", "OBSERVATION", 77, 80]]], ["This distinction might explain why, in the epidemiological studies from various countries, the prevalence of type II virus is consistently lower than that of type I virus (Addie et al., 2003; Benetka et al., 2004; Hohdatsu et al., 1992; Kummrow et al., 2005; Shiba et al., 2007; Vennema, 1999) .DiscussionA recent study indicated that FCoV (FCoV 79-1146 strain) and TGEV (Purdue strain) were most closely related to the wild animal CoV .", [["FCoV", "CHEMICAL", 335, 339], ["FCoV 79-1146", "CHEMICAL", 341, 353], ["type II virus", "ORGANISM", 109, 122], ["type I virus", "ORGANISM", 158, 170], ["FCoV", "GENE_OR_GENE_PRODUCT", 335, 339], ["FCoV 79-1146 strain", "ORGANISM", 341, 360], ["TGEV", "ORGANISM", 366, 370], ["Purdue strain", "ORGANISM", 372, 385], ["CoV", "ORGANISM", 432, 435], ["TGEV", "SPECIES", 366, 370], ["type II virus", "SPECIES", 109, 122], ["type I virus", "SPECIES", 158, 170], ["TGEV", "SPECIES", 366, 370], ["the epidemiological studies", "TEST", 39, 66], ["type II virus", "PROBLEM", 109, 122], ["recent study", "TEST", 307, 319], ["FCoV", "PROBLEM", 335, 339], ["FCoV", "TEST", 341, 345], ["TGEV (Purdue strain", "PROBLEM", 366, 385], ["might explain", "UNCERTAINTY", 17, 30]]], ["Since type II FCoV originated from a double recombination between type I FCoV and type II CCoV (Herrewegh et al., 1998; Pratelli et al., 2003) , it was believed that the S gene of type II FCoV would be more closely related to type II CCoV.", [["type II FCoV", "GENE_OR_GENE_PRODUCT", 6, 18], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 66, 77], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 82, 94], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 180, 192], ["type II FCoV", "PROTEIN", 6, 18], ["S gene", "DNA", 170, 176], ["type II FCoV", "DNA", 180, 192], ["type II CCoV", "PROTEIN", 226, 238], ["type II CCoV", "SPECIES", 226, 238], ["type II FCoV", "PROBLEM", 6, 18], ["a double recombination", "TREATMENT", 35, 57], ["type II FCoV", "PROBLEM", 180, 192], ["type II CCoV", "PROBLEM", 226, 238], ["FCoV", "OBSERVATION", 14, 18]]], ["When the wild animal CoV, type II CCoV, and type II FCoV were aligned (Fig. 2) , however, type II FCoVs had higher similarity to a raccoon dog virus strain CoV/GZ43/03 and a Chinese ferret badger CoV strain CoV/DM95/03 (97.6-99.4%) than to either reference type II FCoV (93.5-97.6%) or type II CCoV (95.2-98.8%).", [["animal CoV", "ORGANISM", 14, 24], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 26, 38], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 44, 56], ["raccoon", "ORGANISM", 131, 138], ["dog virus", "ORGANISM", 139, 148], ["CoV", "ORGANISM", 156, 159], ["GZ43/03", "ORGANISM", 160, 167], ["ferret", "ORGANISM", 182, 188], ["badger CoV", "ORGANISM", 189, 199], ["CoV", "ORGANISM", 207, 210], ["type II CCoV", "PROTEIN", 26, 38], ["type II FCoV", "PROTEIN", 44, 56], ["raccoon dog virus", "SPECIES", 131, 148], ["ferret badger CoV", "SPECIES", 182, 199], ["type II CCoV", "SPECIES", 26, 38], ["type II FCoV", "SPECIES", 44, 56], ["raccoon dog virus", "SPECIES", 131, 148], ["CoV/GZ43/03", "SPECIES", 156, 167], ["Chinese ferret badger CoV", "SPECIES", 174, 199], ["CoV/DM95/03", "SPECIES", 207, 218], ["type II CCoV", "SPECIES", 286, 298], ["type II CCoV", "PROBLEM", 26, 38], ["type II FCoV", "PROBLEM", 44, 56], ["type II FCoVs", "PROBLEM", 90, 103], ["a raccoon dog virus strain CoV", "PROBLEM", 129, 159], ["DM95/03", "TEST", 211, 218], ["FCoV", "TEST", 265, 269], ["type II CCoV", "TEST", 286, 298], ["CoV", "OBSERVATION_MODIFIER", 21, 24]]], ["This finding indicates that, in addition to CCoV, there are viruses from other families of animals (e.g., Mustelidae) that share a common evolutionary origin in the S gene with type II FCoVs.", [["CCoV", "GENE_OR_GENE_PRODUCT", 44, 48], ["Mustelidae", "GENE_OR_GENE_PRODUCT", 106, 116], ["type II FCoVs", "GENE_OR_GENE_PRODUCT", 177, 190], ["S gene", "DNA", 165, 171], ["type II FCoVs", "DNA", 177, 190], ["viruses", "PROBLEM", 60, 67], ["viruses", "OBSERVATION", 60, 67]]]], "3cb410fa0a1e4a839e940971b599274b3efa8f5d": [["PALABRAS CLAVEVentilaci\u00f3n mec\u00e1nica no invasiva; Terapia nasal de alto flujo; Procedimientos generadores de aerosoles; Control de infecci\u00f3n.PALABRAS CLAVEResumen: La enfermedad por coronavirus 2019 (COVID-19) es una infecci\u00f3n del tracto respiratorio causada por un nuevo coronavirus emergente que se reconoci\u00f3 por primera vez en Wuhan, China, en diciembre de 2019.", [["invasiva", "TREATMENT", 38, 46], ["Terapia nasal de alto flujo", "TREATMENT", 48, 75], ["Procedimientos generadores de aerosoles", "TREATMENT", 77, 116], ["coronavirus", "PROBLEM", 180, 191], ["COVID", "TEST", 198, 203]]], ["Mientras que la mayor\u00eda de las personas con COVID-19 desarrollan solo una enfermedad leve o no complicada, aproximadamente el 14% desarrollan una enfermedad grave que requiere hospitalizaci\u00f3n y ox\u00edgeno, y el 5% pueden requerir ingreso en una Unidad de Cuidados Intensivos.", [["Mientras", "TEST", 0, 8], ["COVID", "TEST", 44, 49], ["complicada", "PROBLEM", 95, 105]]], ["En casos severos, COVID-19 puede complicarse por el s\u00edndrome de dificultad respiratoria aguda (SDRA), sepsis y shock s\u00e9ptico y fracaso multiorg\u00e1nico.", [["sepsis", "DISEASE", 102, 108], ["sepsis y shock", "PROBLEM", 102, 116]]], ["Este documento de consenso se ha preparado sobre directrices basadas en evidencia desarrolladas por un panel multidisciplinario de profesionales m\u00e9dicos de cuatro sociedades cient\u00edficas espa\u00f1olas (Sociedad Espa\u00f1ola de Medicina Intensiva y Unidades Coronarias [SEMICYUC], Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica [SEPAR], Sociedad Espa\u00f1ola de Urgencias y Emergencias [SEMES], Sociedad Espa\u00f1ola de Anestesiolog\u00eda, Reanimaci\u00f3n y Terap\u00e9utica del Dolor [SEDAR]) con experiencia en el manejo cl\u00ednico de pacientes con COVID-19 y otras infecciones virales, incluido el SARS, as\u00ed como en sepsis y SDRA.", [["SARS", "DISEASE", 571, 575], ["sepsis", "DISEASE", 589, 595], ["con experiencia en el manejo cl\u00ednico de pacientes con COVID", "TREATMENT", 467, 526], ["incluido el SARS", "PROBLEM", 559, 575], ["as\u00ed como en sepsis y SDRA", "TREATMENT", 577, 602]]], ["El documento proporciona recomendaciones cl\u00ednicas para el soporte respiratorio no invasivo (ventilaci\u00f3n no invasiva, oxigenoterapia de alto flujo con c\u00e1nula nasal) en cualquier paciente con presentaci\u00f3n sospechada o confirmada de COVID-19 con insuficiencia respiratoria aguda.PALABRAS CLAVEEsta gu\u00eda de consenso debe servir como base para una atenci\u00f3n optimizada y garantizar la mejor posibilidad de supervivencia, as\u00ed como permitir una comparaci\u00f3n fiable de las futuras intervenciones terap\u00e9uticas de investigaci\u00f3n que formen parte de futuros estudios observacionales o de ensayos cl\u00ednicos. \u00a9 2020 Publicado por Elsevier Espa\u00f1a, S.L.U. en nombre de Sociedad Espa\u00f1ola de Anestesiolog\u00eda, Reanimaci\u00f3n y Terap\u00e9utica del Dolor.KEYWORDSNon-invasive mechanical ventilation; High-flow nasal therapy; Aerosol-generating procedures; Infection control as well as sepsis and ARDS.", [["nasal", "ANATOMY", 778, 783], ["sepsis", "DISEASE", 853, 859], ["ARDS", "DISEASE", 864, 868], ["insuficiencia respiratoria", "SPECIES", 243, 269], ["invasivo (ventilaci\u00f3n", "TREATMENT", 82, 103], ["invasiva", "TREATMENT", 107, 115], ["oxigenoterapia de alto flujo con c\u00e1nula nasal)", "TREATMENT", 117, 163], ["invasive mechanical ventilation", "TREATMENT", 735, 766], ["High-flow nasal therapy", "TREATMENT", 768, 791], ["Aerosol-generating procedures", "TREATMENT", 793, 822], ["Infection control", "TREATMENT", 824, 841], ["sepsis", "PROBLEM", 853, 859], ["ARDS", "PROBLEM", 864, 868], ["invasive", "OBSERVATION_MODIFIER", 735, 743], ["mechanical ventilation", "OBSERVATION", 744, 766], ["Infection", "OBSERVATION", 824, 833], ["sepsis", "OBSERVATION", 853, 859], ["ARDS", "OBSERVATION", 864, 868]]], ["The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure.KEYWORDSThis consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials. \u00a9 2020 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Anestesiolog\u00eda, Reanimaci\u00f3n y Terap\u00e9utica del Dolor.KEYWORDSEste documento de consenso surge por la situaci\u00f3n de alarma social y sanitaria y por la demanda de los profesionales de pautas de actuaci\u00f3n, por lo que se centra en situaciones espec\u00edficas fuera de la pr\u00e1ctica cl\u00ednica rutinaria en los centros hospitalarios.", [["respiratory", "ANATOMY", 67, 78], ["nasal", "ANATOMY", 143, 148], ["respiratory", "ANATOMY", 237, 248], ["oxygen", "CHEMICAL", 123, 129], ["acute respiratory failure", "DISEASE", 231, 256], ["oxygen", "CHEMICAL", 123, 129], ["oxygen", "SIMPLE_CHEMICAL", 123, 129], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 143, 156], ["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172], ["the noninvasive respiratory support", "TREATMENT", 51, 86], ["noninvasive ventilation", "TREATMENT", 88, 111], ["high flow oxygen therapy", "TREATMENT", 113, 137], ["nasal cannula", "TREATMENT", 143, 156], ["COVID", "TEST", 217, 222], ["acute respiratory failure", "PROBLEM", 231, 256], ["optimized supportive care", "TREATMENT", 322, 347], ["investigational therapeutic interventions", "TREATMENT", 436, 477], ["randomized controlled trials", "TREATMENT", 489, 517], ["respiratory support", "OBSERVATION", 67, 86], ["acute", "OBSERVATION_MODIFIER", 231, 236], ["respiratory failure", "OBSERVATION", 237, 256]]], ["Por tanto, deber\u00e1 ser adaptado a las circunstancias particulares de cada escenario.Introducci\u00f3n generalEl documento que presentamos est\u00e1 elaborado en consenso con las sociedades cient\u00edficas implicadas en el fracaso respiratorio agudo en el paciente adulto y se dirige a una descripci\u00f3n m\u00e1s minuciosa sobre las recomendaciones para el uso de soporte respiratorio no invasivo (SRNI) en el manejo de la insuficiencia respiratoria aguda (IRA) secundaria a la infecci\u00f3n por el nuevo coronavirus SARS-CoV-2, que provoca la enfermedad denominada COVID-19,como complemento a la informaci\u00f3n que emite el Ministerio de Sanidad, Consumo y Bienestar Social (MSC) 1,2 , que se actualiza frecuentemente y que establece una serie de recomendaciones generales.Introducci\u00f3n generalLa Organizaci\u00f3n Mundial de la Salud (OMS) ha declarado recientemente la enfermedad por el SARS-CoV-2 (COVID-19) 3 como una emergencia de salud p\u00fablica de alarma internacional.", [["coronavirus SARS", "DISEASE", 478, 494], ["coronavirus", "SPECIES", 478, 489], ["a la infecci\u00f3n", "PROBLEM", 450, 464], ["CoV", "TEST", 495, 498], ["Introducci\u00f3n", "TREATMENT", 744, 756], ["CoV", "TEST", 859, 862], ["COVID", "TEST", 866, 871]]], ["Esta pandemia en curso de la enfermedad COVID-19 es devastadora, a pesar de la amplia implementaci\u00f3n de medidas de control.", [["a pesar de la amplia implementaci\u00f3n", "TREATMENT", 65, 100]]], ["Estas medidas son esenciales para controlar la epidemia, proteger a los profesionales sanitarios en primera l\u00ednea y mitigar la gravedad de los desenlaces de los enfermos.Introducci\u00f3n generalLos resultados del reciente an\u00e1lisis de las caracter\u00edsticas cl\u00ednicas en una cohorte seleccionada de 1.099 enfermos de COVID-19 en toda China 5 han mostrado que hasta el 15% (173/1.099) desarrollaron enfermedad grave seg\u00fan los criterios cl\u00ednicos de neumon\u00eda comunitaria grave de la American Thoracic Society 6 , y de estos con enfermedad grave, el 20,6% presentaron como desenlace compuesto o ingreso en las unidades de cuidados intensivos (UCI) (33/173, 19%) , o el uso de ventilaci\u00f3n mec\u00e1nica, tanto invasiva como no invasiva (81/173, 46%) o muerte (14/173, 8%).", [["muerte", "TEST", 733, 739], ["Thoracic", "ANATOMY", 480, 488]]], ["Complementariamente, el 2,9% (5/173) requirieron sistemas de oxigenaci\u00f3n extracorp\u00f3rea.Introducci\u00f3n generalEste escenario, de ser extrapolado a la situaci\u00f3n del actual brote en Espa\u00f1a, nos sit\u00faa en la necesidad de anticipar y demandar un plan de contingencia a las autoridades sanitarias nacionales y territoriales para el manejo de los recursos sanitarios y de seguridad para los profesionales que incluyan los procesos de utilizaci\u00f3n de \u00e1reas espec\u00edficas de los centros hospitalarios como son las unidades expertas capaces de atender a pacientes ventilados (UCI, unidades de cuidados respiratorios intermedios [UCRI]), los departamentos de urgencias, las plantas de hospitalizaci\u00f3n dotadas de medios y personal sanitario capaces de afrontar con seguridad y eficiencia el desaf\u00edo epidemiol\u00f3gico del control y tratamiento del brote en Espa\u00f1a de la enfermedad COVID-19.", [["Complementariamente", "TEST", 0, 19], ["personal sanitario capaces de afrontar con seguridad y eficiencia el desaf\u00edo epidemiol\u00f3gico del control", "TREATMENT", 704, 807]]], ["Adem\u00e1s, durante las epidemias previas por virus, SARS (s\u00edndrome respiratorio agudo grave) y MERS (s\u00edndrome respiratorio de Oriente Medio), el personal sanitario present\u00f3 una alta tasa de infecci\u00f3n, del 18,6% de casos durante el brote de MERS y del 21% de casos durante el de SARS 7, 8 .Introducci\u00f3n generalPor ello, desde los grupos de trabajo y de las sociedades cient\u00edficas responsables se deben establecer unos planes de contingencia que prevean la eventual situaci\u00f3n cr\u00edtica para la optimizaci\u00f3n de recursos materiales y humanos para estar preparados con anticipaci\u00f3n ante posibles escenarios desmesurados de demanda imprevista.", [["SARS", "DISEASE", 49, 53], ["SARS", "DISEASE", 275, 279], ["por virus", "PROBLEM", 38, 47], ["SARS", "PROBLEM", 49, 53]]], ["Asegurar que las direcciones de los hospitales tengan un protocolo establecido sobre el equipo de protecci\u00f3n individual (EPI) para profesionales sanitarios.", [["EPI) para profesionales sanitarios", "TREATMENT", 121, 155]]], ["Asegurarse de que el personal sanitario est\u00e9 entrenado en los procedimientos de colocaci\u00f3n y retirada de los EPI.", [["EPI", "TREATMENT", 109, 112]]], ["Optimizaci\u00f3n y anticipaci\u00f3n de los recursos humanos sanitarios para mejorar la seguridad del personal sanitario y planteamiento de las posibles bajas laborables ante la exposici\u00f3n de casos confirmados.", [["humanos", "TEST", 44, 51]]], ["Establecer objetivos claros para el cuidado de los enfermos y sus familiares y pol\u00edtica de visitas de los enfermos ingresados.Introducci\u00f3n generalEn conclusi\u00f3n, no podemos predecir cu\u00e1ntos enfermos graves afectados por la enfermedad por COVID-19 recibiremos, pero debemos anticipar los escenarios, ajustar los recursos de la forma m\u00e1s racional posible, en consonancia con experiencias de otros pa\u00edses afectados, hacer lo mejor que podamos para estar preparados y trabajar juntos para superar la epidemia.Introducci\u00f3n generalLas recomendaciones de este documento de consenso, elaborado entre la Sociedad Espa\u00f1ola de Medicina Intensiva, Cr\u00edtica y Unidades Coronarias (SEMICYUC), la Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR), la Sociedad Espa\u00f1ola de Medicina de Urgencias y Emergencias (SEMES) y la Sociedad Espa\u00f1ola de Anestesiolog\u00eda, Reanimaci\u00f3n y Terapia del Dolor (SEDAR) est\u00e1n basadas, de forma an\u00e1loga, en los estudios de otras pandemias v\u00edricas (gripe, SARS, MERS) y en las \u00faltimas publicaciones sobre el COVID-19.", [["SARS", "DISEASE", 974, 978], ["podemos", "PROBLEM", 164, 171], ["no", "UNCERTAINTY", 161, 163], ["la epidemia", "OBSERVATION", 492, 503]]], ["Con respecto a la COVID-19 (la enfermedad infecciosa causada por el SARS-CoV-2), el 3,4% de los pacientes infectados en China presentaron un s\u00edndrome de distr\u00e9s respiratorio agudo, lo que supone el 40,3% de los pacientes que presentaron una patolog\u00eda grave 5 .", [["a la COVID", "TEST", 13, 23]]], ["Por tanto, es muy importante aplicar una estrategia terap\u00e9utica para de la insuficiencia respiratoria aguda secundaria a la infecci\u00f3n por COVID-19.Introducci\u00f3nUna parte fundamental del manejo de la IRA en los pacientes con COVID-19 es la monitorizaci\u00f3n, preferiblemente no invasiva.", [["COVID", "TEST", 138, 143], ["COVID", "TEST", 223, 228], ["invasiva", "TREATMENT", 273, 281]]], ["Estos pacientes precisan ser ubicados en una habitaci\u00f3n individual, idealmente con presi\u00f3n negativa, lo que conlleva la necesidad de un control centralizado de la monitorizaci\u00f3n (pulsioximetr\u00eda, frecuencia respiratoria) y, preferentemente, con videovigilancia.Estrategia terap\u00e9utica del SRNI en el COVID-19Al igual que otros procesos que provocan IRA, en la infecci\u00f3n por SARS-CoV-2 se puede utilizar la estrategia terap\u00e9utica respiratoria propuesta por Scala y Heunks 10 .", [["Estrategia", "TEST", 260, 270], ["COVID", "TEST", 298, 303], ["IRA", "TEST", 347, 350], ["SARS", "PROBLEM", 372, 376], ["CoV", "TEST", 377, 380]]], ["La oxigenoterapia convencional consiste en la administraci\u00f3n de ox\u00edgeno a diferentes concentraciones y es la base de la pir\u00e1mide terap\u00e9utica.", [["a diferentes concentraciones y es la base de la pir\u00e1mide terap\u00e9utica", "TREATMENT", 72, 140]]], ["Este gas administrado debe estar caliente y humidificado al 100% 11 .", [["Este gas administrado", "TREATMENT", 0, 21], ["y humidificado al", "TREATMENT", 42, 59]]], ["Las ventajas con respecto al ox\u00edgeno convencional son un aporte constante de FiO 2 , reducci\u00f3n del espacio muerto y generaci\u00f3n de una presi\u00f3n positiva que conlleva una redistribuci\u00f3n de l\u00edquido intraalveolar y el reclutamiento alveolar 12 .", [["intraalveolar", "ANATOMY_MODIFIER", 194, 207], ["alveolar", "ANATOMY", 227, 235]]], ["En este caso se suele utilizar una ventilaci\u00f3n en modo controlado y precisa de intubaci\u00f3n traqueal 10 .", [["En este caso", "TREATMENT", 0, 12], ["una ventilaci\u00f3n en modo controlado y precisa de intubaci\u00f3n traqueal", "TREATMENT", 31, 98]]], ["El \u00faltimo escal\u00f3n es la membrana de oxigenaci\u00f3n extracorp\u00f3rea (ECMO) 14 .", [["El \u00faltimo escal\u00f3n es la membrana de oxigenaci\u00f3n extracorp\u00f3rea (ECMO)", "TREATMENT", 0, 68]]], ["Actualmente las terapias respiratorias que definen el SRNI son la TAFCN y la VMNI.Estrategia terap\u00e9utica del SRNI en el COVID-19A nivel orientativo, y teniendo en cuenta lo anteriormente expuesto, los criterios para iniciar el soporte respiratorio, en la IRA secundaria a COVID-19, ser\u00edan los siguientes 15 :Estrategia terap\u00e9utica del SRNI en el COVID-19Criterios cl\u00ednicos:Estrategia terap\u00e9utica del SRNI en el COVID-19\u2022 Disnea moderada-grave con signos de trabajo respiratorio y uso de musculatura accesoria o movimiento abdominal parad\u00f3jico. \u2022 Taquipnea mayor de 30 rpm.Criterios gasom\u00e9tricos:\u2022 PaO 2 /FiO 2 < 200 (o la necesidad de administrar una FiO 2 superior a 0,4 para conseguir una SpO 2 de al menos 92%). \u2022 Fallo ventilatorio agudo (pH < 7,35 con PaCO 2 > 45 mm Hg).Criterios gasom\u00e9tricos:En pacientes sin ninguno de los criterios previos el tratamiento indicado inicialmente ser\u00eda la oxigenoterapia convencional.", [["Hg", "CHEMICAL", 772, 774], ["Estrategia terap\u00e9utica del SRNI en el COVID-19Criterios cl\u00ednicos:Estrategia terap\u00e9utica del SRNI en el COVID-19", "SPECIES", 308, 419], ["Estrategia", "TEST", 82, 92], ["COVID", "TEST", 120, 125], ["orientativo", "TEST", 136, 147], ["a COVID", "TEST", 270, 277], ["siguientes", "TEST", 293, 303], ["Estrategia", "TEST", 308, 318], ["COVID", "TEST", 346, 351], ["Criterios", "TEST", 572, 581], ["gasom\u00e9tricos", "TEST", 582, 594], ["PaO", "TEST", 597, 600], ["FiO", "TEST", 604, 607], ["una FiO", "TEST", 647, 654], ["una SpO", "TEST", 687, 694], ["pH", "TEST", 743, 745], ["PaCO", "TEST", 757, 761], ["abdominal", "ANATOMY", 522, 531]]], ["Ante la presencia de alg\u00fan criterio se indicar\u00eda soporte respiratorio, ya sea invasivo o no invasivo.", [["invasivo", "TREATMENT", 92, 100]]], ["El uso del SRNI para el SARS y otras pandemias virales es controvertido, con tasas de fracaso de la VMNI de alrededor del 30% 16 .Criterios gasom\u00e9tricos:M\u00e1s recientemente, la VMNI tambi\u00e9n se us\u00f3 en pacientes con la IRA por gripe A H1N1, con tasas de fracaso que oscilaron entre el 13 y el 77% [17] [18] [19] .", [["para el SARS", "TEST", 16, 28], ["virales", "TEST", 47, 54], ["A H1N1", "PROBLEM", 229, 235], ["con tasas de fracaso que oscilaron entre el", "TEST", 237, 280]]], ["A pesar de la incertidumbre de la evidencia y la ausencia de ensayos cl\u00ednicos aleatorizados, los datos positivos de la mayor\u00eda de los estudios observacionales sugieren que se puede plantear su uso en pacientes cuidadosamente seleccionados en centros con experiencia Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto 5 y en un ambiente protegido (idealmente habitaciones con presi\u00f3n negativa).", [["ambiente protegido", "TREATMENT", 371, 389], ["idealmente habitaciones con presi\u00f3n negativa", "TREATMENT", 391, 435]]], ["En la presente epidemia de China el 5,1% de los pacientes necesitaron VMNI, un 2,3% con VMI y un 0,5% ECMO 5 .", [["necesitaron VMNI", "TREATMENT", 58, 74]]], ["As\u00ed, la elecci\u00f3n terap\u00e9utica tambi\u00e9n depender\u00e1 de las patolog\u00edas de base del paciente, principalmente respiratorias, de la ubicaci\u00f3n del enfermo (habitaci\u00f3n con presi\u00f3n negativa, habitaci\u00f3n individual cerrada con recambio del aire) y de la posibilidad de la eventual necesidad de procedimientos generadores de aerosoles, por lo que, de forma global, podr\u00edamos encontrarnos con tres escenarios cl\u00ednicos:Criterios gasom\u00e9tricos:1.", [["As\u00ed", "TEST", 0, 3], ["principalmente respiratorias", "PROBLEM", 87, 115], ["habitaci\u00f3n con presi\u00f3n negativa", "TREATMENT", 146, 177]]], ["Pacientes sin patolog\u00eda previa (IRA de novo) con insuficiencia respiratoria hipox\u00e9mica y, por tanto, susceptibles de escalar el tratamiento hasta la ECMO.", [["previa", "PROBLEM", 24, 30], ["la ECMO", "TREATMENT", 146, 153]]], ["La tasa de fracasos del SRNI en este escenario cl\u00ednico, principalmente en la VMNI, es extremadamente alta.", [["La tasa", "TEST", 0, 7]]], ["Solo se podr\u00eda plantear en pacientes muy seleccionados, siempre y cuando se cumplan todos los siguientes criterios 19,21-27 :Criterios gasom\u00e9tricos:\u2022 PaO 2 /FiO 2 > 100 a pesar de oxigenoterapia convencional.Criterios gasom\u00e9tricos:\u2022 Ausencia de fallo multiorg\u00e1nico (APACHE < 20).Criterios gasom\u00e9tricos:\u2022 Es necesario un equipo experto con monitorizaci\u00f3n continua, por lo que se recomienda realizarlo en unidades especiales con pre-especificado ratio de enfermer\u00eda como las UCI y las UCRI. \u2022 Intubaci\u00f3n oro-traqueal (IOT) precoz en la siguiente hora si no existen criterios de mejor\u00eda.", [["monitorizaci\u00f3n continua", "DISEASE", 339, 362], ["criterios", "TEST", 105, 114], ["Criterios", "TEST", 125, 134], ["gasom\u00e9tricos", "TEST", 135, 147], ["PaO", "TEST", 150, 153], ["FiO", "TEST", 157, 160], ["Intubaci\u00f3n", "TEST", 491, 501]]], ["En este sentido, adem\u00e1s de los criterios tradicionales de intubaci\u00f3n, se podr\u00eda considerar la intubaci\u00f3n en los pacientes tratados con TAFCN que presenten un \u00edndice de ROX ([SpO 2 /FiO 2 ] / Frecuencia respiratoria) < 3, < 3,5 y < 4 a las 2, 6 y 12 h del inicio del tratamiento con TAFCN.", [["ROX", "CHEMICAL", 168, 171], ["la intubaci\u00f3n en los pacientes tratados", "TREATMENT", 91, 130], ["SpO", "TEST", 174, 177], ["FiO", "TEST", 181, 184], ["respiratoria", "TEST", 202, 214], ["del inicio del tratamiento con TAFCN", "TREATMENT", 251, 287]]], ["Para la utilizaci\u00f3n del SRNI recomendamos seguir las siguientes consideraciones 29,30 :Criterios gasom\u00e9tricos:\u2022 Titular la FiO 2 para conseguir una SpO 2 objetivo en torno al 95% 31 . \u2022 En caso de usar TAFCN, utilizar flujos superiores a 50 lpm; si es posible, iniciar con 60 lpm.Criterios gasom\u00e9tricos:\u2022 En caso de usar VMNI, utilizar PEEP altas y presiones de soporte bajas (con el objetivo de obtener un VTe < 9 ml/kg de peso ideal) 31,32 .Criterios gasom\u00e9tricos:3.", [["utilizar PEEP", "TREATMENT", 327, 340]]], ["La TAFCN puede ser \u00fatil en estos pacientes en el caso de no tolerancia a la VMNI o para los descansos de la VMNI 33-36 .", [["La TAFCN", "TEST", 0, 8], ["la VMNI", "TEST", 105, 112]]], ["Recomendaciones para la prevenci\u00f3n y control de la infecci\u00f3n en el paciente sometido a SRNI Objetivo Limitar la transmisi\u00f3n de la infecci\u00f3n tanto al personal sanitario como a otros pacientes.Introducci\u00f3nLa utilizaci\u00f3n del SRNI es una pr\u00e1ctica de especial riesgo para la transmisi\u00f3n del SARS-CoV-2 [37] [38] [39] [40] .", [["2 [37] [38] [39] [40", "SIMPLE_CHEMICAL", 295, 315], ["para la prevenci\u00f3n y control", "TREATMENT", 16, 44], ["CoV", "TEST", 291, 294]]], ["La capacidad del SARS-CoV-2 para infectar los trabajadores sanitarios ha sido confirmada, aunque todav\u00eda no se pueden establecer comparaciones con MERS y SARS 40 .", [["SARS", "DISEASE", 154, 158], ["CoV", "TEST", 22, 25], ["ha sido confirmada", "TREATMENT", 70, 88]]], ["En este contexto, es necesario que las administraciones dispongan de los materiales necesarios para un uso seguro del SRNI.Recomendaciones generalesa) El personal sanitario que atienda casos en investigaci\u00f3n o confirmados para infecci\u00f3n por COVID-19 en tratamiento con SRNI debe llevar un equipo de protecci\u00f3n individual (EPI) para la prevenci\u00f3n de infecci\u00f3n 2,22,37,39,41 durante los procedimientos de generaci\u00f3n de aerosoles que se han asociado con un aumento del riesgo de transmisi\u00f3n de pat\u00f3genos a\u00e9reos.", [["COVID", "TEST", 241, 246], ["en tratamiento con SRNI", "TREATMENT", 250, 273]]], ["Las medidas preventivas deben estar dirigidas a microorganismos transmitidos por gotas y por contacto que incluya:Recomendaciones generales\u2022 6,6 (2,3-18,9) Intubaci\u00f3n orotraqueal 4 estudios de casos-control 0,7 (0,1-3,9) 9,2 (4,2-20,2) 8,0 (3,9-16,6) 9,3 (2,9-30,2) Efecto agrupado (I 2 = 61,4%) 6,6 (4,1-10,6) Aspiraci\u00f3n previa a la intubaci\u00f3n Resultados de estudios seleccionados en la revisi\u00f3n sistem\u00e1tica que midieron el riesgo de la transmisi\u00f3n del SARS a los trabajadores de la salud que estuvieron expuestos a los procedimientos enumerados en comparaci\u00f3n con los trabajadores que no estaban expuestos a los mismos procedimientos 48,49 . evidencia disponible acerca de los dispositivos de SRNI como procedimientos invasivos y el riesgo de transmisi\u00f3n de pat\u00f3genos respiratorios a los profesionales sanitarios se relacionan con m\u00e1s consistencia en los casos de intubaci\u00f3n orotraqueal y pacientes con v\u00eda a\u00e9rea artificial, as\u00ed como con la ventilaci\u00f3n no invasiva, aunque los resultados proceden de estudios limitados de muy baja calidad, lo que dificulta la interpretaci\u00f3n (tabla 1).", [["SARS", "DISEASE", 454, 458], ["(0,1-3,9) 9,2 (4,2-20,2) 8,0 (3,9-16,6) 9,3 (2,9-30,2) Efecto", "CHEMICAL", 211, 272], ["0,1-3,9) 9,2 (4,2-20,2) 8,0 (3,9-16,6) 9,3 (2,9-30,2", "SIMPLE_CHEMICAL", 212, 264], ["4,1-10,6", "SIMPLE_CHEMICAL", 301, 309], ["Intubaci\u00f3n orotraqueal", "TREATMENT", 156, 178], ["previa", "PROBLEM", 322, 328], ["a la intubaci\u00f3n", "TREATMENT", 329, 344]]], ["Si este tipo de sala no est\u00e1 disponible, se atender\u00e1 al paciente en una habitaci\u00f3n de uso individual con ba\u00f1o.", [["Si", "CHEMICAL", 0, 2]]], ["La puerta de la habitaci\u00f3n deber\u00e1 permanecer siempre cerrada 39 Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto 7 hipoxemia grave quedar\u00edan ingresados en las unidades especiales. c) Para el traslado intrahospitalario, el paciente y el profesional que traslade al paciente llevar\u00e1n una mascarilla quir\u00fargica.", [["grave quedar\u00edan ingresados", "TREATMENT", 171, 197], ["Para el traslado intrahospitalario", "TREATMENT", 229, 263]]], ["Durante el traslado se cubrir\u00e1 la cama del paciente con una s\u00e1bana limpia desechable que se eliminar\u00e1 como residuo del grupo III 39 .Recomendaciones espec\u00edficas seg\u00fan el tipo de SRNIOxigenoterapia convencional El Ministerio de Sanidad, Consumo y Bienestar Social recomienda administrar el ox\u00edgeno a trav\u00e9s de mascarillas con filtro de aire exhalado, pero estas mascarillas no est\u00e1n disponibles de forma universal en nuestro entorno.", [["Recomendaciones", "TREATMENT", 133, 148], ["est\u00e1n disponibles", "PROBLEM", 376, 393]]], ["No hay estudios que comparen la seguridad en la reducci\u00f3n de la dispersi\u00f3n del SARS-CoV-2 entre el primer tipo de m\u00e1scara y la protecci\u00f3n con mascarilla quir\u00fargica 39 , pero la administraci\u00f3n de ox\u00edgeno se considera un procedimiento generador de aerosoles de riesgo bajo 39, 40 .Terapia de alto flujo con c\u00e1nulas nasalesSe recomienda seguir las recomendaciones generales mencionadas y mantener una distancia m\u00ednima de 2 m con otros pacientes y el personal sanitario no adecuadamente protegido 42 .", [["hay", "PROBLEM", 3, 6], ["CoV", "TEST", 84, 87], ["entre el primer", "TREATMENT", 90, 105]]], ["Aunque en el momento actual existe incertidumbre en relaci\u00f3n con la dispersi\u00f3n de part\u00edculas en este modo terap\u00e9utico, la colocaci\u00f3n de una mascarilla quir\u00fargica por encima de las c\u00e1nulas nasales, aunque no estudiada, podr\u00eda ser una posibilidad ante una situaci\u00f3n extrema.Ventilaci\u00f3n mec\u00e1nica no invasivaSe recomienda mantener una distancia m\u00ednima de 2 m con otros pacientes y el personal sanitario no adecuadamente protegido.", [["incertidumbre en relaci\u00f3n con la dispersi\u00f3n", "TREATMENT", 35, 78], ["estudiada", "PROBLEM", 207, 216], ["Ventilaci\u00f3n", "TREATMENT", 272, 283]]], ["En general, de acuerdo con la evidencia disponible, no hay contraindicaciones para el uso de los SRNI en enfermos con COVID-19, pero la terapia respiratoria utilizada no solo depender\u00e1 de la gravedad de la insuficiencia respiratoria sino de la disponibilidad de una ubicaci\u00f3n que cumpla las recomendaciones de aislamiento y seguridad de la Organizaci\u00f3n Mundial de la salud (OMS).", [["OMS", "DISEASE", 374, 377], ["COVID", "TEST", 118, 123]]], ["Probablemente los casos m\u00e1s graves, que vaticinen una intubaci\u00f3n probable y r\u00e1pida, deber\u00edan ubicarse en las UCI para evitar posibles retrasos en la intubaci\u00f3n que resulten desfavorables para la evoluci\u00f3n de los enfermos ( fig. 1 ).Elecci\u00f3n de la configuraci\u00f3n del respirador:\u2022 Aunque en el momento actual existen dudas en relaci\u00f3n con la dispersi\u00f3n de part\u00edculas en el COVID-19, en la epidemia del SARS se publicaron algunos art\u00edculos que mostraban una dispersi\u00f3n de part\u00edculas con la VMNI de circuito \u00fanico y puerto exhalatorio de no m\u00e1s de 4 pies (1,25 m) 8, 43, 44 . \u2022 Utilizar preferiblemente configuraciones de doble rama, ya que aportan hermetismo al circuito respiratorio tanto inspiratorio como espiratorio.", [["graves", "PROBLEM", 28, 34], ["COVID", "TEST", 370, 375], ["del SARS", "TEST", 395, 403], ["publicaron", "TEST", 407, 417]]], ["Se deber\u00e1n colocar filtros antimicrobianos de alta eficiencia en la rama espiratoria para evitar la contaminaci\u00f3n inversa desde el paciente al respirador 39 . \u2022 En caso de no disponer de sistemas de doble rama y tener que emplear ventiladores de rama \u00fanica, deberemos localizar en la tubuladura \u00fanica el orificio espiratorio y colocar un filtro antimicrobiano de alta eficiencia y baja resistencia para minimizar la dispersi\u00f3n del gas exhalado que pueda contaminar el aire ambiente.", [["deberemos", "TEST", 258, 267]]], ["Parece factible, asimismo, interponer una pieza en T en el circuito para colocar el filtro y la fuga intencional distal al mismo, aunque debe tenerse en cuenta el incremento de espacio muerto. \u2022 En caso de no poder acoplar un filtro antimicrobiano de alta eficiencia en el orificio espiratorio, se deber\u00e1 colocar un filtro antimicrobiano de alta eficiencia entre la interfase paciente/ventilador (sin orificios espiratorios) y el circuito.", [["ventilador", "TREATMENT", 385, 395]]], ["En este caso, el aumento de la resistencia podr\u00eda requerir modificar los par\u00e1metros del ventilador en el sentido de incrementar el nivel de presi\u00f3n de soporte. \u2022 Una alternativa factible a los sistemas de doble rama o rama \u00fanica con fuga es el empleo de sistemas monorrama con v\u00e1lvula activa y colocaci\u00f3n de filtro antimicrobiano a la salida de la v\u00e1lvula activa.\u2022 No recomendamos utilizar Heat and Moisture Exchangers(HME) 45 .Elecci\u00f3n del tipo de interfase:La interfase es el dispositivo de conexi\u00f3n que facilita la relaci\u00f3n f\u00edsica pero tambi\u00e9n funcional entre dos elementos independientes: ventilador y paciente.", [["v\u00e1lvula activa", "DISEASE", 348, 362], ["\u00fanica", "TEST", 223, 228], ["fuga", "TEST", 233, 237], ["Moisture Exchangers(HME)", "TREATMENT", 399, 423]]], ["Es un elemento indispensable en la VMNI, vehiculando la presi\u00f3n positiva hacia el enfermo sin ning\u00fan componente artificial introducido en la v\u00eda a\u00e9rea.", [["vehiculando", "TEST", 41, 52]]], ["Las recomendaciones para el uso de la interfase en la infecci\u00f3n por SARS-CoV-2 son 40,41,46,47 : \u2022 La interfase recomendada es aquella sin orificio espiratorio, no utilizando puertos accesorios si los hubiera. \u2022 La utilizaci\u00f3n del helmet deber\u00eda ser prioritaria en caso de disponer de esta interfase y conocer su t\u00e9cnica de colocaci\u00f3n y mantenimiento. \u2022 En t\u00e9rminos generales, se recomienda utilizar la m\u00e1scara facial total como primera alternativa y, en su defecto, oronasal. \u2022 Es preciso atender y vigilar de forma estricta los puntos de fuga perim\u00e1scara, especialmente en las interfaces oronasales, primero para evitar lesiones sobre la piel del paciente con la protecci\u00f3n adecuada y, por otro lado, mantener el hermetismo al circuito que evita la exhalaci\u00f3n del aire infectado.", [["La utilizaci\u00f3n del helmet", "TREATMENT", 212, 237], ["no", "UNCERTAINTY", 161, 163], ["oronasal", "ANATOMY", 467, 475], ["del aire", "OBSERVATION", 762, 770], ["infectado", "OBSERVATION", 771, 780]]], ["Debe evitarse los parches protectores por aumento de la fuga, recomend\u00e1ndose la aplicaci\u00f3n repetida de aceites hiperoxigenados. \u2022 No se recomienda hacer uso de la interfase nasal, ya que genera m\u00e1s aerosoles y porque, adem\u00e1s, en general en la infecci\u00f3n por SARS-CoV-2 se trata de un fallo hipox\u00e9mico agudo.Elecci\u00f3n del tipo de interfase:3.", [["nasal", "ANATOMY", 173, 178]]], ["Considerando el balance riesgo/beneficio (asfixia vs dispersi\u00f3n) y que estos pacientes est\u00e1n ubicados en habitaciones de alta complejidad al cuidado continuo de personal sanitario especializado, es poco probable la desconexi\u00f3n accidental no detectada ni corregida a tiempo, pero es necesario una ratio de enfermer\u00eda m\u00ednimo seguro. \u2022 Desaconsejamos el uso de codo anti-rebreathing (que adem\u00e1s alberga v\u00e1lvula anti-asfixia) por el riesgo de mayor dispersi\u00f3n del aire espirado.Terapia inhalada 1,39La pandemia actual de los casos de COVID-19 exige mayores precauciones de control de infecci\u00f3n.", [["Terapia inhalada 1,39", "CHEMICAL", 474, 495], ["Terapia inhalada 1,39", "SPECIES", 474, 495], ["beneficio", "PROBLEM", 31, 40]]], ["Los nebulizadores generan part\u00edculas de aerosol del tama\u00f1o de 1-5 m que pueden transportar bacterias y virus al pulm\u00f3n.", [["Los nebulizadores generan part\u00edculas de aerosol del tama\u00f1o", "TREATMENT", 0, 58]]], ["La terapia con nebulizador en pacientes con infecci\u00f3n pand\u00e9mica por COVID-19 tiene el potencial de transmitir COVID-19 potencialmente viable a sujetos susceptibles.", [["La terapia con nebulizador", "TREATMENT", 0, 26], ["COVID", "TEST", 68, 73]]], ["En los \u00faltimos a\u00f1os ha habido un cambio, en algunos centros, del uso de nebulizadores a inhaladores de dosis medida (pMDI) con c\u00e1maras de retenci\u00f3n con c\u00e1mara-v\u00e1lvula espaciadora (de las siglas en ingl\u00e9s Valved-Holding Chambers [VHC] ).", [["a inhaladores de dosis medida (pMDI) con c\u00e1maras de retenci\u00f3n con c\u00e1mara", "TREATMENT", 86, 158], ["v\u00e1lvula espaciadora (de las siglas en ingl\u00e9s Valved", "TREATMENT", 159, 210]]], ["La administraci\u00f3n de terapia inhalada se realizar\u00e1 preferentemente con dispositivo MDI y c\u00e1mara espaciadora.", [["La administraci\u00f3n de terapia inhalada", "TREATMENT", 0, 37]]], ["Sin embargo, es importante se\u00f1alar que en pacientes con insuficiencia respiratoria aguda es dif\u00edcil que puedan recibir el medicamento de forma efectiva con estos dispositivos.Terapia inhalada 1,39La terapia con nebulizaci\u00f3n solo deber\u00eda usarse en las siguientes situaciones:Terapia inhalada 1,391.", [["Terapia inhalada 1,39", "CHEMICAL", 175, 196], ["Terapia inhalada 1,39", "SPECIES", 175, 196], ["La terapia", "TREATMENT", 196, 206]]], ["Enfermedad respiratoria grave y potencialmente mortal (p.ej., aquellos con hipoventilaci\u00f3n o compromiso de ventilaci\u00f3n, EPOC grave, fibrosis qu\u00edstica).", [["fibrosis qu\u00edstica", "DISEASE", 132, 149], ["fibrosis qu\u00edstica", "PROBLEM", 132, 149], ["fibrosis", "OBSERVATION", 132, 140]]], ["Pacientes con mala respuesta al MDI con c\u00e1mara-v\u00e1lvula espaciadora.Terapia inhalada 1,39Sin embargo, a pesar de la gran cantidad de evidencia que sugiere su falta de superioridad o inferioridad, en comparaci\u00f3n con MDI + VHC, el nebulizador abierto todav\u00eda se usa ampliamente en los centros hospitalarios.Terapia inhalada 1,39Dado el brote actual de COVID-19, para reducir el riesgo de transmisi\u00f3n de todas las enfermedades respiratorias infecciosas en los centros hospitalarios alentamos a todos los profesionales sanitarios a considerar seriamente evitar el uso de nebulizadores abiertos en los pacientes con respiraci\u00f3n espont\u00e1nea si no se dispone de los dispositivos mencionados anteriormente.", [["Terapia inhalada 1,39", "CHEMICAL", 67, 88], ["Terapia inhalada 1,39", "CHEMICAL", 304, 325], ["Terapia inhalada 1,39", "SPECIES", 67, 88], ["Terapia inhalada 1,39", "SPECIES", 304, 325], ["v\u00e1lvula", "ANATOMY", 47, 54]]], ["Mantener la seguridad de nuestros pacientes y del personal debe ser nuestra prioridad.Terapia inhalada 1,39Por tanto, si se precisa utilizar aerosolterapia, se recomienda utilizar dispositivos de malla vibrante con pipeta bucal o mascarilla, limitando la dispersi\u00f3n y poniendo encima una mascarilla quir\u00fargica.", [["Terapia inhalada 1,39", "CHEMICAL", 86, 107], ["Terapia inhalada 1,39", "SPECIES", 86, 107]]], ["Debe tenerse en cuenta que si se utiliza pipeta bucal con sistema anti-dispersi\u00f3n las dosis de f\u00e1rmaco depositado (especialmente importante en el caso de los broncodilatadores beta 2 -adren\u00e9rgicos) pueden ser mayores y requerir un ajuste de dosis.", [["Debe tenerse en cuenta que si", "TREATMENT", 0, 29], ["pipeta bucal con sistema anti-dispersi\u00f3n las dosis", "TREATMENT", 41, 91], ["f\u00e1rmaco depositado (especialmente importante en el caso de los broncodilatadores beta", "TREATMENT", 95, 180]]], ["De ser necesarios, es imprescindible colocar mascarilla quir\u00fargica al paciente durante la nebulizaci\u00f3n.Terapia inhalada 1,39Para utilizar terapia inhalada junto con SRNI recomendamos observar los siguientes puntos:Terapia inhalada 1,39\u2022 La recomendaci\u00f3n general para administrar la terapia inhalada es utilizar cartuchos presurizados con un adaptador o c\u00e1mara espaciadora.", [["Terapia inhalada 1,39", "CHEMICAL", 103, 124], ["Terapia inhalada 1,39", "SPECIES", 103, 124], ["Para utilizar terapia", "TREATMENT", 124, 145], ["La recomendaci\u00f3n general para administrar la terapia inhalada", "TREATMENT", 237, 298]]], ["En caso de utilizar VMNI se colocar\u00e1 en la rama inspiratoria del circuito, coordinando la pulsaci\u00f3n con la inspiraci\u00f3n del paciente. \u2022 Si utilizamos aerosolterapia son de elecci\u00f3n los nebulizadores de malla vibrante con adaptaci\u00f3n al codo de la interfase.", [["Si", "CHEMICAL", 135, 137]]], ["Al tratarse de un \u00absistema cerrado\u00bb, no se dispersan al ambiente si la fuga perimascarilla est\u00e1 bien controlada. \u2022 Los nebulizadores tipo jet con tubo en T generan mayores turbulencias y part\u00edculas de mayor tama\u00f1o y mayor facilidad de dispersi\u00f3n de part\u00edculas. \u2022 Si utilizamos TAFCN, lo ideal es utilizar cartuchos presurizados con c\u00e1mara espaciadora, pipeta con nebulizador tipo malla vibrante o un dispositivo de malla acoplado a la rama seca de la c\u00e1mara reservorio de agua. \u2022 En general reduciremos la presi\u00f3n soporte utilizada en VMNI y la temperatura si utilizamos TAFCN.", [["Si", "CHEMICAL", 263, 265], ["Los nebulizadores tipo jet", "TREATMENT", 115, 141], ["En general reduciremos la presi\u00f3n soporte utilizada", "TREATMENT", 480, 531]]]], "1414dd331cc6c6f0079a57308294dbc6dad51a4a": [["Introduction:The novel coronavirus that began in Wuhan, China in December 2019, now termed SARS-CoV-2, has caused a global impact on the health, politics, and economy in 3-short months.", [["SARS", "DISEASE", 91, 95], ["coronavirus", "ORGANISM", 23, 34], ["SARS-CoV", "SPECIES", 91, 99], ["The novel coronavirus", "PROBLEM", 13, 34]]], ["The clinical syndrome from the virus, now termed COVID-19, can consist of mild respiratory symptoms and fever, to ARDS and death in severe cases.", [["respiratory", "ANATOMY", 79, 90], ["respiratory symptoms", "DISEASE", 79, 99], ["fever", "DISEASE", 104, 109], ["ARDS", "DISEASE", 114, 118], ["death", "DISEASE", 123, 128], ["The clinical syndrome", "PROBLEM", 0, 21], ["the virus", "PROBLEM", 27, 36], ["COVID", "TEST", 49, 54], ["mild respiratory symptoms", "PROBLEM", 74, 99], ["fever", "PROBLEM", 104, 109], ["ARDS", "PROBLEM", 114, 118], ["death in severe cases", "PROBLEM", 123, 144], ["mild", "OBSERVATION_MODIFIER", 74, 78], ["respiratory symptoms", "OBSERVATION", 79, 99], ["fever", "OBSERVATION", 104, 109], ["severe", "OBSERVATION_MODIFIER", 132, 138]]], ["This has led to the disease being officially classified as a pandemic on March 11, 2020 and The Unites States Declared a State of Emergency on March 13, 2020.", [["the disease", "PROBLEM", 16, 27], ["disease", "OBSERVATION", 20, 27]]], ["1 At the time of this writing (March 19 th ), there are over 220,000 confirmed cases worldwide, 9,415 cases in the US with 150 deaths.", [["deaths", "DISEASE", 127, 133]]], ["Patients at older age and with medical comorbidities are at the most risk of requiring hospitalization, ICU care, and at risk for death.", [["death", "DISEASE", 130, 135], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["medical comorbidities", "PROBLEM", 31, 52], ["ICU care", "TREATMENT", 104, 112], ["death", "PROBLEM", 130, 135]]], ["In one of the largest epidemiologic studies to date from China with widescale testing, 81% of all infected may have mild symptoms (fever, cough, malaise), 19% required hospitalization, and 5% required critical care; with an overall case-mortality rate of 2.3%.", [["fever", "DISEASE", 131, 136], ["cough", "DISEASE", 138, 143], ["widescale testing", "TEST", 68, 85], ["mild symptoms", "PROBLEM", 116, 129], ["fever", "PROBLEM", 131, 136], ["cough", "PROBLEM", 138, 143], ["malaise", "PROBLEM", 145, 152], ["mortality rate", "TEST", 237, 251], ["mild", "OBSERVATION_MODIFIER", 116, 120]]], ["However, age \u226580 years was associated with a 14.9% case-fatality rate, 8% in 70-79 decade, and 49.0% in critically ill patients.", [["critically ill", "DISEASE", 104, 118], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["fatality rate", "TEST", 56, 69]]], ["3 As surgeons watching this even unfold in the US, we urge everyone to be prepared and to create a surgical department action plan in conjunction with key stakeholders and content experts vital to institutional response such as: Emergency Medicine, Anesthesia, Pulmonary Critical Care, Infectious Disease, Internal Medicine, facility and nursing management, and ultimately coordinated under the Incident Command System.", [["Infectious Disease", "DISEASE", 286, 304], ["nursing management", "TREATMENT", 338, 356], ["Pulmonary", "ANATOMY", 261, 270]]], ["4 Implementing screening by symptoms and exposure risk and mitigating healthcare personnel exposure to COVID-19 patients who require surgery is a key first step.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["symptoms", "PROBLEM", 28, 36], ["surgery", "TREATMENT", 133, 140]]], ["Experience out of China 5 and Singapore 6 have demonstrated that screening by symptoms and routine testing, use of appropriate personal protective equipment Ross et al. Tiered Surgical Response to COVID-19 March 19, 2020 4 (PPE), as well as a coordinated plan involving all aspects of peri-operative care is essential.Introduction:However, the early and continued experience in Italy 7 and Iran have demonstrated that when measures to mitigate the spread of COVID-19 are not implemented early enough, catastrophic scenarios requiring advanced triage criteria, resource management, and extreme flexibility within the healthcare system is required to save as many lives as possible.", [["symptoms", "PROBLEM", 78, 86], ["routine testing", "TEST", 91, 106], ["COVID", "TEST", 197, 202], ["peri-operative care", "TREATMENT", 285, 304], ["COVID", "TEST", 458, 463], ["catastrophic scenarios", "PROBLEM", 501, 523], ["resource management", "TREATMENT", 560, 579]]], ["A review of crisis management principles relevant to healthcare in this Pandemic and a tiered plan to take these factors into account was developed at our facility and presented herein.", [["crisis management", "TREATMENT", 12, 29]]], ["Key to understanding these concepts is the fact that patient surge is unlike typical mass casualty plans that we have become accustom with an acute event (minutes to hours) followed by an acute and relatively short response (hours to days), but instead a prolonged course of resource and personal exhaustion (weeks to months).Our CenterAtrium Health is one of the largest, integrated, public, not-for-profit health care systems in the United States compromising more than 7,500 licensed beds, employing nearly 70,000 people and accounting for more than 12Social DistancingIn the earliest weeks of the epidemic in Wuhan, isolation of patients, and then eventual quarantine of family, communities, and then whole cities was seen.", [["patient", "ORGANISM", 53, 60], ["people", "ORGANISM", 517, 523], ["patients", "ORGANISM", 633, 641], ["patient", "SPECIES", 53, 60], ["people", "SPECIES", 517, 523], ["patients", "SPECIES", 633, 641], ["mass", "OBSERVATION", 85, 89], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["largest", "OBSERVATION_MODIFIER", 364, 371]]], ["This term includes measures from simply limiting unnecessary activities like in large gatherings such as concerts, marathons, and sports games, to more drastic measures like banning all gatherings more than 50 people, closing schools city-wide and in some cases state-wide, and furloughing non-essential personnel from businesses.", [["people", "SPECIES", 210, 216]]], ["8 The goal of these measures is to reduce the spread of the virus so that the doubling time of the virus is increased, the purpose being to have fewer patients present in a shorter time period to hospitals.Social DistancingThis has gone viral in the #flattenthecurve movement, with the publication of Carl Bergstrom's graph illustrating the surge in patients on an exponential scale in relationship to the healthcare capacity as a flat line (Figure 1 .)", [["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 350, 358], ["these measures", "TREATMENT", 14, 28], ["the virus", "PROBLEM", 56, 65], ["the virus", "PROBLEM", 95, 104], ["an exponential scale", "TREATMENT", 362, 382], ["a flat line", "TREATMENT", 429, 440], ["flat line", "OBSERVATION", 431, 440]]], ["Measures such as social distancing would act to slow the spread and prolong the time frame of patients presenting to hospitals.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102]]], ["As we have seen in Italy, when the steeper rise occurs, a higher number of deaths occur as patients who need March 19, 2020 6 intensive care and ventilators have long out-paced the available resources, and a rationing and triage of patients is required.", [["deaths", "DISEASE", 75, 81], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 232, 240], ["ventilators", "TREATMENT", 145, 156]]], ["7 However, with increased testing, meticulous contact tracing, and measured social distancing, South Korea has been able to decrease the rate of spread, and healthcare facilities have not become overburdened.", [["increased testing", "TEST", 16, 33], ["meticulous contact tracing", "TEST", 35, 61]]], ["This often requires difficult capacity and financial decisions during a preparation phase to make room for the anticipated influx of patients.", [["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["difficult capacity", "PROBLEM", 20, 38]]], ["Inherent in this, is assessing the number of currently occupied beds, planned procedures and admissions, and the maximum capacity for floor and ICU beds.", [["ICU beds", "TREATMENT", 144, 152]]], ["A typical OR could house 3-6 patients depending on its size and could be staffed by CRNA's and Anesthesiologist as elective and even urgent cases are cancelled.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Early and proactive bed management is key, as reports from Italy indicate that all non-critical and non-emergent care has ceased as the hospitals are now at 200% capacity.", [["proactive bed management", "TREATMENT", 10, 34]]], ["7 Given these capacity issues, systems are unable to provide adequate care for patients with everyday emergencies like stroke, myocardial infarction, and trauma.", [["myocardial", "ANATOMY", 127, 137], ["stroke", "DISEASE", 119, 125], ["myocardial infarction", "DISEASE", 127, 148], ["trauma", "DISEASE", 154, 160], ["patients", "ORGANISM", 79, 87], ["myocardial", "MULTI-TISSUE_STRUCTURE", 127, 137], ["patients", "SPECIES", 79, 87], ["these capacity issues", "PROBLEM", 8, 29], ["stroke", "PROBLEM", 119, 125], ["myocardial infarction", "PROBLEM", 127, 148], ["trauma", "PROBLEM", 154, 160], ["myocardial", "ANATOMY", 127, 137], ["infarction", "OBSERVATION", 138, 148]]], ["Thus, the early COVID-19 mortality numbers fail to account for many patients who will have a concurrent preventable mortality from other causes as the result of this unanticipated surge and subsequent resource exhaustion.Social DistancingOxygen delivery and mechanical ventilation will no doubt be the highest value resource given the presence in critically ill COVID-19 patients of respiratory failure (54%) and ARDS (31%).", [["respiratory", "ANATOMY", 383, 394], ["Oxygen", "CHEMICAL", 238, 244], ["critically ill", "DISEASE", 347, 361], ["respiratory failure", "DISEASE", 383, 402], ["ARDS", "DISEASE", 413, 417], ["Oxygen", "CHEMICAL", 238, 244], ["patients", "ORGANISM", 68, 76], ["Oxygen", "SIMPLE_CHEMICAL", 238, 244], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 371, 379], ["the early COVID", "TEST", 6, 21], ["DistancingOxygen delivery", "TREATMENT", 228, 253], ["mechanical ventilation", "TREATMENT", 258, 280], ["respiratory failure", "PROBLEM", 383, 402], ["ARDS", "PROBLEM", 413, 417], ["mechanical ventilation", "OBSERVATION", 258, 280], ["respiratory", "ANATOMY", 383, 394], ["failure", "OBSERVATION", 395, 402], ["ARDS", "OBSERVATION", 413, 417]]], ["10 In general, the experience has been that non-invasive oxygenation modalities such as Ross et al. Tiered Surgical Response to COVID-19 March 19, 2020 7 nasal cannula and BiPAP are ineffective and patients at this stage will need mechanical ventilation.", [["nasal", "ANATOMY", 154, 159], ["BiPAP", "CHEMICAL", 172, 177], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 154, 167], ["BiPAP", "SIMPLE_CHEMICAL", 172, 177], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["non-invasive oxygenation modalities", "TREATMENT", 44, 79], ["COVID", "TEST", 128, 133], ["nasal cannula", "TREATMENT", 154, 167], ["BiPAP", "TREATMENT", 172, 177], ["mechanical ventilation", "TREATMENT", 231, 253], ["mechanical ventilation", "OBSERVATION", 231, 253]]], ["Ingenuity with methods to create new ventilators from spare parts and retrofit old machines such as IPPB into working ventilators will be required.", [["methods", "TREATMENT", 15, 22], ["new ventilators", "TREATMENT", 33, 48], ["spare parts", "TREATMENT", 54, 65], ["retrofit old machines", "TREATMENT", 70, 91], ["IPPB", "TREATMENT", 100, 104], ["ventilators", "TREATMENT", 118, 129]]], ["Additionally, if all patients are COVID-19+ as many as 4-patients could be linked in parallel on pressure control settings to attain reasonable minute ventilation and tidal volumes if required.", [["COVID-19", "CHEMICAL", 34, 42], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 57, 65], ["COVID", "TEST", 34, 39], ["pressure control settings", "TREATMENT", 97, 122], ["reasonable minute ventilation", "TREATMENT", 133, 162], ["tidal volumes", "TEST", 167, 180]]], ["11 Finally, while ventilators will be in high demand, endotracheal tubes are copious, and if family members are willing, bagging of patients by family members when no ventilator is available may be required.Personnel AttritionFirst and foremost, a proactive response is needed to limit the unnecessary interactions and contact of all personnel in an effort to minimize exposure risk as early as possible.", [["endotracheal tubes", "ANATOMY", 54, 72], ["endotracheal tubes", "MULTI-TISSUE_STRUCTURE", 54, 72], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["ventilators", "TREATMENT", 18, 29], ["endotracheal tubes", "TREATMENT", 54, 72], ["ventilator", "TREATMENT", 167, 177], ["endotracheal tubes", "OBSERVATION", 54, 72]]], ["Buy-in from all respective division chiefs and departmental coordination will define and facilitate staffing levels.Personnel AttritionSituational flexibility will be paramount in conjunction with clear and efficient communication and multidisciplinary collaboration.", [["Personnel AttritionSituational flexibility", "TREATMENT", 116, 158]]], ["All staffing plans must inherently assume attrition and furloughs required not only as the result of iatrogenic and community exposures, but also due to social instability, and/or resource consumption.", [["iatrogenic and community exposures", "PROBLEM", 101, 135], ["social instability", "PROBLEM", 153, 171], ["iatrogenic", "OBSERVATION", 101, 111]]], ["In large health systems, or even regional cooperatives, a pool of surgeons can be mobilized to start covering cases at satellite hospitals as surgeons at these facilities are furloughed.", [["large", "OBSERVATION_MODIFIER", 3, 8]]], ["Quarantined and senior surgeons can participate March 19, 2020 8 in telemedicine and even virtual critical care to increase the capacity to triage patients and care for the critically ill.", [["critically ill", "DISEASE", 173, 187], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155]]], ["Additionally, since this will be a prolonged surge if measures of social distancing are successful, consideration to weekly rotating teams off service of faculty, APP's, and residents to not deplete or expose all providers at once.Personnel AttritionPrinciples of the crisis standard of care should be used in disaster response when health care needs overwhelm available resources.", [["a prolonged surge", "TREATMENT", 33, 50]]], ["Given the increased need for critical care expertise at this highest level, emergency general surgery (EGS) and trauma coverage should be transitioned to general surgery trained elective surgeons to allow deployment of any surgical critical care (SCC) trained physicians solely to the intensive care setting.", [["SCC", "ANATOMY", 247, 250], ["trauma", "DISEASE", 112, 118], ["SCC", "CANCER", 247, 250], ["critical care expertise", "TREATMENT", 29, 52], ["emergency general surgery", "TREATMENT", 76, 101], ["trauma coverage", "TREATMENT", 112, 127], ["general surgery", "TREATMENT", 154, 169], ["elective surgeons", "TREATMENT", 178, 195], ["any surgical critical care", "TREATMENT", 219, 245]]], ["We recommend a tiered reallocation of Acute Care Surgeons (ACS) faculty as appropriate for each respective facility.", [["ACS", "DISEASE", 59, 62]]], ["At severe manpower shortage levels, non-ACS familiar with high-acuity priorities and hemorrhage control, like vascular, transplant, and hepatobiliary surgeons may be required to take trauma call.", [["vascular", "ANATOMY", 110, 118], ["hepatobiliary", "ANATOMY", 136, 149], ["hemorrhage", "DISEASE", 85, 95], ["trauma", "DISEASE", 183, 189], ["vascular", "MULTI-TISSUE_STRUCTURE", 110, 118], ["hemorrhage control", "TREATMENT", 85, 103], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["hemorrhage", "OBSERVATION", 85, 95], ["vascular", "ANATOMY", 110, 118], ["transplant", "OBSERVATION", 120, 130], ["hepatobiliary", "ANATOMY", 136, 149]]], ["Additionally, when supra-maximum patient capacity, with decreasing providers in Critical Care and Internal Medicine, subspecialized surgeons will likely be called to become general physicians to treat the non-critical patients with COVID-19.", [["COVID-19", "CHEMICAL", 232, 240], ["patient", "ORGANISM", 33, 40], ["patients", "ORGANISM", 218, 226], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 218, 226], ["COVID", "TEST", 232, 237]]], ["However, every nurse, therapists, ancillary staff, and physician regardless of specialty should have some basic training of ventilator management given the possibility of provider depletion and expansion of ICU's.Trainee AllocationLearners inevitably play a role in large-scale responses, and preparations must strike a balance between patient safety and residents' personal safety.", [["patient", "ORGANISM", 336, 343], ["patient", "SPECIES", 336, 343], ["ventilator management", "TREATMENT", 124, 145], ["provider depletion", "PROBLEM", 171, 189], ["expansion of ICU's", "TREATMENT", 194, 212]]], ["While an emergency plan is focused on patient care, it must also support workforce sustainability in the event of quarantine, March 19, 2020 9 illness or injury.", [["illness", "DISEASE", 143, 150], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["injury", "PROBLEM", 154, 160]]], ["Resident participation in emergency preparedness plans is essential in hospitals with training programs.", [["training programs", "TREATMENT", 86, 103]]], ["Planning for trainee allocation or quarantine has not been extensively studied.", [["trainee allocation", "TREATMENT", 13, 31], ["quarantine", "TREATMENT", 35, 45]]], ["[13] [14] [15] There has been no published and distributed plan instituted for residents in such a population health scenario as presented by COVID-19.", [["[13] [14] [15]", "SIMPLE_CHEMICAL", 0, 14]]], ["There was no understanding if residents would be expected to provide surge staffing or if they would be stratified by experience.", [["no", "UNCERTAINTY", 10, 12]]], ["14, 15 This is a gap in medical education that should be addressed as these incidences are unfortunately becoming more frequent.", [["medical education", "TREATMENT", 24, 41]]], ["Local graduate medical education leadership should be involved in preparations, and knowledge of ACGME program requirements is essential.", [["Local graduate medical education", "TREATMENT", 0, 32]]], ["Graduated autonomy and extension of attending physicians by senior residents as well as battlefield promotions of fellows and Chief Residents will be the most logical progression as the response to the crisis escalates and personnel are furloughed or quarantined.Advanced Triage CriteriaUnfortunately, in a resource exhaustion and surge capacity, difficult ethical decisions will have to be made on which patients merit the use of a scarce resource.", [["patients", "ORGANISM", 405, 413], ["patients", "SPECIES", 405, 413], ["the crisis", "PROBLEM", 198, 208], ["a scarce resource", "TREATMENT", 431, 448]]], ["These types of discussions are usually reserved for organ allocation and in cases that require ECMO.", [["organ", "ANATOMY", 52, 57], ["organ", "ORGAN", 52, 57], ["organ allocation", "TREATMENT", 52, 68], ["ECMO", "TREATMENT", 95, 99]]], ["Even in a normal situation where your hospital only has one ICU bed, one ventilator, or one ECMO circuit left, the default is to still give it to the first patient that needs that resource.", [["patient", "ORGANISM", 156, 163], ["patient", "SPECIES", 156, 163], ["ventilator", "TREATMENT", 73, 83], ["one ECMO circuit", "TREATMENT", 88, 104]]], ["However, more complex in our current Pandemic scenario, is that the ventilator you are allocating today to the person with a poor chance of survival may deprive that resource tomorrow to the patient with a moderate chance of survival.", [["patient", "ORGANISM", 191, 198], ["person", "SPECIES", 111, 117], ["patient", "SPECIES", 191, 198], ["the ventilator", "TREATMENT", 64, 78], ["more", "OBSERVATION_MODIFIER", 9, 13], ["complex", "OBSERVATION_MODIFIER", 14, 21]]], ["Several schemas have been created in the past to rationalize the choices that are now in front of many healthcare providers, some of which are to maximize number of life years (favors the young), social value (favors occupations that are deemed valuable in preserving society infrastructure and culture), and instrumental value (those that would have impact on the current outbreak like physicians and nurses).", [["Several schemas", "PROBLEM", 0, 15], ["culture", "TEST", 295, 302]]], ["16 Currently in Italy, reports in over capacity facilities describe making hard decisions to not intubate patients over 65, and no ICU care to patients over 80.", [["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 143, 151]]], ["17 This type of rationing is unthinkable to most Americans with the perception that all aspects of healthcare are an inherent right up to and escalating towards death.", [["death", "DISEASE", 161, 166]]], ["While many practitioners in the US will rightly not want to set hard limits like this, the withholding of surgery with recognition of futility is readily decided upon.", [["surgery", "TREATMENT", 106, 113]]], ["Surgeons inherently understand futility in end-stage cancer, overwhelming sepsis, and advanced age and comorbidities.", [["end-stage cancer", "ANATOMY", 43, 59], ["cancer", "DISEASE", 53, 59], ["sepsis", "DISEASE", 74, 80], ["end-stage cancer", "CANCER", 43, 59], ["end-stage cancer", "PROBLEM", 43, 59], ["overwhelming sepsis", "PROBLEM", 61, 80], ["advanced age and comorbidities", "PROBLEM", 86, 116], ["-stage", "OBSERVATION_MODIFIER", 46, 52], ["cancer", "OBSERVATION", 53, 59], ["overwhelming", "OBSERVATION_MODIFIER", 61, 73], ["sepsis", "OBSERVATION", 74, 80]]], ["COVID-19 patients, with progression to ARDS and multiple risk factors, will have similarly dismal potential for survival.", [["ARDS", "DISEASE", 39, 43], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["ARDS", "PROBLEM", 39, 43], ["multiple risk factors", "PROBLEM", 48, 69], ["ARDS", "OBSERVATION", 39, 43]]], ["Therefore, in the vein of justice and maximizing benefit to all of society, advanced triage criteria based on individual risk factors should be performed before resources become exhausted to ensure that the next salvageable patient has the opportunity to benefit where the current patient likely will not.Clinic Triage and TelemedicineGiven the rapid changes in technology as well as societal healthcare pressures due to the global pandemic, telemedicine should be the frontline triage for specialty surgery clinics.", [["vein", "ANATOMY", 18, 22], ["vein", "MULTI-TISSUE_STRUCTURE", 18, 22], ["patient", "ORGANISM", 224, 231], ["patient", "ORGANISM", 281, 288], ["patient", "SPECIES", 224, 231], ["patient", "SPECIES", 281, 288], ["advanced triage criteria", "TEST", 76, 100], ["individual risk factors", "PROBLEM", 110, 133], ["societal healthcare pressures", "TREATMENT", 384, 413], ["specialty surgery", "TREATMENT", 490, 507], ["vein", "ANATOMY", 18, 22]]], ["18 The limitations for use, such as costs, training, or HIPPA related concerns, may limit the ability to rapidly upload and utilize these platforms for virtual visits, especially when faced with a rapidly progressing pandemic.", [["a rapidly progressing pandemic", "PROBLEM", 195, 225]]], ["For example, during the H1N1 Pandemic, North et al. were able to use telephone screening triage to reduce unnecessary clinic visits yet preserve medical access.", [["Pandemic", "DISEASE", 29, 37], ["telephone screening triage", "TEST", 69, 95]]], ["20 In our specific ACS clinics pre-operative visits were stopped when the Pandemic was declared and the US was seeing increasing numbers.", [["ACS", "DISEASE", 19, 22], ["Pandemic", "DISEASE", 74, 82], ["the US", "TEST", 100, 106], ["increasing numbers", "PROBLEM", 118, 136]]], ["Post-operative patients still need to be evaluated and managed for many issues, such as drains, wounds, and suture removal.Clinic Triage and TelemedicineDue to the time constraints given the increasing community spread, we rapidly developed an ACS clinic patient screening process (eDocument1) that started with already scheduled patients for return to our trauma and EGS clinics.", [["wounds", "ANATOMY", 96, 102], ["trauma", "DISEASE", 357, 363], ["patients", "ORGANISM", 15, 23], ["wounds", "PATHOLOGICAL_FORMATION", 96, 102], ["patient", "ORGANISM", 255, 262], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 255, 262], ["patients", "SPECIES", 330, 338], ["many issues", "PROBLEM", 67, 78], ["drains", "TREATMENT", 88, 94], ["wounds", "PROBLEM", 96, 102], ["suture removal", "TREATMENT", 108, 122], ["the increasing community spread", "PROBLEM", 187, 218], ["wounds", "OBSERVATION", 96, 102], ["suture removal", "OBSERVATION", 108, 122]]], ["If a patient was determined not to need a virtual or physical visit, a telephone call was used to discuss the appointment and manage patient expectations.", [["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 133, 140]]], ["This tool evaluated not only if they had medical issues requiring evaluation, but also screened for potential COVID infections, utilizing the institutional infectious disease risk screening questions, embedded within the screening tool (eDocument 2).", [["infections", "DISEASE", 116, 126], ["infectious disease", "DISEASE", 156, 174], ["medical issues", "PROBLEM", 41, 55], ["evaluation", "TEST", 66, 76], ["potential COVID infections", "PROBLEM", 100, 126], ["the screening tool", "TEST", 217, 235]]], ["Utilizing this risk tool allowed a patient that was high risk to be directed to a COVID-19 testing site.", [["patient", "ORGANISM", 35, 42], ["COVID-19 testing site", "DNA", 82, 103], ["patient", "SPECIES", 35, 42], ["a COVID-19 testing site", "TREATMENT", 80, 103]]], ["All patients designated for upcoming clinics are assessed the week prior to the clinic appointment and determined to: 1.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["In need of objective data, such as a radiograph or laboratory blood work prior to clinic so the type of clinic visit can be determined.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["objective data", "TEST", 11, 25], ["a radiograph", "TEST", 35, 47], ["laboratory blood work", "TEST", 51, 72]]], ["Due to the limited socio-economic resource of most of our patients, many of our patients only have access to Android or Apple smart telephones, if any, so a computer video platform is not always viable.Clinic Triage and TelemedicineWe outfitted our clinic with 2 computers with video capability for patients calling into a virtual communication app (TEAMS \u00ae ) so these patients can connect with a computer, or Android or i-Phone device.", [["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 299, 307], ["patients", "ORGANISM", 369, 377], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 299, 307], ["patients", "SPECIES", 369, 377], ["a computer video platform", "TEST", 155, 180], ["i-Phone device", "TREATMENT", 421, 435]]], ["We elected to use these technology methods for more rapid preparations for virtual evaluations in the clinics and due to the time constraints of the forced social distancing mandates of the community.", [["these technology methods", "TREATMENT", 18, 42], ["virtual evaluations", "TEST", 75, 94]]], ["After reviewing the previously completed screening tool on a patient, an ACS physician or APP perform the virtual visit utilizing a standard virtual exam template (eDocument 3).", [["patient", "ORGANISM", 61, 68], ["APP", "PROTEIN", 90, 93], ["patient", "SPECIES", 61, 68], ["a standard virtual exam template", "TREATMENT", 130, 162]]], ["With the information gleaned from the screening tool and the virtual exam, a management plan is individualized for each patient and the forms are scanned into patients' electronic medical records along with a documented clinic note.Clinic Triage and TelemedicineIf a patient requires a physical appointment in our ACS clinic, they are screened again on arrival for symptoms of a potential COVID-19 infection.", [["ACS", "DISEASE", 314, 317], ["infection", "DISEASE", 398, 407], ["patient", "ORGANISM", 120, 127], ["patients", "ORGANISM", 159, 167], ["patient", "ORGANISM", 267, 274], ["patient", "SPECIES", 120, 127], ["patients", "SPECIES", 159, 167], ["patient", "SPECIES", 267, 274], ["the screening tool", "TEST", 34, 52], ["the virtual exam", "TEST", 57, 73], ["a management plan", "TREATMENT", 75, 92], ["symptoms", "PROBLEM", 365, 373], ["a potential COVID-19 infection", "PROBLEM", 377, 407], ["infection", "OBSERVATION", 398, 407]]], ["Only 1 additional care giver or family member can accompany the patient.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71]]], ["On arrival to the clinic if a patient has any active symptoms of a COVID-19 infection, they are directed to a testing site appropriate for their symptoms per institution protocols.", [["infection", "DISEASE", 76, 85], ["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["any active symptoms", "PROBLEM", 42, 61], ["a COVID-19 infection", "PROBLEM", 65, 85], ["a testing site", "TEST", 108, 122], ["their symptoms", "PROBLEM", 139, 153], ["infection", "OBSERVATION", 76, 85]]], ["Only 1 nurse and 1 attending can evaluate the patient.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53]]], ["Utilizing these methods, in the first week of implementation, out of 21 scheduled ACS clinic patients, we have already identified 19 patients able to be managed by virtual or telephone visits (91% reduction in clinic visit exposure).", [["ACS", "DISEASE", 82, 85], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 133, 141]]], ["Objective data is being obtained for 2 patients (chest radiographs and laboratory values) in order to determine whether they will require a physical clinic visit.", [["chest", "ANATOMY", 49, 54], ["patients", "ORGANISM", 39, 47], ["chest", "ORGANISM_SUBDIVISION", 49, 54], ["patients", "SPECIES", 39, 47], ["Objective data", "TEST", 0, 14], ["chest radiographs", "TEST", 49, 66], ["laboratory values", "TEST", 71, 88], ["chest", "ANATOMY", 49, 54]]], ["One of these 2 patient has staples that will be removed via a nurse visit or at their primary care provider's office, since they live over 1 hour away from our clinic office.Clinic Triage and TelemedicineWhile we are early in the process, transitioning our ACS clinics to a Virtual/Telemedicine Process, with appropriate resources, will continue to allow us to keep patients safe from exposure, preventing potential exposure risk to healthcare staff, as well as maintaining patient safety and perioperative surgical expectations.Tiered ResponseIn reflection of the above principles, led by Acute Care Surgeons with familiarity in Disaster Preparedness and Public Health, in conjunction with the incident command structure, and in an effort to keep in mind a prolonged surge of COVID-19 patients, the following Surgery Department COVID-19 Response Plan was created (Table 1 ).", [["ACS", "DISEASE", 257, 260], ["patient", "ORGANISM", 15, 22], ["patients", "ORGANISM", 366, 374], ["patient", "ORGANISM", 474, 481], ["patients", "ORGANISM", 786, 794], ["patient", "SPECIES", 15, 22], ["patients", "SPECIES", 366, 374], ["patient", "SPECIES", 474, 481], ["patients", "SPECIES", 786, 794], ["staples", "TREATMENT", 27, 34], ["perioperative surgical expectations", "TREATMENT", 493, 528], ["staples", "OBSERVATION", 27, 34]]], ["This has now been disseminated and adapted to each facility, subspecialty surgical service, and is being pivoted to other specialties such as Pulmonary Critical Care and Internal Medicine within Atrium Health.", [["Internal Medicine", "TREATMENT", 170, 187], ["disseminated", "OBSERVATION", 18, 30], ["Pulmonary", "ANATOMY", 142, 151], ["Atrium", "ANATOMY", 195, 201]]], ["4, 12 However, new to this schema is ConditionZero which indicates patient surge and acuity beyond the capacity of the infrastructure and manpower available, a scenario currently being experienced in Italy, Iran, and progressively around the world.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74]]], ["Advancement to higher tiers should follow incident command structure, but may also be required within individual specialties, departments, or divisions plans given manpower and resource depletion.Tiered ResponseAt Alert level, which many facilities in the US have already surpassed, disaster preparedness must begin in earnest and non-time sensitive elective cases, or many cases in high risk patients, should be delayed, cancelled, and rescheduled for no sooner than 3 months in the future.", [["patients", "ORGANISM", 393, 401], ["patients", "SPECIES", 393, 401], ["resource depletion", "TREATMENT", 177, 195]]], ["Additionally, in large health systems and regional collaboratives, efforts to back-up community facilities from larger tertiary departments should be performed to limit transfers required due to quarantined or furloughed surgeons at these sites.Tiered ResponseIn progression to further tiers, great focus is given the Acute Care Surgeon ability to staff trauma, SCC, and EGS services, given their true vertical integration in the hospital from the ED, OR, floor, and ICU.", [["SCC", "ANATOMY", 362, 365], ["trauma", "DISEASE", 354, 360], ["SCC", "DISEASE", 362, 365], ["SCC", "CANCER", 362, 365], ["EGS services", "TREATMENT", 371, 383], ["large", "OBSERVATION_MODIFIER", 17, 22]]], ["Given their flexibility, and critical care training, it will be key to support these ACS faculty with non-ACS surgeons to manage EGS and eventually even trauma.", [["ACS", "DISEASE", 85, 88], ["EGS", "DISEASE", 129, 132], ["trauma", "DISEASE", 153, 159], ["critical care training", "TREATMENT", 29, 51], ["non-ACS surgeons", "TREATMENT", 102, 118], ["EGS", "TEST", 129, 132], ["trauma", "PROBLEM", 153, 159]]], ["This will allow the ACS Surgeons to support expanded ICU's, OR ICU conversion, and ECMO patients.", [["ACS", "DISEASE", 20, 23], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["ICU conversion", "TREATMENT", 63, 77], ["ECMO", "TREATMENT", 83, 87]]], ["At non-trauma centers, in the community, or with no ACS faculty, General Surgeon coverage and adaptation of this plan will be paramount to cover all surgical and COVID-19 patients.", [["ACS", "DISEASE", 52, 55], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["no", "UNCERTAINTY", 49, 51]]], ["At Level 2, healthcare providers will begin to be furloughed, and decreased resources like blood, ventilators, and PPE will be available.", [["blood", "ANATOMY", 91, 96], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["ventilators", "TREATMENT", 98, 109], ["PPE", "TREATMENT", 115, 118]]], ["Subsequently, a 50% drawdown of all elective cases should be performed with focus on completing necessary cardiovascular and cancer cases, but patients with high risk factors should be deferred (age >60, DM, HTN, smoking hx, COPD just released by the American College of Surgeons.", [["cardiovascular", "ANATOMY", 106, 120], ["cancer", "ANATOMY", 125, 131], ["cardiovascular and cancer", "DISEASE", 106, 131], ["DM", "DISEASE", 204, 206], ["HTN", "DISEASE", 208, 211], ["COPD", "DISEASE", 225, 229], ["cardiovascular", "ANATOMICAL_SYSTEM", 106, 120], ["cancer", "CANCER", 125, 131], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["all elective cases", "TREATMENT", 32, 50], ["high risk factors", "PROBLEM", 157, 174], ["DM", "PROBLEM", 204, 206], ["HTN", "PROBLEM", 208, 211], ["COPD", "PROBLEM", 225, 229], ["cancer", "OBSERVATION", 125, 131], ["COPD", "OBSERVATION", 225, 229]]], ["21 Rearrangements of schedule and service coverage responsibility for residents, APP, and faculty should begin, and cycling of on call teams by several days or a week should be encouraged.Tiered ResponseResponse Level 1 will have accumulating provider and staff attrition due to quarantine and illness.", [["illness", "DISEASE", 294, 301], ["illness", "PROBLEM", 294, 301]]], ["Additionally, stocks of PPE, blood, ventilators and other essential infrastructure will be diminished by increasing numbers of COVID-19 patients.", [["blood", "ANATOMY", 29, 34], ["PPE", "GENE_OR_GENE_PRODUCT", 24, 27], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["PPE", "PROBLEM", 24, 27], ["ventilators", "TREATMENT", 36, 47], ["COVID", "TEST", 127, 132], ["essential", "OBSERVATION_MODIFIER", 58, 67], ["infrastructure", "OBSERVATION", 68, 82]]], ["Expanded ICU beds and staffing by the ACS faculty will be required and non-ACS surgeons required to flex to cover EGS.", [["ACS", "DISEASE", 38, 41], ["Expanded ICU beds", "TREATMENT", 0, 17], ["non-ACS surgeons", "TREATMENT", 71, 87], ["EGS", "TEST", 114, 117]]], ["Teams of younger ACS faculty can be deployed to cover medical ICU's if needed, and expect SCC fellows to have battlefield promotions to junior ICU attending status.", [["ACS", "DISEASE", 17, 20], ["SCC", "CANCER", 90, 93]]], ["ECMO should be reserved for young, non-comorbid patients, with single organ dysfunction and acceptable prognosis.", [["organ", "ANATOMY", 70, 75], ["organ dysfunction", "DISEASE", 70, 87], ["patients", "ORGANISM", 48, 56], ["organ", "ORGAN", 70, 75], ["patients", "SPECIES", 48, 56], ["ECMO", "TREATMENT", 0, 4], ["single organ dysfunction", "PROBLEM", 63, 87]]], ["Expect decreasing staff and blood availability as quarantine and social distancing impact the community.Tiered ResponseGraduated resident autonomy and Chief Resident run floor services will be expected.Tiered ResponseFinally, if the surge in patients comes as a tsunami as it did in Italy and Wuhan, Condition Zero will require stretching the infrastructure and manpower beyond the breaking point.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["stretching the infrastructure", "TREATMENT", 328, 357]]], ["In this scenario, ACS surgeons should focus on just ICU patient care, and non-ACS surgeons cover trauma and EGS in a tiered response.", [["trauma", "DISEASE", 97, 103], ["EGS", "DISEASE", 108, 111], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["ACS surgeons", "TREATMENT", 18, 30], ["trauma", "PROBLEM", 97, 103], ["EGS", "TEST", 108, 111]]], ["Non-emergent cases should not be performed, and non-operative modalities should be pursued if possible for all urgent disease processes.", [["non-operative modalities", "TREATMENT", 48, 72], ["all urgent disease processes", "PROBLEM", 107, 135], ["disease", "OBSERVATION", 118, 125]]], ["The export of urgent EGS cases may be required to other centers Advanced triage criteria with consideration of available resources, expected increase in surge volume, patient risk factors, and principles of justice and value unfortunately must be considered for the continuation and betterment of our society.", [["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["urgent EGS cases", "TREATMENT", 14, 30], ["surge volume", "PROBLEM", 153, 165], ["patient risk factors", "PROBLEM", 167, 187], ["increase", "OBSERVATION_MODIFIER", 141, 149]]], ["Novel ventilation strategies should be pursued whenever able, and even emergent non-COVID care may need to be triaged or suspended for certain disease processes if the system, facility, and providers are over-leveraged.", [["Novel ventilation strategies", "TREATMENT", 0, 28], ["emergent non-COVID care", "TREATMENT", 71, 94]]], ["At this level COVID-19+ healthcare workers may need to continue treating COVID-19 patients given the extreme attrition of personnel at this level.Principles to SuccessDo not lose hope.", [["COVID", "DISEASE", 73, 78], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["COVID", "TEST", 14, 19], ["COVID", "TREATMENT", 73, 78]]], ["As Wuhan has taught us with social distancing, strict quarantine and abundant testing, we can beat back this disease and mitigate its effect on our communities.", [["abundant testing", "TEST", 69, 85], ["this disease", "PROBLEM", 104, 116]]], ["In any rapidly evolving crisis, certain principles remain key to combating a constantly evolving and austere situation.", [["rapidly", "OBSERVATION_MODIFIER", 7, 14], ["evolving", "OBSERVATION_MODIFIER", 15, 23], ["crisis", "OBSERVATION", 24, 30]]], ["Even in this response plan, adaptation and integration of individual situations will be required.", [["individual situations", "TREATMENT", 58, 79]]], ["Most of all, a sense of community, purpose and legacy is paramount to keep us mission focused on the health of our patients and community; support and acknowledgement of our risk and sacrifice as physicians, providers\u2026as healers, are not in vain.ConclusionThe current COVID-19 Pandemic is causing a paradigm shift for our globalized world in every sector: economic, social, cultural, and even a religious impact.", [["Pandemic", "DISEASE", 277, 285], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["The brunt of the initial surge of patients was weathered in China and has now expanded to almost every country on Earth.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["All estimates point that the US is on track to have a similar surge of patients like Italy, and therefore now is the time to prepare, coordinate among key stakeholders, set up incident command, and plan for every conceivable contingency.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["the US", "TEST", 25, 31]]], ["The authors desperately hope that social distancing measures will prevail and that our tiered response plan will not be required at its highest level.", [["social distancing measures", "TREATMENT", 34, 60]]], ["However, failure to plan for these eventualities, would make the outcome all the worse if or when they are needed; please use, adapt, share and disseminate for the good of all our patients.", [["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["failure", "OBSERVATION", 9, 16]]]], "2269f102137c683d0a7871a9ea5110298bd3598c": [["IntroductionAerosol therapy is recognised as an effective method of administrating pharmaceuticals.", [["IntroductionAerosol therapy", "TREATMENT", 0, 27], ["administrating pharmaceuticals", "TREATMENT", 68, 98]]], ["The procedure involves generating an aerosol for drug delivery to the lungs to aid in the treatment of respiratory diseases.", [["lungs", "ANATOMY", 70, 75], ["respiratory", "ANATOMY", 103, 114], ["respiratory diseases", "DISEASE", 103, 123], ["lungs", "ORGAN", 70, 75], ["The procedure", "TREATMENT", 0, 13], ["an aerosol", "TREATMENT", 34, 44], ["drug delivery", "TREATMENT", 49, 62], ["respiratory diseases", "PROBLEM", 103, 123], ["lungs", "ANATOMY", 70, 75], ["respiratory diseases", "OBSERVATION", 103, 123]]], ["Nebulised medical aerosol has a typical particle size distribution of 1 to 5 \u00b5m [1].", [["Nebulised medical aerosol", "TREATMENT", 0, 25], ["particle", "OBSERVATION_MODIFIER", 40, 48], ["size", "OBSERVATION_MODIFIER", 49, 53]]], ["If such aerosol particles escape into the indoor environment, they may remain airborne for periods of several hours [2] [3] [4] .IntroductionAerosol generation technologies deliver drugs to the lungs of neonatal, paediatric and adult patients through a variety of patient interfaces.", [["lungs", "ANATOMY", 194, 199], ["lungs", "ORGAN", 194, 199], ["patients", "ORGANISM", 234, 242], ["patient", "ORGANISM", 264, 271], ["patients", "SPECIES", 234, 242], ["patient", "SPECIES", 264, 271], ["IntroductionAerosol generation technologies", "TREATMENT", 129, 172], ["drugs", "TREATMENT", 181, 186], ["lungs", "ANATOMY", 194, 199]]], ["Several factors influence aerosol drug delivery to the lungs, including the aerosol-generating device, the size distribution of the inhaled aerosol, the gas-flow rate, the inhalation pattern and the type of interface [5] [6] [7] [8] [9] .IntroductionDysart et al. [10] reported that the use of high-flow nasal therapy (HFNT) devices is rapidly growing in the clinical setting, for different age groups with a range of disease conditions.", [["lungs", "ANATOMY", 55, 60], ["nasal", "ANATOMY", 304, 309], ["lungs", "ORGAN", 55, 60], ["[5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 217, 236], ["aerosol drug delivery", "TREATMENT", 26, 47], ["the aerosol-generating device", "TREATMENT", 72, 101], ["the inhaled aerosol", "TREATMENT", 128, 147], ["the gas-flow rate", "TEST", 149, 166], ["the inhalation pattern", "TEST", 168, 190], ["high-flow nasal therapy (HFNT) devices", "TREATMENT", 294, 332], ["disease conditions", "PROBLEM", 418, 436], ["lungs", "ANATOMY", 55, 60], ["size", "OBSERVATION_MODIFIER", 107, 111], ["rapidly", "OBSERVATION_MODIFIER", 336, 343], ["growing", "OBSERVATION_MODIFIER", 344, 351]]], ["High-flow nasal therapy studies have reported gas-flow rates of 3 to 20 L/min for paediatrics, and 5 to 60 L/min for adults [11] [12] [13] [14] .", [["nasal", "ANATOMY", 10, 15], ["High-flow nasal therapy", "TREATMENT", 0, 23], ["gas", "TEST", 46, 49], ["flow rates", "TEST", 50, 60]]], ["Studies have reported that several factors influence the quantity of aerosol available for inhalation, including the rate of gas flow delivered, the size of the nasal prongs, humidification, the size of the aerosol droplets and the aerosol generator type and position [11, 13, 15] .", [["nasal", "ANATOMY", 161, 166], ["aerosol", "TREATMENT", 69, 76], ["inhalation", "TREATMENT", 91, 101], ["gas flow", "TEST", 125, 133], ["the nasal prongs", "TREATMENT", 157, 173], ["humidification", "TREATMENT", 175, 189], ["the aerosol droplets", "TREATMENT", 203, 223], ["the aerosol generator type", "TREATMENT", 228, 254], ["gas flow", "OBSERVATION", 125, 133], ["size", "OBSERVATION_MODIFIER", 149, 153], ["nasal prongs", "ANATOMY", 161, 173], ["size", "OBSERVATION_MODIFIER", 195, 199], ["aerosol droplets", "OBSERVATION", 207, 223]]], ["It is likely that these factors also influence the quantity of aerosol available to be released as fugitive emissions.IntroductionFugitive emissions consist of aerosol that has been exhaled from the patient and/or aerosol that escaped from the system prior to inhalation.", [["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["aerosol", "TREATMENT", 63, 70], ["IntroductionFugitive emissions", "TREATMENT", 118, 148], ["aerosol", "TREATMENT", 160, 167], ["aerosol", "TREATMENT", 214, 221], ["is likely", "UNCERTAINTY", 3, 12]]], ["Caregivers and family members are susceptible to unintended inhalation of medication.", [["unintended inhalation of medication", "TREATMENT", 49, 84]]], ["In the occupational setting, studies have highlighted concerns regarding secondary exposure to aerosolised sustained release lipid inhalation targeting (SLIT) cisplatin, pentamidine, adeno-associated serotype 2 vector containing cystic fibrosis transmembrane conductance regulator complementary DNA (tgAAVCF) and ribavirin [16] [17] [18] [19] .", [["cisplatin", "CHEMICAL", 159, 168], ["pentamidine", "CHEMICAL", 170, 181], ["fibrosis", "DISEASE", 236, 244], ["ribavirin", "CHEMICAL", 313, 322], ["[16] [17] [18] [19]", "CHEMICAL", 323, 342], ["cisplatin", "CHEMICAL", 159, 168], ["pentamidine", "CHEMICAL", 170, 181], ["ribavirin", "CHEMICAL", 313, 322], ["lipid", "SIMPLE_CHEMICAL", 125, 130], ["cisplatin", "SIMPLE_CHEMICAL", 159, 168], ["pentamidine", "SIMPLE_CHEMICAL", 170, 181], ["adeno-associated serotype 2", "ORGANISM", 183, 210], ["cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 229, 280], ["DNA", "CELLULAR_COMPONENT", 295, 298], ["ribavirin [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 313, 342], ["cystic fibrosis transmembrane conductance regulator", "PROTEIN", 229, 280], ["secondary exposure", "PROBLEM", 73, 91], ["aerosolised sustained release lipid inhalation targeting (SLIT) cisplatin", "TREATMENT", 95, 168], ["pentamidine", "TREATMENT", 170, 181], ["adeno-associated serotype 2 vector", "TREATMENT", 183, 217], ["cystic fibrosis transmembrane conductance regulator", "TREATMENT", 229, 280], ["DNA (tgAAVCF)", "TREATMENT", 295, 308], ["ribavirin", "TREATMENT", 313, 322], ["cystic", "OBSERVATION_MODIFIER", 229, 235], ["fibrosis", "OBSERVATION", 236, 244]]], ["Additionally, after entering the profession, respiratory therapists are reported to have an increased risk of developing asthma, which, in part, may be due to exposure to a range of aerosolised substances in the clinical setting [20, 21] .IntroductionTo date, only a limited number of studies have examined the potential for fugitive releases during aerosol therapy.", [["asthma", "DISEASE", 121, 127], ["developing asthma", "PROBLEM", 110, 127], ["aerosolised substances", "TREATMENT", 182, 204], ["aerosol therapy", "TREATMENT", 350, 365], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["developing", "OBSERVATION_MODIFIER", 110, 120], ["asthma", "OBSERVATION", 121, 127], ["may be due to", "UNCERTAINTY", 145, 158]]], ["Using photographic imaging, Somogyi et al. [22] captured the release of saline aerosol that originated in a patient's lung, even when the patient was wearing a facemask.", [["lung", "ANATOMY", 118, 122], ["saline aerosol", "SIMPLE_CHEMICAL", 72, 86], ["patient", "ORGANISM", 108, 115], ["lung", "ORGAN", 118, 122], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 108, 115], ["patient", "SPECIES", 138, 145], ["photographic imaging", "TEST", 6, 26], ["the release of saline aerosol", "TREATMENT", 57, 86], ["a facemask", "TREATMENT", 158, 168], ["lung", "ANATOMY", 118, 122]]], ["In addition, high-definition videos have been used to estimate the dispersion distance of smoke particles, which mimicked exhaled aerosol released from non-invasive ventilation and mask ventilation [23, 24] .", [["exhaled aerosol", "TREATMENT", 122, 137], ["non-invasive ventilation", "TREATMENT", 152, 176], ["mask ventilation", "TREATMENT", 181, 197]]], ["Ari et al. [25] examined the mechanical ventilation of a patient with and without expiratory filters, and in the cases without use of a filter, a 160-fold increase of the deposited drug was observed on the exhaust port.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["the mechanical ventilation", "TREATMENT", 25, 51], ["expiratory filters", "TREATMENT", 82, 100], ["a filter", "TREATMENT", 134, 142], ["the deposited drug", "TREATMENT", 167, 185], ["the exhaust port", "TREATMENT", 202, 218], ["mechanical ventilation", "OBSERVATION", 29, 51], ["filter", "OBSERVATION", 136, 142], ["exhaust port", "OBSERVATION", 206, 218]]], ["It was estimated that greater than 45% of the nominal dose could be fugitively released.", [["greater", "OBSERVATION_MODIFIER", 22, 29]]], ["Saeed et al. [26] examined exhalation filters when using jet and vibrating mesh nebulisers (VMN) and found that up to 50% of the generated aerosol was released from the system, as fugitive aerosol, into the surrounding environment.IntroductionElmashae et al. [27] measured aerosol concentrations, released from an adult facemask, in the breathing zone of a manikin, simulating a home-attending healthcare worker at three different distances.", [["VMN", "SIMPLE_CHEMICAL", 92, 95], ["exhalation filters", "TREATMENT", 27, 45], ["jet and vibrating mesh nebulisers", "TREATMENT", 57, 90], ["aerosol concentrations", "TREATMENT", 273, 295], ["an adult facemask", "TREATMENT", 311, 328]]], ["Total aerosol mass concentration ranged from 0.002 to 0.010 mg/m 3 depending on the distance of the manikin relative to the aerosol source, although the medication type was not deemed to be an influencing factor.", [["Total aerosol mass concentration", "TREATMENT", 0, 32], ["an influencing factor", "PROBLEM", 190, 211], ["mass", "OBSERVATION", 14, 18]]], ["McGrath, et al. [28] quantified time-series aerosol concentrations and the size distribution of fugitive aerosol emissions from facemask and mouthpiece interfaces released into an indoor environment.", [["series aerosol concentrations", "TREATMENT", 37, 66], ["fugitive aerosol emissions", "TREATMENT", 96, 122], ["facemask", "TREATMENT", 128, 136], ["size", "OBSERVATION_MODIFIER", 75, 79], ["fugitive aerosol emissions", "OBSERVATION", 96, 122]]], ["The 30-min time-weighted-average aerosol concentration recorded was 0.072 \u00b1 0.001 mg m \u22123 when using a jet nebuliser open-facemask combination.", [["weighted-average aerosol concentration", "TREATMENT", 16, 54], ["a jet nebuliser open", "TREATMENT", 101, 121], ["facemask combination", "TREATMENT", 122, 142]]], ["The effect of simulated aerosol treatment during high-flow therapy on fugitive emissions is unclear from the literature.IntroductionThis study examines fugitive emissions during aerosol drug delivery in combination with highflow therapy.", [["simulated aerosol treatment", "TREATMENT", 14, 41], ["high-flow therapy", "TREATMENT", 49, 66], ["fugitive emissions", "TREATMENT", 70, 88], ["This study", "TEST", 132, 142], ["fugitive emissions", "TREATMENT", 152, 170], ["aerosol drug delivery", "TREATMENT", 178, 199], ["highflow therapy", "TREATMENT", 220, 236]]], ["Fugitive emissions are a potential source of secondary inhalation exposure from medical aerosols that may occur in clinical settings.", [["Fugitive emissions", "PROBLEM", 0, 18], ["secondary inhalation exposure", "PROBLEM", 45, 74], ["medical aerosols", "TREATMENT", 80, 96], ["secondary", "OBSERVATION_MODIFIER", 45, 54], ["inhalation exposure", "OBSERVATION", 55, 74]]], ["A number of key factors were examined that could influence secondary exposure, including supplemental gas-flow rate, patient type and distance from the interface.HFNT Circuit and InterfacesThe Optiflow system (Airvo 2, Fisher & Paykel Healthcare, Auckland, New Zealand) was used.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["supplemental gas-flow rate", "TEST", 89, 115], ["HFNT Circuit", "TREATMENT", 162, 174], ["New Zealand)", "TREATMENT", 257, 269], ["secondary exposure", "OBSERVATION", 59, 77]]], ["An adult breathing circuit (P/N: 900PT552) was used with an adult nasal cannula (P/N: OPT 944) or a tracheostomy interface (P/N OPT 970) with a tracheostomy tube (Shiley Inner Cannula Tracheostomy Tube ID 6.4mm, Medtronic, Galway, Ireland).", [["nasal", "ANATOMY", 66, 71], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 66, 79], ["An adult breathing circuit", "TREATMENT", 0, 26], ["an adult nasal cannula", "TREATMENT", 57, 79], ["a tracheostomy interface", "TREATMENT", 98, 122], ["a tracheostomy tube", "TREATMENT", 142, 161], ["Shiley Inner Cannula Tracheostomy", "TREATMENT", 163, 196], ["breathing circuit", "OBSERVATION", 9, 26], ["tracheostomy tube", "OBSERVATION", 144, 161]]], ["A paediatric breathing circuit (P/N: 900PT531) was used with a paediatric nasal cannula (P/N: OPT 318) or a tracheostomy interface (P/N OPT 970) with a tracheostomy tube (Shiley Paediatric Tracheostomy Tube ID 5.5mm, Medtronic, Galway, Ireland).", [["nasal", "ANATOMY", 74, 79], ["A paediatric breathing circuit", "TREATMENT", 0, 30], ["a paediatric nasal cannula", "TREATMENT", 61, 87], ["a tracheostomy interface", "TREATMENT", 106, 130], ["a tracheostomy tube", "TREATMENT", 150, 169], ["Shiley Paediatric Tracheostomy Tube", "TREATMENT", 171, 206], ["tracheostomy tube", "OBSERVATION", 152, 169]]], ["The Airvo 2 HFNT system features a humidifier with an integrated flow source and was used with a nebuliser adapter.", [["nebuliser adapter", "PROTEIN", 97, 114], ["a humidifier", "TREATMENT", 33, 45], ["a nebuliser adapter", "TREATMENT", 95, 114], ["flow", "OBSERVATION", 65, 69]]], ["The nebuliser adapter was positioned at the humidification chamber.", [["nebuliser adapter", "PROTEIN", 4, 21], ["The nebuliser adapter", "TREATMENT", 0, 21], ["the humidification chamber", "TREATMENT", 40, 66], ["humidification chamber", "OBSERVATION", 44, 66]]], ["All testing was completed at clinically relevant gas-flow rates (10 L/min, 40 L/min and 60 L/min for simulated adult HFNT and 2 L/min, 10 L/min and 20 L/min during simulated paediatric HFNT).", [["All testing", "TEST", 0, 11], ["flow rates", "TEST", 53, 63]]], ["A tracheostomy interface is not operated at 2 L/min in the clinical setting, as a result, no runs were performed at this setting.Inhaled DoseNasal cannulas were positioned in the nose of anatomically relevant nose-throat models, in accordance with manufacturers' instructions.", [["nose", "ANATOMY", 179, 183], ["nose", "ANATOMY", 209, 213], ["nose", "ORGAN", 179, 183], ["nose", "ORGANISM_SUBDIVISION", 209, 213], ["A tracheostomy interface", "TREATMENT", 0, 24], ["runs", "PROBLEM", 93, 97], ["Inhaled DoseNasal cannulas", "TREATMENT", 129, 155], ["tracheostomy interface", "OBSERVATION", 2, 24], ["nose", "ANATOMY", 179, 183], ["throat", "ANATOMY", 214, 220]]], ["The nose-throat models were connected to a breathing simulator (Harvard Apparatus Dual Phase Control Respirator, Harvard Apparatus, MA, USA) via a collecting filter (RespirGard II 303, Baxter, Dublin, Ireland).", [["nose", "ANATOMY", 4, 8], ["a breathing simulator", "TREATMENT", 41, 62], ["a collecting filter", "TREATMENT", 145, 164], ["nose", "ANATOMY", 4, 8], ["throat", "ANATOMY", 9, 15]]], ["A healthy adult breath pattern (tidal volume 500 mL, breath rate 15 BPM and inspiratory: expiratory ratio 1:1) and a healthy paediatric breathing pattern (tidal volume 250 mL, breath rate 25 BPM and inspiratory: expiratory ratio 1:2) were used.", [["A healthy adult breath pattern", "PROBLEM", 0, 30], ["tidal volume", "TEST", 32, 44], ["breath rate", "TEST", 53, 64], ["expiratory ratio", "TEST", 89, 105], ["a healthy paediatric breathing pattern", "PROBLEM", 115, 153], ["tidal volume", "TEST", 155, 167], ["breath rate", "TEST", 176, 187], ["expiratory ratio", "TEST", 212, 228]]], ["Inhaled dose was determined by quantifying the mass of drug on a filter positioned distal to the trachea.", [["trachea", "ANATOMY", 97, 104], ["trachea", "MULTI-TISSUE_STRUCTURE", 97, 104], ["Inhaled dose", "TREATMENT", 0, 12], ["a filter", "TREATMENT", 63, 71], ["mass", "OBSERVATION", 47, 51], ["trachea", "ANATOMY", 97, 104]]], ["The tracheostomy interface and tracheostomy tube were attached directly to a collecting filter.", [["tube", "TISSUE", 44, 48], ["The tracheostomy interface", "TREATMENT", 0, 26], ["tracheostomy tube", "TREATMENT", 31, 48], ["a collecting filter", "TREATMENT", 75, 94], ["tracheostomy interface", "OBSERVATION", 4, 26], ["tracheostomy tube", "OBSERVATION", 31, 48], ["filter", "OBSERVATION", 88, 94]]], ["Additional figures containing photographs of the three different combinations of the test rigs are supplied as supplementary material ( Figures S1-S3) .Inhaled DoseThe humidifier was powered on and allowed to come to temperature (37 degrees Celsius) and a 2 mL dose of albuterol sulphate (2 mg/mL) (GlaxoSmithKline Ltd., Dublin, Ireland) was nebulised.", [["albuterol sulphate", "CHEMICAL", 269, 287], ["albuterol sulphate", "CHEMICAL", 269, 287], ["albuterol sulphate", "SIMPLE_CHEMICAL", 269, 287], ["the test rigs", "TEST", 81, 94], ["The humidifier", "TREATMENT", 164, 178], ["a 2 mL dose of albuterol sulphate", "TREATMENT", 254, 287], ["three different", "OBSERVATION_MODIFIER", 49, 64]]], ["Experiments were performed using the Aerogen Solo, vibrating mesh nebuliser (Aerogen Ltd., Galway, Ireland).", [["the Aerogen Solo", "TREATMENT", 33, 49], ["vibrating mesh nebuliser (Aerogen Ltd.", "TREATMENT", 51, 89]]], ["Albuterol was used as it is a commonly nebulised drug utilised in the characterisation of aerosol drug delivery systems.", [["Albuterol", "CHEMICAL", 0, 9], ["Albuterol", "CHEMICAL", 0, 9], ["Albuterol", "SIMPLE_CHEMICAL", 0, 9], ["Albuterol", "TREATMENT", 0, 9], ["a commonly nebulised drug", "TREATMENT", 28, 53], ["aerosol drug delivery systems", "TREATMENT", 90, 119]]], ["At the end of each dose administration, the drug captured on a filter was eluted using 10 mL of deionised water.", [["each dose administration", "TREATMENT", 14, 38], ["a filter", "TREATMENT", 61, 69], ["deionised water", "TREATMENT", 96, 111]]], ["The mass of drug was quantified by means of UV spectrophotometry at a wavelength of 276 nm and interpolation on a standard curve of albuterol sulphate concentrations (200 to 3.125 \u00b5g/mL).", [["albuterol sulphate", "CHEMICAL", 132, 150], ["albuterol sulphate", "CHEMICAL", 132, 150], ["albuterol sulphate", "SIMPLE_CHEMICAL", 132, 150], ["UV spectrophotometry", "TREATMENT", 44, 64], ["a standard curve of albuterol sulphate concentrations", "TREATMENT", 112, 165], ["mass", "OBSERVATION", 4, 8]]], ["Results for inhaled dose are expressed as the percentage of the nominal dose placed in the nebuliser's medication cup.Anatomical ModelsA previously described, an airway model of the adult nose-throat region was used as the adult model [29] .", [["airway", "ANATOMY", 162, 168], ["nose", "ANATOMY", 188, 192], ["airway", "MULTI-TISSUE_STRUCTURE", 162, 168], ["nose", "ORGANISM_SUBDIVISION", 188, 192], ["inhaled dose", "TREATMENT", 12, 24], ["the nominal dose", "TREATMENT", 60, 76], ["the nebuliser's medication cup", "TREATMENT", 87, 117], ["airway", "ANATOMY", 162, 168], ["throat", "ANATOMY", 193, 199]]], ["A model of a small child nose-throat region (nasal cavity, pharynx and larynx) with a volume of~22.3 cm 3 is based on a scan of a 5-year-old female, and was used as the paediatric model [30] ).Characterising Fugitive EmissionsThe aerodynamic particle sizer (APS) (APS, model 3321 TSI Inc., St. Paul, MN, USA) was the primary aerosol monitoring instrument used in this study.", [["nose-throat region", "ANATOMY", 25, 43], ["nasal cavity", "ANATOMY", 45, 57], ["pharynx", "ANATOMY", 59, 66], ["larynx", "ANATOMY", 71, 77], ["APS", "DISEASE", 258, 261], ["APS", "DISEASE", 264, 267], ["throat", "ORGANISM_SUBDIVISION", 30, 36], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 45, 57], ["pharynx", "ORGAN", 59, 66], ["larynx", "ORGAN", 71, 77], ["female", "ORGANISM", 141, 147], ["a small child nose-throat region (nasal cavity, pharynx and larynx", "PROBLEM", 11, 77], ["a volume", "TEST", 84, 92], ["a scan", "TEST", 118, 124], ["The aerodynamic particle sizer", "TEST", 226, 256], ["APS", "TEST", 264, 267], ["the primary aerosol monitoring instrument", "TREATMENT", 313, 354], ["this study", "TEST", 363, 373], ["small", "OBSERVATION_MODIFIER", 13, 18], ["throat", "ANATOMY", 30, 36], ["region", "ANATOMY_MODIFIER", 37, 43], ["nasal cavity", "ANATOMY", 45, 57], ["pharynx", "ANATOMY", 59, 66], ["larynx", "ANATOMY", 71, 77], ["volume", "OBSERVATION_MODIFIER", 86, 92], ["22.3 cm", "OBSERVATION_MODIFIER", 96, 103], ["Fugitive Emissions", "OBSERVATION", 208, 226], ["aerodynamic", "OBSERVATION_MODIFIER", 230, 241], ["particle sizer", "OBSERVATION", 242, 256]]], ["Throughout the experiments, the APSs continuously measured aerosol mass concentrations and size distributions (0.5 to 20 \u00b5m) of the airborne concentration in the room.", [["mass", "OBSERVATION", 67, 71], ["size", "OBSERVATION_MODIFIER", 91, 95], ["distributions", "OBSERVATION_MODIFIER", 96, 109]]], ["The APSs were located at a distance of 0.8 m and 2.2 m away from the patient interface ( Figure 1 ).", [["APSs", "CANCER", 4, 8], ["patient", "ORGANISM", 69, 76], ["APSs", "DNA", 4, 8], ["patient", "SPECIES", 69, 76]]], ["The two distances were chosen on the basis that the distance of 0.8 m was approximately one arm's length away, simulating a caregiver holding a nebuliser/facemask to a patient's face.", [["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["a nebuliser/facemask", "TREATMENT", 142, 162]]], ["The distance of 2.2 m was selected as it approximately represented the distance between beds in a primary care centre, simulating a patient situated in a bed next to the patient receiving the aerosol therapy.Temperature, Humidity and Airflow CharacteristicsThe laboratory room in which the study was conducted had dimensions L = 6.06 m, W = 2.70 m and H = 2.71 m.", [["patient", "ORGANISM", 132, 139], ["patient", "ORGANISM", 170, 177], ["patient", "SPECIES", 132, 139], ["patient", "SPECIES", 170, 177], ["the aerosol therapy", "TREATMENT", 188, 207], ["Temperature", "TEST", 208, 219], ["Humidity", "TEST", 221, 229], ["the study", "TEST", 286, 295], ["dimensions", "TEST", 314, 324], ["L", "TEST", 325, 326], ["W", "TEST", 337, 338], ["2.2 m", "OBSERVATION_MODIFIER", 16, 21]]], ["The air change rate was measured using the tracer gas decay method with CO2 as the tracer [31] , and a GrayWolf probe IQ-610 (GrayWolf Sensing Solutions; Shelton, CT, USA) was used for gas detection.", [["CO2", "CHEMICAL", 72, 75], ["IQ-610", "CHEMICAL", 118, 124], ["CO2", "CHEMICAL", 72, 75], ["IQ-610", "CHEMICAL", 118, 124], ["CO2", "SIMPLE_CHEMICAL", 72, 75], ["The air change rate", "TEST", 0, 19], ["the tracer gas", "TEST", 39, 53], ["the tracer", "TEST", 79, 89], ["a GrayWolf probe IQ", "TEST", 101, 120], ["GrayWolf Sensing Solutions", "TREATMENT", 126, 152], ["CT", "TEST", 163, 165], ["gas detection", "TEST", 185, 198], ["air change", "OBSERVATION", 4, 14]]], ["The air change rate was calculated to be approximately 0.65 h \u22121 .Temperature, Humidity and Airflow CharacteristicsRoom temperature and relative humidity in the laboratory room were measured using a digital hygro-thermometer-datalogger (Model DHM200, Pacer Instrument, Chippewa Falls, WI, USA) and values recorded were in the ranges 18.5 to 23.8 \u00b0C and 47.3 to 66.9%, respectively.", [["The air change rate", "TEST", 0, 19], ["Temperature", "TEST", 66, 77], ["Room temperature", "TEST", 115, 131], ["Pacer Instrument", "TREATMENT", 251, 267], ["\u00b0C", "TEST", 346, 348], ["air change", "OBSERVATION", 4, 14]]], ["The experiments took place over a three-week period.Data Analysis and StatisticsThe data analysis for this study was performed using statistical package IBM SPSS Statistics 24 (IBM Corp., Armonk, NY, USA, 2013).", [["Data Analysis", "TEST", 52, 65], ["The data analysis", "TEST", 80, 97], ["this study", "TEST", 102, 112]]], ["Summary and descriptive statistics were performed on the aerosol concentrations.", [["the aerosol concentrations", "TREATMENT", 53, 79]]], ["All distribution characteristics are summarised by arithmetic mean and standard deviations.Inhaled DoseThe overall trend, as shown in Table 1 , indicated that for both the nasal cannula and tracheostomy interfaces, as the flow rate increased, there was a corresponding decrease in inhaled dose (%).Inhaled DoseWhen the adult scenarios were compared under the same flow-rate conditions, similar inhaled doses were found between the nasal cannula and the tracheostomy interface.", [["nasal", "ANATOMY", 172, 177], ["nasal", "ANATOMY", 431, 436], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 172, 185], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 431, 444], ["arithmetic mean", "TEST", 51, 66], ["the nasal cannula", "TREATMENT", 168, 185], ["tracheostomy interfaces", "TREATMENT", 190, 213], ["the flow rate", "TEST", 218, 231], ["similar inhaled doses", "TREATMENT", 386, 407], ["the nasal cannula", "TREATMENT", 427, 444], ["the tracheostomy interface", "TREATMENT", 449, 475], ["standard deviations", "OBSERVATION", 71, 90], ["overall", "OBSERVATION_MODIFIER", 107, 114], ["trend", "OBSERVATION_MODIFIER", 115, 120], ["nasal cannula", "ANATOMY", 172, 185], ["tracheostomy interfaces", "OBSERVATION", 190, 213], ["decrease", "OBSERVATION_MODIFIER", 269, 277], ["nasal cannula", "ANATOMY", 431, 444], ["tracheostomy interface", "OBSERVATION", 453, 475]]], ["The paediatric nasal cannula only delivered 2.5% to 11% of the tracheostomy dose under the same flow-rate conditions.", [["nasal", "ANATOMY", 15, 20], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 15, 28], ["The paediatric nasal cannula", "TREATMENT", 0, 28], ["the tracheostomy dose", "TREATMENT", 59, 80], ["nasal cannula", "ANATOMY", 15, 28]]], ["The paediatric nasal cannula scenarios had a lower inhaled dose than the adult scenarios, while the paediatric tracheostomy scenarios had a higher inhaled dose than the adult scenarios.Inhaled DoseWhen comparing the inhaled dose for the tracheostomy interface and the nasal cannula for the paediatric and adult patients under the same flow-rate conditions (10 L/min), there was a noticeable difference in the inhaled dose, which indicated that additional factors were influencing drug delivery.", [["nasal", "ANATOMY", 15, 20], ["nasal", "ANATOMY", 268, 273], ["DoseWhen", "CHEMICAL", 193, 201], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 15, 28], ["DoseWhen", "SIMPLE_CHEMICAL", 193, 201], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 268, 281], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["The paediatric nasal cannula scenarios", "TREATMENT", 0, 38], ["a lower inhaled dose", "TREATMENT", 43, 63], ["the paediatric tracheostomy scenarios", "TREATMENT", 96, 133], ["Inhaled", "TREATMENT", 185, 192], ["the tracheostomy interface", "TREATMENT", 233, 259], ["the nasal cannula", "TREATMENT", 264, 281], ["drug delivery", "TREATMENT", 480, 493], ["nasal cannula", "OBSERVATION", 15, 28], ["tracheostomy", "OBSERVATION", 237, 249], ["nasal cannula", "ANATOMY", 268, 281]]], ["Inhaled dose recorded during each nebulisation event using simulated adult and paediatric breathing profiles for the nasal cannula and tracheostomy interfaces, mean and standard deviations over the three events.", [["nasal", "ANATOMY", 117, 122], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 117, 130], ["Inhaled dose", "TREATMENT", 0, 12], ["paediatric breathing profiles", "TREATMENT", 79, 108], ["the nasal cannula", "TREATMENT", 113, 130], ["tracheostomy interfaces", "TREATMENT", 135, 158], ["standard deviations over the three events", "PROBLEM", 169, 210], ["nasal cannula", "ANATOMY", 117, 130], ["tracheostomy interfaces", "OBSERVATION", 135, 158]]], ["The APSs were set to record data at 20 s intervals for a total of 30 min.", [["APSs", "DNA", 4, 8]]], ["The initial five-minute period established a baseline measurement of ambient aerosol in the room prior to activating the nebuliser.", [["ambient aerosol", "TREATMENT", 69, 84], ["activating the nebuliser", "TREATMENT", 106, 130]]], ["The remaining 25 min was selected to monitor for fugitive emissions during the nebulisation period and the consequent aerosol decay.", [["the nebulisation period", "TREATMENT", 75, 98], ["the consequent aerosol decay", "TREATMENT", 103, 131], ["aerosol decay", "OBSERVATION", 118, 131]]], ["After each nebulisation event, the laboratory was vented, and the aerosol concentration was monitored until it returned to ambient levels.Temperature, Humidity and Airflow CharacteristicsThe laboratory room in which the study was conducted had dimensions L = 6.06 m, W = 2.70 m and H = 2.71 m.", [["vented", "TREATMENT", 50, 56], ["the aerosol concentration", "TREATMENT", 62, 87], ["Temperature", "TEST", 138, 149], ["Humidity", "TEST", 151, 159], ["the study", "TEST", 216, 225], ["dimensions", "TEST", 244, 254], ["L", "TEST", 255, 256], ["W", "TEST", 267, 268]]], ["The air change rate was measured using the tracer gas decay method with CO2 as the tracer [31] , and a GrayWolf probe IQ-610 (GrayWolf Sensing Solutions; Shelton, CT, USA) was used for gas detection.", [["CO2", "CHEMICAL", 72, 75], ["IQ-610", "CHEMICAL", 118, 124], ["CO2", "CHEMICAL", 72, 75], ["IQ-610", "CHEMICAL", 118, 124], ["CO2", "SIMPLE_CHEMICAL", 72, 75], ["The air change rate", "TEST", 0, 19], ["the tracer gas", "TEST", 39, 53], ["the tracer", "TEST", 79, 89], ["a GrayWolf probe IQ", "TEST", 101, 120], ["GrayWolf Sensing Solutions", "TREATMENT", 126, 152], ["CT", "TEST", 163, 165], ["gas detection", "TEST", 185, 198], ["air change", "OBSERVATION", 4, 14]]], ["The air change rate was calculated to be approximately 0.65 h \u22121 .Temperature, Humidity and Airflow CharacteristicsRoom temperature and relative humidity in the laboratory room were measured using a digital hygro-thermometer-datalogger (Model DHM200, Pacer Instrument, Chippewa Falls, WI, USA) and values recorded were in the ranges 18.5 to 23.8 \u2022 C and 47.3 to 66.9%, respectively.", [["The air change rate", "TEST", 0, 19], ["Temperature", "TEST", 66, 77], ["Room temperature", "TEST", 115, 131], ["Pacer Instrument", "TREATMENT", 251, 267], ["C", "TEST", 348, 349], ["air change", "OBSERVATION", 4, 14]]], ["The experiments took place over a three-week period.Data Analysis and StatisticsThe data analysis for this study was performed using statistical package IBM SPSS Statistics 24 (IBM Corp., Armonk, NY, USA, 2013).", [["Data Analysis", "TEST", 52, 65], ["The data analysis", "TEST", 80, 97], ["this study", "TEST", 102, 112]]], ["Summary and descriptive statistics were performed on the aerosol concentrations.", [["the aerosol concentrations", "TREATMENT", 53, 79]]], ["All distribution characteristics are summarised by arithmetic mean and standard deviations.Inhaled DoseThe overall trend, as shown in Table 1 , indicated that for both the nasal cannula and tracheostomy interfaces, as the flow rate increased, there was a corresponding decrease in inhaled dose (%).Inhaled DoseWhen the adult scenarios were compared under the same flow-rate conditions, similar inhaled doses were found between the nasal cannula and the tracheostomy interface.", [["nasal", "ANATOMY", 172, 177], ["nasal", "ANATOMY", 431, 436], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 172, 185], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 431, 444], ["arithmetic mean", "TEST", 51, 66], ["the nasal cannula", "TREATMENT", 168, 185], ["tracheostomy interfaces", "TREATMENT", 190, 213], ["the flow rate", "TEST", 218, 231], ["similar inhaled doses", "TREATMENT", 386, 407], ["the nasal cannula", "TREATMENT", 427, 444], ["the tracheostomy interface", "TREATMENT", 449, 475], ["standard deviations", "OBSERVATION", 71, 90], ["overall", "OBSERVATION_MODIFIER", 107, 114], ["trend", "OBSERVATION_MODIFIER", 115, 120], ["nasal cannula", "ANATOMY", 172, 185], ["tracheostomy interfaces", "OBSERVATION", 190, 213], ["decrease", "OBSERVATION_MODIFIER", 269, 277], ["nasal cannula", "ANATOMY", 431, 444], ["tracheostomy interface", "OBSERVATION", 453, 475]]], ["The paediatric nasal cannula only delivered 2.5% to 11% of the tracheostomy dose under the same flow-rate conditions.", [["nasal", "ANATOMY", 15, 20], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 15, 28], ["The paediatric nasal cannula", "TREATMENT", 0, 28], ["the tracheostomy dose", "TREATMENT", 59, 80], ["nasal cannula", "ANATOMY", 15, 28]]], ["The paediatric nasal cannula scenarios had a lower inhaled dose than the adult scenarios, while the paediatric tracheostomy scenarios had a higher inhaled dose than the adult scenarios.Inhaled DoseWhen comparing the inhaled dose for the tracheostomy interface and the nasal cannula for the paediatric and adult patients under the same flow-rate conditions (10 L/min), there was a noticeable difference in the inhaled dose, which indicated that additional factors were influencing drug delivery.Peak Aerosol ConcentrationsFigures 2 and 3 represent the averaged for each of the three runs per scenario and demonstrate the initial five-minute baseline of ambient concentration, the increase in aerosol concentration during the nebulisation period and the consequent decay following the nebulisation.", [["nasal", "ANATOMY", 15, 20], ["nasal", "ANATOMY", 268, 273], ["DoseWhen", "CHEMICAL", 193, 201], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 15, 28], ["DoseWhen", "SIMPLE_CHEMICAL", 193, 201], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 268, 281], ["patients", "ORGANISM", 311, 319], ["patients", "SPECIES", 311, 319], ["The paediatric nasal cannula scenarios", "TREATMENT", 0, 38], ["a lower inhaled dose", "TREATMENT", 43, 63], ["the paediatric tracheostomy scenarios", "TREATMENT", 96, 133], ["Inhaled", "TREATMENT", 185, 192], ["the tracheostomy interface", "TREATMENT", 233, 259], ["the nasal cannula", "TREATMENT", 264, 281], ["drug delivery", "TREATMENT", 480, 493], ["Peak Aerosol ConcentrationsFigures", "TREATMENT", 494, 528], ["ambient concentration", "TREATMENT", 652, 673], ["aerosol concentration", "TREATMENT", 691, 712], ["the nebulisation", "TREATMENT", 779, 795], ["nasal cannula", "OBSERVATION", 15, 28], ["tracheostomy", "OBSERVATION", 237, 249], ["nasal cannula", "ANATOMY", 268, 281], ["increase", "OBSERVATION_MODIFIER", 679, 687], ["aerosol concentration", "OBSERVATION", 691, 712]]], ["The increase in aerosol concentrations can be attributed to fugitive emissions from the high-flow therapy interfaces.", [["The increase in aerosol concentrations", "PROBLEM", 0, 38], ["fugitive emissions", "PROBLEM", 60, 78], ["the high-flow therapy interfaces", "TREATMENT", 84, 116], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["aerosol concentrations", "OBSERVATION", 16, 38], ["fugitive emissions", "OBSERVATION", 60, 78], ["high", "OBSERVATION_MODIFIER", 88, 92], ["flow therapy", "OBSERVATION", 93, 105]]], ["Table 2 summarises the peak aerosol concentrations recorded at a distance of 0.8 m from the patient interface.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["the peak aerosol concentrations", "TREATMENT", 19, 50]]], ["Across all scenarios, the ratio of averaged peak measurements at respective distances of 2.2 and 0.8 m ranged from 0.20 to 1.27.", [["the ratio", "TEST", 22, 31]]], ["As shown in Figure 2 , the main differences arose during the period between five and fifteen minutes after the commencement of nebulisation.", [["nebulisation", "TREATMENT", 127, 139], ["main", "OBSERVATION_MODIFIER", 27, 31], ["differences", "OBSERVATION_MODIFIER", 32, 43]]], ["During this period, proximity to the interface resulted in higher concentrations.", [["higher concentrations", "PROBLEM", 59, 80], ["higher concentrations", "OBSERVATION", 59, 80]]], ["The peak concentration was reached between 7 to 15 min for the distance of 0.8 m away from the patient interface, and between 9 to 15 min for the 2.2 m distance.", [["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["The peak concentration", "TEST", 0, 22], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22]]], ["However, the majority of the peak concentrations occurred between 10 and 14 min corresponding to the duration of the nebulisation period, highlighting the cumulative fugitive emissions from the high-flow therapy interfaces.Time-Weighted Averaged Aerosol ConcentrationsThe mean and standard deviation of the averaged five-minute baseline ambient aerosol concentration was 0.011 \u00b1 0.008 mg m \u22123 .", [["the peak concentrations", "PROBLEM", 25, 48], ["the cumulative fugitive emissions", "PROBLEM", 151, 184], ["the high-flow therapy interfaces", "TREATMENT", 190, 222], ["the averaged five-minute baseline ambient aerosol concentration", "TREATMENT", 303, 366], ["majority", "OBSERVATION_MODIFIER", 13, 21], ["peak concentrations", "OBSERVATION", 29, 48], ["cumulative", "OBSERVATION_MODIFIER", 155, 165], ["fugitive emissions", "OBSERVATION", 166, 184], ["high", "OBSERVATION_MODIFIER", 194, 198], ["flow therapy", "OBSERVATION", 199, 211]]], ["Table 3 summarises the 30-minute time-weighted averages for the nasal cannula and tracheostomy scenarios for adult and paediatric patients at a distance of 0.8 m and 2.2 m.", [["nasal", "ANATOMY", 64, 69], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 64, 77], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["the nasal cannula", "TREATMENT", 60, 77], ["tracheostomy scenarios", "TREATMENT", 82, 104], ["nasal cannula", "ANATOMY", 64, 77]]], ["For all scenarios where the air-flow rate was below 20 L/min, higher aerosol concentrations were recorded at a distance of 0.8 m from the patient interface.", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["the air-flow rate", "TEST", 24, 41], ["higher aerosol concentrations", "PROBLEM", 62, 91]]], ["However, when the air-flow rate was 40 L/min or above, higher concentrations were recorded at a distance of 2.2 m dueTime-Weighted Averaged Aerosol ConcentrationsThe mean and standard deviation of the averaged five-minute baseline ambient aerosol concentration was 0.011 \u00b1 0.008 mg m \u22123 .", [["the air-flow rate", "TEST", 14, 31], ["the averaged five-minute baseline ambient aerosol concentration", "TREATMENT", 197, 260], ["mean", "OBSERVATION_MODIFIER", 166, 170]]], ["Table 3 summarises the 30-minute time-weighted averages for the nasal cannula and tracheostomy scenarios for adult and paediatric patients at a distance of 0.8 m and 2.2 m.", [["nasal", "ANATOMY", 64, 69], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 64, 77], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["the nasal cannula", "TREATMENT", 60, 77], ["tracheostomy scenarios", "TREATMENT", 82, 104], ["nasal cannula", "ANATOMY", 64, 77]]], ["For all scenarios where the air-flow rate was below 20 L/min, higher aerosol concentrations were recorded at a distance of 0.8 m from the patient interface.", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["the air-flow rate", "TEST", 24, 41], ["higher aerosol concentrations", "PROBLEM", 62, 91]]], ["However, when the air-flow rate was 40 L/min or above, higher concentrations were recorded at a distance of 2.2 m dueTime-Weighted Averaged Aerosol ConcentrationsThe mean and standard deviation of the averaged five-minute baseline ambient aerosol concentration was 0.011 \u00b1 0.008 mg m \u22123 .", [["the air-flow rate", "TEST", 14, 31], ["the averaged five-minute baseline ambient aerosol concentration", "TREATMENT", 197, 260], ["mean", "OBSERVATION_MODIFIER", 166, 170]]], ["Table 3 summarises the 30-min time-weighted averages for the nasal cannula and tracheostomy scenarios for adult and paediatric patients at a distance of 0.8 m and 2.2 m.", [["nasal", "ANATOMY", 61, 66], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 61, 74], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["the nasal cannula", "TREATMENT", 57, 74], ["tracheostomy scenarios", "TREATMENT", 79, 101], ["nasal cannula", "ANATOMY", 61, 74]]], ["For all scenarios where the air-flow rate was below 20 L/min, higher aerosol concentrations were recorded at a distance of 0.8 m from the patient interface.", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["the air-flow rate", "TEST", 24, 41], ["higher aerosol concentrations", "PROBLEM", 62, 91]]], ["However, when the air-flow rate was 40 L/min or above, higher concentrations were recorded at a distance of 2.2 m due to the increasing dispersion of the aerosol throughout the room.", [["the air-flow rate", "TEST", 14, 31], ["increasing", "OBSERVATION_MODIFIER", 125, 135], ["dispersion", "OBSERVATION_MODIFIER", 136, 146]]], ["For both the nasal cannula and the tracheostomy during simulated adult breathing, there was a decrease in aerosol concentrations with increasing gas-flow rate.", [["nasal", "ANATOMY", 13, 18], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 13, 26], ["the nasal cannula", "TREATMENT", 9, 26], ["the tracheostomy", "TREATMENT", 31, 47], ["a decrease in aerosol concentrations", "PROBLEM", 92, 128], ["nasal cannula", "ANATOMY", 13, 26], ["tracheostomy", "OBSERVATION", 35, 47], ["decrease", "OBSERVATION_MODIFIER", 94, 102], ["aerosol concentrations", "OBSERVATION", 106, 128], ["flow rate", "OBSERVATION", 149, 158]]], ["While both interfaces yielded comparable aerosol concentrations at 10 L/min, there was a greater decrease in concentration for the nasal cannula in comparison with the tracheostomy at higher flow rates.", [["nasal", "ANATOMY", 131, 136], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 131, 144], ["comparable aerosol concentrations", "TREATMENT", 30, 63], ["a greater decrease in concentration", "PROBLEM", 87, 122], ["the nasal cannula", "TREATMENT", 127, 144], ["the tracheostomy", "TREATMENT", 164, 180], ["comparable", "OBSERVATION_MODIFIER", 30, 40], ["aerosol concentrations", "OBSERVATION", 41, 63], ["greater", "OBSERVATION_MODIFIER", 89, 96], ["decrease", "OBSERVATION_MODIFIER", 97, 105], ["concentration", "OBSERVATION_MODIFIER", 109, 122], ["nasal cannula", "OBSERVATION", 131, 144], ["tracheostomy", "OBSERVATION", 168, 180]]], ["At 60 L/min, the tracheostomy aerosol concentrations were twice those of the nasal cannula concentrations.Time-Weighted Averaged Aerosol ConcentrationsDifferent trends were observed for the nasal cannula and tracheostomy during paediatric breathing.", [["nasal", "ANATOMY", 77, 82], ["nasal", "ANATOMY", 190, 195], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 77, 90], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 190, 203], ["the tracheostomy aerosol concentrations", "TREATMENT", 13, 52], ["the nasal cannula concentrations", "TREATMENT", 73, 105], ["the nasal cannula", "TREATMENT", 186, 203], ["tracheostomy", "TREATMENT", 208, 220], ["nasal cannula", "ANATOMY", 77, 90], ["nasal cannula", "ANATOMY", 190, 203], ["tracheostomy", "OBSERVATION", 208, 220]]], ["The highest aerosol concentration was observed at the lowest gas-flow rate for the nasal cannula, while the highest concentration was observed at the highest gas-flow rate for the tracheostomy interface.Time-Weighted Averaged Aerosol ConcentrationsThere was a noticeable difference between the aerosol concentrations measured for the nasal cannula and the tracheostomy interface during simulated paediatric breathing.", [["nasal", "ANATOMY", 83, 88], ["nasal", "ANATOMY", 334, 339], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 83, 96], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 334, 347], ["The highest aerosol concentration", "TREATMENT", 0, 33], ["the nasal cannula", "TREATMENT", 79, 96], ["the tracheostomy interface", "TREATMENT", 176, 202], ["the aerosol concentrations", "TREATMENT", 290, 316], ["the nasal cannula", "TREATMENT", 330, 347], ["the tracheostomy interface", "TREATMENT", 352, 378], ["simulated paediatric breathing", "PROBLEM", 386, 416], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["aerosol concentration", "OBSERVATION", 12, 33], ["nasal cannula", "ANATOMY", 83, 96], ["tracheostomy interface", "OBSERVATION", 180, 202], ["aerosol concentrations", "OBSERVATION", 294, 316], ["nasal cannula", "ANATOMY", 334, 347], ["tracheostomy interface", "OBSERVATION", 356, 378], ["paediatric breathing", "OBSERVATION", 396, 416]]], ["However, the same variations did not occur between the nasal cannula and tracheostomy interface for the adult patient or between adult and paediatric patients with the tracheostomy interface.", [["nasal", "ANATOMY", 55, 60], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 55, 68], ["patient", "ORGANISM", 110, 117], ["patients", "ORGANISM", 150, 158], ["patient", "SPECIES", 110, 117], ["patients", "SPECIES", 150, 158], ["the nasal cannula", "TREATMENT", 51, 68], ["tracheostomy interface", "TREATMENT", 73, 95], ["the tracheostomy interface", "TREATMENT", 164, 190], ["nasal cannula", "ANATOMY", 55, 68], ["tracheostomy interface", "OBSERVATION", 73, 95], ["tracheostomy interface", "OBSERVATION", 168, 190]]], ["Table 4 summarises the average mass median aerodynamic diameter (MMAD) over the 30-min period, in terms of mass concentrations recorded by the APS at a distance of 0.8 m away from the patient interface.", [["APS", "DISEASE", 143, 146], ["patient", "ORGANISM", 184, 191], ["patient", "SPECIES", 184, 191], ["mass concentrations", "PROBLEM", 107, 126], ["aerodynamic diameter", "OBSERVATION", 43, 63], ["mass", "OBSERVATION", 107, 111]]], ["Summary of the averaged mass median aerodynamic diameter during each nebulisation event when using two interfaces (nasal cannula and tracheostomy) with three gas-flow rates for simulated adult and paediatric patients, mean and standard deviations over the three events.Breathing Pattern/Gas-Flow RateAverage MMAD (\u00b5m) When considered in combination with Table 3 , the MMAD for the paediatric breathing patterns for the nasal cannula interface are reflective of the ambient aerosol concentrations, not the fugitive emissions released from the nebuliser system.", [["nasal", "ANATOMY", 115, 120], ["nasal", "ANATOMY", 419, 424], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 115, 128], ["patients", "ORGANISM", 208, 216], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 419, 432], ["patients", "SPECIES", 208, 216], ["the averaged mass median aerodynamic diameter", "PROBLEM", 11, 56], ["nasal cannula", "TREATMENT", 115, 128], ["tracheostomy", "TREATMENT", 133, 145], ["Breathing Pattern", "TEST", 269, 286], ["the paediatric breathing patterns", "TREATMENT", 377, 410], ["the nasal cannula interface", "TREATMENT", 415, 442], ["the ambient aerosol concentrations", "TREATMENT", 461, 495], ["mass", "OBSERVATION", 24, 28], ["median", "OBSERVATION_MODIFIER", 29, 35], ["aerodynamic diameter", "OBSERVATION", 36, 56], ["nasal cannula", "ANATOMY", 419, 432], ["aerosol concentrations", "OBSERVATION", 473, 495]]], ["For the remaining combinations, all MMADs were in 1 to 2 \u00b5m for both the 0.8 and 2.2 m distances.Nasal Cannula TracheostomyThe MMAD was comparable for the tracheostomy interface and the nasal cannula at 10 L/min, regardless of the patient interface or gas-flow rates.", [["Nasal", "ANATOMY", 97, 102], ["nasal", "ANATOMY", 186, 191], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 186, 199], ["patient", "ORGANISM", 231, 238], ["patient", "SPECIES", 231, 238], ["all MMADs", "TREATMENT", 32, 41], ["Nasal Cannula Tracheostomy", "TREATMENT", 97, 123], ["the tracheostomy interface", "TREATMENT", 151, 177], ["the nasal cannula", "TREATMENT", 182, 199], ["gas-flow rates", "TEST", 252, 266], ["Cannula Tracheostomy", "OBSERVATION", 103, 123], ["tracheostomy", "OBSERVATION", 155, 167], ["nasal cannula", "ANATOMY", 186, 199]]], ["Overall, as the gas-flow rates increased, the MMAD across all patient interfaces decreased.Potential Inhalation ExposureAs a worked example, two different types of patient interfaces for high-flow therapy were examined, during aerosol delivery, to estimate the potential inhalation exposure.", [["patient", "ORGANISM", 62, 69], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 62, 69], ["patient", "SPECIES", 164, 171], ["the gas-flow rates", "TEST", 12, 30], ["patient interfaces", "TREATMENT", 164, 182], ["high-flow therapy", "TREATMENT", 187, 204], ["aerosol delivery", "TREATMENT", 227, 243], ["decreased", "OBSERVATION_MODIFIER", 81, 90], ["flow therapy", "OBSERVATION", 192, 204], ["inhalation exposure", "OBSERVATION", 271, 290]]], ["The first was a caregiver, who was assumed to be at the distance of 0.8 m from the patient, while the bystander was assumed to be at the distance of 2.2 m.", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90]]], ["Inhalation exposure was calculated for the adult nasal cannula scenario and the paediatric tracheostomy, both at 10 L/min, using the time-series averaged data for each scenario.", [["nasal", "ANATOMY", 49, 54], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 49, 62], ["Inhalation exposure", "TREATMENT", 0, 19], ["the adult nasal cannula scenario", "TREATMENT", 39, 71], ["the paediatric tracheostomy", "TREATMENT", 76, 103], ["tracheostomy", "OBSERVATION", 91, 103]]], ["To focus solely on the fugitive emissions from each interface, the five-minute baseline average of the aerosol concentration was subtracted from the time-series data.", [["the aerosol concentration", "TREATMENT", 99, 124]]], ["Short-term exposure inhalation rate of 1.3 \u00d7 10 \u22122 m 3 /min and 4.8 \u00d7 10 \u22123 m 3 /min were selected to represent the caregiver and the bystander, respectively.", [["Short-term exposure inhalation rate", "TREATMENT", 0, 35]]], ["The caregiver was assumed to have a 'light intensity' activity level, while the bystander was assumed to have a 'sedentary/passive' activity level [32] .", [["a 'light intensity' activity level", "PROBLEM", 34, 68]]], ["In this scenario, the caregiver and the bystander were estimated to be potentially exposed to 8.5% and 3.2% of the original drug, respectively, for the nasal cannula interface, with corresponding values of 10.2% and 2.3% for the tracheostomy interface, respectively.DiscussionThis study examined the potential for secondary inhalation of medical aerosols emitted during high-flow therapy.", [["nasal", "ANATOMY", 152, 157], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 152, 165], ["the nasal cannula interface", "TEST", 148, 175], ["This study", "TEST", 276, 286], ["secondary inhalation of medical aerosols", "PROBLEM", 314, 354], ["high-flow therapy", "TREATMENT", 370, 387], ["nasal cannula", "ANATOMY", 152, 165], ["tracheostomy interface", "OBSERVATION", 229, 251], ["flow therapy", "OBSERVATION", 375, 387]]], ["Fugitive emissions were examined for both a nasal cannula and a tracheostomy interface under three different gas-flow rates during simulated paediatric and adult breathing.", [["nasal", "ANATOMY", 44, 49], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 44, 57], ["a nasal cannula", "TREATMENT", 42, 57], ["a tracheostomy interface", "TREATMENT", 62, 86], ["nasal cannula", "ANATOMY", 44, 57], ["tracheostomy", "OBSERVATION", 64, 76]]], ["For each patient, a breathing simulator and a head model with a nasal cannula or a tracheostomy interface with a tracheostomy tube, were used to simulate healthy adult and paediatric breathing.", [["head", "ANATOMY", 46, 50], ["nasal", "ANATOMY", 64, 69], ["patient", "ORGANISM", 9, 16], ["head", "ORGANISM_SUBDIVISION", 46, 50], ["patient", "SPECIES", 9, 16], ["a breathing simulator", "TREATMENT", 18, 39], ["a head model", "TREATMENT", 44, 56], ["a nasal cannula", "TREATMENT", 62, 77], ["a tracheostomy interface", "TREATMENT", 81, 105], ["a tracheostomy tube", "TREATMENT", 111, 130], ["tracheostomy tube", "OBSERVATION", 113, 130]]], ["Once released into the environment, the APS characterised time-series aerosol concentrations and size distributions, which were reflective of the fugitive emissions from high-flow interface selection.", [["APS", "DISEASE", 40, 43], ["the fugitive emissions", "PROBLEM", 142, 164], ["high-flow interface selection", "TREATMENT", 170, 199], ["size", "OBSERVATION_MODIFIER", 97, 101], ["fugitive emissions", "OBSERVATION", 146, 164], ["high", "OBSERVATION_MODIFIER", 170, 174], ["flow interface", "OBSERVATION", 175, 189]]], ["While the current methodology did not isolate the fugitive emissions from the ambient aerosol, the changes in time-series concentrations highlighted that ambient aerosol was only a minor contributor as shown in Figures 2 and 3 .", [["the ambient aerosol", "TREATMENT", 74, 93], ["ambient aerosol", "TREATMENT", 154, 169]]], ["The increases in aerosol concentrations were attributed to the release of fugitive aerosol into the surroundings.DiscussionThe current approach did not differentiate between aerosol that was released prior to inhalation, or aerosol that was possibly exhaled after inhalation.", [["The increases in aerosol concentrations", "PROBLEM", 0, 39], ["aerosol", "TREATMENT", 174, 181], ["aerosol", "TREATMENT", 224, 231], ["increases", "OBSERVATION_MODIFIER", 4, 13], ["aerosol concentrations", "OBSERVATION", 17, 39], ["fugitive aerosol", "OBSERVATION", 74, 90]]], ["While the use of collection filters has been widely used as a suitable method to determine the inhalation dose [33, 34] , it might not be truly representative of a simulation of real exhalation.", [["collection filters", "TREATMENT", 17, 35]]], ["However, since the overall percentage of the inhaled dose is relatively small, it is assumed that the majority of the fugitive emissions consists of aerosol escaping prior to inhalation.DiscussionVibrating mesh nebuliser technology generates aerosol by a contraction and expansion of a vibrational element producing movement on an aperture plate to produce an aerosol; this approach does not require any compressed air to generate the aerosol.", [["aerosol escaping", "TREATMENT", 149, 165], ["DiscussionVibrating mesh nebuliser technology", "TREATMENT", 186, 231], ["a vibrational element", "PROBLEM", 284, 305], ["an aperture plate", "TREATMENT", 328, 345], ["an aerosol", "TREATMENT", 357, 367], ["the aerosol", "TREATMENT", 431, 442], ["small", "OBSERVATION_MODIFIER", 72, 77], ["fugitive emissions", "OBSERVATION", 118, 136], ["aerosol escaping", "OBSERVATION", 149, 165], ["air", "OBSERVATION", 415, 418]]], ["The size of the aerosol and flow are determined by the exit diameter of the aperture holes [35] .", [["size", "OBSERVATION_MODIFIER", 4, 8], ["aerosol", "OBSERVATION", 16, 23], ["flow", "OBSERVATION", 28, 32], ["exit", "OBSERVATION_MODIFIER", 55, 59], ["diameter", "OBSERVATION_MODIFIER", 60, 68]]], ["Previous research showed that the residual mass remaining in a VMN was independent of the patient interface, heating and humidification settings [26, 28] .", [["VMN", "SIMPLE_CHEMICAL", 63, 66], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["the residual mass", "PROBLEM", 30, 47], ["heating and humidification settings", "TREATMENT", 109, 144], ["residual", "OBSERVATION_MODIFIER", 34, 42], ["mass", "OBSERVATION", 43, 47]]], ["As the same VMN was used for each scenario, the aerosol generation rate should be consistent across all scenarios with changes in inhaled dose and fugitive emissions influenced by the patient interface, the gas-flow rate and the breathing profiles.DiscussionThe results indicate that the inhaled dose (%) decreased with an increased gas-flow rate.", [["VMN", "SIMPLE_CHEMICAL", 12, 15], ["patient", "ORGANISM", 184, 191], ["patient", "SPECIES", 184, 191], ["the aerosol generation rate", "TREATMENT", 44, 71], ["changes in inhaled dose", "TREATMENT", 119, 142], ["fugitive emissions", "TREATMENT", 147, 165], ["the gas-flow rate", "TEST", 203, 220], ["the breathing profiles", "TEST", 225, 247], ["the inhaled dose", "TREATMENT", 284, 300], ["an increased gas", "TEST", 320, 336], ["increased", "OBSERVATION_MODIFIER", 323, 332], ["gas", "OBSERVATION", 333, 336], ["flow rate", "OBSERVATION", 337, 346]]], ["The only exception was the nasal cannula at the paediatric breathing profiles at 10 L/min, which had a lower inhaled dose than at 20 L/min.", [["nasal", "ANATOMY", 27, 32], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 27, 40], ["the nasal cannula", "TREATMENT", 23, 40], ["a lower inhaled dose", "TREATMENT", 101, 121], ["nasal cannula", "OBSERVATION", 27, 40]]], ["Although there is no clear explanation for this result, one potential reason may be that at 20 L/min more aerosol was forced through the system, including, perhaps, some drug that has rained out in the head model.", [["head", "ANATOMY", 202, 206], ["head", "ORGANISM_SUBDIVISION", 202, 206], ["no clear explanation for", "UNCERTAINTY", 18, 42], ["head", "ANATOMY", 202, 206]]], ["All the remaining trends were consistent with other studies.", [["other studies", "TEST", 46, 59], ["consistent with", "UNCERTAINTY", 30, 45]]], ["Perry et al. [13] examined the inhaled dose during high-flow nasal cannula therapy using the Aerogen Solo device.", [["nasal", "ANATOMY", 61, 66], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 61, 74], ["the inhaled dose", "TREATMENT", 27, 43], ["high-flow nasal cannula therapy", "TREATMENT", 51, 82], ["the Aerogen Solo device", "TREATMENT", 89, 112]]], ["For simulated adult breathing, the inhaled doses were found to be 0.8% and 0.2% for gas-flow rates of 10 and 40 L/min, respectively.", [["simulated adult breathing", "PROBLEM", 4, 29], ["the inhaled doses", "TREATMENT", 31, 48], ["gas-flow rates", "TEST", 84, 98]]], ["However, this study found 5.35 \u00b1 2.81% and 2.56 \u00b1 1.38% for 10 and 40 L/min, respectively.", [["this study", "TEST", 9, 19]]], ["During simulated paediatric breathing, 1.2, 0.1 and 0% were found for gas-flow rates of 3, 10 and 20 L/min, as compared to this study's findings of 3.23 \u00b1 1.58, 0.42 \u00b1 0.06 and 1.17 \u00b1 0.28% for flow rates of 2, 10 and 20 L/min.", [["simulated paediatric breathing", "TEST", 7, 37], ["gas-flow rates", "TEST", 70, 84], ["this study's findings", "TEST", 123, 144], ["flow rates", "TEST", 194, 204]]], ["Dailey et al. [36] examined the inhaled dose using a high-flow nasal cannula and reported considerably higher values of 26.7% to 27.4% at 10 L/min, 11.6% to 14.2% at 30 L/min and 3.5% to 5.9% at 50 L/min.", [["nasal", "ANATOMY", 63, 68], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 63, 76], ["the inhaled dose", "TREATMENT", 28, 44], ["a high-flow nasal cannula", "TREATMENT", 51, 76]]], ["Perry et al. [13] used a lower tidal volume for the paediatric breathing profiles setting than the present study; while Dailey et al. used an inspiratory-expiratory ratio of 1:2, an Albuterol sulphate mixture (2.5 mg/0.5 mL).", [["Albuterol sulphate", "CHEMICAL", 182, 200], ["Albuterol sulphate", "CHEMICAL", 182, 200], ["Albuterol", "SIMPLE_CHEMICAL", 182, 191], ["sulphate", "SIMPLE_CHEMICAL", 192, 200], ["a lower tidal volume", "TREATMENT", 23, 43], ["the present study", "TEST", 95, 112], ["an Albuterol sulphate mixture", "TREATMENT", 179, 208], ["inspiratory", "ANATOMY", 142, 153]]], ["Neither study reported the length of the tubing or the internal diameter of the nasal prongs making a direct comparison difficult.", [["nasal", "ANATOMY", 80, 85], ["Neither study", "TEST", 0, 13], ["the nasal prongs", "TREATMENT", 76, 92], ["length", "OBSERVATION_MODIFIER", 27, 33], ["tubing", "OBSERVATION", 41, 47], ["internal", "OBSERVATION_MODIFIER", 55, 63], ["diameter", "OBSERVATION_MODIFIER", 64, 72], ["nasal prongs", "ANATOMY", 80, 92]]], ["While there are differences between the studies at each flow rate, the overall trends remain similar.", [["the studies", "TEST", 36, 47], ["each flow rate", "TEST", 51, 65], ["overall", "OBSERVATION_MODIFIER", 71, 78], ["trends", "OBSERVATION_MODIFIER", 79, 85], ["similar", "OBSERVATION_MODIFIER", 93, 100]]], ["Direct comparisons between inhaled dose are difficult due to several factors influencing the drug available for inhalation, such as the position of components in the ventilator circuit, simulated breathing settings and humidification affect the inhaled dose [37] [38] [39] .", [["inhaled dose", "TREATMENT", 27, 39], ["inhalation", "TREATMENT", 112, 122], ["the ventilator circuit", "TREATMENT", 162, 184], ["simulated breathing settings", "TREATMENT", 186, 214], ["humidification affect the inhaled dose", "TREATMENT", 219, 257], ["ventilator circuit", "OBSERVATION", 166, 184]]], ["Golshahi et al. [40] reported that increasing the tubing length from 20 cm to 50 cm increased the deposition fraction in the tube from 1.2% to 13.3%; this compared with a tube of length 1.8 m used in the current study.DiscussionThe higher the inhaled dose, the higher the fugitive emissions.", [["tube", "TISSUE", 125, 129], ["tube", "TISSUE", 171, 175], ["the deposition fraction", "TEST", 94, 117], ["a tube of length", "TREATMENT", 169, 185], ["the current study", "TEST", 200, 217], ["The higher the inhaled dose", "TREATMENT", 228, 255], ["increasing", "OBSERVATION_MODIFIER", 35, 45], ["tubing", "OBSERVATION_MODIFIER", 50, 56], ["length", "OBSERVATION_MODIFIER", 57, 63], ["20 cm", "OBSERVATION_MODIFIER", 69, 74], ["deposition", "OBSERVATION_MODIFIER", 98, 108], ["fraction", "OBSERVATION_MODIFIER", 109, 117], ["tube", "OBSERVATION", 125, 129], ["fugitive emissions", "OBSERVATION", 272, 290]]], ["This indicated that the majority of the loss mechanisms occurred prior to exiting the patient interface.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["the loss mechanisms", "PROBLEM", 36, 55], ["majority", "OBSERVATION_MODIFIER", 24, 32], ["loss", "OBSERVATION", 40, 44]]], ["Dailey et al. [36] reported that increased flow rate could increase turbulence and impactive loss of aerosol within the tubing, which means less aerosol is reaching the patient interface and available for inhalation and/or to be released as fugitive aerosol.DiscussionIn this study, a vibrating mesh nebuliser was used to generate the medical aerosol, previous work reported that with aerosol generated from VMN has a MMAD of 4 \u00b5m [28] .", [["patient", "ORGANISM", 169, 176], ["VMN", "SIMPLE_CHEMICAL", 408, 411], ["patient", "SPECIES", 169, 176], ["increased flow rate", "PROBLEM", 33, 52], ["impactive loss of aerosol within the tubing", "TREATMENT", 83, 126], ["inhalation", "TREATMENT", 205, 215], ["this study", "TEST", 271, 281], ["a vibrating mesh nebuliser", "TREATMENT", 283, 309], ["the medical aerosol", "TREATMENT", 331, 350], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["turbulence", "OBSERVATION_MODIFIER", 68, 78], ["impactive loss", "OBSERVATION", 83, 97]]], ["However, the observed averaged MMAD of the fugitive emissions ranged from 1.248 to 1.793 \u00b5m across all scenarios.", [["the fugitive emissions", "TEST", 39, 61], ["fugitive emissions", "OBSERVATION", 43, 61]]], ["The aerosol released into the environment was considerably smaller than originally generated by the nebuliser.", [["The aerosol", "TREATMENT", 0, 11]]], ["The larger sized aerosol, in combination with the air flow, experiences greater inertia that can increase the rate of impaction and deposition of the larger sized aerosol within the system and upon the head model.", [["head", "ANATOMY", 202, 206], ["head", "ORGANISM_SUBDIVISION", 202, 206], ["The larger sized aerosol", "TREATMENT", 0, 24], ["the air flow", "PROBLEM", 46, 58], ["impaction", "PROBLEM", 118, 127], ["the larger sized aerosol within the system", "PROBLEM", 146, 188], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["sized", "OBSERVATION_MODIFIER", 11, 16], ["aerosol", "OBSERVATION", 17, 24], ["air flow", "OBSERVATION", 50, 58], ["greater", "OBSERVATION_MODIFIER", 72, 79], ["inertia", "OBSERVATION_MODIFIER", 80, 87], ["impaction", "OBSERVATION", 118, 127], ["deposition", "OBSERVATION_MODIFIER", 132, 142], ["larger", "OBSERVATION_MODIFIER", 150, 156], ["sized", "OBSERVATION_MODIFIER", 157, 162], ["aerosol", "OBSERVATION", 163, 170], ["system", "ANATOMY", 182, 188], ["head", "ANATOMY", 202, 206]]], ["The consequence of this is that the fugitively emitted aerosol is dominated by a lower sized fraction of aerosol, decreasing the MMAD.", [["MMAD", "PROTEIN", 129, 133], ["a lower sized fraction of aerosol", "TREATMENT", 79, 112], ["lower", "OBSERVATION_MODIFIER", 81, 86], ["sized", "OBSERVATION_MODIFIER", 87, 92], ["fraction", "OBSERVATION_MODIFIER", 93, 101], ["aerosol", "OBSERVATION_MODIFIER", 105, 112], ["decreasing", "OBSERVATION_MODIFIER", 114, 124]]], ["Bhashyam et al. [11] reported the volume median diameter of aerosol in a nasal cannula aerosol delivery system using a 3 L/min driving flow.", [["nasal", "ANATOMY", 73, 78], ["the volume median diameter of aerosol", "TREATMENT", 30, 67], ["a nasal cannula aerosol delivery system", "TREATMENT", 71, 110], ["diameter", "OBSERVATION_MODIFIER", 48, 56], ["nasal cannula", "ANATOMY", 73, 86]]], ["The aerosol exiting the nebuliser was 5.0 \u00b1 0.2 \u00b5m, which reduced to 2.2 \u00b1 0.2 \u00b5m from an adult cannula and 1.9 \u00b1 0.3 \u00b5m from a paediatric cannula.", [["The aerosol exiting the nebuliser", "TREATMENT", 0, 33], ["an adult cannula", "TREATMENT", 87, 103], ["a paediatric cannula", "TREATMENT", 126, 146]]], ["Although higher gas-flow rates were used in the current study, similar trends were found with a decrease in the size fraction and the size leaving the patient interface.", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["higher gas-flow rates", "TEST", 9, 30], ["the current study", "TEST", 44, 61], ["a decrease in the size fraction", "PROBLEM", 94, 125], ["higher", "OBSERVATION_MODIFIER", 9, 15], ["decrease", "OBSERVATION_MODIFIER", 96, 104], ["size", "OBSERVATION_MODIFIER", 112, 116], ["fraction", "OBSERVATION_MODIFIER", 117, 125], ["size", "OBSERVATION_MODIFIER", 134, 138]]], ["Berlinski [34] reported that the aerosol size fraction exiting the tip of the tracheostomy tube was 1.20 to 1.77 \u00b5m.", [["tracheostomy tube", "ANATOMY", 78, 95], ["tube", "TISSUE", 91, 95], ["the aerosol size fraction", "TREATMENT", 29, 54], ["the tracheostomy tube", "TREATMENT", 74, 95], ["size", "OBSERVATION_MODIFIER", 41, 45], ["tip", "OBSERVATION_MODIFIER", 67, 70], ["tracheostomy tube", "OBSERVATION", 78, 95]]], ["Berlinski [33] reported that aerosol changed its characteristics when travelling through a tracheostomy tube; the effects were more noticeable for nebulised aerosol than metered dose inhalers or valved aerosol reservoirs.", [["aerosol", "TREATMENT", 29, 36], ["a tracheostomy tube", "TREATMENT", 89, 108], ["nebulised aerosol", "TREATMENT", 147, 164], ["metered dose inhalers", "TREATMENT", 170, 191], ["valved aerosol reservoirs", "TREATMENT", 195, 220], ["tracheostomy tube", "OBSERVATION", 91, 108]]], ["Additionally, during simulated adult breathing with gas-flow rates of 10, 40 and 60 L/min, there were comparable trends between the nasal cannula and the tracheostomy interface.", [["nasal", "ANATOMY", 132, 137], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 132, 145], ["gas", "TEST", 52, 55], ["flow rates", "TEST", 56, 66], ["the nasal cannula", "TREATMENT", 128, 145], ["the tracheostomy interface", "TREATMENT", 150, 176], ["nasal cannula", "ANATOMY", 132, 145], ["tracheostomy interface", "OBSERVATION", 154, 176]]], ["This could indicate that the size distributions of fugitive emissions are independent of the patient interface and are governed instead by the flow velocities in these scenarios.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["fugitive emissions", "PROBLEM", 51, 69], ["the flow velocities", "TEST", 139, 158], ["size", "OBSERVATION_MODIFIER", 29, 33], ["distributions", "OBSERVATION_MODIFIER", 34, 47], ["fugitive emissions", "OBSERVATION", 51, 69], ["flow velocities", "OBSERVATION", 143, 158]]], ["The size fraction of the released aerosol has implications, as the aerosol can remain airborne for longer periods, which has been linked to secondary inhalation exposure [41] .DiscussionAerosol concentration is governed by local factors including room dimensions and layout, air turbulence, air-flow rates and temperature that influence dispersion and decay [41] [42] [43] .", [["DiscussionAerosol", "CHEMICAL", 176, 193], ["DiscussionAerosol", "SIMPLE_CHEMICAL", 176, 193], ["DiscussionAerosol concentration", "TREATMENT", 176, 207], ["air turbulence", "TEST", 275, 289], ["air-flow rates", "TEST", 291, 305], ["size", "OBSERVATION_MODIFIER", 4, 8], ["fraction", "OBSERVATION_MODIFIER", 9, 17], ["aerosol", "OBSERVATION_MODIFIER", 34, 41], ["air turbulence", "OBSERVATION", 275, 289], ["air-flow", "OBSERVATION", 291, 299]]], ["However, previous research by McGrath at al. [44] was conducted in the same laboratory that allows for comparisons between the current study and fugitive emissions from a standard jet nebuliser using manufacturer-prescribed 8 L/min.", [["the current study", "TEST", 123, 140], ["a standard jet nebuliser", "TREATMENT", 169, 193], ["manufacturer", "TREATMENT", 200, 212]]], ["Adult and paediatric head models were connected to patient interfaces; a facemask and mouthpiece without an expiratory filter on the exhaled port.", [["head", "ANATOMY", 21, 25], ["head", "ORGANISM_SUBDIVISION", 21, 25], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["Adult and paediatric head models", "PROBLEM", 0, 32], ["a facemask", "TREATMENT", 71, 81], ["mouthpiece", "TREATMENT", 86, 96], ["an expiratory filter", "TREATMENT", 105, 125], ["the exhaled port", "TREATMENT", 129, 145], ["head", "ANATOMY", 21, 25], ["expiratory filter", "OBSERVATION", 108, 125], ["exhaled port", "OBSERVATION", 133, 145]]], ["When adjusted to reflect the analysis in the present study, aerosol concentration ranged from 0.221 to 0.323 mg m \u22123 , which is comparable with the observed concentration range of 0.290 to 0.370 mg m \u22123 in the current study.DiscussionWhile this study indicates that the caregiver is exposed to higher fugitive emissions than a bystander, due to proximity to the patient interface, it is worth noting the calculated exposure ratios for bystanders versus caregivers.", [["patient", "ORGANISM", 362, 369], ["patient", "SPECIES", 362, 369], ["the analysis", "TEST", 25, 37], ["aerosol concentration", "TEST", 60, 81], ["the current study", "TEST", 206, 223], ["this study", "TEST", 240, 250]]], ["The caregiver inhaled 8.5% of the original drug using the nasal cannula, as compared to 10.2% for the tracheostomy.", [["nasal", "ANATOMY", 58, 63], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 58, 71], ["The caregiver inhaled", "TREATMENT", 0, 21], ["the nasal cannula", "TREATMENT", 54, 71], ["the tracheostomy", "TREATMENT", 98, 114], ["nasal cannula", "ANATOMY", 58, 71], ["tracheostomy", "OBSERVATION", 102, 114]]], ["However, the bystander inhaled 3.2% for the nasal cannula scenario compared with 2.3% in the tracheostomy scenario.", [["nasal", "ANATOMY", 44, 49], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 44, 57], ["the bystander inhaled", "TREATMENT", 9, 30], ["the nasal cannula scenario", "TREATMENT", 40, 66], ["the tracheostomy scenario", "TREATMENT", 89, 114], ["nasal cannula", "ANATOMY", 44, 57], ["tracheostomy scenario", "OBSERVATION", 93, 114]]], ["This was due to occurrence of the peak exposure, which has been previously documented in indoor air quality studies [45, 46] .DiscussionThere was a contrast between the aerosol concentrations recorded during the nasal cannula scenario for the paediatric and adult patients, which was not reflected in the tracheostomy scenarios.", [["nasal", "ANATOMY", 212, 217], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 212, 225], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["the peak exposure", "PROBLEM", 30, 47], ["indoor air quality studies", "TEST", 89, 115], ["the aerosol concentrations", "TREATMENT", 165, 191], ["the nasal cannula scenario", "TREATMENT", 208, 234], ["peak exposure", "OBSERVATION", 34, 47], ["nasal cannula", "ANATOMY", 212, 225], ["tracheostomy scenarios", "OBSERVATION", 305, 327]]], ["The paediatric nasal cannula had smaller tubing dimensions and components, which could have affected the aerosol exiting the interface.", [["nasal", "ANATOMY", 15, 20], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 15, 28], ["The paediatric nasal cannula", "TREATMENT", 0, 28], ["nasal", "ANATOMY", 15, 20], ["cannula", "OBSERVATION", 21, 28], ["smaller", "OBSERVATION_MODIFIER", 33, 40], ["tubing", "OBSERVATION_MODIFIER", 41, 47], ["dimensions", "OBSERVATION_MODIFIER", 48, 58], ["components", "OBSERVATION_MODIFIER", 63, 73], ["aerosol", "OBSERVATION", 105, 112], ["interface", "OBSERVATION_MODIFIER", 125, 134]]], ["For the adult nasal cannula (OPT 944), the inner diameter of the nasal prongs was 3.5 mm at the narrowest point, while for the paediatric nasal cannula (OPT 318), the inner diameter of the nasal prongs was 2 mm at the narrowest point.", [["nasal", "ANATOMY", 14, 19], ["nasal prongs", "ANATOMY", 65, 77], ["nasal", "ANATOMY", 138, 143], ["nasal prongs", "ANATOMY", 189, 201], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 14, 27], ["inner", "TISSUE", 43, 48], ["nasal prongs", "MULTI-TISSUE_STRUCTURE", 65, 77], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 138, 151], ["inner", "TISSUE", 167, 172], ["nasal prongs", "MULTI-TISSUE_STRUCTURE", 189, 201], ["the adult nasal cannula", "TREATMENT", 4, 27], ["the inner diameter of the nasal prongs", "TREATMENT", 39, 77], ["the paediatric nasal cannula", "TREATMENT", 123, 151], ["the inner diameter of the nasal prongs", "TREATMENT", 163, 201], ["nasal cannula", "ANATOMY", 14, 27], ["inner", "OBSERVATION_MODIFIER", 43, 48], ["diameter", "OBSERVATION_MODIFIER", 49, 57], ["nasal prongs", "ANATOMY", 65, 77], ["3.5 mm", "OBSERVATION", 82, 88], ["narrowest", "OBSERVATION_MODIFIER", 96, 105], ["inner", "OBSERVATION_MODIFIER", 167, 172], ["diameter", "OBSERVATION_MODIFIER", 173, 181], ["nasal prongs", "ANATOMY", 189, 201], ["narrowest", "OBSERVATION_MODIFIER", 218, 227]]], ["Studies have reported that the characteristics of the paediatric setup reduced the aerosol exiting the cannula during high-flow therapies [13, 47] .", [["the paediatric setup", "TREATMENT", 50, 70], ["the aerosol", "TREATMENT", 79, 90], ["the cannula", "TREATMENT", 99, 110], ["high-flow therapies", "TREATMENT", 118, 137], ["cannula", "OBSERVATION_MODIFIER", 103, 110]]], ["Since the same tubing and tracheostomy interface (12 mm at the narrowest point) was used for the adult and paediatric tracheostomy, with different breathing profiles, this could explain why the same differences were not observed in this case.ConclusionsFugitive emissions released during aerosol therapies present potential risks to healthcare workers in a clinical setting.", [["the same tubing", "TREATMENT", 6, 21], ["tracheostomy interface", "TREATMENT", 26, 48], ["the adult and paediatric tracheostomy", "TREATMENT", 93, 130], ["different breathing profiles", "PROBLEM", 137, 165], ["ConclusionsFugitive emissions", "TREATMENT", 242, 271], ["aerosol therapies", "TREATMENT", 288, 305], ["tubing", "OBSERVATION", 15, 21], ["tracheostomy interface", "OBSERVATION", 26, 48], ["12 mm", "OBSERVATION_MODIFIER", 50, 55], ["tracheostomy", "OBSERVATION", 118, 130]]], ["No studies have previously quantified time-series aerosol concentrations and the size distribution of fugitive emissions from high-flow therapy.", [["aerosol concentrations", "TREATMENT", 50, 72], ["fugitive emissions", "TEST", 102, 120], ["high-flow therapy", "TREATMENT", 126, 143], ["size", "OBSERVATION_MODIFIER", 81, 85], ["distribution", "OBSERVATION_MODIFIER", 86, 98], ["fugitive emissions", "OBSERVATION", 102, 120], ["high", "OBSERVATION_MODIFIER", 126, 130], ["flow therapy", "OBSERVATION", 131, 143]]], ["Potential inhalation exposure to fugitive emissions during high-flow aerosol therapy was examined using adult and paediatric scenarios for both nasal cannula and tracheostomy interfaces.", [["nasal", "ANATOMY", 144, 149], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 144, 157], ["Potential inhalation exposure", "PROBLEM", 0, 29], ["fugitive emissions", "TREATMENT", 33, 51], ["high-flow aerosol therapy", "TREATMENT", 59, 84], ["both nasal cannula", "TREATMENT", 139, 157], ["tracheostomy interfaces", "TREATMENT", 162, 185], ["fugitive emissions", "OBSERVATION", 33, 51], ["nasal cannula", "ANATOMY", 144, 157], ["tracheostomy interfaces", "OBSERVATION", 162, 185]]], ["This study confirmed the release of fugitive emissions into the environment during aerosol high-flow treatment.", [["This study", "TEST", 0, 10], ["fugitive emissions", "TREATMENT", 36, 54], ["aerosol high-flow treatment", "TREATMENT", 83, 110], ["fugitive emissions", "OBSERVATION", 36, 54], ["flow treatment", "OBSERVATION", 96, 110]]], ["The results showed that variations in interface type, patient (adult or paediatric) and gas-flow rates all impacted the quantity and characteristics of fugitive emissions.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["gas-flow rates", "TEST", 88, 102], ["fugitive emissions", "PROBLEM", 152, 170], ["interface type", "OBSERVATION", 38, 52], ["fugitive emissions", "OBSERVATION", 152, 170]]], ["The highest aerosol concentration of 0.370 \u00b1 0.046 mg m \u22123 was recorded from the paediatric tracheostomy with a gas-flow rate of 20 L/min, which also corresponded to the second highest inhaled dose across all the scenarios.", [["The highest aerosol concentration", "TREATMENT", 0, 33], ["the paediatric tracheostomy", "TREATMENT", 77, 104], ["a gas", "TEST", 110, 115], ["the second highest inhaled dose", "TREATMENT", 166, 197]]], ["It was observed that as the gas-flow rate increased, the inhaled dose decreased, and the fugitive emissions decreased.", [["the gas-flow rate", "TEST", 24, 41], ["the inhaled dose", "TREATMENT", 53, 69], ["the fugitive emissions", "TEST", 85, 107], ["fugitive", "OBSERVATION_MODIFIER", 89, 97], ["emissions", "OBSERVATION_MODIFIER", 98, 107], ["decreased", "OBSERVATION_MODIFIER", 108, 117]]], ["Overall, the results can be used to develop approaches for healthcare providers and patients to inform best practice to mitigate the risks of fugitive emissions in clinical practice.ConclusionsSupplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/6/254/s1, Figure S1 : A photograph highlighting the physical setup for the paediatric nasal cannula set up, Figure S2 : A photograph highlighting the physical setup for the adult nasal cannula set up, Figure S3", [["nasal", "ANATOMY", 375, 380], ["nasal", "ANATOMY", 468, 473], ["patients", "ORGANISM", 84, 92], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 468, 481], ["patients", "SPECIES", 84, 92], ["the paediatric nasal cannula", "TREATMENT", 360, 388], ["the physical setup", "TREATMENT", 435, 453], ["the adult nasal cannula", "TREATMENT", 458, 481], ["nasal cannula", "ANATOMY", 468, 481]]]], "PMC7224139": [["IntroductionIn recent years, surgical education has increased its focus on the non-technical skills such as communication and interpersonal relationships while continuing to strive for technical excellence for procedures and patient care.", [["patient", "ORGANISM", 225, 232], ["patient", "SPECIES", 225, 232], ["surgical education", "TREATMENT", 29, 47], ["procedures and patient care", "TREATMENT", 210, 237]]], ["An awareness of the ethical aspects of surgical practice that involve non-technical skills and judgment is of vital concern to surgical educators and encompasses disparate issues ranging from adequate supervision of trainees to surgical care access.", [["surgical practice", "TREATMENT", 39, 56], ["surgical educators", "TREATMENT", 127, 145], ["disparate issues", "PROBLEM", 162, 178], ["surgical care access", "TREATMENT", 228, 248]]], ["The general ethical principles of autonomy, non-maleficence, beneficence, and justice as outlined by Beauchamp and Childress [1] offer a framework for a study of surgical ethics with an understanding that overlap as in a Venn diagram occurs with ethical issues in the African context (Table 1).", [["a study", "TEST", 151, 158], ["surgical ethics", "TREATMENT", 162, 177]]], ["Autonomy may include decisions involving the family and community as well as honoring religious beliefs; beneficence requires quality and safe medical care; non-maleficence may involve refusing to provide services outside one\u2019s area of expertise; and justice can include access and affordability as well as research that benefits the community in which it takes place as well as the local researchers.", [["safe medical care", "TREATMENT", 138, 155]]], ["Topics of interest include:access to care (socioeconomic issues and distance from health facilities);resource utilization and decision making based on availability and cost of resources, including ICU and terminal extubation;informed consent (both communication about reasonable expectations post-procedure and research participation);research ethics, including local projects, international collaboration, authorship;quality and safety including supervision of less experienced professionals;religious and cultural issues that may affect any ethical decision making.Autonomy\u2014religion and culture ::: MethodsAs the ethics of surgical care and research are examined, the influence of traditional beliefs must always be considered and respected, even in times of disagreement regarding the decisions reached for treatment and procedures.", [["post-procedure", "TREATMENT", 292, 306], ["culture", "TEST", 589, 596], ["surgical care", "TREATMENT", 625, 638], ["traditional beliefs", "TREATMENT", 683, 702], ["treatment", "TREATMENT", 810, 819], ["procedures", "TREATMENT", 824, 834]]], ["To enter the next world missing a limb may be worse than death.", [["limb", "ANATOMY", 34, 38], ["death", "DISEASE", 57, 62], ["limb", "ORGANISM_SUBDIVISION", 34, 38], ["death", "PROBLEM", 57, 62], ["limb", "ANATOMY", 34, 38]]], ["Culture also plays a significant role in decisions; a major tenet of Western medical ethics, patient autonomy, especially that of many African women wherein ultimate decision making belongs to the husband or family, may be diminished when elders or family or community must agree about medical decisions or treatment plans [8].", [["patient", "ORGANISM", 93, 100], ["women", "ORGANISM", 143, 148], ["patient", "SPECIES", 93, 100], ["women", "SPECIES", 143, 148], ["Culture", "TEST", 0, 7]]], ["Even access to care may be influenced by culture and beliefs.Autonomy\u2014informed consent ::: MethodsInformed consent plays an essential role in both clinical practice and research.", [["culture", "TEST", 41, 48]]], ["The ethics surrounding informed consent involve two areas of medical/surgical practice: (1) consent for procedures with an accurate understanding of risks and benefits and realistic view of post-procedure or treatment outcome; and (2) informed consent for inclusion in a research study with full disclosure in understandable language of any possible risk.", [["procedures", "TREATMENT", 104, 114], ["post-procedure", "TREATMENT", 190, 204], ["a research study", "TEST", 269, 285]]], ["In clinical practice, studies reveal that not all surgeons obtain informed consent for every operation or procedure.", [["every operation", "TREATMENT", 87, 102], ["procedure", "TREATMENT", 106, 115]]], ["Patients undergo operations without knowing who will operate or the reason for the operation or even what operation will be performed.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the operation", "TREATMENT", 79, 92], ["what operation", "TREATMENT", 101, 115]]], ["Patient satisfaction was captured in African settings, but little information was found describing patient understanding of possible outcomes from operation including quality of life [9\u201311].", [["patient", "ORGANISM", 99, 106], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 99, 106]]], ["A Nigerian study of informed consent forms used in 33 tertiary-care facilities revealed a relatively difficult reading level (13\u201315 years old), absence of information such as permission for transfusion, tissue disposal, and anesthesia risks, with less than 10% mentioning provision for an interpreter or answering patient\u2019s questions, and only about 11% describing specific risks [12].", [["tissue", "ANATOMY", 203, 209], ["tissue", "TISSUE", 203, 209], ["patient", "ORGANISM", 314, 321], ["patient", "SPECIES", 314, 321], ["A Nigerian study", "TEST", 0, 16], ["transfusion", "TREATMENT", 190, 201], ["tissue disposal", "TREATMENT", 203, 218], ["anesthesia risks", "TREATMENT", 224, 240]]], ["Just as the role of the physician in Western healthcare has evolved from the final arbiter of decision making to a collaborating partner with the patient (and perhaps family), the view of collaborative decision making will be seen more frequently in the African context as education increases awareness of this issue.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153]]], ["An increase in knowledge of litigation is occurring in the African context as well, so this may also play a role as it has in the West [13].", [["increase", "OBSERVATION_MODIFIER", 3, 11]]], ["The physician or researcher seeking informed consent must remember to consider community/family decision making in the African context rather than total autonomy of the patient [14\u201316].Beneficence\u2014quality and safety including supervision ::: MethodsQuality and safety should be aimed for in all areas of surgical and medical care.", [["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["MethodsQuality", "TREATMENT", 242, 256], ["surgical and medical care", "TREATMENT", 304, 329], ["surgical", "OBSERVATION", 304, 312]]], ["Quality and safety include supervision of less experienced professional trainees and non-surgeons who perform surgical procedures [17\u201319].", [["surgical procedures", "TREATMENT", 110, 129]]], ["A survey of medical officers in Ghana reported that during their training period they were not supervised for a significant number of the reported procedures (7 of 42 Cesarean sections; 5 of 26 exploratory laparotomies; 8 of 23 inguinal herniorrhaphies; and 4 of 18 appendectomies) [20].", [["sections", "ANATOMY", 176, 184], ["inguinal", "ANATOMY", 228, 236], ["Cesarean sections", "TREATMENT", 167, 184], ["exploratory laparotomies", "TEST", 194, 218], ["23 inguinal herniorrhaphies", "TREATMENT", 225, 252], ["inguinal", "ANATOMY", 228, 236]]], ["Meara and colleagues in 2015 cited the need for increased supervision of new graduates after formal surgical training as well as for more training and supervision of associate clinicians and general practice physicians who perform operations, anesthesia, or obstetrics [21].", [["formal surgical training", "TREATMENT", 93, 117], ["anesthesia", "TREATMENT", 243, 253]]], ["In Kenya, newly trained surgery residents may be posted to district hospitals where they face a number of challenges including lack of supervision in addition to inadequate surgical instruments and low volume of cases.", [["inadequate surgical instruments", "TREATMENT", 162, 193], ["low volume of cases", "PROBLEM", 198, 217], ["low volume", "OBSERVATION_MODIFIER", 198, 208]]], ["Some countries such as Niger are recognizing the need for regular, if not continuous, supervision of those general practitioners trained to do surgical procedures wherein general surgeons make periodic visits to district hospitals to provide continuing education and supervision [23].Beneficence\u2014quality and safety including supervision ::: MethodsAnother ethical issue is the disproportionate burden that women and children bear regarding access to surgery because of lack of safe cesarean sections for obstructed labor and for untreated obstetric fistulas [24].Justice and non-maleficence\u2014ethics of international collaboration and \u201cglobal surgery\u201d ::: MethodsThe increasing interest in international collaboration and \u201cglobal surgery\u201d from high-income countries in North America [25], Europe, and Asia adds another component for study.", [["sections", "ANATOMY", 491, 499], ["obstructed labor", "DISEASE", 504, 520], ["obstetric fistulas", "DISEASE", 539, 557], ["women", "ORGANISM", 406, 411], ["children", "ORGANISM", 416, 424], ["women", "SPECIES", 406, 411], ["children", "SPECIES", 416, 424], ["surgical procedures", "TREATMENT", 143, 162], ["surgery", "TREATMENT", 450, 457], ["safe cesarean sections", "TREATMENT", 477, 499], ["obstructed labor", "PROBLEM", 504, 520], ["untreated obstetric fistulas", "PROBLEM", 529, 557], ["global surgery", "TREATMENT", 634, 648], ["Methods", "TREATMENT", 654, 661], ["\u201cglobal surgery", "TREATMENT", 720, 735], ["study", "TEST", 831, 836], ["fistulas", "OBSERVATION", 549, 557], ["increasing", "OBSERVATION_MODIFIER", 665, 675], ["interest", "OBSERVATION_MODIFIER", 676, 684]]], ["Elmin Steyn and J. Edge in the Division of Surgery, Stellenbosch University in Cape Town, provide a succinct and valuable treatise on the ethical pros and cons of surgical tourism (particularly in trauma), surgical education, and research involving institutions outside SSA [26].", [["trauma", "DISEASE", 197, 203], ["Surgery", "TREATMENT", 43, 50], ["surgical tourism", "TREATMENT", 163, 179], ["J. Edge", "OBSERVATION", 16, 23], ["Surgery", "OBSERVATION", 43, 50], ["surgical tourism", "OBSERVATION", 163, 179]]], ["A pertinent report from Burundi involves expatriate surgeons who rely on translators (sometimes their host surgeons) to obtain informed consent for surgical procedures [27].", [["surgical procedures", "TREATMENT", 148, 167]]], ["The commercial use of DNA samples collected in Africa by a research center in the UK has come under criticism in 2019 [28].Justice\u2014access to care, both socioeconomic and location ::: MethodsBecause access to safe and affordable surgery has attracted overdue and appropriate attention following the Lancet Report of 2015 where it is part of three of the six surgical indicators of the state of surgical care [29] as well the release of the Disease Control Priorities, Third Edition, Essential Surgery the same year, the ethics of access will be the first area of consideration because, without access, other ethical issues become moot.", [["DNA", "CELLULAR_COMPONENT", 22, 25], ["DNA samples", "TEST", 22, 33], ["MethodsBecause access", "TREATMENT", 183, 204], ["affordable surgery", "TREATMENT", 217, 235], ["surgical care", "TREATMENT", 393, 406], ["Essential Surgery", "TREATMENT", 482, 499], ["moot", "PROBLEM", 629, 633], ["Disease", "OBSERVATION", 439, 446], ["moot", "OBSERVATION", 629, 633]]], ["The lack of health professional human resources in Africa as well as the concentration of health professionals in urban areas is well documented [30\u201332].", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37]]], ["The lack of sufficient surgeons across the continent is being addressed through initiatives of the West African College of Surgeons (WACS), College of Surgeons of East, Central and Southern Africa (COSECSA), Association of Surgeons of South Africa (ASSA), Pan African Association of Surgeons (PAAS) [33], Pan African Academy of Christian Surgeons (PAACS) [34], and other groups dedicated to training surgeons as well as holding high standards for practicing surgeons and providing continuing professional development (CPD).", [["practicing surgeons", "TREATMENT", 447, 466]]], ["Ethical issues arise when access is complicated by available care that is unaffordable or is scarce as noted for burn care in the Republic of South Africa [35].", [["burn", "DISEASE", 113, 117], ["Ethical issues", "PROBLEM", 0, 14], ["burn care", "TREATMENT", 113, 122]]], ["As noted above from the Lancet indicators, grave economic devastation may face families involved in long-term and complex medical care resulting from medical catastrophes such as road traffic injuries, chronic illness, or cancer.", [["cancer", "ANATOMY", 222, 228], ["traffic injuries", "DISEASE", 184, 200], ["chronic illness", "DISEASE", 202, 217], ["cancer", "DISEASE", 222, 228], ["cancer", "CANCER", 222, 228], ["grave economic devastation", "TREATMENT", 43, 69], ["complex medical care", "TREATMENT", 114, 134], ["medical catastrophes", "PROBLEM", 150, 170], ["chronic illness", "PROBLEM", 202, 217], ["cancer", "PROBLEM", 222, 228], ["chronic", "OBSERVATION_MODIFIER", 202, 209], ["illness", "OBSERVATION", 210, 217], ["cancer", "OBSERVATION", 222, 228]]], ["African physicians frequently understand medical costs and may factor these into discussions with colleagues as well as treatment options offered to patients.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["treatment options", "TREATMENT", 120, 137]]], ["Universal free or low-cost health care, one of the targets of the Sustainable Development Goals (SDGs), is an answer but financing is problematic in low-resource environments [36].", [["low-cost health care", "TREATMENT", 18, 38]]], ["A 2018 study asserted:We estimated that 287,282,013 (29.0%) people and 64,495,526 (28\u00b72%) women of childbearing age are located more than 2-h travel time from the nearest hospital.", [["people", "ORGANISM", 60, 66], ["women", "ORGANISM", 90, 95], ["people", "SPECIES", 60, 66], ["women", "SPECIES", 90, 95]]], ["Marked differences were observed within and between countries, ranging from less than 25% of the population within 2-h travel time of a public hospital in South Sudan to more than 90% in Nigeria, Kenya, Cape Verde, Swaziland, South Africa, Burundi, Comoros, S\u00e3o Tom\u00e9 and Pr\u00edncipe, and Zanzibar.", [["Marked differences", "PROBLEM", 0, 18], ["Pr\u00edncipe", "TREATMENT", 271, 279], ["Zanzibar", "TREATMENT", 285, 293]]], ["Only 16 countries reached the international benchmark of more than 80% of their populations living within a 2-h travel time of the nearest hospital [40].Justice and autonomy\u2014resource utilization including end-of-life decision making ::: MethodsResource utilization and decision making based on availability and cost of resources, including ICU (if available), are daily concerns of surgeons and other physicians.", [["MethodsResource utilization", "TREATMENT", 237, 264]]], ["On a macro-level, some studies seek to understand the economics and resource utilization in the African healthcare sectors [41].", [["some studies", "TEST", 18, 30]]], ["On a micro- or local level, heathcare expenditures and efficiencies are affected by unnecessary operation cancelations, unwillingness to perform terminal extubation, and national formularies that determine resource allocation [2, 42\u201345].", [["a micro", "TEST", 3, 10], ["unnecessary operation cancelations", "TREATMENT", 84, 118], ["terminal extubation", "TREATMENT", 145, 164]]], ["Terminal extubation and end-of-life decision making are fraught with cultural, ethical, and legal ramifications.", [["Terminal extubation", "TREATMENT", 0, 19]]], ["Very little data exist about attitudes toward terminal extubation in Africa; for example, 0.2 ICU beds per 100 hospital beds are found in Zambia [46].", [["terminal extubation", "TREATMENT", 46, 65]]], ["At the 2013 Durban Ethics Round Table, participants were asked to respond to the statement, \u201cThere is no moral difference between withholding and withdrawing a mechanical ventilator\u201d; of 22 respondents, five were from South Africa (the only African country represented) and four of those five agreed.", [["participants", "SPECIES", 39, 51], ["moral difference", "PROBLEM", 105, 121], ["a mechanical ventilator", "TREATMENT", 158, 181], ["no", "UNCERTAINTY", 102, 104]]], ["One salient fact is the lack of specific legal protection in South Africa for withdrawal of support.", [["withdrawal of support", "TREATMENT", 78, 99]]], ["\u201cWithdrawing of ventilator support is not universal.", [["ventilator support", "TREATMENT", 16, 34]]], ["However, even when withdrawing mechanical ventilation is acceptable, the approach to achieve this end point is highly variable and individualized\u201d [47].", [["mechanical ventilation", "TREATMENT", 31, 53]]], ["Only 11 responses, all from South Africa, were in this study for Consensus for Worldwide End-of-Life Practice for Patients in Intensive Care Units (WELPICUS) study [49].", [["Patients", "ORGANISM", 114, 122], ["Patients", "SPECIES", 114, 122], ["this study", "TEST", 50, 60]]], ["A subsequent article \u201cAdding Africa\u201d was published in 2015.", [["Africa\u201d", "TREATMENT", 29, 36]]], ["They pointed out the sparse Africa participation and gave a plea for further study in the African context.Justice and autonomy\u2014resource utilization including end-of-life decision making ::: MethodsAlthough the definition of appropriate end-of-life care may differ between religions and cultures, and even between fairly similar individuals, the WELPICUS study demonstrates that consensus can be achieved for the majority of definitions and statements relating to end-of-life practices.", [["further study", "TEST", 69, 82], ["appropriate end-of-life care", "TREATMENT", 224, 252], ["cultures", "TEST", 286, 294], ["the WELPICUS study", "TEST", 341, 359], ["end-of-life practices", "TREATMENT", 463, 484]]], ["Physicians working in limited resource settings and multicultural communities in which critical care and palliative care are relatively young specialties can both contribute significantly to this important discussion and would definitely benefit from being part of this process.", [["palliative care", "TREATMENT", 105, 120]]], ["We urge critical care and palliative care surgeons and researchers to include colleagues in Kenya, Africa, and around the developing world in future studies so that they are truly \u201cworldwide\u201d [50].Justice and autonomy\u2014resource utilization including end-of-life decision making ::: MethodsWhen resources are limited, creating policies that maximize the use of limited resources is a strategy but may still meet objections from both health professions and patients/family [51].", [["patients", "ORGANISM", 454, 462], ["patients", "SPECIES", 454, 462], ["palliative care surgeons", "TREATMENT", 26, 50]]], ["Informed consent becomes a critical factor in any discussion and subsequent decision.Justice\u2014research ethics, shared authorship, collaboration, informed consent, and use of African literature databases ::: MethodsResearch required of surgery trainees for their accreditation as well as all research efforts that involve collaboration with international partners raise ethical issues surrounding equality of sharing credit.", [["surgery trainees", "TREATMENT", 234, 250]]], ["Research into appropriate treatments and procedures in the African context is vital.", [["procedures", "TREATMENT", 41, 51]]], ["Employing literature databases such as AJOL and Bioline increases the exposure to African-generated research.", [["AJOL", "TREATMENT", 39, 43], ["Bioline", "TREATMENT", 48, 55]]], ["International collaborators must be intentional in including African colleagues in research projects from the planning stages through the completion, data analysis, and final written reports and must offer co-authorship as well as acknowledgment for contributions [57].", [["data analysis", "TEST", 150, 163]]], ["Rwanda Ministry of Health documents state: \u201cIn the event that the PI is foreign, it is important the Rwandan collaborator be a co-PI on any publication, consistent with the guidelines for authorship addressed in the Roles and Responsibilities of Investigators document\u201d [59].", [["foreign", "OBSERVATION", 72, 79]]], ["In one study of 114 articles published in five peer-reviewed Sudanese medical journals, informed consent was not documented in 69.3% of the articles, and surprisingly, 88.6% of those researchers failed to report approval by an ethics body [62].", [["one study", "TEST", 3, 12]]], ["Also, online data collection and storage methods such as REDCap (which may be institution-based in the West as well as in Africa) [65] focus attention on the issue of data ownership and how data are used.", [["online data collection", "TEST", 6, 28], ["storage methods", "TREATMENT", 33, 48]]], ["Assuring research participants of privacy and confidentiality is a hallmark of ethical study design.Results and conclusionAfter reviewing the literature concerning ethical topics in surgical and medical practice in SSA in light of the practical experience of the three surgeon authors, the ethical issues arising from the practice of surgery with the intention to address the challenges should be a vital component of training in SSA and elsewhere.", [["participants", "SPECIES", 18, 30], ["ethical study", "TEST", 79, 92], ["the ethical issues", "PROBLEM", 286, 304], ["surgery", "TREATMENT", 334, 341]]], ["Potential ethics curriculum topics based on principles of autonomy, beneficence, non-maleficence, and justice include: informed consent and patient comprehension; confidentiality and protecting patient data; end-of-life decision making; access to appropriately trained medical professionals; resource utilization; and research ethics.", [["patient", "ORGANISM", 140, 147], ["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 140, 147], ["patient", "SPECIES", 194, 201]]], ["Leadership and advocacy are required to implement additions to training curriculum; therefore, the issues raised should be added to the continuing professional development of practicing surgeons, academic faculty, and other health professionals.", [["training curriculum", "TREATMENT", 63, 82]]], ["As the various surgical societies and associations seek to raise standards, improve safety and quality, and create more uniform curricula for trainees across the continent, surgical ethics should be a core subject.", [["surgical ethics", "TREATMENT", 173, 188], ["surgical societies", "OBSERVATION", 15, 33]]]]}